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Abstract 
Prostate cancer is the 2nd most common cancer among men worldwide with an estimated 
1.1 million men diagnosed with the disease in 2012 and accounting for more than 300,000 deaths 
in 2012. According to the GLOBOCAN 2012 report, it is estimated that prostate cancer will 
overtake lung cancer, which is currently the most common form of cancer affecting men globally, 
in the last ten years. This thesis focuses on the development of novel nanomedicine-based 
therapeutic approaches for focal ablation of primary prostate cancer and targeted 
chemotherapeutics of the treatment of metastatic prostate cancer lesions in bone.  
Focal prostate cancer therapy is an effective approach that can successfully eradicate single 
tumor lesions. However, the focal therapy approaches have limitations with regard to treating high-
volume and multi-modal tumor lesions as well as lacks the ability to selectively ablate cancer 
lesions. To address these therapeutic limitations, we have developed nanodroplets (average 
diameter ~ 200nm) encapsulating perfluorocarbons (PFC’s), namely perfluoropentane (PFP) and 
perfluorohexane (PFH), which can rapidly expand reaching > 500 µm in < 1µsecond when exposed 
to therapeutic ultrasound before they collapse. The pulsating microbubbles have proved successful 
in mechanically fractionating neighboring cells with significantly reduced cavitation parameter 
thresholds. To test the tumor ablation efficiency of the different PFC (PFP or PFH)-encapsulated 
nanodroplets, we developed 3D-prostate cancer spheroids from PC-3 and C4-2B cancer cells using 
aqueous-two-phase-systems (ATPS) on an agarose 3D tumor phantom model that mimicked the 
cells inside a tissue extracellular-matrix. The applied treatment groups included no ND with lower-
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pressure (13 MPa), no ND with high-pressure (28 MPa), PFP-loaded NDs with low-pressure (13 
MPa), and PFH-loaded NDs with lower-pressure (13 MPa). During the treatments such high-
pressure and low-pressure with nanodroplets, cavitation bubbles were observed at the transducer 
focus and cells were observed to be mechanically ruptured. After the treatments, we evaluated the 
ablated area of the spheroids. No nanodroplets at low-pressure could ablate less than 20 % area for 
both spheroid models. However, regular histotripsy with high-pressure ablated around 80 % of the 
spheroids. Whereas, PFP-nanodroplets with low-pressure destroyed 40 % of the spheroids, and 
PFH-nanodroplets could ablate almost 80 % of the spheroids. These results indicate both PFC-
loaded nanodroplets significantly reduce the histotripsy threshold, and PFH-loaded nanodroplets 
with low-pressure can destroy cells as efficiently as high-pressure. 
The current bone metastases therapy modalities are riddled with its fair share of limitations 
such as their inability to efficaciously deliver the therapeutic concentrations of anti-cancer agents 
to the target site. To address these limitations, in the second part of this dissertation we designed 
bone-targeted nanoparticles that can encapsulate and deliver a high dose of Cabazitaxel (CTX) to 
prostate cancer lesions in bone. We further studied the targeted nanoparticles internalization profile 
into cancer cells as well as bone cells grown in a bone-like microenvironment. The project 
comprised of three major aims: i) We first designed non-targeted “smart” nanoparticles containing 
amphiphilic triblock copolymers, poly(ethylene)-b-poly(acrylic acid)-b-poly(methyl 
methacrylate), that have the ability to self-assemble in an aqueous medium to form nano-sized 
micelles that can encapsulate anti-cancer agents like CTX in their hydrophobic core. Cross-linkage 
of the PAA blocks using ketal-linkers resulted in an acid-labile shell that stabilized the drug-loaded 
micelles at physiologic pH, but allowed selective release of the loaded cargo in acidic 
environments. The in-vitro study of the non-targeted, CTX-loaded cross-linked nanoparticles 
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exhibited a significantly higher therapeutic effect than free CTX without any cytotoxicity issues. 
Moreover, the particles did not have any biocompatibility issues based on the studies conducted 
such as, red blood cell hemolysis, protein adsorption, and platelet activation tests. Further, this 
non-targeted “smart” nanoparticle exhibited a limited macrophage uptake < 10% compared to 
cancer cells > 90%. ii) We conjugated the non-targeted nanoparticles with either a specific peptide 
sequence called pVTK or a small molecule bisphosphonate (BP) to actively target mineralizing or 
hydrolyzing bone surfaces in prostate cancer lesions, respectively. We characterized the size of the 
bone targeted particles (60-90 nm) and confirmed their binding affinity towards bone 
hydroxyapatite (HA) powder. Further, we examined both bone targeted nanoparticles uptake 
profiles into prostate cancer cell lines (PC-3 and C4-2B) and bone cell lines (MC3T3, RAW 264.7 
bone macrophages, and RANKL activated RAW 264.7) on regular tissue culture plates as well as 
on bone-like surfaces (BLS). Results showed that increasing the number of BP-targeting 
copolymer in the particle formulation was able to augment the normalized particle fluorescence 
intensity in RAW 264.7 macrophages on regular culture plates. Additionally, the overall cellular 
uptake profile of bone-targeted nanoparticles trends was different in the presence of BLS compared 
to that of regular tissue culture plates. The results indicate that C4-2B and MC3T3 osteoblast cells 
were effectively targeted by pVTK bone-targeted nanoparticles. While, BP bone-targeted 
nanoparticles are capable of targeting PC-3 and RAW 264.7 macrophage cells. These results 
collectively indicate that pVTK- and BP-based bone targeting strategies can facilitate selective 
delivery of chemotherapeutic agents to metastatic prostate cancer in bone and the cross-talk 
between cancer cells and bone cells could be inhibited by using a specific targeting strategy (pVTK 
or BP), which opens doors to new personal bone metastasis therapies. 
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Introduction 
1.1 Objective 
 Prostate cancer is the second leading cause of cancer death in men in the US behind lung 
cancer. In the US, prostate cancer is diagnosed in approximately 1 of every 6 men, with 1 out of 
39 men dying because of this disease [1].  The American Cancer Society estimates approximately 
180,890 new cases of prostate cancer will be diagnosed in 2016 with 26,120 deaths occurring from 
the disease in the US [1]. Tremendous advances in the detection and treatment of prostate cancer 
especially, the widespread use of prostate-specific antigen (PSA) screening over the past four 
decades have led to a significant increase in the 5-year survival rate for local prostate cancer, which 
is almost 100% [1]. Although improving the treatment rate of prostate cancer localized to the 
prostate gland, almost four-fifth of patients whose prostate cancer have spread to a distant organ 
(metastasize) survive no more than five years [2].  
 The main treatment approaches for prostate cancer are radical prostatectomy (RP) which 
is an operation to remove the partial or whole prostate gland with surrounding tissues or radiation 
therapy. These treatment strategies are capable of increasing the survival rate of patients 
diagnosed with primary cancer. However, they are associated with significant complications and 
side effects such as incontinence and erectile dysfunction that greatly deteriorate the patient’s 
quality of life [3, 4]. A recent review showed that the specimen in 49% of men undergoing RP 
show insignificant or indolent cancer (i.e. organ-confined cancer lesion < 0.5 mL) [5]. In 
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comparison, 73% of patients initially enrolled in active surveillance who underwent RP reveal 
significant cancer on RP specimens [6]. 
Another treatment strategy of prostate cancer is hormonal therapy as the male sex hormone 
testosterone is known to stimulate the growth of prostate cancer cells. In this treatment option,  
testosterone is inhibited or the production level is decreased by some hormonal medications (i.e. 
Flutamide, Bicalutamide, Nilutamide, Leuprolide, Goserelin, Triptorelin, Histrelin, etc) in order 
to prevent testosterone binding to the cancer cells resulting in the shrinking and slowing down the 
cancer cells growth [7]. However, after a period of time the cancer cells develop resistance to this 
therapy by not responding to the treatment anymore. Moreover, the side effects include hot flashes, 
decreased sexual desire, loss of bone density with an increased risk of fracture (osteoporosis), 
erectile dysfunction, fatigue, increased risk of diabetes and heart attacks/strokes, weight gain, 
decreased muscle mass, anemia, and memory loss have been observed [7, 8]. 
In the case of hormonal therapy resistance, chemotherapy is another option with/out 
hormone therapy for patients whose metastatic prostate cancer have grown despite hormone 
therapy [9-11]. Paclitaxel and docetaxel have been used against prostate cancer for a long time and 
Cabazitaxel (CTX) was recently approved by FDA for patients with mCRPC who were 
previously treated with a docetaxel-containing regimen [12]. It is similar to its taxen ancestors. 
Nevertheless, disparate of the new drug has poor affinity for P-glycoprotein-mediated efflux 
pumps that leads to taxane resistance in tumors in the case of P-glycoprotein overexpression [13].  
The other issues on chemotherapeutics they are typically associated with adverse side effects 
including hypersensitivity reactions, peripheral edema, and pericardial effusions because of the 
Tween 80 used to solubilize the drug [14]. Further, non-specific distribution of taxanes throughout 
the body results in neural, cardiac, and musculoskeletal toxicities [15]. 
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The current therapeutic modalities radiotherapy, hormone therapy, and chemotherapy are 
not aimed to specifically treat the disease at the bone metastasis stage, but they may contribute to 
treat them. Moreover, in the presence of multiple bone metastatic nodules, these modalities are 
greatly limited to treat and lead to systemic side effects due to the lack of desired drug 
concentration in bone. In addition, in the case of the advanced stage of the metastasis, various 
complications may be noticeable such as osteolysis, spinal cord compression, hypercalcemia, 
increased fracture incidence, and permanent pain due to the fact that the bone metabolism and 
microenvironment are disrupted and induce imbalance between bone formation and bone 
resorption [16, 17]. Moreover, around two-third of pain patients suffering from bone metastases 
complain about break-through pain, which described as a simultaneous appearance of strong pain 
despite taking of strong pain killers, or analgesics [18]. 
Bisphosphonates (BPs) have been preferred due to its dual functionality namely, for the 
treatment of bone metastasis as well as for the reduction the occurrence of pain because of broken 
bone or excess bone hydrolysis. BPs have potent inhibitor functions on osteoclast-mediated bone 
resorption via binding to the bone mineral following their uptake by osteoclasts through fluid-
phase endocytosis from acidified bone surface during osteolytic resorption [19]. Inside the 
osteoclasts, it acts by inhibiting the prenylation of small GTPases that control cytoskeletal 
function, vesicular trafficking, and apoptosis [20, 21]. In addition to this osteoclast activity, they 
have been shown to have direct effects on non-resorbing cells in the presence of resorbing 
osteoclasts with transcytosis uptake mechanism [22]. Further having functions in bone 
environment BPs show that they are able to strongly reduce invasion and migration of PC-3 
prostate cancer cells [23]. Alendronate (ALE), a BP, also inhibits PC-3 cell adhesion to 
extracellular matrix proteins in vitro [24] and secretion of MMPs by tumor cells [25]. Other 
4 
 
bisphosphonates (clodronate, pamidronate, ibandronate and zoledronate) have been shown to 
induce apoptosis of breast cancer cells in vitro [26, 27], inhibit angiogenesis, [28, 29] and at high 
concentrations inhibit cell proliferation [30]. Although BPs have all these extraordinary features 
their therapeutic activity in bone metastasis is insufficient due to ineffective therapeutic 
concentration. 
To address the current treatment problems associated with primary and bone-metastasized 
prostate cancer, this dissertation has two main strategies: i) investigating nanodroplet-mediated 
histotripsy, a novel ultrasound-based focal ablation method, in a 3D prostate cancer spheroid 
model to overcome aforementioned issues of primary cancer treatments (Chapter 2), ii) 
engineering bone targeted “smart” polymeric micelles that are able to encapsulate a large dose of 
anti-cancer agents without any toxic effects and specifically carry the therapeutics to prostate 
metastasized bone lesion (Chapter 3 and 4). 
 
1.2 Ablation Techniques 
Currently available ablation modalities are radiofrequency ablation (RFA), microwave 
ablation (MWA), laser ablation (LA), and high-intense focused ultrasound (HIFU) that are thermal 
based and minimally invasive coupled with imaging modalities such as ultrasound imaging, 
computed tomography (CT), and magnetic resonance imaging (MRI) to monitor tumor location, 
shrinkage, and temperature changes [31, 32]. The underlying principle of each technique relies on 
heating up the diseased tissue resulting in the denaturation of proteins, followed by cell death. 
Basically, RFA is an electrosurgical technique that uses high-frequency alternating current (AC) 
and inserts the electrode to heat tumor for thermal coagulation. During treatment, temperature is 
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increased between 60-100 °C to induce protein coagulation with damage to cytosolic and 
mitochondrial enzymes and DNA-histone complexes leading to coagulative necrosis [33]. A main 
drawback of RFA is the difficulty in targeting a tumor whereby the blood flow through adjacent 
vessels cool the temperature down leading to incomplete ablation, which is called the “heat-sink” 
effect [34]. 
The second ablation technique is MWA, which uses higher frequency between 900 MHz 
and 2.5 GHz comparing to RFA and the inserted probes function as an antenna to create 
electromagnetic field inside the tumor to generate heat based on rapid oscillation of water 
molecules. This causes molecular friction and a rapid rise in thermal energy throughout the field 
leading to kill the tumor cells [35]. 
Laser thermal ablation is another technique to induce thermally mediated coagulation 
necrosis employed for tumor destruction. The aim is similar to RFA and MWA techniques but in 
here the intense and highly focused laser beam delivers a high energy dose to the diseased area. 
However, water and hemoglobin absorb the light beam which limits the penetration depth. 
Therefore, this issue is overcome with near-infrared (NIR) laser light that is ideal for in vivo 
hyperthermia applications. NIR light demonstrates maximal penetration of tissue comparing to 
other light sources, thereby reaching deep inside the tissue. However, even NIR laser source can 
penetrate only a maximum of ~1 cm so it is used only for superficial tumors not deep tissue tumors 
[36].  
Penetration problem is solved with ultrasound based ablation strategies that are able to 
target deeper tissue. One of the most widely used ultrasound ablation techniques is high-intensity 
focal ultrasound (HIFU) that focuses acoustic energy into a focal point that is aligned to the tumor 
tissue leading to heat generation, which induces protein coagulation and necrosis similar to RFA 
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and MWA [37-39]. While these minimally invasive techniques require an electrode or antenna to 
deliver electromagnetic waves, HIFU system is totally non-invasive. Therefore, it does not disturb 
the tumor lesion or overlay tissues with probe insertion. While all of these thermally-based ablation 
techniques have shown success, these techniques are limited due to the “heat-sink” effect [40]. 
Another limitation of thermal ablation techniques is non-homogenous temperature distribution 
through the tumor lesion lowers its efficacy results in not killing 100% of tumor cells, regrowth of 
residual tumor at the ablation margin, and inability to effectively treat large size tumors with a 
single treatment session so treatment takes a long time. Furthermore, the treatment is evaluated 
before and after with imaging systems such as CT or MRI due to lacking of real time imaging 
(except HIFU system) and MRI thermometry system is used to monitor simultaneously 
temperature changes during treatment and assure feedback in real-time with MRI/HIFU system 
[39, 41].  
Most of these limitations can be addressed by histotripsy, which is a new US-based 
treatment strategy with certain advantages over the existing ablative techniques. Histotripsy 
therapy uses high-intensity, focused ultrasound pulses in a short time period (< 10 µs), which is 
different than high intensity focused ultrasound (HIFU) thermal ablation, to produce non-thermal 
tissue fractionation [42, 43]. In histotripsy, the delivery of high-pressure, focused ultrasound pulses 
leads to generating a cluster of microbubbles (bubble cloud) from pre-existing gas pockets in the 
tissue where the rapid expansion and collapse of the microbubbles disrupts cells and other tissue 
structures [44-49]. Moreover, histotripsy is not affected by the heat-sink effect, a safe ablation 
ability even proximity to vessels [50], and more importantly the cavitation cloud and the resulting 
tissue damage can be monitored in real-time with ultrasound imaging system [51]. All these 
7 
 
advantages suggest that histotripsy has the potential to overcome many of the limitations facing 
invasive surgery and thermal ablation procedures.  
It is clear that tremendous efforts have been made in the last decades to improve the 
currently available ablation techniques. A major limitation of all techniques is that there is no 
selectivity and targetability mechanisms that are able to discriminate tumors from surrounding 
healthy tissues to minimize the many side effects and increase the ablation efficiency. In specific 
to histotripsy, for example, the treatment currently relies upon MRI or ultrasound imaging to 
successfully target the tumor volume, which can often be difficult for small or multi-focal tumor 
nodules. Developing a strategy to target histotripsy to specific cells of interest (i.e. tumor cells) 
will undoubtedly improve the success of histotripsy ablation and extend this ablation approach to 
a much broader patient population. To improve the effectiveness of histotripsy, our team has 
developed ultrasound active perfluorocarbon encapsulated nano-sized polymeric particles that 
have promising results addressing the current ablation techniques problem. In the next section, 
ultrasound active particle design is mentioned with a historical perspective and the following 
section will give more details on ultrasound active nanodroplet-based histotripsy from synthesis 
to US characterization. 
1.2.1 Ultrasound Active Particles 
 Ultrasound (US) is one of the most frequently used diagnostic imaging methods. It is a 
non-invasive, high penetration signal, and comparatively inexpensive imaging method besides that 
owning safety, portability, and real-time images [52]. To improve image contrast, ultrasound 
contrast agents (UCA) are used to enhance the backscattered signal. The main point behind UCA 
is an impedance mismatch between the contrast agent and the adjacent tissue to enhance the 
received signal strength [53]. There is a great interest to capsulate gas, perfluorocarbons, or air 
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within protein, lipid, or polymer shell to form microbubbles (1-10 µm) to increase the acoustic 
impedance mismatch [54]. The history of ultrasound active materials started at the end of the 
1960s, it was observed that agitated saline injection increased detectable US signal during the 
examination due to the fact that enrichment of gas pockets in the solution as a result of agitation 
process enabled to backscatter to the applied US signal [55]. However, the produced bubbles were 
unstable because of high surface tension. More than 20 years later of this observation, the first 
commercially available, FDA approved air-filled microbubbles with an albumin shell -Albunex®- 
was developed [56]. Other UCAs filled with air that had been clinically approved in Europe and 
Japan are Echovist® and Levovist® shelled by galactose. However, all these air filled microbubbles 
were withdrawn from the market because of stability issues and very short circulation time related 
to the high solubility of air in water [57, 58]. This issue is overcome by replacing the air with 
nonsoluble gasses, PFCs, with their low solubility in the aqua system and good biocompatibility 
features. PFCs entrapped in phospholipid or cross-linked serum albumin microparticles (Optison®, 
Sonazoid®, SonoVue®, Luminity®) have been on the market that are frequently used in cardiology 
and liver/kidney imaging [59, 60]. Other than these microbubbles, there have been many polymer 
based microbubbles that are currently in clinical trials but not FDA approved. For example, 
poly(D,L-lactide-co-glycolide) (PLGA) is the most common biocompatible, degradable polymer 
is preferred to form MB to adjust US scattering for the imaging of cardiovascular diseases [61] 
and as well as identification of lymph nodes near tumor lesion [62].  
Besides the application of MBs in imaging, they have also been employed to enhance 
drug/gene delivery, especially tumor inhibition with the support of US to increase the permeability 
of the vascular/cell membrane using US sonoporation or cavitation effect [63]. Although MBs 
offer promising effect for both enhancing the imaging capabilities of US and being used for therapy 
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with combination of drug/gene delivery, they have significant limitations that restrict the further 
employment of US systems for the treatment of solid tumors. For instance, MBs are unable to pass 
through the vasculature and accumulate inside the solid tumor bed since the MBs are too large to 
take advantage of the tumor’s leaky vasculature that forms less than 600-800 nm cutoff size gaps 
between the endothelial cells, and poor lymphatic drainage, which is called enhanced permeability 
and retention (EPR) effect [64]. Another restriction of MB applications is that they are not stable 
in blood circulation, macrophages can easily detect and phagocytize the microbubbles because of 
their micron sizes, and lacking of biocompatible shield. Therefore, the microbubbles are rapidly 
cleared from the circulation, which leads to high volume injection or continuous dosing during 
imaging or treatment to reach effective US signal [65]. Because of these limitations of MBs, many 
research groups have recently designed nanodroplets and nanoemulsions that can extravasate into 
a tumor’s interstitial space for targeted imaging [66-69], drug delivery [70], and  ablation [71, 72]. 
However, these previous studies were focused only thermal ultrasound ablation with HIFU not 
histotripsy. Therefore this technique enhances the concerns related to HIFU tissue ablation with 
requiring long treatment duration and superficial skin burns and does not allow for cell selective 
ablation due to thermal spread [73]. 
1.2.2 ND Mediated Histotripsy 
One of the primary obstacles facing all ablation techniques is achieving tissue targetebility 
and cellular level selectivity that can discriminate tumor cells from the healthy cells. Although 
histotripsy has shown a significant improvement in precision and targeting capabilities compared 
to thermal ablation methods, histotripsy still requires the visualization of a tumor prior to treatment 
using non-invasive imaging modalities in order to apply the treatment to a tumor. In addition, 
histotripsy requires very high pressures (> 25 MPa) to ablate the tissue. To address these concerns, 
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our group has developed an approach that combines acoustically sensitive nanoparticles with 
histotripsy, termed nanodroplet-mediated histotripsy (NMH). In order to lower the pressure 
required for histotripsy and use the advantage of tumor microenvironment where systemically 
administered nanoparticles (< 600 nm) can passively accumulate because of the dense network of 
vessels with defective vascular architecture and lack of a smooth muscle layer resulting in large 
fenestrations [64], our research team has engineered fluorinated amphiphilic triblock copolymers 
that self-assemble in aqueous medium to form nano-sized droplets (< 300 nm) encapsulating liquid 
perfluorocarbons in the core [46]. These NDs can be functionalized with targeting agents such as 
peptides, antibodies, or small molecules in order to enhance the NDs accumulation near/inside the 
tumor cells and can kill the tumor selectively while protecting the surrounding healthy tissues 
under reduced histotripsy pressure.  
Since perfluorocarbons are not miscible with most of the organic solvents and aqua based 
solutions [74], they have been preferred to be encapsulated inside emulsion with its lipid portion 
or they need some contents such as amphiphilic feature having hydrophobic blocks or fluorinated 
components to increase their solubility [75-78]. For this reason, we preferred the fluorinated 
monomer, HDFMA, to be able to increase perfluorocarbons solubility in the system. However, 
fluorinated polymer PHDFMA faces similar solubility problem of perfluorocarbons because of the 
high number of fluorine contents. Therefore, we added co-monomer MMA and co-polymerized 
with HDFMA to solubilize HDFMA containing polymer in organic solvents. The middle block 
plays an important role in the triblock copolymer design. Since this block reacts with two side 
blocks, it should have two functional end groups and form a thin shell layer in the middle of the 
formulated nanodroplets allowing phase transition. Therefore, it should contain another 
functionality to be further reacted to the cross-linker. With these design aspects, we set the ATRP 
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reaction with anthracene functional, Br-end group initiator with t-BA monomer to synthesize PtBA 
with a molecular weight around 1500 Da. PtBA, is used as a precursor of cross-linkable block that 
further can easily be hydrolyzed into acid groups to be able to be functionalized for shell cross-
linked after self-assembly of block copolymer into nanodroplets. The third block of the block 
copolymer is PEG, which gains this triblock copolymer structure not only hydrophilic character to 
increase the copolymer’s solubility in aqua environment but also hemocompatibility, which means 
no protein adsorption on the particles, no macrophage recognition and minimum interaction with 
blood cells during blood circulation so that PEG can enhance the particle circulation time. To 
couple the PEG block to the middle block Anth-PtBA-N3, we introduced the alkyne functionality 
on the PEG block. To do that, commercially available monohydroxyl end functional PEG (2 kDa) 
was reacted with 4-pentynoic acid. After well-characterized individual blocks were synthesized, 
they were coupled to each other via one-pot “click” reactions between alkyne functional PEG and 
azide functional PtBA and retro DA reaction between furan protected maleimide functional 
P(HDFMA-co-MMA) and anthracene functional PtBA was occurred. The successful coupling was 
initially confirmed by 1H NMR spectroscopy. Last but not least in copolymer synthesis, PEG-b-
PtBA-b-P(HDFMA-co-MMA) copolymers were hydrolyzed using TFA in order to achieve COOH 
functionality that can react with a diamine functional crosslinker to form a cross-linked shell after 
self-assembly of block copolymer into nanodroplets. We demonstrated that perfluoropentane 
(PFP)-loaded nanodroplets allowed for a 2.5-fold decrease in the acoustic pressure required for 
histotripsy ablation. Further, PFP-loaded nanodroplets did not show particle size and concentration 
changes upon incubation with bovine serum albumin (BSA) for 24 h at 37 °C [46]. In another 
study, we demonstrated the feasibility of using the PFP-loaded nanodroplet-mediated histotripsy 
approach for targeted ablation in agarose tissue phantoms containing a layer of embedded red 
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blood cells [79]. Moreover, we investigated the effect of ultrasound frequency (345 kHz-3 MHz) 
on nanodroplet-mediated histotripsy (NMH), with results showing that lower frequency improved 
the effectiveness of NMH by increasing the size of the focal region, increasing bubble expansion, 
and decreasing the cavitation threshold [80] (The details of this study can be found in Appendix 
1). Finally, a separate study was conducted by our team to compare two different perfluorocarbon 
types, perfluoropentane (PFP, boiling point~29°C, surface tension~9.5 mN/m) and 
perfluorohexane PFH, boiling point ~56°C, surface tension~1.2 mN/m), on the nanodroplet 
formulations. Both PFP-loaded and PFH-loaded nanodroplets significantly reduced NMH 
cavitation threshold compared to the histotripsy threshold. However, the investigation of 
sustainable cavitation nuclei over multiple pulses pointed out PFH-loaded nanodroplets cavitation 
activity were able to survive over 1000 pulses, whereas PFP-loaded nanodroplets were destroyed 
by the cavitation process in less than 50 pulses, likely due to the lower boiling point [81, 82]. 
Appendix 2 discusses the ND composition effect on histotripsy with details. Lastly, to understand 
the physical mechanisms underlying the nanodroplet cavitation process, Appendix 3 elucidates 
the role of positive and negative pressure on cavitation nucleation in NMH [83].  Last but not least, 
Chapter 2 investigates the efficiency of these well characterized in both material and US sides 
NDs in 3D prostate cancer spheroid ablation. 
 
1.3 Bone Metastasis 
The reason of prostate cancer mortality is not from the primary cancer burden but 
metastasis spread of the primary cancer cells to distant organs, especially bone. Bone is the most 
frequent site of prostate cancer metastasis identified at autopsy in up to 90% of patients dying from 
prostate cancer bone metastasis [84, 85]. Although improving the treatment outcomes of prostate 
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cancer localized to the prostate gland, two-thirds of patients whose prostate cancer have spread to 
distant organ live no more than five years [2]. The main reason of high death rate of bone 
metastasis is a lack of effective targeting therapy options to minimize the cancer progression in 
bone. It is clear that urgently designing of an effective therapeutic system for the treatment of bone 
metastasis that requires understanding the molecular interactions between tumor cells and bone 
microenvironment. To target these interactions might open new treatment strategies of bone 
metastasis. 
1.3.1 Mechanism of Metastases 
 
Metastasis is an extremely complex process whereby cancer cells circulate throughout the 
body, establishing new colonies in distal organs different than the tumor originated organ (primary 
organ). To colonize a secondary site, like bone, a cancer cell must successfully complete a cascade 
of linked sequential steps: 1) detach from the primary tumor site; 2) intravasate into the newly 
formed vasculature, and gain access to the circulation, lymphatics or peritoneal space and survive 
in these environments against immune response and physical forces; 3) adhere to distant target 
 
Figure 1.1 The cycle of metastasis from the primary tumor to a bone. 
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organ; 4) proliferate in the metastatic site of bone, which requires blood supply to the tumor for 
further expansion [86, 87]. The cancer cells can survive as entering the wide channeled sinusoids 
of the bone-marrow cavity and are placed to develop bone metastases as seen in Figure 1.1. The 
metastasized tumor cells supposed to have certain properties like mesenchymal-epithelial 
transition (MET) to proliferate and spread out in bone and make the microenvironment a favored 
place for tumor cells, It is necessity that tumor cells have the ability to migrate across the sinusoidal 
wall, assault the marrow stroma, produce their own blood supply and travel to the endosteal bone 
surface [88]. At this location, they stimulate the activity of osteoclasts or osteoblasts, thereby 
determining whether the subsequent bone metastasis is osteolytic or osteoblastic, which will be 
discussed with details under the title of “Bone Remodeling in Cancer Lesion”. Each of these events 
involves significant molecular interactions between the tumor cells and the bone 
microenvironment cells resulting in disruption of normal bone processes [86, 88].  
1.3.2 Bone Biology and Bone Remodeling 
Bone is a rigid and dense connective tissue that consists of water, inorganic matter, and 
organic material. 
Hydroxyapatite (HA) 
(Ca10(PO4)6(OH)2) is 
the main inorganic 
matter which stores 
99% of the body 
calcium. Organic 
matrix is comprised of 
 
Figure 1.2 Bone microenvironment and regular bone remodeling cycle.  
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75% collagen and non-collagenous proteins. Deposition of inorganic mineral in the empty spaces 
of the collagen frame is responsible for strength, rigidness, and density of bone tissue [89]. 
Bone microenvironment houses a variety biological compartments such as marrow, nerves, 
blood vessels, endosteum, periosteum, cartilage, and cells. Further, several types of cells, such as 
mesenchymal stem cells, hematopoietic stem cells, preosteoblasts, and mature cells of the osseous 
tissue are in there with active duties not only related to bone functions but also immune cells and 
blood cells formations [90, 91]. Osteoblasts, osteoclasts, and osteocytes are three main types of 
mature osseous cells that remodel the dynamic nature of bone as depicted in Figure 1.2. The 
osteoblast is a mononucleate cell which has a key role on bone forming by depositing a protein 
matrix.  On the other site, osteoclast that is a multinucleate bone resorbing cell is responsible for 
bone degradation and function by secreting acidic hydrogen ions and a variety of proteolytic 
enzymes. Osteoblasts migrate to the surface of bone where they can become entrapped through the 
deposition of bone matrix around them. In the formed lacunae, osteoblast can transform osteocytes. 
Osteoblasts and osteoclasts are vital cells in the bone remodeling cycle since they have a direct 
function in bone health by balancing bone formation and bone resorption through the bone 
remodeling cycle [89]. Bone remodeling can be altered by various parameters. Various factors, 
such as PTH, calcitonin, vitamin D, growth hormones, steroids, and cytokines, are also actively 
involved in bone remodeling. The imbalance between bone formation and bone resorption results 
in undesired effect such as bone loss, enlarged, or weak bones, and fractures [92, 93]. Disease 
states such as osteoporosis and tumor metastases affect remodeling. [89, 94]. 
1.3.3 Bone Remodeling in Cancer Lesion 
Bone turnover is a regular process of the removal of old bone called bone resorption and 
forming of by new bone. Due to this regular bone resorption and formation make bone 
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microenvironment rich in metabolite ingredients providing a favorable place to progress and 
proliferate of the tumor cells. Thus prostate cancer cells frequently metastasize to the skeletal 
system. Because of bone microenvironment with its rich metabolite ingredients that provides a 
favorable place to progress and proliferate of the tumor cells. It is well-known that prostate cancer 
preferentially localizes to bone with highly active bone turnover because of aforementioned 
reasons [86, 95-97]. Although prostate cancer is radiographically characterized as osteoblastic, 
recent molecular studies have shown that many bone metastases contain either osteoblastic, 
osteolytic, or both characters [98]. 
For instance, prostate cells secrete a variety of factors such as endothelin-1 (ET-1) [99], 
bone morphogenetic proteins (BMP) [100], insulin-like growth factor (IGF) [101], platelet-derived  
 
 
Figure 1.3 Bone vicious cycle. 
The interaction between tumor cells and bone micro enviorement. 
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growth factor (PDGF) [102], parathyroid hormone-related protein (PTHrP) [103], transforming 
growth factor-β (TGF-β) [104] that direct or indirectly promotes bone mineralization. For instance, 
ET-1 is a significant mediator of osteoblastic bone metastases and is found in a high level in the 
plasma of advanced prostate cancer patients [105]. Moreover, it is secreted by prostate cancer cells 
and activates tumor cell proliferation. Bone microenvironment with IL-1β, TNF-α, and TGF-β also 
supports the expression of ET-1[106]. Bone morphogenetic proteins (BMPs) are a member of the 
TGF-β family. They have functions not only on new bone formation but also some roles on 
apoptosis, differentiation, proliferation, and morphogenesis [98]. Proteins such as TGF-β activated 
by PSA from prostate cancer cells and MMPs secreted by osteoblasts also contribute to augment 
of IGF-I leading to cancer cell growth in bone. In addition to these osteoblastic factors, metastases 
prostate cancer cells produce several other factors that enhance osteoclast activity. Prostate cancer 
cells have been shown to secrete the receptor activator of nuclear factor κ B ligand (RANKL), 
which causes differentiation of osteoclast precursor cells into active osteoclasts [107]. PTHrP, IL-
11, and IL-6 factors trigger osteoblasts to express RANKL and decrease the level of OPG, which 
is a soluble decoy receptor that inhibits osteoclast differentiation through its binding to RANKL 
[108]. Other than RANKL/RANK/OPG bone resorption factors are IL-8, TNF-α, and vascular 
endothelial growth factor (VEGF) induce osteoclastogenesis [109-111]. As a result of these factors 
related to bone resorption, the growth factors, such as TGF-β and IGFs and Ca2+ are released from 
bone matrix that promotes more tumor cell growth and this tumor cells and bone cells interaction 
cycle is called ‘vicious cycle’ [112] as described in Figure 1.3. 
1.3.4 Limitations Current Bone Metastases Therapy 
The current prostate cancer therapeutic modalities -hormone therapy and chemotherapy- 
are not aimed to specifically treat the tumor in the bone lesion so these therapies have limitations 
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such as lacking of desired drug concentration in bone. In addition, in the case of advanced stage 
of the metastasis various complications may be noticeable such as osteolysis, spinal cord 
compression, hypercalcemia, increased fracture incidence and permanent pain due to the fact that 
the bone metabolism and microenvironment are disrupted and induce imbalance between bone 
formation (osteoblast activity) and bone resorption (osteoclast activity) [16, 113]. Moreover, 
around two-thirds of patients have suffered from bone metastases complain about break-through 
pain, which described as a simultaneous appearance of strong pain, which is one of the skeletal-
related events (SRE), despite of taking of strong pain killers, or analgesics [114].  
Bisphosphonates (BPs), which FDA approved in treating multiple myeloma, breast cancer 
metastasis and prostate cancer metastasis to bone, are addressed some of above limitations [115] 
as an adjuvant therapy to prevent SRE for managing of metastatic bone pain, and lowering the risk 
of broken bones. Further, BPs are co-administered with doxorubicin, docetaxel and paclitaxel to 
enhance anticancer therapeutic activity [116-119]. 
 
Figure 1.4 Basic structures of pyrophosphate and bisphosphonates. 
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Development of BPs in chronological perspective gives a brief information about BPs 
actions, target, and limitations. In the late of 1960s Fleisch et al. reported the first biological 
function of pyrophosphate on inhibition of the formation and dissolution of calcium phosphate 
crystals which has a key regulator of bone resorption and formation [120]. However, the major 
issue of pyrophosphate is the rapid hydrolysis in the circulation before reaching to bone. This 
unstable form of the formulation where the oxygen bind to two phosphates (P-O-P) is replaced by 
a carbon (P-C-P) called bisphosphonates which are a more chemically stable member of 
pyrophosphate analogues (Figure 1.4). This elemental substitution overcomes a main issue of 
hydrolysis of the bonds, and enhances the stability of the structure with a capable of being 
delivered to bone [121]. 
BPs have a high affinity for hydroxyapatite constituting the major bone inorganic structure 
due to the fact that the oxygen atoms bound to phosphate chelate the Ca2+ ions in bone [122]. The 
major target cell population of BPs is osteoclasts as explained in bone biology and bone 
remodeling section because osteoclasts release the factors that make the environment rich in 
acidity and proteases results in degrading bone surface in which BPs bound [123, 124]. The 
released BPs from the bone surface is internalized by osteoclasts via fluid-phase endocytosis [125] 
exhibiting inhibition effect through either mitochondrial adenine nucleotide translocase (ANT) 
pathway with not containing nitrogen atoms in the BPs structure [126] or mevalonate pathway 
with containing a nitrogen atom [127]. The BPs that have a direct function in the second pathway 
are (10-100)-folds more potent than the BPs formulation acted in the ANT pathway. Basically, 
mevalonate pathway requires for prenylation of small GTPases like Rac, Ras, or Rab, which has a 
direct role in cholesterol synthesis, cytoskeletal organization, bone resorption, and cell 
morphology [128]. Inhibition of prenylation reduces the osteoclast activity and triggers apoptosis 
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[129]. In addition to BPs’s antiresorptive role, BPs have direct functions such as antitumor [130], 
antiangiogenic [131], and antimigratory [132] effects.  
Neither cancer chemotherapy nor BP based cancer therapies demonstrate desired level 
therapeutic activity like slowing down tumor progression or increasing the lifespan of bone 
metastasized patients [133]. Recently, nanomedicine/macromolecular based approaches have 
attracted tremendous attention as a drug delivery vehicle. These nanoparticles can accumulate in 
tumor tissue because of the EPR effect that described under the title of ND mediated Histotripsy 
(NMH), which is called passive targeting, as well. By these nanomedicine approaches, the active 
drug concentration can be enhanced in tumor microenvironment while minimizing the systemic 
side effect of the drug. However, the drug dose at bone tumor microenvironment is usually low by 
the passive targeting, resulting in the poor efficacy for tumor inhibition. To further improve the 
specific targeting and delivery efficiency to bone metastasis, active targeting ability of the 
nanomedicine approach is essential. Furthermore, the excess of irregular bone formation or bone 
degradation due to the disease effects on bone face to exposure of HA to blood carries, which 
provide active targeting opportunities to bone metastasized tumor lesion in bone. BPs, acidic or 
phosphorylated peptides, and noncollagenous proteins have been preferred to target bone 
metastasis to carry higher chemotherapeutics or imaging markers to distinguished the disease level 
[134, 135]. 
1.3.5 Peptide vs. Bisphosphonate Targeting 
Small peptides are one of the common motives for bone targeting drug delivery, which is 
inspired by bone tissue engineering concepts aiming to grow bone cells by manipulating the bone 
crystal structures. Basically, biological form crystals have been wide-range studied and shown that 
a subset of the matrix macromolecules are closely integrated with the mineral phase that regulates 
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crystal growth and also provide an anchoring point for cells and proteins connect to matrix proteins 
to the bone crystals [136, 137]. These macromolecules are basically in acidic character, which are 
noncollagenous proteins (phosphophoryn, bone Gla protein, osteonectin and bone small 
proteoglycan 11) that are found in bone exhibit binding affinity on hydroxyapatite with as low as 
10-7 M of dissociation constant due to the repeating (being rich in) amino acids such as glutamic 
or aspartic acid. These amino acids display a negative charge because of carboxylate groups on 
the amino acid structures so they are able to chelate calcium ions on the surface of HA. Also, 
peptide sequences of repetitive glutamic acid and ascorbic acid units interacted exclusively with 
HA in vitro and in vivo [136-138]. Other than these acidic character amino acid units, 
phosphorylated amino acids also exhibit a specific adsorption on HA structures with a positive 
correlation of phosphorylated numbers [139]. For instance, Kohn’s group has identified HA-
specific peptide sequence through the use of phage display that containing more than 109 
bacteriophage expressing sequences against interested HA material [140]. After selection of 
interested peptide sequences, these peptides were further characterized with computational 
modeling, and ELISA and shown that the apatite-specific 12-mer peptide VTKHLNQISQSY 
(VTK) [140, 141]. After the identification of the 12-mer peptide, VTK, it was phosphorylated 
through the serine residue on VTK (pVTK) and characterized in terms of biomimetic apatite. It 
was demonstrated that pVTK had a 10-fold increase in adsorption to the apatite surface comparing 
to VTK peptide. Furthermore, pVTK are able to inhibit the mineralization in pre-osteoblastic cells 
with a dose-dependent response [142].  
Another strategy for bone targeting is BPs decorated nanoparticles or polymers due to the 
fact that BPs have a strongly binding affinity to bone HA mentioned in previous sections in detail. 
The use of BPs on nanomedicine tools has several significant advantages. For example, ALE, 
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which is a member of BPs, is decorated on the particles because of its primary NH2 groups that 
allow its conjugation easily to the COOH unit of any nanomedicine tools. Further, BPs coupled 
particle are able to show synergistic effects with the carried therapeutics through the particles in 
addition to BPs that can be coupled to the particle surface with degradable linkages (pH sensitive 
or enzyme sensitive) so in the active environment where the linkage is broken and free BPs can be 
released for extra therapeutic activity [143].  
In the literature some studies compared the binding kinetics of peptides and BPs to HA. 
For instance, 8 repeating units of Asp or Glu peptide demonstrated faster binding to HA compared 
with PAM, or ALE in first 1 h in vitro but then a similar high binding profile for within 24 h [144, 
145]. In the HA binding comparison of PEG-D-(Asp)8 with PEG-ALE is 80% and 66% for 1 h 
incubation, respectively [145]. Nonetheless, ALE functionalized gold NPs showed faster and 6 or 
16-fold higher binding in HA compared with Glu, or phosphonic acid, respectively [146]. Wang 
et al. compared the in vivo bone binding location of acidic peptide and ALE. They showed that 
peptide could bind to resorption side while ALE-particles bound to both bone formation and 
resorption sites [145]. 
1.3.6 Bone Targeted Drug Delivery Strategies with Macromolecules or Nanoparticles 
A few bone targeted drug delivery studies were conducted on different bone metastasis and 
bone diseases such as breast, prostate cancer bone metastasis and osteosarcoma bone cancer with 
different therapeutics and nanomedicine tools [143, 147]. For example, one of the greatest example 
of peptide ((AspSerSer)6) based delivery systems is shown by Zhan et al. who used dioleoyl 
trimethylammonium propane (DOTAP)-based cationic liposomes to carry osteogenic siRNA 
targeting casein kinase-2 interacting protein-1. With this bone targeted gene delivery system, they 
exhibited that this approach significantly promoted bone formation, enhanced the bone micro-
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architecture and increased the bone mass in both healthy and osteoporotic rats [148]. In another 
study, Thamake et al. designed ALE coated PLGA nanoparticles that co-encapsulated curcumin 
and bortezomib to further enhance the therapeutic efficiency and overall clinical outcome of the 
treatment of bone metastatic breast cancer. Even though these drugs are known as synergistic effect 
once used in combination, the researcher did not see any synergism in the anti-osteoclastogenic 
activity of these agents. In vivo imaging modalities exhibited that higher ALE-particles 
accumulated in tumor metastasized bone comparing to controls. Further, ALE-coated PLGA 
nanoparticles protected bone resorption and decreased the rate of tumor growth in an intraosseous 
model of bone metastasis [149]. Another research carried out by Miller et al. by conjugating 
paclitaxel (PTX) and ALE with PEG to increase water solubility of PTX and target to bone for the 
treatment of bone metastatic breast cancer. They showed that combined therapeutic effect with 
PTX (anti-cancer agent) and ALE (anti-angiogenic, and anti-cancer agent in high dose) as 
improving PTX’s pharmacokinetics, biodistribution, and enhancing its efficacy while reducing its 
side-effects [150]. The same group also worked on dendritic PEG bearing ALE and PTX to 
increase number of targeting unit on the micellar particles and tested on PC-3 prostate cancer in 
vitro model showing a high cytotoxicity, comparable to that of free PTX and ALE combination. 
Further, they showed that prolonged half-life of the drugs with this conjugation strategy in mice 
[151]. Segar et al. also tested ALE and TNP-470, which is a potent anti-angiogenic agent, 
conjugated with N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer through a Glycine-
Glycine-Proline-Norleucine linker that can be cleavable by cathepsin K enzyme, which is cysteine 
protease over expressed at the bone resorption site. By using TNP-470 conjugated macromolecular 
delivery system, they reduced the too many side effects of free drug formulation in clinic such as 
neurological dysfunction, and low WBC counts, which prevented clinical applications. They 
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demonstrated that ALE and TNP-470 conjugated HPMA reduced VEGF-induced vascular 
hyperpermeability by 92% and remarkably inhibited osteosarcoma growth in mice by 96% with 
co-delivery of two synergistic drugs [152]. Uludag group developed thiol-BPs coupled to micellar 
and liposomal particles to create mineral binding nanocarriers. They tested 3 different drugs, 
carboxyfluorescein (CF), DOX, and lysozyme (LYZ) in the particle formulations. The drug 
entrapped in BP-liposome showed a slower release profile from treated collagen/HA scaffold 
model. Therefore, they concluded that this prolong release profile of collagen/HA composite 
scaffold and BP-liposomes are promising for bone tissue engineering and regenerative medicine 
applications [153, 154]. The most common bone targeting moiety is ALE because of its primary 
NH2 functional group leading its conjugation to the polymers or nanoparticles easily. Chaudhari 
et al. first time showed that zoledronate (ZOL) conjugated PEG-polybutyl cyanoacrylate (PBCA) 
NPs used on BO2 and MCF-7 breast cancer cell lines. Basically they designed ZOL-conjugated 
DOX-loaded PEGylated PBCA NPs for bone metastasis treatment. They found that enhanced 
cytotoxic effect in both BO2 and MCF-7 cell lines due to higher uptake following ZOL-mediated 
endocytosis as compared to free drug conditions. Further, the in vivo study demonstrated that 
DOX-loaded ZOL-conjugated PEG-PBCA NPs were highly localized to the tumor infected bone. 
Based on the cell cycle and apoptosis analyses this treatment strategy showed synergetic effect in 
tumor cells [155]. 
 All in all, Chapter 3 of this thesis describes the engineering of high-dose anticancer agent 
(CTX) loaded “smart” micellar nanoparticles to control drug release profile and delivery of the 
agent efficiently to the diseased tissue with minimal toxic effect to healthy tissues. After the 
selection of optimum anticancer agent carrier particle formulation, Chapter 4 investigates the 
bone targeting capability of BP or pVTK-labeled of the characterized particle formulation in 
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Chapter 3 and their bone and cancer cells uptake differences in bone like microenvironment. 
Finally, Chapter 5 discusses the conclusion of this research work and proposes future work to 
advance the developed bone-targeted drug carrier systems to preclinical studies. 
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Non-invasive Ablation of Prostate Cancer Spheroids Using Acoustically-
Activated Nano-Droplets 
The material in this chapter is submitted to the following journal: O. Aydin, E. Vlaisavljevich, 
Y. Y. Durmaz, Z. Xu, and M. ElSayed “Mechanical Ablation of Prostate Cancer Spheroids 
Using Acoustically-Activated Nano-Droplets”, Molecular Pharmaceutics. 
2.1 Introduction 
The widespread use of prostate-specific antigen (PSA) screening and the increase in life 
expectancy have increased the number of men diagnosed with prostate cancer [156]. These patients 
are routinely managed with definitive therapy including radical prostatectomy (RP) or radiation 
therapy (RT), which are associated with significant complications and side effects such as 
incontinence and erectile dysfunction that greatly deteriorate patient’s quality of life [3, 4]. 
Analysis of RP specimen reveals that 49% of men undergoing RP show insignificant or indolent 
cancer (i.e. organ-confined cancer lesion < 0.5 mL) [5] compared to 73% of the patients initially 
enrolled in active surveillance who undergo RP and reveal a significant cancer on RP specimens 
[6]. Analysis of RP specimens showed that 38% were unifocal [157] and 80% of the total tumor 
volume in multifocal disease arose from the index tumor with extracapsular extension present in 
only 28% of these patients [158]. These results clearly indicate that a large population of prostate 
cancer patients have a biologically unifocal disease, which suggests the potential for using focal 
therapy (i.e. targeted ablation of the cancer lesions) as an alternative treatment strategy to RP [159]. 
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Success of focal therapy depends on the ability to detect and image tumor tissue, target the cancer 
lesions, monitor the therapeutic response, and assess the results [159]. 
Histotripsy is a noninvasive tissue ablation technique that controllably fractionates soft 
tissue using a dense cavitation bubble cloud generated by short duration ultrasound pulses under 
high acoustic pressure (~25-30 MPa) [43, 49, 160]. Earlier research shows that histotripsy 
treatments initiate and maintain a dense cavitation bubble cloud over multiple pulses (often >100) 
until the treated tissue is completely fractionated into a liquid homogenate with complete loss of 
the cellular structure [43, 49, 161]. The process by which histotripsy achieves tissue fractionation 
has been shown to be the rapid expansion and collapse of cavitation bubbles, which fractionates 
soft tissues into an acellular homogenate by inducing very large strains to the adjacent tissue 
structures [162]. Currently, non-invasive tissue removal using histotripsy is being clinically 
evaluated in benign prostatic hyperplasia [163], deep vein thrombosis [164], congenital heart 
disease [165, 166], and cancer [45, 167]. Despite the promise of histotripsy as an ablation therapy, 
the limitation of histotripsy is that 1) it is not targeted, and 2) it requires very high pressure. In 
some applications, very high pressure cannot be achieved due to the limited acoustic window or 
deep located target. Therefore, nanodroplet-mediated histotripsy (NMH) can be used to overcome 
the limitations by lowering the threshold. 
To address the limitations of histotripsy, our group has developed acoustically-activated 
nanodroplets to achieve selective mechanical fractionation of diseased tissue at low acoustic 
pressure. Specifically, we designed and synthesized an amphiphilic triblock copolymer composed 
of a hydrophilic poly(ethylene glycol) (PEG) block, a central poly(acrylic acid) (PAA) block, and 
a  hydrophobic poly(heptadecafluorodecyl methacrylate-co-methyl methacrylate) (P(HDFMA-co-
MMA)) block, which proved to self-assemble and encapsulate 2% v/v perfluorocarbon (PFC) 
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forming acoustically-activated nanodroplets [168]. We used a chemical cross-linker to covalently 
“stitch” the central PAA blocks forming a flexible polymer shell that displays a brush of 
biocompatible PEG chains, which can be further functionalized to display different ligands (e.g. 
sugars, peptides, antibodies, or aptamers) to allow selective targeting to specific disease sites. Our 
earlier results show that  the nanodroplets rapidly expand forming microbubbles (>500µm) before 
energetically collapsing at an acoustic pressure that is 2.5-fold lower than the acoustic pressure 
needed to generate the same bubble cloud using the histotripsy pulse alone [168]. Results also 
confirm the feasibility of imaging nanodroplets expansion into microbubbles and their subsequent 
cavitation using therapeutic ultrasound, which is the basis for their potential use in ultrasound-
guided ablation therapy [45, 80, 83]. We investigated the effect of changing the PFC core from 
perfluoropentane (PFP, boiling point ~29 ºC, surface tension ~9.5 mN/m) to perfluorohexane 
(PFH, boiling point ~56 ºC, surface tension ~11.9 mN/m) on the acoustic and ablative properties 
of PFP-loaded and PFH-loaded nanodroplets [169]. Both PFP-loaded and PFH-loaded 
nanodroplets exhibited a significantly reduced cavitation threshold compared to the cavitation 
threshold of histotripsy alone. However, the PFH-loaded nanodroplets maintained the bubble cloud 
over 1000 pulses compared to PFP-loaded nanodroplets, which were destroyed by the cavitation 
process in less than 50 pulses likely due to the lower boiling point of the PFP core [80, 169]. 
Further, the PFH-loaded nanodroplets generated well-defined ablation lesions in the RBCs layers 
sandwiched in tissue-mimicking gel phantoms indicating a stronger ablative capacity compared to 
PFP-loaded nanodroplets [168]. 
In this study, we expand on our previous research studying NMH and investigate the 
feasibility of achieving ablation of PC-3 and C4-2B prostate cancer cells in vitro using PFP- and 
PFH-loaded nanodroplets at acoustic pressures significantly below the regular histotripsy. When 
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using a single ultrasound pulse of <2 cycles in duration, cavitation can be reliably generated with 
the peak negative pressure directly exceeds the intrinsic threshold of the medium without any 
externally injected agents. The histotripsy intrinsic threshold is ~26-30 MPa for water-based soft 
tissues such as tumors. Within nanodroplets, cavitation can be generated by a single ultrasound 
pulse of <2 cycles significantly lower pressures than the histotripsy intrinsic threshold [45, 80, 
168, 169]. While prior work had demonstrated the initial feasibility of the NMH process, this study 
represents the first time NMH will be used for the treatment of cancer cells, which is a significant 
step in the development of this technology. Specifically, we examine the effect of histotripsy 
pulses on the viability of individual 3D spheroids of PC-3 and C4-2B cancer cells suspended in 
culture medium and encapsulated in tissue-mimicking gel phantoms in order to gain an 
understanding of the process in which NMH mechanically fractionates cancer cells in 3D cellular 
microenvironment into acellular homogenates. We evaluate the effect of incubating individual PC-
3 and C4-2B prostate cancer cells and their 3D spheroids in solution and gel phantoms with PFP- 
and PFH-loaded nanodroplets on cell viability when treated with ultrasound at different 
frequencies. We quantitatively compared the ablative capacity of PFP- and PFH-loaded 
nanodroplets against PC-3 and C4-2B spheroids and evaluated the viability of cellular debris.  
Results clearly show the potential of these acoustically-activated nanodroplets in achieving image-
guided ultrasound-mediated ablation of prostate cancer. 
 
2.2 Experimental Section 
2.2.1 Materials 
2,2`- (ethylenedioxy)-bis(ethylamine) (Sigma-Aldrich, 98%, St. Luis, MO), 2-(N-
morpholino)ethanesulfonic acid monohydrate (MES, Sigma-Aldrich, >99.9 % St. Luis, MO), 
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tetrahydrofuran anhydrous (THF, Sigma-Aldrich, >99.9 % St. Luis, MO), resazurin sodium salt 
(Sigma-Aldrich, St. Luis, MO), PEG Bioultra 35,000 (Sigma-Aldrich, St. Luis, MO), Dextran 
500,000 (Spectrum, Gardena, Ca), Bovine Serum Albumin (BSA, Sigma-Aldrich, St. Luis, MO), 
Ultrapure Agarose (Invitrogen, Carlsbad, Ca) were used as delivered. RPMI medium 1640, fetal 
bovine serum (FBS), 0.25% trypsin/0.20% ethylene diamine teraacetic acid (EDTA), phosphate 
buffered saline (PBS), penicillin/streptomycin/ amphotericin, sodium pyruvate, nonessential 
amino acid solutions, the Live/Dead cytotoxicity Kit for mammalian cells (Calcein AM and 
Ethidium homodimer-1), and agarose were purchased from Invitrogen Corporation (Carlsbad, 
CA). Perfluoropentane (PFP, Alfa Aesar, 97% ca. 85% n-isomer) and perfluorohexane (PFH, 
SynQuest Lab, > 98%) were directly used without prufication. N-hydroxy succinimide (NHS, 97 
%), and N-(3-Dimethylaminopropyl)-N ethylcarbodiimide hydrochloride (EDC, >98 %) were 
purchased from Fluka (St. Luis, MO). T-75 flasks, Costar 96-well plates, and cell culture supplies 
were purchased from Corning Inc. (Corning, NY). 
 
2.2.2 Instruments 
A 500 MHz Varian Mercury system (Palo Alto, CA) was used to record all the 1H NMR 
and 13C NMR spectra of polymer blocks at room temperature. Gel permeation chromatography 
(GPC) analysis was done using a Viscotek GPCmax Autosampler system consisting of a pump 
and Water 2414 refractive index (RI) detector. The molecular weight and molecular weight 
distribution of synthesized polymers were determined based on their elution volume on a Styragel 
HR 4E column compared to a series of poly(methyl methacrylate) standards (PolyAnalitik Inc, 
Canada) using THF as a mobile phase at a flow rate of 1 mL/min at 35 oC. The data was analyzed 
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using Viscotek OmniSEC Omni-01 software. Perkin-Elmer FT-IR Spectrum 4100 type A machine 
was used to confirm the azidation of different polymer blocks. 
2.2.3 Formulation of PFP- and PFH-Loaded Nanodroplets 
The amphiphilic, triblock PEG45-b-PAA12-b-P(HDFMA8-co-MMA20) copolymer was used 
to prepare PFP- and PFH-loaded nanodroplets with equal PFC loading (2% v/v) following 
published protocols [168]. Briefly, the PEG45-b-PAA12-b-P(HDFMA8-co-MMA20) polymer was 
synthesized using a combination of atom transfer radical polymerization (ATRP) and “click” 
coupling techniques followed by purification and confirmation of polymer composition using 
GPC, 1H NMR, and MALDI techniques following established protocols [80, 168]. Formulation of 
different nanodroplets started by dissolving the copolymer in tetrahydrofuran (THF) (0.2% w/v) 
and cooling down the polymer solution to 0 °C before adding the PFP (2% v/v) or PFH (2% v/v) 
while vigorously stirring the copolymer-perfluorocarbon mixture (Figure 2.1). An equal volume 
of deionized water was added drop-wise to the polymer/PFC mixture to initiate micelle formation 
while keeping the solution in an ice bath for 1h before transferring the micelles solution to a 
dialysis bag (MWCO of 1 KDa) and dialyzing overnight against ice-cold 2-(N-
morpholino)ethanesulfonic acid monohydrate solution (MES buffer, pH 5.5) to remove the THF 
and obtain  a milky solution of uncross-linked PFP- and PFH-loaded nanodroplets. Each 
formulation was transferred to a round bottom flask and mixed with 2,2`-(ethylenedioxy)-
bis(ethylamine) to cross-link the carboxylic acid groups in the central PAA block in the polymer 
backbone via NHS/EDC coupling chemistry forming the cross-linked nanodroplets with a flexible 
polymer shell. Shell cross-linked nanodroplets were dialyzed against ice-cold water for 12 hours 
to remove the unreacted cross-linker and reaction byproducts. 
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Figure 2.1 Schematic presentation showing the formulation of PFP- and PFH-loaded nanodroplets 
using amphiphilic PEG45-b-(PAA)12-b-P(HDFMA8-co-MMA20) copolymers. 
 
2.2.4 Nanodroplets Characterization 
Size and concentration of PFP- and PFH-loaded nanodroplets were measured using the 
Nanoparticle Tracking Analysis (NTA) at 37°C. The NanoSight™ LM10 system (Malvern 
Instruments, Amesbury, UK) equipped with a temperature-controlled 405 nm laser module, a high 
sensitivity scientific Complementary Metal Oxide Semiconductor (sCMOS) camera (Hamamatsu, 
Orca, Hamamatsu City, Japan), and a syringe pump was used for the collection of NTA data. 
Briefly, nanodroplets solutions were diluted to the appropriate concentration using deionized water 
before imaging where 60s videos (5 videos per sample) were acquired and analyzed using the NTA 
software (Version 3.0, Build 0066) at 37 °C. We plotted nanodroplets concentration as a function 
of droplet size with the error bars representing the standard deviation of the repeat measurements 
for each sample. The mean size and standard deviation values obtained by the NTA software 
correspond to arithmetic values calculated with the sizes of all particles analyzed by the software. 
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The error bars displayed on the graphs were obtained by the standard deviation of a minimum of 
five different samples.  
We investigated the stability of PFH-loaded nanodroplets NDs when incubated bovine 
serum albumin (BSA) as a model serum protein for 24 hours at 37 °C while stirring by monitoring 
the change in droplets size and concentration using NTA.  This analysis was done by mixing  900 
µL of PFH-nanodroplets with 100 µL of BSA (20 µg/mL) and imaging droplets solution following 
our  previously published protocol [168]. All statistical evaluations were carried out with unpaired 
two tailed Student’s t tests where p < 0.05 indicates statistically significant difference between 
groups. 
2.2.5 Cell Culture 
PC-3 and C4-2B prostate cancer cells were cultured following published protocols [170]. 
Briefly, both cell lines were cultured in RPMI-1640 supplemented with 10% FBS and 1% 
antibiotic/antimycotic solution. PC-3 and C4-2B cells were incubated at 37 °C and 5% CO2 while 
changing the culture medium every other day and passaging the cells using 0.05% trypsin/EDTA 
solution after reaching 80% confluence. The passage number for PC-3 and C4-2B cells used in the 
cytotoxicity and ablation studies was in the range between 25 and 40. 
We used the Aqueous Two-Phase System (ATPS) to prepare PC-3 and C4-2B spheroids 
following published protocols [171] with minor modifications. Briefly, 5.0% (w/w) of PEG 
(35,000 Da) and 12.8% (w/w) of dextran (500,000 Da) stock solutions were prepared in the culture 
medium and kept at 37°C. The surface of flat-bottom 24-well plates and cell holders were coated 
with 300 µL and 650 µL of a boiled agarose solution 2% (w/v) in double distilled water, 
respectively, to get a non-adherent surface. We allowed the agarose solution to cool down to room 
temperature and solidify in 10 min before washing twice with PBS and adding 500 µL of 5.0% 
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(w/w) PEG solution to each well. PC-3 and C4-2B cells were prepared at a concentration of 
700,000 cells/µL in 12.8% (w/w) aqueous dextran before adding 0.8 µL of this cell solution to the 
PEG solution in each well. Given that PEG and dextran solutions are immiscible, we allowed the 
cells to aggregate and grow at the interface for 24-48 hours to get uniform spherical spheroids. We 
measured the horizontal and vertical diameters of each spheroid using an inverted microscope 
(Olympus IX51, Melville, NY) before adding more culture medium and incubating for longer 
periods of time to increase the size of the spheroids. The spheroids were ready for use in 2 days of 
culture under these conditions We confirmed the viability of the cultured spheroids by incubating 
them with a solution of 3 µM Calcein AM and ethidium homodimer-1 for 2 hours before washing 
excess dye using PBS and examining the spheroids under an Olympus IX51 fluorescent 
microscope (Melville, NY) coupled with 130 W U-HGLGPS fluorescence light source and a TL4 
power supply unit. Fluorescent images were captured and analyzed using the Olympus image 
software analySIS® where green and red fluorescence indicated live and dead cells, respectively. 
2.2.6 Nanodroplets Cytotoxicity 
We evaluated the non-specific toxicity PFP- and PFH-loaded nanodroplets by incubating 
them with PC-3 and C4-2B cells. Briefly, PC-3 and C4-2B cells were seeded at a seeding density 
of 10 x 103 cells/well in 96-well plates and allowed to adhere for 24 h before adding the 
nanodroplets at concentrations between 0-100 µg/mL and incubating for 48 h. At the end of the 
incubation period, the culture medium was removed and the cells were incubated with 200 μL of 
the Resazurin dye at a dilution of 1/10 for 4 h before measuring solution fluorescence (λex= 570 
nm, λem= 590 nm) using the Fluoroskan Ascent FL plate reader (Thermo Fisher Scientific, 
Waltham, MA). Fluorescence values were normalized to that observed with PC-3 and C4-2B cells 
incubated in the regular culture medium (control group) to calculate the percentage of viable cells 
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in response to different treatments. The nanodroplets concentration that resulted in a statistically 
significant reduction in cell viability was considered cytotoxic. 
2.2.7 Ablation of PC-3 and C4-2B Cells and Spheroids in Solution  
A 345 kHz ultrasound transducer was designed to generate a histotripsy bubble cloud and 
image the cavitation of PC-3 and C4-2b cells and spheroids using a clinical ultrasound imaging 
system (Philips HDI 5000 Ultrasound system, Bothell WA, USA). The 345 kHz transducer was 
designed to generate short, high-pressure, 1-2 cycle histotripsy pulses and had a geometric focus 
of 150 mm, an aperture size of 272 mm, and an effective f-number of 0.55. Elements were driven 
in phase with a custom high-voltage pulser that was developed in-house. The pulser was connected 
to a field-programmable gate array (FPGA) board (Altera DE1 Terasic Technology, Dover, DE) 
specifically programmed for histotripsy pulsing. This setup allowed the transducers to output short 
pulses consisting of less than two cycles. A fiber optic probe hydrophone built in-house [172] was 
used to measure the acoustic output pressure of the transducers. At high negative pressure levels 
(p- > 23 MPa), the acoustic output could not be directly measured due to cavitation at the fiber tip. 
Therefore, these pressures were estimated by a summation of the output focal p- values from 
individual transducer elements with these approximations assuming minimal nonlinear distortion 
of the waveform occurring within the focal region. In a previous study [44], this estimated p- was 
found to be accurate within 15% compared to direct focal pressure measurements in water and in 
a medium (1,3 butanediol) with a higher cavitation threshold. The transducer was placed inside a 
tank of degassed water at room temperature (22°C) with the elements completely submerged. A 
computer-positioning system was built to support the tube containing the treatment solution and 
to adjust the position of the tube with respect to the transducer focus. The desired concentration (2 
x 108 particles/mL) of PFP- or PFH-NDs was added to the solution of 200,000 individual PC-3 or 
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C4-2B prostate cancer and, in a separate study to three PC-3 or C4-2B spheroids in 2 mL of PBS 
in the treated tube. Individual PC-3/C4-2B cells and spheroids were suspended in PBS before being 
added to the rubber tube, which was placed in the focal zone of the 345 kHz array transducer 
placed inside a degassed water tank at room temperature. The tube was positioned in the focal zone 
of the 345 kHz array transducer using a PC-controlled console and scanned from the bottom to the 
top and vice versa for 5 minutes to ensure the exposure of the while volume of the solution to the 
ultrasound treatment (Figure 2.2). At the end of the 5 min ablation treatment, the solutions of PC-
3 and C4-2B cells/spheroids were collected and mixed with the resazurin dye to quantify the 
fraction of viable cells following the same protocol described earlier and used to assess NDs 
toxicity. The number of viable PC-3 and C4-2B cells was normalized to that incubation in PBS 
without exposure to NDs or ultrasound treatments to calculate the effect of different treatments on 
the viability of individual cancer cells and 3D spheroids. 
 
Figure 2.2 Schematic drawing of the experimental setup incorporating a 345 kHz transducer with 
the focus aligned to the center of test tubes containing either prostate cancer spheroids alone 
(control) or spheroids mixed with PFP or PFH-loaded nanodroplets (test). 
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2.2.8 Visualizing the Ablation of PC-3 and C4-2B Spheroids in a Tissue Mimicking 
Environment 
We investigated the effect of PFP- and PFH-NDs on PC-3 and C4-2B spheroids in agarose 
phantoms as an accepted 3D model of cancer cell-tissue matrix interactions [173-175].  Tissue 
phantoms containing 2% (w/v) agarose were prepared by slowly mixing agarose powder into PBS 
heated to the boiling temperature and keeping the solution stirring on a hot plate until the gel turned 
completely transparent and allowed to boil for an additional 10 minutes. Agarose solutions were 
allowed to cool down before being degassed under a partial vacuum (~20 kPa, absolute) for 30 
minutes. Agarose phantoms containing the nanodroplets were prepared by slowly adding the 
desired volume of the nanodroplets solution into the cold agarose solution while stirring before 
pouring into rectangular polycarbonate holders with acoustic windows and keeping this mixture at 
room temperature to allow the agarose solution to solidify forming tissue phantoms with embedded 
PFP- or PFH-loaded nanodroplets or without nanodroplets (control phantoms). 
A 500 kHz ultrasound transducer was designed to generate a histotripsy bubble cloud and 
image the cavitation of PC-3 and C4-2B cells and spheroids. The 500 kHz transducer was designed 
to generate short, high-pressure, 1-2 cycle histotripsy pulses and had a geometric focus of 40 mm, 
an aperture size of 71 mm, and an effective f-number of 0.56. Elements were driven in phase with 
a custom high-voltage pulser that was developed in-house. The pulser was connected to a field-
programmable gate array (FPGA) board (Altera DE1 Terasic Technology, Dover, DE) specifically 
programmed for histotripsy pulsing. This setup allowed the transducers to output short pulses 
consisting of less than two cycles. A fiber optic probe hydrophone built in-house [172] was used 
to measure the acoustic output pressure of the transducers. 
A high-speed 1 megapixel CCD camera (Phantom V210, Vision Research) with a frame 
rate of 2000 frame per second (fps) was aligned above the microscope (Nikon Eclipse Ti, 10X 
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magnification) (Figure 2.3) to study the interactions between the generated bubble cloud and the 
cancer cells over multiple pulses. The camera was externally triggered from the FPGA signal board 
to synchronize recorded images with the histotripsy pulse at specific delay intervals. An exposure 
time of 20 µs was used for each recorded frame and the camera was triggered to record images 24 
µs after the arrival of each pulse. The 3D spheroids were formulated following the ATPS method 
described earlier. These spheroids were cultured on agarose gels for 3 days at 37°C and 5% CO2 
before treating the cells with 100 histotripsy pulses applied at a pulse repetition frequency of 1 Hz. 
The camera recorded 20 images after each pulse using a 10X magnification lens. In approximately 
3 of these images, the bubble cloud was still present while cell displacement and deformation was 
observed in the following images since these effects lasted significantly longer than the bubble 
cloud [162]. 
 
Figure 2.3 The 3D spheroids phantom histotripsy set-up. 
(A) A custom built microscope transducer-tank with a three-axis positioning system was built to 
investigate the ability of nanodroplet-mediated histotripsy to fractionate tumor spheroids. (B) Prostate 
cancer spheroids were aligned at the transducer focus using a micro-positioner, and histotripsy pulses 
were applied to the spheroids which were embedded inside an agarose gel to mimic a three-dimension 
tissue structure. 
To examine the ability of PC-3 cells to regrow after NDs-mediated ablation, the 
homogenate of PC-3 spheroids incubated with PFH-NDs and treated with histotripsy were 
collected after treatment and centrifuged at 1000 rpm for 5 min. The collected homogenate was 
mixed with 500 µL of fresh RPMI 1640 medium, seeded in a 24-well plate, and incubated for 48 
A B 
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hours under the regular culture conditions. Untreated (no PFH-NDs and no histotripsy pulses) PC-
3 spheroids were processed following the same protocol and used as a control group.  After 48 
hours, the ability of the cultured homogenate to grow viable cells was evaluated using the resazurin 
viability assay coupled with microscopic examination using an inverted microscope (Olympus 
IX51, Melville, NY) with a 4X objective lens.  
 
2.3 Results and Discussion 
2.3.1 Formulation and Characterization of PFP- and PFH-Loaded Nanodroplets 
Our previous reports show that PEG45-b-(PAA)12-b-P(HDFMA8-co-MMA20) triblock 
copolymer can efficiently encapsulate PFP and PFH forming nanodroplets (NDs) [74, 80, 83, 168, 
169] and we followed the same formulation protocol to obtain PFP- and PFH-loaded NDs for these 
studies. Results of the NTA shows that PFP-and PFH-loaded NDs have a similar average size and 
size distribution profiles (Figure 2.4A, Table 2.1). Specifically, the average size of PFP-loaded 
NDs   was between 100 nm and 450 nm with the size of major peak < 300 nm (Figure 2.4A) and 
an average diameter of 177 ± 1.9 nm (Table 2.1). In comparison, PFH-loaded NDs exhibited a 
slightly larger size distribution between 100 nm and 600 nm with 3 peaks in the range of 200-300 
nm, 300-450 nm, and 450-600 nm (Figure 2.4A) and an average diameter of 233.9 ± 3.9 nm 
(Table 2.1).  The larger size of the PFH-loaded NDs compared to PFP-loaded ones can be a result 
of the difference in miscibility between PFP and PFH in the THF/copolymer mixture. Briefly, our 
experimental observations indicate that PFP homogenously disperses in the THF/copolymer 
mixture during NDs formulation whereas, PFH tends to phase separate from the THF/copolymer 
mixture.  We broke down PFH phase separation by drop-wise addition of water to the 
THF/polymer mixture and vigorous mixing, which triggered breakdown of the PFH phase and 
40 
 
mixing with the aqueous phase coupled with self-assembly of the polymer forming PFH-loaded 
NDs. The hydrophilic PEG corona stabilized both PFP- and PFH-loaded NDs and inhibited their 
aggregation or precipitation in solution at 4 °C and 25 °C. Given that >99% PFP- and PFH-loaded 
NDs have an average diameter < 400 nm, they are in the size range to preferentially extravasate 
across tumor’s leaky vasculature and accumulate in tumor tissue with low risk of inducing 
pulmonary embolism [176, 177]. 
 
Figure 2.4 Size distribution of PFP and PFH-loaded NDs. 
(A) The concentration and size distribution of PFP (blue line) and PFH (red line)-loaded nanodroplets 
(B) Stability test of PFH-NDs in the presence or absence of BSA for 24 h at 37 °C, PFH-NDs at 0h (blue 
line), PFH-NDs at 24h (red line), and PFH-NDs at 24h with presence of BSA (green line). All 
measurements were calculated using Nanoparticles Tracking Analysis (NTA) and NTA 3.0 build 66 
software. Results are the average of five independent experiments ± standard error of the mean (error 
bars not shown for B to clearly seen the lines). 
 
Table 2.1 Size distribution of PFP or PFH-loaded nanodroplets with 10%, 50%, 90% of particles 
size fraction and their average size. 
Size (nm) D10 D50 D90 Mean 
PFP-NDs 111.0±1.4 155.7±2.1 268.5±6.7 177.9±1.9 
PFH-NDs 135.3±2.6 192.7±5.3 373.7±7.2 233.9±3.9 
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Serum albumin is the major soluble blood protein, which adsorbs to the surface of particles 
in the systemic circulation and labels them for hepatic clearance [170, 178].  We investigated the 
stability of the PFH-NDs upon incubating with bovine serum albumin (BSA) at 37 °C for 24 h by 
monitoring the change in NDs size and concentration using NTA. Results show that the average 
diameter of PFH-NDs before incubating at 37 °C (0 h) is 251.9 ± 11.2 nm, which dropped to 221.5 
± 8.7 nm after incubating the NDs at 37 °C for 24 hours (Figure 2.4B). This drop in average NDs 
size is a result of the loss of the fraction of NDs with an average size ~500 nm, which resulted in 
~40% of NDs concentration probably due to loss of poorly encapsulated PFH in large NDs. 
Incubation of PFH-NDs with BSA at 37 ℃ for 24h similarly reduced average NDs size to 228.7 ± 
10.3 nm and NDs concentration was similar in the presence and absence of BSA (Figure 2.4B).  
These results indicate that the PEG corona limits the interaction of PFH-NDs with BSA, which 
increased NDs against complete dissolution and aggregation in the presence of BSA as a model 
serum protein at 37 °C. It is worth noting that the size of  PFP-NDs  did not change under similar 
experimental conditions but the concentration decreased by 20%  at 37 ℃ regardless of the 
presence or absence of BSA [168]. These results indicate that PFP-NDs and PFH-NDs will exhibit 
minimal interaction with serum proteins in vivo. 
2.3.2 Cytotoxicity of PFP- and PFH-Loaded Nanodroplets 
To investigate the toxicity of the nanodroplet particles, we performed in vitro cytotoxicity 
experiments using a resazurin viability assay, which is a very common dye to show cell viability, 
proliferation and cytotoxicity with a simple, rapid, sensitive, and reliable way. Basically, it relies 
on reduction of resazurin (blue, nonfluorescent form) to resorufin (pink, highly fluorescent) by 
viable cells. The metabolized form of the dye enters the cytosol and is converted to the fluorescent 
form by mitochondrial enzyme activity by accepting the electron from NADPH, FADH, NADH, 
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and cytochromes [179]. Both prostate cancer cell lines were treated with a variety of concentrations 
between 0 to 100 µg/mL of PFP or PFH-loaded nanodroplets calculated initial polymer weight 
that added to the formulation and the end volume of the dialysis step in ND formulation for 24 h 
under regular cell culture conditions compared to negative controls of non-treated cells and 
positive controls of Triton-x 100 treated cells. It is important to highlight the maximum 
concentration that we used is 100 times more than used in the tube cell ablation particle 
concentration. Further, results show that incubation of PFP- and PFH-loaded NDs with PC-3 and 
C4-2B cells did not affect their viability up to a concentration of 100 µg/mL except only PFH-
NDs at the highest particle concentration (Figure 2.5). Overall, this result points to biocompatible 
character of the particles. As a result, particle concentration even at 50 µg/mL of NDs 
concentration (> 80-fold more particle concentration what we used for NMH) usage is not expected 
to be an issue in vivo because of the particles cytotoxicity profile. 
 
Figure 2.5 Evaluation of in vitro toxicity of PFP- and PFH-loaded nanodroplets towards 
PC-3 (A) and C4-2B (B) prostate cancer cells as a function of concentration of the polymeric carrier (0-
100 µg/mL) with Triton-X 100 positive control. Results are the average of two independent 
experiments with 5 replicates ± standard error of the mean. We compared cell viability under each 
condition to the viability of untreated cells (negative control) using one-way ANOVA with Tukey test 
where # for PFH denotes p ≤ 0.05, and ## denotes p ≤ 0.01. 
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2.3.3 Ablation of PC-3 and C4-2B Cells and Spheroids in Solution 
We investigate the effect of combining individual prostate cancer cells and spheroids with 
PFP- and PFH-loaded NDs in a rubber tube and exposing this mixture to histotripsy pulses as 
shown in Figure 2.2. We hypothesized that applying histotripsy pulses with peak negative 
pressures of ~10.7–12.8 MPa would activate the PFP- and PFH-NDs resulting in generation of a 
bubble cloud that would energetically collapse and cause the mechanical ablation of individual 
cancer cells and 3D tumor spheroids. In comparison, PC-3/C4-2B cells/spheroids mixed with the 
NDs but were not treated with histotripsy pulses and PC-3/C4-2B cells/spheroids not mixed with 
the NDs but treated with histotripsy pulses will not experience ablative forces and will remain 
viable after the treatment. To test this hypothesis, we added an equal number (2 × 108 droplets/mL) 
of PFP- and PFH-loaded NDs to the designated tubes before applying histotripsy pulses to the 
center of the tube at a pulse repetition frequency of 10 Hz and peak negative pressure of 10.7 MPa. 
The tubes containing NDs showed a bubble cloud in the center of the tube (Figure 2.2) which was 
monitored in real time using a clinical ultrasound imaging system. In contrast to, no cavitation 
bubble clouds were observed in the tubes without NDs. Quantifying the changes in cell viability 
in response to different treatments using the resazurin dye show the ablative capacity associated 
with each treatment (Figure 2.6). Results show that PC-3 and C4-2B cells (Figure 2.6A) and 
spheroids (Figure 2.6B) that were not incubated with NDs or treated with ultrasound exhibited 
100% viability at the end of the treatment and were used a reference for normalization of other 
treatments. Similarly, incubating PC-3 and C4-2B cells (Figure 2.5A) and spheroids (Figure 
2.5B) with PFP- and PFH-NDs without shining ultrasound did not affect cell viability. However, 
exposure to 1-2 cycle histotripsy pulses at low acoustic pressure (10.7 MPa) in absence of NDs 
caused less than ~20% reduction in the viability of both PC-3 and C4-2B cells (Figure 2.6A). By 
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combining PFP- and PFH-NDs and exposure to 1-2 cycle histotripsy (10.7 MPa), significant 
ablation of PC-3 and C4-2B cells and spheroids was observed (Figure 2.6). 
 
Figure 2.6 Effect of PFP and PFH-loaded nanodroplets on the viability of PC-3 and C4-2B cultured 
as individual cells (A) or 3D spheroids (B) upon exposure to 1-2 cycle histotripsy pulses (10.7 MPa) 
applied with a pulse repetition frequency of 345 kHz. 
Cell viability was measured using Resazurin viability assay and results were normalized to untreated 
cells (negative control; – NDs and – US). Results are the average of four experiments ± standard error 
of the mean. We compared cell viability under each condition to the viability of untreated cells (negative 
control) using one-way ANOVA with Tukey test where * denotes p ≤ 0.05, ** denotes p ≤ 0.01, *** 
denotes p ≤ 0.001, and **** denotes p ≤ 0.0005. 
 
Specifically, combining the NDs with ultrasound resulted in ablation of 40-70% and 60-
70% of suspended PC-3 and C4-2B cells, respectively (Figure 2.6A). Similarly, combining the 
NDs with ultrasound resulted in ablation of 40%-60% of PC-3 and C4-2B spheroids (Figure 2.6B). 
Upon added nanodroplets to cell/spheroid samples with applied 10.7 MPa ultrasound, we got quite 
further ablation therapeutic effects. For example, PFP-nanodroplets with ultrasound resulted in the 
death of almost 80% and 60% of the individual PC-3 and C4-2B cells, respectively (Figure 2.6A). 
PFH-nanodroplet results showed cell death rates of 40% and 75% for the PC-3 and C4-2B cells, 
respectively. On the other hand, more than 50% and 40% of the PC-3 and C4-2B spheroids were 
destroyed with PFP-nanodroplets, respectively. Moreover, the therapeutic activity of PFH-
45 
 
nanodroplets on PC-3 and C4-2B spheroids reached to 70% and 60% cell ablation, respectively 
(Figure 2.6B). The nanodroplets containing PFP or PFH resulted in higher cavitation so these 
offer higher therapeutic activity in response to the histotripsy treatment based on the viability assay 
results. These ablation rates of cells/spheroids are obtained just after single treatment in a certain 
time interval. These ablation rates can be improved by using targeted NDs and scanning the 
ultrasound therapy focus to cover the entire tumor volume, which will be expected to achieve 
complete ablation of the target tumor. It is worth noting that these ablation rates of cells/spheroids 
are obtained from treating in a certain time interval. The cell ablation rates are expected to be 
improved when using targeted NDs. In addition, by scanning the ultrasound therapy focus to cover 
the entire tumor volume, we expect to achieve complete ablation of the entire target tumor. 
2.3.4 Visualizing the Ablation of PC-3 and C4-2B Spheroids in a Tissue Mimicking 
Environment 
We investigated the ability of PFP- and PFH-loaded NDs to ablate PC-3 and C4-2B 
spheroids in an environment that mimics the mechanical properties that exist in vivo. We utilized 
the ATPS to grow millimeter-sized spheroids in 2 days, which were placed on an agarose gel and 
allowed to grow and establish cell-gel interactions. We applied ultrasound pulses at peak negative 
pressures of 12.8 MPa and 26.2 MPa to the spheroids layer. The formation of a bubble cloud and 
the associated cell fractionation was monitored using high speed optical imaging after each pulse. 
Results show that histotripsy pulses (26.2 MPa) and the bubble cloud generated by the NDs at low 
acoustic pressure (12.8 MPa) fractionated the spheroids in the targeted region, forming an acellular 
homogenate (Figure 2.7A-C).  Using these images, we quantified the ablation area in response to 
different treatments (Figure 2.7D). Results show that applying US at acoustic pressure below the 
histotripsy intrinsic threshold (12.8 MPa) in tissue phantoms that were not loaded with either NDs 
did not cause significant ablation (<20%) of the embedded spheroids. In comparison, applying 
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histotripsy pulses at acoustic pressures near the intrinsic threshold (26.2 MPa) caused a statistically 
higher ablation of the embedded spheroids, reaching 80% of the spheroids area. Combining PFP-
NDs with ultrasound at a peak negative pressure of 12.8 MPa caused an ablation of ~40% of the 
embedded spheroids. Whereas, combining PFH-NDs with ultrasound at a peak negative pressure 
of 12.8 MPa ablated ~80% of the embedded spheroids, similar to the ablation observed with the 
histotripsy pulses applied at high acoustic pressure (26.2 MPa). It is worth noting that, while only 
80% of the total spheroid volume was ablated in these experiments, this volume represented the 
entire targeted region in which the histotripsy bubble cloud was generated. The observed 
difference in ablative capacity of PFP- and PFH-loaded NDs is likely due to the difference in the 
stability of the NDs over multiple pulses. Our earlier research showed that PFH-NDs generate a 
bubble cloud with a large number of sustainable cavitation nuclei remaining over multiple pulses 
compared to PFP-NDs, which can only generate a bubble cloud during the initial pulses [80]. 
Another important point that drawn attention in here is the ablation is carried out only in the region 
of bubble activities under the transducer focal point, which dictates the damage location. Since the 
purpose of this study was to demonstrate the ability of NMH to fractionate tumor cells and 
investigate the mechanism of the resulting damage, histotripsy was only applied to a single location 
to compare the efficiency of ND formulations in the same conditions. Therefore, the fractionation 
is localized in the ultrasound focal region treated with the bubble cloud, while the untreated 
spheroid region remained intact, demonstrating the precision of NMH ablation. This approach 
explains why the reported ablation percentages for all tested cases are below 100%, since the 
treatment focus was not scanned to cover the entire tumor spheroids. Previous studies have shown 
that histotripsy using high pressure pulses alone can completely homogenize the target tissue 
volume with no viable cells remaining by scanning the therapy focus to cover the entire volume, 
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which is validated by the results of this study that show NMH completely fractionated the portion 
of the tumor that was exposed to the bubble cloud. This finding suggests that NMH will be capable 
of completely fractioning 100% of the tumor volumes under the circumstance of mapping the 
histotripsy transducer focus to cover the whole spheroid volume.  
Although the difference between nanodroplets and microbubbles for particle-assisted 
histotripsy is not specifically investigated in this study, we have discussed these features in some 
of our previous works [45, 79]. In general, we would expect to achieve similar cell fractionation 
using both nanodroplets and microbubbles for enhanced histotripsy in cases where cavitation 
bubbles are generated. The primary differences between these two approaches are more related to 
1) particle size and 2) cavitation initiation properties rather than any differences between the 
fractionation process that occurs once the cavitation bubbles are formed, which appears to be 
similar for NMH, histotripsy, and microbubble-enhanced histotripsy based on previous 
observations. The advantage of using nanodroplets rather than microbubbles, as discussed in the 
previous studies, is that the nanodroplets can 1) be synthesized into the optimal size range to 
accumulate inside a tumor volume [168] while microbubbles are too large and 2) cavitation 
initiation from nanodroplets shows a distinct threshold behavior similar to the histotripsy intrinsic 
threshold, [79] which has many advantages for developing NMH for selective ablation. In contrast, 
microbubbles do not show the same distinct threshold behavior, since the initial threshold behavior 
is not dominated by bubble nucleation as is the case with nanodroplets. 
Further, we investigated the residual viability of cancer spheroids after treatment with PFH-
NDs by evaluating cell growth from the ablated spheroids. We compared cell growth using 
microscopic examination and fraction of viable cells as shown in Figure 2.8. Microscopic 
examination shows low density of viable cells emerging from the homogenate of PC-3 spheroids 
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treated with PFH-NDs compared to highly dense cells observed with untreated cells (Figure 2.8A). 
Results of the resazurin assay shows that the number of viable cells established from the culture 
of PC-3 homogenate was ~20% of the number of viable cells established from the untreated PC-3 
(control group) (Figure 2.8B). These results show the low viability and the proliferation of residual 
cells after NDs treatment. 
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Figure 2.7 3D tumor model cell-bubble results demonstrate nanodroplet-mediated histotripsy can 
fractionate prostate cancer cells into accellular debris. 
A PC-3 prostate cancer spheroid was cultured on an agarose tissue phantom to mimic cells inside a tissue 
extracellular matrix. 100 histotripsy pulses were applied to the call layer containing nanodroplets at a 
pressure significantly below the histotripsy threshold without nanodroplets. (A) Digitized video capture 
images of NMH during treatment, cavitation bubbles were observed at the transducer focus and cells 
were observed to be mechanically ruptured. After treatment, no/less cells remained intact in the region 
in which the histotripsy bubble cloud was observed. (B) PC-3 3D spheroid NMH, the first column is the 
treatment of no ND with 12.8 MPa of US pressure, the second column is the PFP NDs mediated 
histotripsy with 12.8 MPa of US pressure, the third column is no ND with 26.2 MPa of US pressure, and 
the forth column is the PFH NDs mediated histotripsy with 12.8 MPa of US pressure. Each row is 
separated with before, during, and after US treatments. The spheroid border, cavitation bubbles, and 
ablated spheroid section were encircled with red, white, and yellow colors, respectively to be easily 
distinguished the treatment efficiency. The cross bar is 200 µm. (C) C4-2B 3D spheroid NMH, the first 
column is the treatment of no ND with 12.8 MPa of US pressure, the second column is the PFP NDs 
mediated histotripsy with 12.8 MPa of US pressure, the third column is no ND with 26.2 MPa of US 
pressure, and the forth column is the PFH NDs mediated histotripsy with 12.8 MPa of US pressure. Each 
row is separated with before, during, and after US treatments. The spheroid border, cavitation bubbles, 
and ablated spheroid section were encircled with red, white, and yellow colors, respectively to be easily 
distinguished the treatment efficiency. The cross bar is 200 µm. (D) Calculation of the fractionated 
spheroid area after the ablation treatment with lower pressure (12.8 MPa), high pressure (26.2 MPa), PFP 
loaded NDs, or PFH loaded NDs. The areas are calculated from the ultrafast recording camera images 
equipped with a 4X microscope objective. Results are the average of three independent experiments ± 
standard error of the mean. 
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Figure 2.8 (A) Regrown of the ablated PC-3 cells with PFH-NDs under US for 2 days comparing 
to untreated spheroids under light microscopy (the cross-bar shows 200 µm) and (B) assayed with 
resazurin viability dye. 
 
2.4 Conclusions 
Results of this study show the ability of nanodroplets-mediated histotripsy to ablate 
prostate cancer cells and spheroids in solution and in tissue-mimicking phantoms. Further, the 
results indicate that PFP-NDs and PFH-NDs exhibit minimal interaction with the model blood 
protein, serum albumin in the model system as monitoring the particle sizes. The ability to ablate 
PC-3 and C4-2B spheroids using PFP- and PFH-NDs at acoustic pressures below the histotripsy 
intrinsic threshold. The PFH-NDs formulation with low pressure demonstrated that NMH can be 
used to fractionate cancer cells and tumor spheroids with similar efficient to conventional 
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histotripsy but at significantly reduced acoustic pressure. This finding suggests that NMH has the 
potential to achieve selective ablation of tumors while sparing the surrounding normal tissue. 
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Formulation of acid-sensitive micelles for delivery of cabazitaxel into 
prostate cancer cells 
The material in this chapter is published from the following article: O. Aydin, I. Youssef, Y. Y. 
Durmaz, G. Tiruchinapally, and M. E. H. ElSayed, “Formulation of Acid-Sensitive Micelles for 
Delivery of Cabazitaxel into Prostate Cancer Cells” Molecular Pharmaceutics, 2016, 13 (4), 
1413–1429 (2016). 
 
3.1 Introduction 
Taxanes is a family of hydrophobic, small molecular weight, drug molecules that include 
paclitaxel, docetaxel, and cabazitaxel, which exhibit cytotoxic activity against rapidly proliferating 
cancer cells [180]. Taxanes exhibit their cytotoxicity by blocking cell cycle progression through 
stabilizing the microtubules, centrosomal impairment, induction of abnormal spindles, and 
suppression of spindle microtubule dynamics, which triggers apoptosis by aberrant mitosis or by 
subsequent multinucleated G1-like state related to mitotic slippage depending on cell type and 
drug schedule [181]. The FDA approved the use of paclitaxel (Taxol®, Bristol-Myers Squibb, 
Princeton, NJ) for treatment of ovarian cancer [182], recurrent and metastatic breast cancer [183], 
and as a second line therapy for  patients with HIV-related Kaposi’s sarcoma and non-small cell 
lung carcinoma [184, 185]. The FDA also approved the use of docetaxel (Taxotere®, Sanofi-
Aventis LLC, Bridgewater, NJ) for treatment of advanced breast [186], lung [187], and ovarian 
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cancer [188]. However, clinical use of taxanes is associated with significant side effects including 
hypersensitivity reactions, neurotoxicity, bone marrow suppression, fluid retention (i.e. edema, 
ascites, pleural effusions), diarrhea, nausea, vomiting, numbness, and loss of hair due to the non-
specific distribution to healthy tissues [189, 190]. Further, the use of surfactants such as cremophor 
and polysorbate 80 to increase the intrinsically poor aqueous solubility of taxanes (e.g. paclitaxel’s 
and docetaxel’s solubility = 0.7 µg/mL and 6-7 µg/mL, respectively) has been shown to enhance 
the toxicity of the parent drug by causing allergic reactions, peripheral edema, and pericardial 
effusions [14, 191, 192]. Alternative formulations such as drug-loaded liposomes, albumin-based 
nanoparticles, polymer-drug conjugates, and self-assembled micelles have been developed to 
eliminate the need for toxic solubilizing agents and to target the loaded chemotherapeutic cargo to 
cancer cells [193-196]. Many of these strategies proved successful in enhancing the therapeutic 
activity of the loaded anticancer drug and reducing the associated toxicity in clinical settings 
leading to the development and clinical use of Abraxane (paclitaxel-loaded albumin nanoparticles) 
for treatment of breast, lung, and pancreatic cancer [197, 198], and Opaxio (polyglutamic acid-
paclitaxel conjugate), which is being evaluated in Phase III trials in patients with advanced ovarian 
cancer (NCT00108745) [199]. 
CTX is a chemotherapeutic agent that proved effective in killing resistant prostate cancer 
cells in vitro and in preclinical animal models [200]. These results led to FDA approval of 
cabazitaxel (Jevtana®, Sanofi-Aventis LLC, Bridgewater, NJ) as a new treatment option for 
patients with castrate-resistant prostate cancer (CRPC) whose disease progresses during or after 
docetaxel treatment [201-203]. Activity of CTX in CRPC is attributed to its poor affinity for the 
ATP-dependent P-glycoprotein (P-gp) efflux pump compared to docetaxel, which is a strong 
substrate for P-gp [204, 205]. Given that CTX is a lipophilic, practically insoluble in water, and 
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chemically unstable drug [206], it is formulated as lyophilized powder in single-use vials 
containing 60 mg anhydrous CTX and 1.56 gm of the polysorbate 80 surfactant to aid its 
dissolution when mixed with the appropriate diluent made of 13% (w/w) ethanol in water [207]. 
Preparation of CTX for infusion into CRPC patients requires two dilutions and the use of 
polysorbate 80 as a solubility enhancer increase the risk for development of side effects particularly 
hypersensitivity reactions including generalized erythema, hypotension, and bronchospasm [208]. 
We are interested in developing surfactant-free, water-soluble, and stable formulations of CTX 
that can be eventually targeted towards cancer cells in both the primary tumor (i.e. prostate gland) 
and distant metastases (e.g. cancer lesions in bone). To achieve this goal, we focused on the 
development of water-soluble nano-sized micelles that can encapsulate CTX in their core, shuttle 
the CTX cargo into the cytoplasm of aggressive prostate cancer cells, and trigger efficient cancer 
cell death. 
We report the synthesis of a new amphiphilic triblock copolymer composed of a 
hydrophilic poly(ethylene glycol) (PEG) block, a central poly(acrylic acid) (PAA) block, and a 
hydrophobic poly(methyl methacrylate) (PMMA) block. We evaluated the ability of poly(ethylene 
glycol-b-acrylic acid-b-methyl methacrylate) (PEG-b-PAA-b-PMMA) copolymer to self-
assemble into micelles that encapsulate NR (a hydrophobic fluorescent dye) and CTX in the 
hydrophobic core. We report the synthesis of the acid-labile 2,2’-(propane-2,2-diylbis(oxy)-
diethanamine linker and its reaction with the carboxylic acid groups in the central PAA block to 
cross-link adjacent polymer chains forming shell cross-linked micelles (SCLM). We compared the 
release of the loaded cargo (i.e. NR and CTX) from uncross-linked micelles (NSCLM) and SCLM 
upon incubation in aqueous buffer solutions with physiologic (pH = 7.4) and endosomal (pH = 
5.0) pH values. We investigated the uptake of CTX-loaded SCLM and NSCLM into PC-3 and C4-
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2B prostate cancer cells and the associated anticancer activity compared to free CTX at different 
drug concentrations. We evaluated micelle’s biocompatibility by measuring the hemolysis of red 
blood cells (RBCs) and platelets aggregation upon incubation with different micelle 
concentrations. We also measured the adsorption of bovine serum albumin (BSA) as a model 
serum protein to the surface of SCLM and NSCLM as a function of incubation time and subsequent 
uptake of opsonized micelles by THP-1 macrophages. 
 
3.2 Experimental Section 
3.2.1 Materials 
Cabazitaxel (CTX) is a generous gift from Sanofi-Aventis US LLC (Bridgewater, New 
Jersey). Poly(ethylene glycol) monomethylether (PEG, Mn: 5000 g/mol, Sigma-Aldrich), Copper 
(I) bromide (CuBr, Sigma-Aldrich, 99.9 %), anhydrous tetrahydrofuran (THF, Sigma-Aldrich, 
>99.9 %), triethylamine (TEA, Sigma-Aldrich, ≥99%), N,N’- dicyclohexylcarbodiimide (DCC, 
Sigma-Aldrich, 99 %), N-(2-hydroxyethyl)-phthalimide (Sigma-Aldrich, 99%), 1,6-diphenyl-
1,3,5-hexatriene (DPH, Sigma-Aldrich, 98%), resazurin sodium salt (Sigma-Aldrich), 2-methoxy 
propene (Sigma-Aldrich, 97%), phorbol myristate acetate (PMA, Sigma-Aldrich, ≥99%), benzene 
(anhydrous, Sigma-Aldrich, 99.8%), 2-propanol (anhydrous, Sigma-Aldrich, 99.5%), p-toluene 
sulfonic acid (Sigma-Aldrich, ≥98.5%), 4-pentynoic acid (Sigma-Aldrich, 99 %), α-
bromoisobutyryl bromide (Sigma-Aldrich, 98%), adenosine 5’-diphosphate (ADP, Sigma-
Aldrich, ≥95%), N-hydroxy succinimide (NHS, Fluka, 97 %), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC, Fluka, >98 %), dimethylaminopyridine (DMAP, Acros, 
99 %), sodium azide (NaN3, Acros, 99 %), trifluoroacetic acid (TFA, Acros, 99 %), Nile red (TCI 
AMERICA, Portland, OR), and Tween ®20 (EMD Chemicals, Billerica, MA) were used as 
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delivered without further purification. Methyl methacrylate (Sigma-Aldrich, MMA, 99 %), tert-
butyl acrylate (Sigma-Aldrich, tBA, 98 %), and N, N, N’, N’’, N’’-pentamethyldiethylenetriamine 
(PMDETA, Sigma-Aldrich, 99 %) were first purified by passing through a basic alumina column 
to remove the added inhibitor before using. 
3.2.2  Instruments 
A 500 MHz Varian Mercury system (Palo Alto, CA) was used to record all the 1H NMR 
and 13C NMR spectra of polymer blocks, the acid-labile linker, and the micelles at room 
temperature. Gel permeation chromatography (GPC) analysis was done using a Viscotek GPCmax 
Autosampler system consisting of a pump and Water 2414 refractive index (RI) detector. The 
molecular weight and molecular weight distribution of synthesized polymers were determined 
based on their elution volume on a Styragel HR 4E column compared to a series of poly(methyl 
methacrylate) standards (PolyAnalitik Inc, Canada) using THF as a mobile phase at a flow rate of 
1 mL/min at 35 °C. The data was analyzed using Viscotek OmniSEC Omni-01 software. Perkin-
Elmer FT-IR Spectrum 4100 type A machine was used to confirm the azidation of different 
polymer blocks. The 90Plus particle size analyzer (Brookhaven Instruments Corporation, 
Holtsville, NY) was used to measure micelles’ size and surface charge. The JEOL 3011 high 
resolution electron microscope (JEOL USA Inc., Peabody, MA) was used to image micelles 
morphology. 
3.2.3 Synthesis of amphiphilic PMMA-b-PAA-b-PEG copolymer 
Amphiphilic PMMA-b-PAA-b-PEG triblock copolymer was synthesized by a combination 
of atom transfer radical polymerization (ATRP) technique and “click” coupling reactions (Figure 
3.1). Briefly, the hydrophobic PMMA block was synthesized using the ATRP technique [209] and 
utilized as a macro initiator for copolymerization of tert-butyl acrylate (tBA) to obtain the PMMA-
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b-PtBA-Br copolymer. The bromine (Br) end groups were converted to azide (N3) to allow “click” 
coupling to the alkyne-functionalized PEG block forming the (PMMA-b-PtBA-b-PEG)  
 
Figure 3.1 Scheme for the synthesis of PEG-b-PAA-b-PMMA copolymers. 
copolymer. Acid hydrolysis was used to remove the tert-butyl groups in the central PtBA block 
and obtain the desired (PMMA-b-PAA-b-PEG) copolymer. 
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3.2.4 Synthesis of the hydrophobic PMMA block 
The hydrophobic PMMA block was synthesized by ATRP following published protocols 
[210]. Briefly, the MMA monomer (30 mL, 282 mmol), CuBr catalyst (202 mg, 1.41 mmol), 
N,N,N′,N′,N′′-pentamethyldiethylenetriamine (PMDETA) ligand (294 mg, 1.41 mmol), ethyl-2-
bromoisobutyrate initiator (207 μL, 1.41 mmol), and 30 mL of toluene were introduced into a 
Schlenk tube and the reaction mixture was degassed by three freeze–pump–thaw cycles. The tube 
was then placed in a temperature-controlled oil bath at 40 °C for 21 min. The polymerization 
mixture was diluted with THF, passed through a neutral alumina column to remove the copper 
complex. THF was removed by rotary evaporation and the mixture was precipitated in hexane. 
Results show that 30% of MMA monomers were converted into PMMA block with Mn,theo = 4855 
g/mol, Mn,NMR = 4400 g/mol, Mn,GPC = 4855 g/mol, and Mw/Mn = 1.27. 1H NMR of the PMMA 
block (500 MHz, CDCl3, δ) shows: 4.21 (2H, CH3-CH2-O-CO-C(CH3)2), 3.57 (s, 3H, CH3-O-CO), 
1.95 (2H, CH2-C(CH3)-CO), 1.85 (6H, O-CO-C(CH3)2), 1.22 (3H, CH3-CH2-O-CO-C(CH3)2) 
(Appendix D, Figure D.1). 
3.2.5 Synthesis of azide-functionalized PMMA-b-PtBA-N3 copolymer 
The PMMA block was used as a macro initiator for block copolymerization with tert-butyl 
acrylate to obtain PMMA-b-PtBA block copolymer. Briefly, PMMA (2.22 g, 0.5 mmol), CuBr (72 
mg, 0.5 mmol), PMDETA (104 μL, 0.5 mmol), tBA (7.32 mL, 50 mmol), and 18.3 mL toluene 
were introduced into a Schlenk tube and the reaction mixture was degassed by three freeze–pump–
thaw cycles. The tube was then placed in a temperature-regulated oil bath at 80 °C for 6 h. The 
reaction mixture was diluted with THF before passing through a neutral alumina column to remove 
the copper complex, THF was removed by rotary evaporation and the mixture was precipitated in 
cold methanol/water (80/20 v/v). Mn,NMR: 8000 g/mol. Mn,GPC: 9596 g/mol, Mw/Mn: 1.23. 1H NMR 
of the PMMA-b-PtBA-Br polymer (500 MHz, CDCl3, δ) shows: 4.05 (2H, CH3-CH2-O-CO and 
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1H, CH2-CH-Br), 3.56 (s, 3H, CO-O- CH3), 2.24 (CH2CH-CO), 1.86-0.82 (6H, O-CO-C(CH3)2, 
CO-O-C(CH3)3, CH2-CCH3,) (Appendix D, Figure D.2). 
The terminal Br groups in PMMA-b-PtBA-Br polymer were converted to azide by reacting 
with excess NaN3 to allow “click” coupling to the alkyne-functionalized PEG block. Briefly, 
PMMA-b-PtBA-Br (1 g, 1.25 x 10-1 mmol) and 20 equivalents of NaN3 (0.16 g, 2.5 mmol) were 
stirred together in DMF overnight at 50 °C. The polymer was dissolved in CH2Cl2, extracted with 
water followed by reverse extraction of the water phase with CH2Cl2, combining the organic 
layers, and drying over Na2SO4. Finally, the organic layer was evaporated to obtain the PMMA-
b-PtBA-N3 Polymer. Mn,GPC = 10,073 g/mol, Mw/Mn = 1.18. 1H NMR (500 MHz, CDCl3, δ) shows: 
4.05 (2H, CH3-CH2-O-CO), 3.77 (CH2CH-N3), 3.58 (s, CO-O-CH3), 2.26 (CH2-CH-CO), 1.93-
0.83 (6H, O-CO-C(CH3)2, CO-O-C(CH3)3, CH2-CCH3,) (Appendix D, Figure D.3). 
3.2.6 Synthesis of alkyne-functionalized poly(ethylene glycol) (PEG-Alkyne) 
PEG (Mn: 5000 g/mol) with mono-hydroxyl functional end group (5 g, 1.0 mmol), 4-
pentynoic acid (147 mg, 1.5 mmol), N,N'-dicyclohexylcarbodiimide (DCC) (206 mg, 1.0 mmol), 
4-dimethylaminopyridine (DMAP) (122 mg, 1.0 mmol), and 25 mL of dichloromethane (DCM) 
were introduced into a round bottom flask and allowed to stir overnight at room temperature. After 
filtration of the formed salts, the reaction mixture was concentrated by rotary evaporation and the 
PEG polymer was precipitated three times in diethyl ether followed by filtration. The yield was 
3.80 gm (76%) with 94% functionalization efficiency. 1H NMR (500 MHz, CDCl3, δ): 4.26 (t, 2H, 
CO-O-CH2), 3.71 (t, 2H CO-O-CH2-CH2-O), 3.65 (bs, 450H, O-CH2-CH2), 3.38 (s, 3H, CH2-CH2-
O-CH3), 2.58 (2H, CH2-CH2-CO-O), 2.51 (2H, CH2-CH2-CO-O), 1.99 (1H, alkyne proton) 
(Appendix D, Figure D.4). 
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3.2.7 “Click” coupling of PMMA-b-PtBA-N3 and PEG-Alkyne blocks 
PEG-Alkyne (447 mg, 8.78 x 10-2 mmol, 1 equivalent), PMMA-b-PtBA-N3 (710 mg, 9.66 
x 10-2 mmol, 1.1 equivalent), CuBr (15.1 mg, 1.05 x 10-1 mmol, 1.2 equivalent), PMDETA (21.9 
μL, 1.05 x 10-1 mmol, 1.2 equivalent), and 6 mL of DMF were introduced into a Schlenk tube and 
the reaction mixture was degassed by three freeze-pump-thaw cycles before placing the tube in an 
oil bath at room temperature for 48 h. The reaction mixture was diluted with THF, passed through 
a neutral alumina column to remove the copper complex, and the polymer was precipitated twice 
in diethyl ether and a third time in methanol before being collected by centrifugation. The polymer 
product was dissolved in DCM and precipitated several times in a DCM/hexane mixture to remove 
unreacted PEG following a published protocol [210]. The molecular weight and molecular weight 
distribution of the PMMA-b-PtBA-b-PEG polymer are Mn,GPC = 20,281 g/mol and Mw/Mn = 1.08. 
1H NMR (500 MHz, CDCl3, δ) shows: 7.46 (bs, 1H, triazole ring proton), 4.25 (CH2CH-triazole 
and CO-O-CH2), 4.05 (2H, CH3-CH2-O-CO), 3.64 (bs, O-CH2-CH2), 3.59 (s, CO-O-CH3), 3.38 (s, 
3H, CH2-CH2-O-CH3), 3.05 (2H, triazole-CH2-CH2-CO-O), 2.76 (2H, triazole-CH2-CH2-CO-O), 
2.26 (CH2-CH-CO), 1.93-0.83 (6H, O-CO-C(CH3)2, CO-O-C(CH3)3, CH2-CCH3) (Appendix D, 
Figure D.5). 
The tert-butyl groups in the central block were hydrolyzed using trifluoroacetic acid (TFA) 
to obtain the corresponding carboxylic acid. Briefly, the PMMA-b-PtBA-b-PEG polymer was 
dissolved in DCM followed by adding 10-fold TFA (compared to the molar concentration of the 
tert-butyl groups) at 0°C under argon atmosphere. The reaction mixture was stirred for 30 min at 
0°C and allowed to stand stirring for 24 h at room temperature. DCM and TFA were evaporated 
with an air stream and the PMMA-b-PAA-b-PEG polymer was precipitated in methanol. Mn,GPC = 
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14,860 g/mol and Mw/Mn = 1.15 for the PMMA-b-PAA-b-PEG polymer. 1H NMR (500 MHz, 
CDCl3, δ) showed complete loss of the tert-butyl protons at 1.45 ppm (Appendix D, Figure D.6). 
3.2.8 Synthesis of acid-labile 2,2’-(Propane-2,2-diylbis(oxy))-diethanamine cross-linker 
The acid-labile 2,2’-(Propane-2,2-diylbis(oxy))-diethanamine cross-linker was 
synthesized following published methods [211-215]. Briefly, N-(2-hydroxyethyl)-phthalimide (5.0 
g, 26.15 mmol, 1 equivalent) was completely dissolved in 100 mL of dry benzene and cooled down 
to 0 °C in an ice bath. 2-methoxy propene (2.5 mL, 26.15 mmol, 1 equivalent) was carefully added 
to the solution along with p-toluene sulfonic acid (50 mg, 0.78 mmol). The reaction mixture was 
stirred for 1.5 h while keeping the temperature at 0 °C to avoid loss of the highly volatile 2-
methoxy propene. The flask was then connected to a trap and the mixture was heated to 45 °C 
under high vacuum to remove the methanol formed during the reaction. Additional benzene was 
added and subsequently evaporated for 6 h before quenching the reaction by adding triethylamine 
(6.67 mL) and allowing the reaction mixture to warm up to room temperature. Acetic anhydride 
(1.33 mL) was added to convert unreacted alcohol groups into the corresponding acetate and the 
mixture was stirred overnight. The reaction mixture was then precipitated by drop wise addition 
to hexane. The precipitated powder was collected and recrystallized twice from ethyl acetate 
yielding a white solid. Reaction yield was 70%. 1H NMR (500 MHz, CDCl3, δ) shows: 1.3 (6H, s, 
CH3-C), 3.6 (4H, t, CH2-O), 3.80 (4H, t, CH2-N), 7.4-7.8 (8H, dt, ArH) (Appendix D, Figure 
D.7). Calculated [M + H] + (C23H22N2O6) m/z = 422.15 and found [M + Na] + = 445.1.  
The formed 2,2’-(Propane-2,2-diylbis(oxy))bis(diethane-2,1diyl)bis(isoindoline-1,3-
dione) (400 mg) was deprotected by refluxing overnight with 5 mL of 6 M NaOH to obtain 2,2’-
(Propane-2,2-diylbis(oxy))-diethanamine. The final product was extracted three times by a mixture 
of CHCl3/iPrOH (1/1 v/v) and dried over anhydrous sodium sulfate before evaporating the organic 
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layer to obtain an amber-colored oil. The reaction yield was 50%. 1H NMR (500 MHz, CDCl3, δ) 
shows: 1.36 (6H, s, CH3-C), 1.44 (4H, bs, NH2), 2.81 (4H, t, CH2-NH2), 3.45 (4H, t, CH2-O). 13C 
NMR (500 MHz, CDCl3) δ (ppm for TMS): 24.98, 42.18, 62.88, and 99.79. Calculated [M + H] + 
(C7H19N2O2) m/z = 162.14 and found [M + H] + = 163.14 and [M + Na] + = 185.1. 
3.2.9 Formulation of PMMA-b-PAA-b-PEG polymers into micelles 
Amphiphilic PMMA-b-PAA-b-PEG polymer (10 mg, 8.66x10-4 mmol) was dissolved in 
1.5 mL of THF by stirring for 5 minutes before adding drop wise to 15 mL of water in a sonicating 
water bath. After 2 hours of stirring at room temperature, the solution mixture was transferred to 
a dialysis bag (MWCO 1KDa), which was placed in a large water bath for 24 hours. After 24 h of 
dialysis, the solution of uncross-linked micelles (NSLCM) was lyophilized to obtain the 
corresponding powder. Micelle cross-linkage using the acid-labile 2,2’-(Propane-2,2-
diylbis(oxy))-diethanamine started by acidifying the NSCLM solution down to pH 4.0 by adding 
1N HCl followed by 150 μL of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC) (8.28 mg, 4.32x10-2 mmol) and 150 μL of N-hydroxy succinimide (NHS) (2.49 mg, 
2.16x10-2 mmol) in 100 mM 2-(N-morpholino)ethanesulfonic acid (MES) solution and stirring for 
3 hours to form the NHS esters of the carboxylic acid groups in the central PAA block. The pH of 
the micelle solution was adjusted to 9.2 using a 1N NaOH solution before adding the 2,2’-
(Propane-2,2-diylbis(oxy))-diethanamine cross-linker and stirring the reaction mixture for 9 h at 
room temperature. By adjusting the amount of the 2,2’-(Propane-2,2-diylbis(oxy))-diethanamine 
cross-linker added to the micelle solution, we cross-linked 50% or 100% of the NHS-activated 
carboxylic acid groups in the central PAA block to obtain shell cross-linked micelles (SCLM). 
Specifically, 0.44 mg, 0.27x10-2 mmol and 0.88 mg, 0.54x10-2 mmol of the 2,2’-(propane-2,2-
diylbis(oxy))-diethanamine cross-linker were added to the NHS-activated NSCLM solution to 
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prepare SCLM-50 (50% PAA cross-linkage density) and SCLM-100 (100% PAA cross-linkage 
density), respectively. After 9 hours of stirring at room temperature, the reaction mixture was 
dialyzed against double distilled H2O with pH 9.0 for 24 h before lyophilization (Figure 3.2). 
 
Figure 3.2 A schematic drawing showing the formulation of PEG-b-PAA-b-PMMA polymers into 
NR- and CTX-loaded NSCLM and SCLM micelles. 
 
NR- and CTX-loaded micelles were formulated following the same protocol. Briefly, 
PMMA-b-PAA-b-PEG polymer (15 mg, 8.66 x10-4 mmol) was dissolved in 2.25 mL of THF by 
stirring for 5 minutes before adding the 10% w/w solution of NR or CTX and stirring for an 
additional 30 min at room temperature. This solution mixture was added drop wise into 22.5 mL 
of double distilled water while sonicating to trigger micelle formation followed by stirring for 2 h 
at room temperature to obtain a homogenous solution of NR- or CTX-loaded NSCLM solution. A 
fraction of the NR- or CTX-loaded NSCLM solution was reacted with NHS/EDC to convert the 
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carboxylic acid groups of the PAA block into the activated NHS ester before adding the 2,2’-
(Propane-2,2-diylbis(oxy))-diethanamine cross-linker following the same procedure described 
earlier to prepare SCLM. We controlled the amount of the cross-linker added to the reaction 
mixture to prepare NR- and CTX-loaded SCLM-50 and SCLM-100 micelles to investigate the 
effect of shell cross-linkage density on the loading and release of the NR and CTX cargo. NR- and 
CTX-loaded NSCLM were transferred to dialysis bags with a MWCO of 1 KDa and dialyzed 
against double distilled water containing tween 80 (0.5% w/v) for 2 hours to remove free NR and 
CTX from the micelles solution followed by dialysis against double distilled water for 24 hours 
before lyophilization to obtain NR- and CTX-loaded NSCLM as dry powder. NR- and CTX-
loaded SCLM-50 and SCLM-100 micelles were dialyzed against double distilled water with pH 
9.0 for 24 h before lyophilization.  
After lyophilization, 1 mg of the dry powder was dissolved in 10 mL of THF followed by 
measuring UV absorbance at 550 nm and 230 nm to quantify the amount of NR and CTX present 
in solution using concentration versus absorbance calibration curves (NR concentration range was 
0-50 µM and CTX concentration range was 0-300 µM). We calculated NR and CTX content in 
the dry micelles and their loading efficiency using the following equations. 
𝐍𝐑/𝐂𝐓𝐗 𝐂𝐨𝐧𝐭𝐞𝐧𝐭 (%𝐖𝐞𝐢𝐠𝐡𝐭)  =
𝑪𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑵𝑹 𝒐𝒓 𝑪𝑻𝑿 𝒊𝒏 𝒅𝒓𝒚 𝒑𝒐𝒘𝒅𝒆𝒓
𝑻𝒐𝒕𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒕𝒉𝒆 𝒅𝒓𝒚 𝒑𝒐𝒘𝒅𝒆𝒓
 𝒙 𝟏𝟎𝟎 % …Eq. 3.1 
𝐋𝐨𝐚𝐝𝐢𝐧𝐠 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 (%)  =
𝑪𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑵𝑹 𝒐𝒓 𝑪𝑻𝑿 𝒊𝒏 𝒅𝒓𝒚 𝒑𝒐𝒘𝒅𝒆𝒓
𝑨𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑵𝑹 𝒐𝒓 𝑪𝑻𝑿 𝒖𝒔𝒆𝒅 𝒊𝒏 𝒎𝒊𝒄𝒆𝒍𝒍𝒆 𝒇𝒐𝒓𝒎𝒖𝒍𝒂𝒕𝒊𝒐𝒏
 𝒙 𝟏𝟎𝟎 % Eq. 3.2 
3.2.10 Micelles characterization 
The transition of PMMA-b-PAA-b-PEG polymer from unimers to micelles in aqueous 
solutions was investigated by monitoring the change in NR fluorescence upon increasing 
polymer’s concentration following a published protocol [216]. Specifically, self-assembly of the 
PMMA-b-PAA-b-PEG polymer into micelles and NR encapsulation in the hydrophobic core has 
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been shown to increase its fluorescence signal, which was used to measure the critical micelle 
concentration (CMC) of this amphiphilic polymer. Briefly, PMMA-b-PAA-b-PEG polymer was 
dissolved in DI water at different concentrations ranging from 0.0001 to 0.6 mg/mL. A 0.1 mM 
stock solution of NR in THF was prepared and 10 µL aliquots were transferred to glass vials and 
allowed to air dry for 2 hours at room temperature before adding 1 mL of different polymer 
solutions, mixing in a sonicating water bath for 1 hour, and allowing to stand at room temperature 
for 2 hours. The fluorescence intensity of NR in different polymer solutions was measured (λex= 
550 ± 2 nm, λem= 620 ± 2 nm) using a Fluoroskan Ascent FL plate reader (Thermo Fisher 
Scientific, Waltham, Ma), which was plotted against polymer concentration to determine the 
CMC. Further, the size and zeta potential of empty and NR/CTX-loaded NSCLM, SCLM-50, and 
SCLM-100 micelles were measured using a 90Plus particle size analyzer with ZetaPALS 
capability (Brookhaven Instruments Corporation, Holtsville, NY) at 25 °C following established 
protocols [217]. The morphology of NSCLM was visualized using the JEOL 3011 high resolution 
electron microscope. Briefly, 1 mg of NSCLM micelles was dissolved in 1 mL of distilled water 
by mixing and 10µl of the solution was placed on a 400 mesh grid (Ted Pella Inc., Redding, CA) 
before imaging at a magnification of 10,000X under an accelerating voltage of 300kV. 
3.2.11 NR and CTX Release Studies  
Release of NR and CTX from NSCLM, SCLM-50, and SCLM-100 was investigated as a 
function of solution pH and incubation time. Briefly, 1 mg of NR- and CTX-loaded NSCLM, 
SCLM-50, and SCLM-100 micelles were dissolved in 2 mL of PBS with pH 7.4 or 5.0 before 
transferring to dialysis cassettes (MWCO 3,500 Da), which were immersed in 150 mL of PBS (pH 
7.4) or acetate buffer (pH 5.0) containing 0.5% w/v Tween20 and kept at 37°C while stirring at 
150 rpm. Release of NR from NR-loaded micelles was quantified by drawing four 200 µL samples 
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from the release media after 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 10, 13, and 24 
hours from immersing the dialysis cassettes in the release solution followed by measuring NR 
fluorescence in the collected samples (λex = 550 nm, λem = 620 nm) using the Fluoroskan plate 
reader. Similarly, release of CTX from CTX-loaded micelles was quantified by drawing four 200 
µL samples from the release media after 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours from immersing the 
dialysis cassettes in the release solutions followed by measuring the amount of CTX in each sample 
using high pressure liquid chromatography (HPLC). Briefly, CTX solutions were analyzed using 
a C18 Ascentis Express column (Water Corp, Milford, MA; 2.7 μm, 15 cm x 3.0 mm) connected 
to a Waters HPLC system equipped with a UV dual absorbance detector. A mixture of solvent A 
(650 mL of H2O and 350 mL of ACN) and solvent B (250 mL of H2O and 750 mL of ACN) was 
used as a mobile phase to resolve the released CTX on the C18 column starting with a gradient of 
solvent A:solvent B of 100:0 for 7 min, 62:38 for 29 min, 22:78 for 0.1 min, and 100:0 for 9 min 
at a flow rate of 0.6 mL/min while keeping the column at 40 °C throughout the analytical run. 
Absorbance of the eluting CTX molecules was measured at 230 nm. The total amount of the 
released CTX was calculated based on UV absorbance versus concentration calibration curve 
using the Waters Breeze software. 
3.2.12 Cell Culture 
PC-3 and C4-2B prostate cancer cells were a generous gift from Dr. Evan Keller 
(University of Michigan) and were cultured following published protocols [218]. Briefly, PC-3 
cells were cultured in RPMI-1640 while C4-2B cells were cultured in T-medium, which were both 
supplemented with 10% fetal bovine serum (FBS; Gibco, Carllsbad, CA) and 1% antibiotic-
antimycotic solution (Gibco, Carllsbad, CA). PC-3 and C4-2B cells were incubated at 37 °C and 
5% CO2 while changing the culture medium every other day and passaging the cells using 0.05% 
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Trypsin-EDTA solution after reaching 80% confluence. The passage number for PC-3 and C4-2B 
cells used in the uptake and cytotoxicity studies was in the range between 25 and 40. 
HEK 293 human embryonic kidney cells were a generous gift from Dr. Rhima Coleman 
(University of Michigan) and were cultured in DMEM medium supplemented with 10% fetal 
bovine serum. The cells were incubated at 37 °C and 5% CO2 while changing the culture medium 
every other day and passaging the cells using 0.5% Trypsin-EDTA solution after reaching 80% 
confluence. 
Non-adherent THP-1 acute monocytic leukemia cells were a generous gift from Dr.  Katsuo 
Kurabayashi and Dr. Jianping Fu (University of Michigan), which were cultured in RPMI-1640 
medium supplemented with 10% FBS and 120 µM β-mercaptoethanol. THP-1 cells were activated 
into phagocytic and adherent ones by seeding in 24-well plates at a seeding density of 200,000 
cells/well followed by incubating with regular culture medium supplemented with 200 nM phorbol 
myristate acetate (PMA) for 3 days. Differentiated and adherent THP-1 cells were cultured for 5 
more days in PMA free culture medium before using in uptake studies. Both non-adherent and 
differentiated THP-1 cells were cultured in a humidified 5% CO2 at 37 °C. 
3.2.13 Cellular uptake studies 
PC-3 and C4-2B human prostate cancer cells were seeded in 24-well plates at a seeding 
density of 2 x 105 cells/well and allowed to adhere for 24 h before incubating with free NR, or NR-
loaded NSCLM, SCLM-50 and SCLM-100 micelles at equivalent NR concentrations (1, 2, 5, 10 
and 100 nM) for 2 h. Treated PC-3 and C4-2B cells were washed three times with PBS before 
being trypsinized with 0.05% trypsin-EDTA solution, centrifuged at 1000 rpm for 5 min to form 
pellets, suspended in 1 mL PBS, and analyzed using CyAn™ ADP Flow Analyzer (Beckman 
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Coulter, Brea, CA) at characteristic NR excitation (λex = 488 nm) and emission  (λem = 617 nm) 
wave lengths. 
We investigated the effect of NSCLM, SCLM-50, and SCLM-100 micelles on the fluidity 
of PC-3 and C4-2B cell membranes using the 1,6-diphenyl-1,3,5-hexatriene (DPH) probe 
following published protocols [219]. Briefly, suspensions of PC-3 and C4-2B were washed twice 
with PBS before incubating with 2 µM DPH staining solution for 1 h at 37 °C. Cells were pelleted 
down and washed twice with PBS to remove excess DPH before suspending them in PBS and 
mixing with different micelle solutions at a micelle concentration of 1 nM [220]. We measured the 
fluorescence intensity of DPH (λex = 365 nm and λem = 400–500 nm) directly before adding the 
micelle solution and at different incubation time points up to 1 hour using a QM4 fluorescence 
spectrophotometer (Perkin-Elmer, Waltham, MA). Using DPH fluorescence at different time 
points, we calculated the change in membrane microviscosity using the following equation. 
ro / r = 1 + C(r) T τ / η Eq …………………………………………………………….... Eq. 3.3 
Where ro is the limiting fluorescence anisotropy for DPH, which equals 0.362 and r is the measured 
fluorescence anisotropy at different time points. T is the absolute temperature, τ is the exited state 
lifetime that equals 10 ns, and C(r) is a molecular shape parameter, which equals 8.6 x 105 
poise.deg-1.s-1 [219]. Membrane microviscosity was normalized to its intrinsic (base line) viscosity 
observed before incubating with different micelles to show the change in membrane fluidity in 
response to different micelles as a function of incubation time. 
3.2.14 Anticancer activity of CTX-loaded micelles  
PC-3 and C4-2B cells were seeded at a seeding density of 10 x 103 cells/well in 96-well 
plates and allowed to adhere for 24 h before incubating with free CTX, CTX-loaded NSCLM, 
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SCLM-50 and SCLM-100 micelles at equivalent concentrations (500, 200, 100, 75, 50, 25, 10, 
7.5, 5, 2.5, 1, 0.5 and 0.1 nM) of CTX for 48 h. PC-3 and C4-2B cells were also incubated with 
empty NSCLM, SCLM-50 and SCLM-100 micelles at the same amounts used to deliver different 
doses of CTX to assess the intrinsic toxicity of the micelles. At the end of the incubation period, 
the culture medium was aspirated and cells were incubated with 200 μL of the Resazurin dye at a 
dilution of 1/10 for 3 h before measuring solution fluorescence (λex= 570 nm, λem= 590 nm) using 
the Fluoroskan Ascent FL plate reader. Fluorescence values were normalized to that observed with 
PC-3 and C4-2B cells incubated in the regular culture medium (control group) to calculate the 
percentage of viable cells in response to different treatments. 
3.2.15 Intrinsic micelles toxicity 
We evaluated the micelles toxicity on normal healthy cells by incubating HEK 293 cells 
with empty NSCLM and SCLM-50 micelles. Briefly, HEK 293 cells were seeded at a seeding 
density of 10,000 cells/well in 96-well plates and allowed to adhere overnight before incubating 
with empty (no CTX loading) NSCLM and SCLM-50 micelles for 48 hours. We measured the 
change in the proliferation of HEK 293 cells incubated with increasing concentrations of NSCLM 
and SCLM-50 micelles reaching 50-100 folds the IC50 of CTX when delivered using the same 
carriers compared to untreated HEK 293 cells (control). Change in cell proliferation was quantified 
by aspirating the particles solution and incubating the cells with 200 μL of the Resazurin dye at a 
dilution of 1/10 for 4 hours before measuring solution fluorescence (λex= 570 nm, λem= 590 nm) 
using the Fluoroskan Ascent FL plate reader. Fluorescence values were normalized to that of 
untreated HEK 293 cells (control group) to calculate the percentage of viable cells in response to 
different concentrations of NSCLM and SCLM-50 micelles. 
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3.2.16 Hemocompatibility assays 
We evaluated the hemocompatibility of NSCLM, SCLM-50, and SCLM-100 micelles by 
investigating the adsorption of bovine serum albumin (BSA) as a model serum protein to micelles 
surface as function of time and micelles interaction with red blood cells (RBCs) and platelets in 
vitro. Briefly, blood samples were freshly collected from human volunteers following IRB-
approved protocols into 10 mL EDTA-coated vacutainer tubes before centrifuging at 3,000 rpm 
for 5 min to separate the RBCs from the plasma supernatant. The RBCs layer was washed three 
times with 0.15 M sodium chloride solution before diluting to a total volume of 10 mL using PBS 
(pH 7.4) by gently inverting the tube following published protocols [221]. Approximately 2.5 x 
107 RBCs were mixed with 550 µL of PBS (pH 7.4) and 250 µL of 1 µM NSCLM, SCLM-50 or 
SCLM-100 solutions in Eppendorf tubes that were incubated in a shaking water bath at 37 °C for 
1 h. All tubes were centrifuged at 14,000g for 5 min to pellet down the RBCs and 200 µL of the 
supernatant solutions were transferred into a flat-bottom 96-well plate to measure the UV 
absorbance of the leaked hemoglobin at 541 nm using the Multiskan microplate reader (Thermo 
Fisher Scientific Inc., Waltham, MA). Absorbance of each supernatant solution was normalized to 
the UV absorbance of the supernatant solution of RBCs incubated with Triton X-100 (positive 
control) to calculate % RBCs hemolysis triggered by incubation with different micelle 
formulations. 
To investigate platelets interaction with different micelles, we collected fresh blood from 
euthanized C57BL/6 mice using 20 gauge needles flushed with 3.2% sodium citrate, which was 
mixed with 1 volume HEPES tyrode buffer before centrifuging twice at 50Xg for 10 min to collect 
the platelet rich plasma (PRP) layer. The blood was centrifuged one more time with 1 volume of 
HEPES tyrode buffer at 1200Xg to collect the platelet poor plasma (PPP) layer. We mixed 10µL 
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of 1 µM NSCLM, SCLM-50, and SCLM-100 solutions with 500µL of PRP solution pre-warmed 
to 37 °C followed by monitoring platelets aggregation over a period of 10 minutes using the Aggro-
Link data reduction system (Chrono-log Corporation, Havertown, PA) following published 
protocols [222-224]. Similarly, we monitored platelet aggregation upon mixing 500 µL of PRP 
solution with 10µL of 10µM ADP and collagen (5µM) (1:1 v/v) mixture and PBS as positive and 
negative controls, respectively. 
Finally, we investigated binding of bovine serum albumin (BSA) as a model serum protein 
to SCLM-50 micelles (test) and G5-(NH2)128 dendrimers (positive control) to assess micelles 
opsonization as a function of incubation time. Briefly, SCLM-50 micelles and G5-(NH2)128 
particles were dissolved in PBS (pH 7.4) at a 250 nM particle concentration, mixed with BSA 
solution (0.5 mg/mL) in a quartz cuvette, and incubated at 37 °C for 60 min. We measured the 
fluorescence of BSA tryptophan residues (λex = 280 nm, λem = 300–400 nm) at time zero (I°) and 
at different incubation time points (I) using the QM4 fluorescence spectrophotometer (Perkin-
Elmer, Waltham, MA). We quantified the quenching of BSA fluorescence as a function of 
incubation time by dividing initial BSA fluorescence (I°) by that observed at different time points 
(I). We compared the calculated I°/I ratio for BSA incubated with different particle solutions to 
that of BSA alone at different time points using student's t test to determine the statistical 
significance in the observed change in BSA fluorescence at different time points. 
3.2.17 Macrophages uptake of opsonized micelles 
We investigated the phagocytosis of NSCLM, SCLM-50, and SCLM-100 micelles by 
differentiated THP-1 (dTHP-1) cells to determine their ability to resist opsonization and clearance 
by activated macrophages. Briefly, NR-loaded NSCLM, SCLM-50, and SCLM-100 were 
dissolved in PBS at a NR concentration of 10nM before mixing with 4 mL fetal bovine serum 
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(FBS) and incubating for 1 hour at 37°C to allow micelles opsonization by serum proteins. The 
opsonized particles were then incubated in regular culture medium with dTHP-1 cells for 2 hours 
at 37 °C followed by aspirating the culture medium, washing the cells with PBS, and treatment 
with accutase to detach the THP-1 cells forming a cell suspension. THP-1 cell suspensions were 
centrifuged at 1,000 rpm for 5 min and suspended in PBS before being analyzed by flow cytometry 
using CyAn™ ADP Analyzer to determine the number of NR- labeled cells. Uptake of FITC-IgG 
(Phagocytosis Assay Kit, Cayman Chemical, Ann Arbor, MI) by dTHP-1 cells was quantified 
following manufacturer’s protocol. Uptake of different particles into dTHP-1 cells was normalized 
to that of FITC-IgG (positive control) to determine the ability of different particle to resist 
opsonization by serum proteins and phagocytosis by activated macrophages. 
 
3.3 Results and Discussion 
3.3.1 Synthesis of amphiphilic PMMA-b-PAA-b-PEG polymer 
It is critical to achieve control over the size/molecular weight of the hydrophilic and 
hydrophobic blocks to trigger the assembly of narrowly dispersed micelles. Therefore, we utilized 
a combination of ATRP technique and alkyne-azide cycloaddition “click” reaction to synthesize 
the amphiphilic PMMA-b-PAA-b-PEG polymer with a well-defined composition and molecular 
weight. The literature provides multiple examples of the ability to inhibit non-specific adsorption 
of serum proteins to particles surface and the associated clearance by phagocytic macrophages 
using a “brush” of PEG chains with an average molecular weight of 5kDa [225]. Therefore, we 
decided to use a 5kDA PEG block in the synthesis of the PMMA-b-PAA-b-PEG polymer. Given 
FDA approval of using PMMA, PtBA, and PAA polymers as excipients in controlled-release 
pharmaceutical formulations,[226-228] we similarly used MMA and tBA monomers to synthesize 
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the hydrophobic PMMA block and central PAA block, respectively. To achieve 
hydrophilic/hydrophobic balance in polymer composition, the target molecular weight of the 
hydrophobic block was 5kDa. By adjusting the molar feed ratio of the MMA monomer, the ethyl-
2-bromoisobutyrate initiator, and PMDETA ligand to 200/1/1 and allowing the polymerization 
reaction to go for 21 min at 40 °C, we were able to synthesize the PMMA block with the desired 
molecular weight. Calculating the ratio between the methyl protons of the MMA monomers 
appearing at 3.57 ppm to the initiator protons at 4.21 ppm shows the polymerization of 44 MMA 
units forming the PMMA block with a MnNMR of 4,603 g/mol (Appendix D, Figure D.1). GPC 
analysis of the PMMA block shows a symmetric unimodal peak indicating a MnGPC of 4,855 g/mol 
and a polydispersity index (PDI, Mw/Mn) of 1.27 (Appendix D, Figure D.9). Both 1H NMR and 
GPC analysis confirms successful synthesis of the PMMA block with the desired molecular 
weight. 
We used PMMA-Br as a macro-initiator to start the polymerization of tBA monomers with 
the goal of extending the PMMA block with 25 units of tBA monomers. By adjusting the ratio of 
tBA monomers, PMMA-Br as a macroinitiator, and PMDETA ligand to 100/1/1, 27 tBA 
monomers were polymerized into the PtBA block with MnNMR of 8,063 g/mole as shown in the 
1H 
NMR spectrum (Appendix D, Figure D.2). GPC analysis of the PMMA-b-PtBA-Br copolymer 
shows a symmetric peak with an earlier elution volume indicating a MnGPC of 9,596 g/mol and a 
PDI (Mw/Mn) of 1.23. The terminal Br groups transformed to azide were monitored by 1H NMR 
(Appendix D, Figure D.3) and FT-IR. Similarly, our results show that commercial PEG was 
reacted with 4-pentynoic acid and results show that ≥ 95% of the terminal OH groups were 
converted to alkynes (Appendix D, Figure D.4). PEG-alkyne and PMMA-b-PtBA-N3 were 
“clicked” with a 95% efficiency to form the PMMA-b-PtBA-b-PEG polymer, which is confirmed 
75 
 
by the characteristic proton of the triazole ring at 7.46 ppm (Appendix D, Figure D.5) and loss of 
the azide and alkyne peaks on the FTIR spectrum. The 1H NMR spectrum of PMMA-b-PtBA-b-
PEG polymer shows a MnNMR of 11,547 g/mol while GPC analysis shows a MnGPC of 14,860 g/mol 
and a PDI (Mw/Mn) of 1.15. We decided to polymerize tBA monomers instead of AA monomers 
to avoid the reported reaction of the carboxylic acid groups with the metal complexes, which 
interferes with ATRP [229]. We removed the tert-butyl groups by acid-mediated hydrolysis using 
TFA, which is confirmed by the disappearance of the methyl protons of the tert-butyl groups at 
1.43 ppm (Appendix D, Figure D.6). 
3.3.2 Micelles formulation and characterization   
Similar to other amphiphilic polymers,[230, 231] we expected PMMA-b-PAA-b-PEG 
polymer to self-assemble into micelles with the PMMA block forming the hydrophobic core, the 
PAA block forming a hydrophilic shell, and the PEG block forming an extended brush when added 
to aqueous solutions. To determine the critical micelle concentration (CMC) of PMMA-b-PAA-b-
PEG polymer, we monitored the change in the intensity of NR fluorescence upon increasing 
polymer concentration in water. Specifically, we relied on monitoring the increase in NR 
fluorescence upon transitioning from the bulk aqueous solution to the hydrophobic environment 
within the micelle’s core to determine whether the polymer exists in a unimer or micelle 
conformation similar to previous reports [232, 233]. Results show baseline NR fluorescence in 
presence of low concentrations (0.1-10 µg/mL) of PMMA-b-PAA-b-PEG polymer, which 
gradually increased with the increase in polymer concentration above 11 µg/mL (Figure 3.3). This 
change in NR fluorescence as a function of polymer concentration shows that the PMMA-b-PAA-
b-PEG polymer switches from a unimer to a self-assembled micelle at a critical micelle 
concentration (CMC) of 11 µg/mL (Figure 3.3). Given that the literature shows CMC values 
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ranging between 0.3 and 70 µg/mL for different polymer compositions,[234-239] the observed 
low CMC for PMMA-b-PAA-b-PEG polymer indicates the stability of the formed micelles and 
their potential as drug delivery vehicles. 
 
Figure 3.3 The relationship between the concentration of PEG-b-PAA-b-PMMA polymer and NR 
fluorescence, which is used to calculate the critical micelle concentration (CMC). 
 
One of the key challenges with self-assembled carriers including micelles is their dilution 
when injected into the systemic circulation, which brings polymer concentration below the CMC 
causing rapid release of the loaded cargo before reaching the targeted tissue [240]. For micelles 
loaded with chemotherapeutic agents, the “burst” release of the loaded cargo results in significant 
systemic toxicity,[241] which dramatically reduces their clinical value. To address this issue, we 
designed an acid-labile linker with two terminal amine (NH2) groups, which can react with the 
carboxylic acid groups (COOH) in the central PAA block to cross-link or “stitch” adjacent polymer 
chains forming an acid-sensitive shell. We hypothesized that SCLM will retain the loaded drug 
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better than NSCLM and will selectively release their cargo when internalized via endocytosis into 
cancer cells in response to the acidic pH of the endosomes. 
Both 1H NMR and 13C NMR analysis were used to confirm shell cross-linkage in SCLM 
compared to NSCLM (Figure 3.4). Figure 3.4A shows the 1H NMR spectrum of the diamine 
cross-linker and the four characteristic Ha-Hd proton peaks. Specifically, the protons (Ha) of the 
two germinal methyl groups are observed as a singlet at δ 1.36 ppm, the two CH2 protons (Hb) 
next to the oxygen atoms are observed as a triplet at δ 3.45 ppm, the two CH2 protons (Hc) next to 
the amines are observed as a multiplet at δ 2.81 ppm, and the amine protons (Hd) are observed as 
a broad singlet at δ 1.44 ppm. By comparing the 1H NMR spectra of SCLM and NSCLM (Figure 
3.4B), one can identify the characteristic proton peaks of the linker in SCLM spectrum, which 
confirms successful cross-linkage of the polymer shell. Briefly, the protons (Ha) of the two 
germinal methyl groups are observed as a triplet at δ 0.96 ppm with a coupling constant <1.0 Hz, 
which indicates that Ha protons are tightly packed close to the Hb protons. Similarly, Hb and Hc 
protons are observed as multiplets at δ 3.33 ppm and δ 3.05 ppm while the amine proton (Hd) is 
observed at δ 7.66 ppm indicating the formation of amide bonds confirming shell cross-linkage. 
The 13C NMR spectra of the diamine cross-linker, SCLM, and NSCLM provide additional 
evidence of successful shell cross-linkage in SCLM. Specifically, the 13C NMR spectrum of the 
diamine linker in CDCl3 shows the two germinal CH3 (Ca) at δ 24.98 ppm, the peaks of Cb and Cc 
carbons at δ 62.88 ppm and δ 42.18 ppm, respectively, while the quaternary carbon (Cd) peak is 
observed at δ 99.79 ppm (Figure 3.4C). Similarly, the 13C NMR of SCLM shows Ca, Cb and Cc 
peaks at δ 23.54, δ 62.15 and δ 51.05 ppm (Figure 3.4D), which corresponds to their characteristic 
shifts observed in the cross-linker spectrum. It is important to note that the characteristic cross-
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linker peaks are missing in the 1H NMR and 13C NMR spectra of NSCLM confirming successful 
cross-linkage of the polymer shell in SCLM only. 
 
Figure 3.4 NMR Spectra of the pH-labile cross-linker. 
(A) 1H NMR and (C) 13C NMR of the acid-labile 2,2’-(propane-2,2-diylbis(oxy))-diethanamine cross-
linker recorded in CDCl3. (B) 
1H NMR and (D) 13C NMR of the NSCLM and SCLM micelles recorded 
in D2O, which confirms successful cross-linkage of central PAA blocks. 
 
We characterized the size and surface charge of empty (no cargo) and NR- and CTX-loaded 
micelles in NSCLM and SCLM using dynamic light scattering and zeta potential measurements, 
respectively. Results show that empty NSCLM and those loaded with NR and CTX have similar 
average sizes of 48.41 ± 3.92 nm, 42.88 ± 4.81 nm, and 46.68 ± 7.65 nm, respectively (Figure 
3.5). Similarly, empty and NR- and CTX-loaded SCLM had average diameters of 46.44 ± 11.80 
nm, 47.64 ± 15.48 nm, and 54.06 ± 9.14 nm, respectively. There was no statistical difference 
between empty and loaded micelles regardless of the type of cargo or whether the micelles shell  
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was cross-linked or not, 
which indicates the 
stability of the formed 
micelles and their 
suitability to 
encapsulate a range of 
therapeutic molecules. 
Given that the gaps in 
the endothelial lining of 
tumor vasculature are 
200-600 nm in size,[242] both NSCLM and SCLM can easily penetrate across leaky tumor 
vasculature and accumulate in tumor tissue in vivo. The recorded zeta potential of NSCLM and 
SCLM is -38.1 ± 3.16 mV and -24.5 ± 6.71 mV, respectively. The observed negative surface 
charge of the micelles is probably due to the free COOH groups in the central PAA block, which 
in combination with the PEG brush will minimize non-specific interaction with serum proteins and 
the subsequent clearance by phagocytic macrophage cells (e.g. Kupffer cells in the liver) [225]. 
3.3.3 Nile Red and Cabazitaxel release from NSCLM and SCLM 
Release of drug molecules from the micelles’ hydrophobic core is expected to change as a 
function of solution pH and incubation time. To test this hypothesis, we evaluated the release of 
NR as a model hydrophobic drug encapsulated in NSCLM, SCLM-50, and SCLM-100 in PBS (pH 
7.4) and citrate buffer (pH 5.0) to predict NR release in the systemic circulation and the acidic 
endosomes, respectively. Results show that encapsulation efficiency of NR in NSCLM, SCLM-
50, and SCLM-100 micelles was 82.29 ± 7.53%, 71.64 ± 6.61%, and 81.15 ± 7.32%, respectively. 
 
Figure 3.5 The size of empty, NR-, and CTX-loaded micelles. 
Results show the average + standard error of the mean (SEM) of three 
independent solutions for each micelle formulation. 
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We aimed to achieve 10% w/w loading of NR in different micelles and results show 7.60±0.64%, 
6.69±0.38%, and 7.51±0.59% w/w loading in NSCLM, SCLM-50, and SCLM-100 micelles, 
respectively. Using micelle solutions containing 0.5 mg/mL polymer (i.e. ~50-folds the CMC) and 
encapsulating NR loaded in dialysis bags with MWCO 3,500 Da, we investigated NR release in 
different buffer solutions by measuring NR fluorescence (λex=550 nm and λem=620 nm) at different 
time points up to 30 h. 
Results show that 0.52 ± 0.14% of the loaded NR was released from NSCLM after 3h in 
PBS (pH 7.4) and gradually increased with the increase in incubation time reaching 43.59 ± 1.38% 
of the loaded NR after 30h (Figure 3.6A). In comparison, 0.26 ± 0.11% of the loaded NR was 
released after 3h of dialyzing SCLM-100 micelles against PBS (pH 7.4), which gradually increased 
reaching 28.35 ± 0.88% of the loaded NR after 30h. The observed decline in cumulative NR release 
from SCLM-100 compared to NSCLM clearly indicates that cross-linkage of the carboxylic acid 
groups in the central PAA block significantly reduces “burst” release of the loaded cargo at 
physiologic pH. Reducing the number of cross-linked carboxylic acid groups by 50% in SCLM-
50 resulted in release of 0.3 ± 0.08% of the loaded NR over 3h, which gradually increased reaching 
45.20 ± 0.93% of the loaded NR after 30h. Comparing NR release profiles from SCLM-50 and 
SCLM-100 shows that controlling the degree of cross-linkage of carboxylic acid groups in the 
central PAA block controls the release of the encapsulated cargo in physiologic pH. 
By changing the dialysis solution to citrate buffer, we investigated the release of the 
encapsulated NR in acidic environment (pH 5.0) similar to that of the endosomes. Results show 
that 0.06 ± 0.03% of the loaded NR in NSCLM was released over 1.5h and gradually increased 
reaching 90.93 ± 1.36% of the loaded cargo over 30h (Figure 3.6A). In comparison, 0.68 ± 0.22% 
of the loaded NR in SCLM-100 micelles was released over 3h and increased reaching 46.52 ± 
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1.49% over 30h, which is significantly higher (p ≤ 0.001) than NR released observed in neutral 
PBS (pH 7.4). Similarly, 1.18 ± 0.16% of the loaded NR in SCLM-50 micelles was released over 
3h and increased reaching 80.89 ± 3.69 % over 30h, which is significantly higher (p ≤ 0.001) than 
NR released observed in neutral PBS (pH 7.4). Difference in NR release profiles from SCLM-50 
and SCLM-100 in neutral (pH 7.4) and acidic (pH 5.0) buffers clearly confirms the sensitivity of 
the cross-linked polymer shell to the acidic stimuli as a release mechanism that still discriminates 
between different micelles based on their shell cross-linkage density. 
 
Figure 3.6 NR and CTX release profile from the micelle formulations. 
Release of NR (A) and CTX (B) from NSCLM, SCLM-50 and SCLM-100 micelles in PBS (pH 7.4) and 
acetate buffer (pH 5.0) solutions as a function of time. 
 
Similarly, we prepared CTX-loaded NSCLM, SCLM-50, and SCLM-100 aiming to 
achieve 10% w/w loading of CTX and results show w/w loading of 5.18 ± 0.53%, 3.77 ± 0.36%, 
and 4.72 ± 0.04%, respectively. Results also show that encapsulation efficiency of CTX in 
NSCLM, SCLM-50, and SCLM-100 micelles was 54.63 ± 5.94%, 39.13 ± 3.89%, and 49.58 ± 
0.41%, respectively. Size of CTX-loaded NSCLM and SCLM-100 particles was 46.68 ± 7.65 nm 
and 54.06 ± 9.14 nm, which is similar to the size of empty and NR-loaded micelles (Figure 3.5). 
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We quantified CTX release from CTX-loaded NSCLM, SCLM-50, and SCLM-100 micelle 
solutions loaded in dialysis bags with MWCO 3,500 Da and placed in PBS (pH 7.4) and citrate 
buffer (pH 5.0) at different time points up to 30 h. As expected, CTX was quickly released from 
NSCLM in PBS buffer (pH 7.4) starting with 4.12 ± 0.63% within 2 h and gradually increasing to 
reach 83.21 ± 0.52% of the loaded cargo after 30 hours (Figure 3.6B). CTX release from NSCLM 
into citrate buffer (pH 5.0) started with 14.11 ± 0.34% of the cargo within 1h and gradually 
increased reaching 93.16 ± 1.01% over 30 hours (Figure 3.6B). In comparison, CTX release from 
SCLM-100 micelles in PBS buffer (pH 7.4) started with 4.1 ± 0.83% over 2h and gradually 
increased to 37.43 ± 2.35% over 30h (Figure 3.6B), which is a lower cumulative release than that 
observed with NSCLM due to cross-linkage of 100% of the central acrylic acid groups. In citrate 
buffer (pH 5.0), CTX release started at 8.56 ± 0.22% over 2 hours and increased to 51.26 ± 0.39% 
over 30h due to hydrolysis of the acid-labile linker and release of the encapsulated cargo (Figure 
3.6B). SCLM-50 micelles released 1.09 ± 0.41% of the loaded CTX over 2h in PBS buffer (pH 
7.4) which increased to 40.45 ± 1.83% over 30h, which is a similar release profile to that observed 
with SCLM-100 micelles in neutral pH. However, 9.68 ± 1.40% of the loaded CTX was released 
over 2h in citrate buffer (pH 5.0) and increased to 87.13 ± 0.71% over 30h (Figure 3.6B). This 
higher CTX release in acidic citrate buffer is a result of cross-linkage of only 50% of the central 
acrylic acid groups. These results collectively indicate successful formulation of acid-sensitive 
SCLM that efficiently encapsulated CTX and retained the bulk of the loaded cargo at physiologic 
pH but quickly released it in response to acidic stimuli similar to those established in the endosome. 
3.3.4 Cell uptake of NR-loaded micelles 
We investigated the uptake of NR-loaded NSCLM, SCLM-50, and SCLM-100 micelles 
compared to free NR into PC-3 and C42B cells after incubating for 2h at 37°C by measuring the 
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percentage of NR-labeled cells and the intensity of NR fluorescence per cell as a function of NR 
concentration (1, 5, 10, 100 nM) using flow cytometry. Results show that NR-loading into 
NSCLM, SCLM-50, and SCLM-100 micelles labeled 95.74 ± 0.27%, 45.23 ± 1.61%, and 44.11 ± 
2.64% of PC-3 cells, which is significantly higher than the 24.35 ± 0.56 % cells labeled by free 
NR at NR concentration of 1nM (Figure 3.7A). At higher NR concentrations, 100% of PC-3 cells 
were labeled upon incubation with free NR and NR-loaded micelles. However, by analyzing the 
intensity of intracellular fluorescence at each concentration of NR, results show that NR loading 
into NSCLM, SCLM-50, and SCLM-100 micelles significantly increased the amount of NR 
delivered into the cytoplasm of each cell compared to free NR at 5, 10, and 100nM (Figure 3.7C). 
Incubating C42B cells with 1nM on NR loaded into NSCLM, SCLM-50, and SCLM-100 
micelles results in labeling 43.84 ± 7.97%, 17.37 ± 1.91%, and 18.32 ± 1.31% of the cells 
compared to labeling 21.81 ± 8.43% of the cells by the free NR (Figure 3.7B). At higher NR 
concentrations (5, 10, and 100nM), 100% of PC-3 cells were labeled upon incubation with free 
NR and NR-loaded micelles. However, analysis of the intensity of intracellular fluorescence at 
each concentration shows that NSCLM exhibit higher intracellular fluorescence at a low 
concentration of 5nM compared to free NR (Figure 3.7D). Whereas, SCLM-50 and SCLM-100 
micelles exhibited higher intracellular fluorescence compared to free NR only at the concentration 
of 100nM (Figure 3.7D). 
The observed increase in intracellular fluorescence of PC-3 and C42B cancer cells upon 
incubation with NR-loaded NSCLM compared to free NR and NR-loaded SCLM-50 and SCLM-
100 micelles (Figure 3.7C and 3.7D) is an interesting observation that prompted further 
investigation. 
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Figure 3.7 Uptake of free NR, NR-loaded NSCLM, SCLM-50, and SCLM-100 micelles into PC-3 
(A and C) and C4-2B (B and D) prostate cancer cells. 
Results are the average of four samples + standard error of the mean. Statistical difference between the 
uptake of SCLM-50 and SCLM-100 micelles and the uptake of free NR (*) and NSCLM (#) was 
evaluated using two-way ANOVA with Tukey's multiple comparisons test where * and # denote P ≤ 
0.05, ** and ## denote P ≤ 0.01, *** and ### denote P ≤ 0.001, and **** and #### denote P ≤ 0.0005. 
 
We hypothesized that dilution of the NSCLM solution in the culture medium led to release 
of PEG-b-PAA-b-PMMA unimers that insert the hydrophobic PMMA block into the cell 
membrane causing an increase in membrane fluidity, which enhances the diffusion of NR into the 
cells. To test this hypothesis, we investigated the interaction between NSCLM and SCLM-100 
micelles with PC-3 and C42B cells based on the change in the fluorescence polarization spectrum 
of DPH compared to untreated (control) cells following published methods [220, 243, 244]. 
Results show that PC-3 and C42B cells treated with NSCLM at the concentration needed to deliver 
1nM of NR show a rapid drop in membrane microviscosity within 15 minutes, which remained 
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constant for 60 minutes (Figure 3.8A and B). In comparison, cells treated with SCLM-100 
micelles did not exhibit any change in membrane microviscosity, which was similar to that 
observed with control cells (i.e. treated with DPH only) (Figure 3.8A and B). These results are 
supported by previous reports showing that P85 block copolymer increases the fluidity of the cell 
membrane when used at concentrations lower than the critical micelle concentration (CMC) due 
to interaction of the hydrophobic poly(propylene oxide) block with the lipid bilayer [245]. 
 
Figure 3.8 The change in microviscosity of the membranes of PC-3 (A) and C4-2B (B) prostate 
cancer cells. 
That indicated by the drop in DPH fluorescence as a function of incubation time with NSCLM and 
SCLM-100 micelles. Results show the average of the calculated microviscosity at different time points 
normalized to its initial value (time = 0 min, 1.40 ± 0.22 poise for PC-3 cells and 24.43 ± 0.52 poise for 
C4-2B cells) ± standard error of the mean. 
 
3.3.5 Cytotoxicity of CTX-loaded micelles  
We compared the effect of free CTX and CTX-loaded NSCLM, SCLM-50, SCLM-100 
micelles on the viability of PC-3 and C4-2B prostate cancer cells as a function of CTX 
concentration (0.1-500 nM). Results also show that NSCLM and SCLM-50 micelles exhibit higher 
toxicity towards PC-3 (Figure 3.9A) and C4-2B cells (Figure 3.9B) compared to equal 
concentrations of free CTX. The difference in cytotoxicity of different micelles compared to free 
CTX is indicated by the difference in their IC50 values (Figure 3.9 and Table 3.1). Results show 
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IC50 for CTX-loaded NSCLM and SCLM-50 micelles of 0.60 ± 0.17 and 0.76 ± 0.18 nM, 
respectively, which is significantly lower than the IC50 of free CTX (0.96 ± 0.20 nM) in PC-3 cells. 
Similarly, the IC50 of CTX-loaded NSCLM and SCLM-50 micelles (2.66 ± 0.81 and 1.72 ± 0.52 
nM) in C4-2B cells is significantly lower than that of the free drug (3.33 ± 0.63 nM). The observed 
higher activity of CTX-loaded NSCLM and SCLM-50 micelles can be attributed to higher uptake 
and efficient release of the cytotoxic cargo into cancer cells compared to the free drug. 
 
Figure 3.9 Effect of free CTX, CTX-loaded micelles, and empty micelles on PC-3 (A) and C4-2B 
(B) prostate cancer cells as a function of equivalent CTX concentration (0.01 - 500 nM). 
Each experiment was carried out in triplicate. Results represent the average ± standard error of the mean. 
Curves were fitted to a log concentration versus % surviving fraction (% SF) model using Graphpad 
Prism Software. The IC50 value for each treatment (dotted horizontal line) was calculated using Graphpad 
Prism Software. 
 
It is interesting to note that SCLM-100 micelles are less toxic to cancer cells compared to 
NSCLM and SCLM-50 micelles despite of their similar uptake, which is probably a result of the 
higher cross-linkage density of the central acrylic acid block resulting in slower or incomplete 
release of the encapsulated CTX cargo (Figure 3.8 and Table 3.1). Similarly, the observed higher 
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toxicity of NSCLM and SCLM-50 micelles towards PC-3 cells compared to C4-2B can be 
attributed to a combination of factors including difference in intrinsic sensitivity towards CTX 
indicated by the lower IC50 of free CTX with PC-3 cells compared to C4-2B cells (Table 3.1). 
Table 3.1 The IC50 of free CTX and CTX-loaded micelles in PC-3 and C4-2B cells 
 
Treatment 
IC50 in PC-3 Cells 
(nM) 
IC50 in C4-2B Cells 
(nM) 
Free CTX 0.96 ± 0.20 3.33 ± 0.63 
CTX-loaded NSCLM 0.60 ± 0.17 2.66 ± 0.81 
CTX-loaded SCLM-50 0.76 ± 0.18 1.72 ± 0.52 
CTX-loaded SCLM-100 5.08 ± 0.74 2.66 ± 0.56 
Further, the difference in the kinetics and net micelles uptake by both cells lines indicated 
by higher intracellular fluorescence observed with NR-loaded NSCLM and SCLM-50 micelles in 
PC-3 cells (Figure 3.7C) compared to C4-2B (Figure 3.7D) leading to a higher intracellular 
concentration of the toxic cargo in the cytoplasm of PC-3 compared to C4-2B resulting in higher 
cell death. The difference in micelles uptake between both cell lines has been reported and 
correlated with difference in the composition of the lipid membrane of both cell lines,[243, 246] 
which further supports these results. 
We also examined the effect of empty micelles (i.e. no CTX loading) on PC-3 and C42B 
cells viability using the same micelles concentrations used to deliver a specific concentration of 
the toxic CTX cargo. Results show that empty NSCLM, SCLM-50, and SCLM-100 micelles did 
not negatively affect the viability of PC-3 and C42B cells (Figure 3.9). Furthermore, results also 
show no reduction in proliferation or viability of HEK 293 cells (a model of healthy organs) when 
incubated with NSCLM and SCLM-50 micelles at concentrations that are 50-100 folds higher than 
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the IC50 of CTX delivered by these carriers (Figure 3.10). These results collectively indicate the 
biocompatibility of the polymeric carrier and the acid-labile linker used in micelles formulation. 
 
Figure 3.10 Effect of empty NSCLM and SCLM-50 micelles on HEK 293 cells as a function 
of micelles concentration used to deliver a given concentration of CTX (0.01 - 100 nM). 
Each experiment was carried out in triplicate. Results represent the average ± standard error of 
the mean. 
 
3.3.6 Micelles Hemo-Compatibility 
In vivo activity of our micelles will depend on a delicate balance between their selective 
cytotoxicity towards prostate cancer cells while remaining inert towards healthy tissues and cells. 
The interaction between the micelles and serum proteins, red blood cells (RBCs), and macrophages 
in the blood influences micelles residence in the systemic circulation, clearance by the reticular 
endothelial system (RES), and their distribution profile [247, 248]. Therefore, we investigated 
RBCs hemolysis and platelet activation upon incubating with NSCLM, SCLM-50, and SCLM-
100 micelles to determine their hemo-compatibility. Results show that incubating NSCLM, 
SCLM-50, and SCLM-100 micelles needed to deliver 100 and 1000 nM of CTX with RBCs caused 
hemolysis of only 3-4% of the cells, which is similar to the baseline hemolysis observed upon 
incubating RBCs with PBS (control) (Figure 3.11A). The lack of hemolytic capacity of our 
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micelles at 50-500 folds the IC50 of CTX-loaded micelles is a result of high surface PEGylation, 
which has been shown to reduce the hemolytic activity of particulate carriers [249]. 
 
Figure 3.11 Micelles hemo-compatibility tests. 
(A) The % of RBCs hemolysis upon incubating with NSCLM, SCLM-50, SCLM-100, normalized to 
that observed upon incubating the RBCs with Triton X-100 (positive control) for 60 min. RBCs were 
incubated with PBS (negative control) to determine baseline hemolysis due to cell handling. (B) The % 
of aggregated platelets observed upon incubation with PBS (negative control), NSCLM, SCLM-50, 
SCLM-100, and Col/ADP (positive control). Results show the average + standard error of the mean. The 
observed RBCs hemolysis and platelets aggregation upon incubation with different micelle compositions 
was compared to that observed upon incubation with PBS two-way ANOVA with Tukey’s multiple 
comparisons test. 
 
Similarly, we investigated platelets activation when incubated with NSCLM, SCLM-50, 
and SCLM-100 micelles compared to collagen/ADP mixture (positive control) using light 
transmission aggregometry following published protocols [224]. Results show that SCLM-50 and 
SCLM-100 micelles caused insignificant platelet aggregation that was similar to that observed 
with PBS (negative control) (Figure 3.11B). However, NSCLM caused a slight increase in platelet 
aggregation compared to PBS, which can be attributed to the release of polymer unimers and 
exposure of the hydrophobic PMMA block that bind to and activate platelets in solution. These 
results collectively indicate that SCLM-50 micelles are most suited for in vivo testing. 
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3.3.7 Micelles opsonization & macrophage uptake 
Adsorption of serum proteins to particulate carriers including micelles has been shown to 
be a key mediator of their recognition and clearance by the tissue-fixed macrophages including 
Kupffer cells in the liver plus splenic and lung macrophages [248]. Given that albumin is a major 
plasma protein,[250] we investigated its adsorption to micelles surface to determine the liability 
of different formulations to opsonization by serum proteins in vivo. We measured the change in 
the intrinsic fluorescence of the two tryptophan residues (λex is 280 nm and λem is 300-400 nm) 
located in albumin’s hydrophobic binding site to quantify albumin’s adsorption to SCLM-50 
micelles compared to G5-NH2 (positive control) as a function of time following published 
protocols [64, 77]. Results show that the fluorescence intensity of BSA mixed with SCLM-50 
remained constant throughout the experiment with Iº/I ∼ 1.1, which is similar to the intrinsic 
fluorescence of free BSA (Figure 3.12A). In comparison, cationic G5-NH2 particles strongly 
quenched BSA intrinsic fluorescence indicated by the difference in fluorescence intensity at the 
beginning of the study (Iº) and at different time points (I) with more than 2-folds difference after 
60 minutes. Results clearly show that the PEG corona of SCLM-50 coupled with micelles neutral 
surface suppressed the albumin adsorption to particle’s surface, which will dramatically reduce 
micelles clearance by the reticular endothelial system. 
In order to investigate the effect of exposing different micelles to serum proteins on their 
recognition and internalization by tissue-resident macrophages, we evaluate the uptake of NR-
loaded NSCLM, SCLM-50, and SCLM-100 micelles by differentiated THP-1 cells using flow 
cytometry. Specifically, we incubated 10 nM of NR-loaded NSCLM, SCLM-50, and SCLM-100 
micelles with fetal bovine serum (FBS) for 1 hour at 37°C to allow adsorption of a protein corona 
to particle’s surface before incubating with differentiated and activated dTHP-1 cells. Uptake of 
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fluorescently-labeled FITC-IgG was used to assess the phagocytic activity of dTHP-1 cells (i.e. 
positive control). Results show that FITC-IgG particles were internalized by 90% of dTHP-1 cells 
indicating strong activity of the phagocytosis machinery in these cells (Figure 3.12B). 
 
Figure 3.12 Micelles opsonization and macrophage uptake tests. 
(A) The change in fluorescence intensity of BSA (Iº/I) upon incubation of 0.2 mg/mL BSA with 250 nM 
of cationic G5-(NH2)128 (positive control) and SCLM-50 particles (test) at 37 ºC for 60 minutes. Results 
are the average of three samples ± standard error of the mean. Statistical difference between the 
fluorescence intensity of BSA (Iº/I) upon incubation with different particles compared to that observed 
with free BSA at the same incubation time point is denoted by ** or ****, which indicates p ≤ 0.01 or p 
≤ 0.0005, respectively. (B) Uptake of free NR, NR-loaded SCLM-50 and SCLM-100 micelles, and FITC-
IgG (positive control) into differentiated THP-1 (dTHP-1) cells after incubating for 2 hours at equivalent 
NR concentration of 10 nM. Results are the average of three samples + standard error of the mean. Uptake 
of NSCLM, SCLM-50, and SCLM-100 was compared to that of free NR (#) and FITC-IgG (*) using 
two-way ANOVA with Tukey's multiple comparisons test where * and # denote P ≤ 0.05, ** and ## 
denote P ≤ 0.01, *** and ### denote P ≤ 0.001, and **** and #### denote P ≤ 0.0005. 
 
In comparison, SCLM-50 and SCLM-100 micelles were internalized by only 5% and 7% of 
dTHP-1 cells, which is similar to the uptake of free NR. This indicates the poor recognition of 
cross-linked micelles by activated macrophages even after exposure to serum proteins. In 
comparison, NSCLM labeled 50% of dTHP-1 cells indicating efficient delivery of the NR dye into 
the cells, which is not surprising given the similar effect observed with PC-3 and C4-2B cells 
(Figure 3.7) and the effect of polymer unimers on membrane fluidity (Figure 3.8). The observed 
higher uptake of 10 nM NR-loaded SCLM-50 and SCLM-100 by prostate cancer cells coupled 
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with their significantly lower recognition and uptake by activated macrophages clearly indicate 
their ability to achieve selective delivery of their cargo to cancer cells while evading clearance by 
tissue-resident macrophages. Further, the optimized hydrolysis kinetics of the shell cross-linker in 
SCLM-50 coupled with efficient release of the loaded cargo make this micelle composition 
particularly suited to be a platform for targeted delivery of anticancer drug into prostate cancer 
cells. 
 
3.4 Conclusions 
Results show the successful synthesis of an amphiphilic triblock copolymer (PMMA-b-
PAA-b-PEG), which proved to self-assemble in aqueous media forming nano-sized micelles that 
efficiently encapsulate hydrophobic small molecules like Nile Red and cabazitaxel. Cross-linkage 
of the polymer shell using an acid-labile linker allows controlled and tunable release of the 
cytotoxic cargo. SCLM-50 micelles exhibited the highest cytotoxic activity towards PC-3 and C4-
2B cancer cells in vitro with IC50 values that are significantly lower than free CTX. Further, 
SCLM-50 micelles did not cause hemolysis of RBCs, trigger platelet activation, acquire an 
albumin corona, or get phagocytosed by activated macrophages, which make this micelle platform 
an ideal carrier for selective delivery of CTX into prostate cancer cells. 
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Differential Targeting of Prostate Cancer Cells, Osteoblasts, and 
Osteoclasts using pVTK Peptide- and Bisphosphonate-Functionalized 
Micelles 
 
The material in this chapter is submitted to the following journal: O. Aydin, G. Tiruchinapally, I. 
Youssef, H. Ramaraju, Y. Y. Durmaz, K. Kozloff, D. H. Kohn, and M. ElSayed “Differential 
Targeting of Prostate Cancer Cells, Osteoblasts, and Osteoclasts using pVTK Peptide- and 
Bisphosphonate-Functionalized Micelles”, Advanced Healthcare Materials. 
4.1 Introduction 
In the US, prostate cancer is diagnosed in nearly 1 of every 7 men, with 1 out of 39 men 
dying because of this disease [1]. Tremendous advances in the detection and treatment of primary 
prostate cancer, especially widespread use of prostate-specific antigen (PSA) screening over the 
past four decades, have led to a significant increase in the 5-year survival rate for local prostate 
cancer, which is now almost 100% [1]. Bone is the most frequent site of prostate cancer metastasis 
identified at autopsy in up to 90% of patients dying from prostate cancer bone metastasis [84, 85]. 
Although improving the treatment rate of prostate cancer localized to the prostate gland, 27 % of 
patients whose prostate cancer metastasized to distant organs live more than five years [2].  
It is clear that the reason of prostate cancer mortality is not from the primary cancer burden 
but metastatic spread of the primary cancer cells to distant organs. The bone is the most frequent 
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site of prostate cancer metastasis due to the fact that the bone microenvironment supports fertile 
ground with high turnover rate and protection to the cancer cells described with the “Seed & Soil” 
theory [251, 252]. After occupying sites of highly active bone turnover, cancer cells start to 
manipulate and take control of the bone metabolism to make the environment more favorable place 
for tumor cells [253]. Prostate cancer cells have been shown to secrete the receptor activator of 
nuclear factor κ B ligand (RANKL), which causes differentiation of osteoclast precursor cells into 
active osteoclasts (i.e. bone degrading cells) [107]. Metastatic prostate cancer cells also secrete IL-
8, TNF-α, and vascular endothelial growth factor (VEGF), which induce osteoclastogenesis (i.e. 
formation of osteoclasts) [109-111]. Activated osteoclasts cause localized degradation of the bone 
matrix in the cancer lesion, which causes a sharp drop in the environment pH down to as low as 
4.5 [254]. Degradation of the bone matrix causes an increase in local Ca2+ concentration and the 
release of multiple growth factors such as transforming growth factor-β (TGF-β) and insulin-like 
growth factor (IGF) that support the growth and proliferation of prostate cancer cells [112]. 
Interestingly, prostate cancer cells have been shown to secrete multiple factors such as endothelin-
1 (ET-1), bone morphogogenetic proteins (BMP), platelet-derived growth factor (PDGF), and 
parathyroid hormone-related protein (PTHrP) that directly and indirectly activate osteoblasts 
(bone-forming cells) to deposit new bone matrix at the resorption sites to form crystallized woven 
bone [98, 255]. This irregular bone formation or bone degradation forms defects on the bone 
structure leading to increase hydroxyapatite surface area [256]. Further, excess amount of bone 
formation harbors positively charges Ca2+ ions on apatite surface [257]. The enhancement of 
surface area and Ca2+ provide targeting possibilities to metastasized bone hydroxyapatite. All these 
activation processes of osteoblasts and osteoclasts by metastatic prostate cancer cells and 
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enhancement of cancer cell proliferation by the established osteolytic activity in the cancer lesion 
constitute a “vicious cycle” increases the proliferation of cancer cells [258]. 
According to the type of stimulating factors, either osteoclasts or osteoblasts can be active 
and determine whether the subsequent bone metastasis is osteolytic, osteoblastic, or in mix form. 
Each of these events involves significant molecular interactions between the tumor cells and the 
bone microenvironment cells cross-talks resulting in the disruption of normal bone processes [86, 
88]. Prostate cancer is even radiographically characterized as osteoblastic. Recent molecular 
studies have showed that many bone metastases are mixed and contain both osteoblastic and 
osteolytic characteristics [98]. 
 Current bone metastasis therapeutic options consist of systemic treatments such as 
hormone therapy and chemotherapy. In details, hormone therapy is also called androgen 
deprivation therapy (ADT) that relies on reducing level of male hormones that stimulate prostate 
cancer cells so the goal of ADT is to shrink the prostate cancer. Nevertheless, ADT is not 
completely cure prostate cancer and in a while the cells gain resistance against ADT. Whereas, the 
most effective chemotherapy is taxenes, which approved by FDA for the treatment of primary 
prostate cancer and hormone resistance prostate cancer. The principle action mechanism of taxenes 
is suppression of microtubule functions as stabilizing the microtubules so triggering of apoptosis 
by aberrant mitosis [259]. However, neither are more than palliative care to improve the quality of 
bone metastasized the patients’ life [260]. In addition, in the case of advanced metastatic disease 
various complications may be noticeable, such as osteolysis, spinal cord compression, 
hypercalcemia, increased fracture incidence, and permanent pain due to the fact that bone 
metabolism and microenvironment are disrupted and there is an imbalance between osteoblast and 
osteoclast activity [16, 113]. Moreover, around two-thirds of patients have suffered from bone 
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metastases complain about break-through pain, which is described as a simultaneous appearance 
of strong pain, despite of taking of strong pain killers and/or analgesics [114]. Therefore, pain is 
included in one of the skeletal-related events (SRE) of bone metastasis. 
One of the clinically preferred therapeutics for bone metastatic cancer is bisphosphonates 
(BPs). Pamidronate, Risedronate, Alendronate, and Zolendronate are common BPs in the market 
containing nitrogen in their structures shown in Figure 1.4. This nitrogen content where located 
in a specific orientation of the backbone of the BPs makes these BPs are extremely potent and 
constitute a ‘pharmacophore’ [261]. Zolendronate is shown the most potent BP between all BPs 
because of contribution of nitrogen content and as well as hydrophobic binding pocket of 
imidiazole [262, 263]. In molecular level, BPs knock-down of prenylation of small GTPases like 
Rac, Ras, or Rab, which have a role on cholesterol synthesis, cytoskeletal organization, bone 
resorption, and cell morphology [128]. Inhibition of prenylation reduces the osteoclast activity and 
triggers apoptosis [129]. Because of these pharmacological effects, BPs reduce the resorptive 
capability of osteoclasts. In addition to BPs’s antiresorptive role, BPs have direct functions such 
as antitumor [130], antiangiogenic [131], and antimigratory [132] effects. Further BPs are co-
administered with doxorubicin, docetaxel and paclitaxel [116-119] as cocktail therapies for the 
treatment of bone metastasis. BPs are FDA-approved against osteoporosis, Paget’s disease, 
pediatric bone diseases [264], multiple myeloma, breast cancer metastasis, or prostate cancer to 
bone [115] as an adjuvant therapy to prevent SRE for managing of metastatic bone pain, and 
lowering the risk of broken bones since BPs have potent inhibitor functions on osteoclast-mediated 
bone resorption via binding to the bone mineral and then is taken up by osteoclasts through fluid-
phase endocytosis from acidified bone surface during osteolytic resorption [19]. 
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Neither cancer chemotherapy nor BP-based cancer therapies demonstrate the desired level 
of therapeutic activity in terms of regressing tumor progression or increasing lifespan of bone 
metastasized patients [133]. These therapies have limitations such as environment mediated drug 
resistance in bone metastasis in the presence of plenty cytokines and growth factors [265] and not 
being able to achieve the desired drug concentration in bone because of lacking of bone 
targetebility. Due to drug resistance and inefficient chemotherapy concentration in metastasized 
bone, higher concentration of chemotherapy is employed which leading to non-specific systemic 
side effects [266]. These limitations may be addressed by targeted delivery to cancer lesions and 
specific cells in these lesions [149, 267] . 
Recently, nano- and macromolecular-based approaches have attracted tremendous 
attention as drug delivery vehicles. These vehicles can accumulate into tumor tissue because of the 
enhanced permeation and retention (EPR) effect [242] and enhance the concentration of active 
drug in the tumor microenvironment while minimizing the systemic side effect of the drug. 
However, the drug dose that reaches the bone tumor microenvironment is usually low when only 
relying on passive targeting, resulting in the poor efficacy for tumor inhibition seen clinically. To 
further improve the specific targeting and delivery efficiency to bone metastasis, active targeting 
of nanomedicine approaches is essential. Furthermore, the excess of irregular bone formation or 
bone degradation due to the tumor cells effects on bone anatomy provides active targeting 
opportunities to metastasized tumor lesion in bone. BPs, acidic or phosphorylated peptides, as well 
as noncollagenous proteins have been used to carry higher amount of chemotherapeutics or 
imaging markers to identify metastatic lesions in bone [134, 135]. 
Segvich et. al identified specific peptide sequences (APWHLSSQYSRT, 
VTKHLNQISQSY and STLPIPHEFSRE) using the phage display that contains more than 109 
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bacteriophages expressing sequences against target bone-like mineral and hydroxyapatite disk 
[140]. These identified peptides are specifically designed for dual functions like adhering the 
apatite layer, whereas promoting cell adhesion with the cell recognition perspective so that these 
dual-functional peptides can improve bone tissue regeneration. After selection of interested 
peptide sequences, these peptides were further characterized with computational modeling and 
ELISA to identify the apatite-specific 12-mer peptide VTKHLNQISQSY (VTK) [140, 141]. After 
the identification of the 12-mer peptide, VTK, it was phosphorylated through the serine residue on 
VTK (pVTK) and characterized in terms of bio-mimetic apatite. pVTK had a 10-fold increase in 
adsorption to the apatite surface compared to VTK peptide. Furthermore, pVTK are able to inhibit 
the mineralization in pre-osteoblastic cells with a dose dependent response [142]. As conclusion, 
the logic of using pVTK as a bone targeted ligand, therapeutics encapsulated in pVTK-targeted 
particles might be delivered to metastasized lesion in bone efficiently. In addition, the direct effect 
in osteoblasts may also contribute to inhibition of the cross-talk between the tumor cells and 
osteoblasts.  
Due to high affinity of BPs the bone apatite as mentioned previous, they are well-known 
and well-studied bone targeting small molecules other to carry therapeutics to bone in a carrier 
than their pharmacological activity in osteoclasts and cancer cells [135, 143, 150]. BPs are 
electrostatically adsorbed on bone apatite and chelate to the Ca2+ ions in the bone [268]. Once 
carriers are conjugated with BPs, they gain osteotropicity [150]. Therefore, particles conjugated 
with BPs not only carry therapeutics to metastasized bone to kill the cancer cells but also 
synergistic combination of decorated BPs on the particle to osteoclasts leading to slow-down 
osteoclasts resorption.  
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The main idea of bone targeted particles regardless of targeting ligand type is to deliver 
drugs to the targeted organ. However, there have been no investigation about specificity of these 
targeting ligands in terms of cellular internalization difference between the cells (cancer cells, 
osteoblasts, and osteoclasts) on a bone-like surface. As indicated before, different cancer cells 
interact with bone microenvironment in unique ways leading to variation in whether the tumor 
cells/bone become osteolytic, osteoblastic, or mixed form. For example, PC-3 prostate cancer is a 
known osteolytic character [269, 270], whereas C4-2B prostate cancer is in a mixed form of 
osteolytic and osteoblastic [271, 272]. Despite these differences, the internalization of bone-
targeted particle into various tumor and bone cells through BLS has not been investigated, yet. We 
hypothesize that the internalization rate of bone targeted particles (peptide or BP) could be 
different on BLS compared to regular tissue culture plate surfaces, perhaps due to the cells 
manipulating BLS. 
To the best of our knowledge there is no comparison between peptide (pVTK)- and BP-
targeted particles despite their individual importance on bone targeting in different cell lines on 
BLS. To test the cellular level targetibility differences of pVTK vs BP, we report the synthesis of 
two different novel bone-targeted particles with pVTK- or BP-based, pH sensitive “smart” 
particles (Figure 4.1). In our previous study we developed shell-cross-linked, pH-sensitive 
polymeric micellar particles containing a triblock copolymer composed of a hydrophilic 
poly(ethylene glycol) (PEG) block, a central poly(acrylic acid) (PAA) block, and a hydrophobic 
poly(methyl methacrylate) (PMMA) block [273]. We loaded the non-targeted “smart” particles 
with a model drug and showed amenable drug release kinetics and high biocompatibility. In the 
present work, we functionalized these particles with a PEG block targeted by either pVTK or BP, 
which has a unique function like directing and accumulating the “smart” particles in metastasized 
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bone. We evaluated the physicochemical characterization of varying percentages (5, 10, and 20%) 
ligands on either pVTK or BP-targeted particles. We compared the binding capability of FITC-
labeled pVTK and BP particles upon incubation in aqueous buffer with bone powder at pH 7.4 as 
a function of targeting ligand density. To test our hypothesis, we investigated the uptake of FITC-
labeled, pVTK and BP-decorated particles into PC-3/C4-2B prostate cancer cells, MC3T3 pre-
osteoblasts, RAW 264.7 macrophages, and activated RAW 264.7 osteoclast cells versus non-
targeted control particles. We measured the uptake of these particles into cells cultured on regular 
culture plates versus BLS. We also encapsulated an anti-cancer agent, Cabazitaxel (CTX), into the 
core of non-targeted, pVTK-, or BP-decorated particles. Finally, we explored the therapeutic effect 
of CTX-loaded non-targeted, pVTK, or BP-targeted particles on the following four cell lines on 
BLS: PC-3, C4-2B, MC3T3, RAW 264.7, and RANKL activated RAW 264.7 cells. 
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Figure 4.1 The hypothesized M-pVTK and M-BP nanomedicine-based therapies to modulate 
cancer cells in bone microenvironment. 
 
4.2 Experimental Section 
4.2.1 Materials 
Cabazitaxel (CTX) was purchased from Selleckchem (Houston, US). Imidazole 4-
carboxylic acid (Ark Pharma Inc, USA), tert-butyl-3-bromopropionate (Sigma-Aldrich), 
potassium hydroxide (KOH, Sigma-Aldrich), phosphorus pentachloride (PCl5, Sigma-Aldrich), 
N,N-diisopropylethylamine (DIPEA, Alfa Aesar), 4-pentynoic acid (Aldrich, 98%), N,N'-
dicyclohexylcarbodiimide (DCC, TCI chemicals), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC, Sigma-Aldrich), 2-(N-morpholino)ethanesulfonic acid 
(MES, Sigma-Aldrich) N-hydroxy succinimide (NHS, Fluka), 4-dimethylaminopyridine (DMAP, 
Sigma-Aldrich, 99%), trifluoroacetic acid (TFA, Acros chemicals, 99 %), phosphonic acid 
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(H3PO3, Sigma-Aldrich), phosphonic oxychloride (POCl2, Alfa Aesar), chlorobenzene (Alfa 
Aesar), anhydrous tetrahydrofuran (THF, Sigma-Aldrich, >99.9 %), methyl methacrylate (Sigma-
Aldrich, MMA, 99 %), tert-butyl acrylate (tBA, Sigma-Aldrich, tBA, 98 %), and N, N, N’, N’’, 
N’’-pentamethyldiethylenetriamine (PMDETA, Sigma-Aldrich, 99 %) were first purified by 
passing through a basic alumina column to remove the added inhibitor before using. 1,4-Dioxane 
(Anhydrous, Sigma-Aldrich), triethylamine (TEA, Sigma-Aldrich, ≥99%), 98%), 4-pentynoic acid 
(Sigma-Aldrich, 99 %), sodium hydride (NaH, Sigma-Aldrich, 60% dispersion in mineral oil, 
washed with hexane before use). Poly(ethylene glycol) monomethylether (PEG, Mn: 5000 g/mol, 
Sigma-Aldrich), α-NHS-ω-Alkyne PEG (Mn: 5000 from Rapp Polymere, Germany). Copper (I) 
bromide (CuBr, Sigma-Aldrich, 99.9%), sodium azide (NaN3, Acros Chemicals), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide HCl (EDC.HCl, Aldrich), hydroxybenzotriazole (HOBt, 
Sigma-Aldrich), triethylamine (TEA, Sigma-Aldrich), tetrahydrofuran anhydrous (THF, Sigma-
Aldrich, >99.9 %), dichloromethane anhydrous (DCM, Sigma-Aldrich, >99.9 %), N-N-
dimethylformamide anhydrous (DMF, Sigma-Aldrich, >99.9 %), resazurin sodium salt (Sigma-
Aldrich), hydroxyapatite (HA, Sigma-Aldrich, reagent grade powder), Trizma® Pre-set crystals 
(pH: 7.5, Sigma-Aldrich), pVTK-NH2 (targeting ligand made with 12 amino acids, phosphorilated 
VTKHLNQISQSY, GeneScript, NJ, US) were used as received.  
 
4.2.2  Instruments 
All the polymer blocks, the acid-labile linker and the micelles were characterized by 
nuclear magnetic resonance spectroscopy (NMR) at room temperature. 1H NMR and 13C NMR 
spectra of 5–10 % (w/w) solutions in CDCl3, DMSO-d6 or D2O were recorded on 400, 500 and 
700 MHz Varian Mercury systems (Palo Alto, CA) at room temperature, respectively. NMR 
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spectra were referenced using Me4Si (0 ppm), residual CHCl3 (δ 1H-NMR 7.26 ppm, 13C-NMR 
77.0 ppm, CD3SOCD3 (δ 1H-NMR 2.49 ppm, 13C-NMR 39.5 ppm and D2O (δ 1H-NMR 4.56 ppm). 
Gel permeation chromatography measurements were obtained from a Viscotek GPCmax 
Autosampler system consisting of a pump and Water 2414 refractive index (RI) detector. The 
molecular weight and molecular weight distribution of final polymers were determined based on 
their elution volume on an Styragel HR 4E column compared to a series of poly(methyl 
methacrylate) standards (PolyAnalitik Inc, Canada) using THF as a mobile phase at a flow rate of 
1 ml/min at 35 oC. Data were analyzed using Viscotek OmniSEC Omni-01 software. 
Perkin-Elmer FT-IR Spectrum 4100 type A was used in determination of the formation of 
the azide function group. 
Dynamic Light Scattering (DLS) 90Plus particle size analyzer (Brookhaven Instruments 
Corporation, Holtsville, NY) was used to measure micelles size and surface charge of the micelles. 
4.2.3 Synthesis of non-targeted, pVTK targeting, and BP-targeting amphiphilic 
copolymers 
4.2.3.1 Synthesis of PMMA-Br (1) 
The hydrophobic PMMA block was synthesized by ATRP reaction by following our 
published protocol [273]. Briefly, the MMA monomer (30 mL, 282 mmol), CuBr catalyst (202 
mg, 1.41 mmol), PMDETA (294 mg, 1.41 mmol), ethyl-2-bromoisobutyrate as initiator (207 μL, 
1.41 mmol), and 30 mL of toluene were introduced into a Schlenk tube and the reaction mixture 
was degassed by three freeze–pump–thaw cycles. The reaction mixture was then placed in a 
temperature-controlled oil bath at 40 °C for 21 min (Figure 4.2). After the given time, the 
polymerization mixture was diluted with THF, passed through a neutral alumina column to remove 
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the copper complex. THF was removed by rotary evaporation and the mixture was precipitated in 
hexane. PMMA-Br (1) Conversion: 30%, Mn,NMR = 5201 g/mol.  
1H NMR of the PMMA block (700 MHz, CDCl3): δ 1.12 (3H, CH3-CH2-O-CO-C(CH3)2, 
Ha), 1.60 (6H, O-CO-C(CH3)2, Hc), 1.80 (s, 3H, CH2-C-CH3, He), 1.80-2.00 (2H, CH2-C(CH3)-
CO, Hd), 3.57 (s, 3H, CH3-O-CO, Hf), 4.08 (2H, CH3-CH2-O-CO-C(CH3)2, Hb); 13C NMR (175 
MHz, CDCl3): δ 14.10 (Ca), 16.44, 18.74, 22.64 (Cd), 25.25, 29.04, 31.57 (Ch), 34.64, 40.82 (Ce), 
44.53, 44.88 (Cf), 51.80 (Cj), 54.37 (Cg), 60.04 (Cb), 68.0 (Cg-Br), 176.97 (Cc), 177.78 (Ci), 178.09 
(Ci). 
4.2.3.2 Synthesis of PMMA-b-PtBA-Br copolymer (2) 
The PMMA block was used as a macro initiator for block copolymerization with tert-butyl 
acrylate to obtain PMMA-b-PtBA block copolymer. Briefly, PMMA-Br (1, 2.22 g, 0.5 mmol), 
CuBr (72 mg, 0.5 mmol), PMDETA (104 μL, 0.5 mmol), tBA (7.32 mL, 50 mmol), and 18.3 mL 
toluene were introduced into a Schlenk tube and the reaction mixture was degassed by three 
freeze–pump–thaw cycles. The reaction mixture was then placed in a temperature-regulated oil 
bath at 80 °C for 6 h. The reaction mixture cooled down to room temperature and diluted with 
THF before passing through a neutral alumina column to remove the copper complex, THF was 
removed by rotary evaporation and the mixture was precipitated in cold methanol/water (80/20 
v/v) to obtain PMMA-b-PtBA-Br (2). In the 1H NMR we found 21 CH protons of PtBA polymer 
indicating that we were able to attach 21 tBA units. Mn,NMR: 7892g/mol.  
1H NMR of the PMMA-b-PtBA-Br block copolymer (700 MHz, CDCl3): δ 1.22 (3H, CH3-
CH2-O-CO-C(CH3)2, Ha), 1.52 (6H, O-CO-C(CH3)2, Hc), 1.42 (s, 9H, -C-(CH3)3, Hi), 1.80 (s, 3H, 
CH2-C-CH3, He), 1.80-1.94  (2H, CH2-C(CH3)-CO, Hd), 1.96 (CH2CH-CO, Hh), 2.24 (CH2CH-
CO, Hg), 3.57 (s, 3H, CH3-O-CO, Hf), 4.08 (3H, CH3-CH2-O-CO-C(CH3)2, Hb & Hh-Br); 13C NMR 
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(175 MHz, CDCl3): δ 16.29 (Ca), 18.60, 27.57 (Ch), 27.89 (Cn),27.96 (Cd), (29.56, 29.90, 30.206 
Cg),  37.25 (Ce), (41.28, 41.76, 42.21, (Cl), 44.41, 44.53 (Ck), 44.75, 45.40 (Cf), 51.70, 52.42, 52.58 
(Cj), 53.30, 54.10, 54.27, 54.32, 60.38 (Cb), 80.21 (Co), (173.82, 174.07 (Cc), (176.85, 177.01, 
177.68 (Cm), (177.95, 177.98, 178.27 (Ci). 
4.2.3.3 Synthesis of azide functionalized PMMA-b-PtBA-N3 copolymer (3) 
The terminal Br groups in PMMA-b-PtBA-Br polymer were converted to azide by reacting 
with excess NaN3 to allow “click” coupling to the alkyne-functionalized PEG block. Accordingly, 
PMMA-b-PtBA-Br (2, 1 g, 1.25 x 10-1 mmol) and 20 equivalents of NaN3 (0.16 g, 2.5 mmol) were 
stirred together in DMF at 50 °C for 24 h. The polymer was dissolved in DCM, extracted with 
water followed by reverse extraction of the water phase with DCM, combined the organic layers, 
washed with brine solution and dried over Na2SO4. Finally, the organic layer was evaporated to 
obtain the PMMA-b-PtBA-N3 (3). Mn,GPC = 10,073 g/mol, Mw/Mn = 1.18. 
1H NMR of the PMMA-b-PtBA-N3 block co-polymer (700 MHz, CDCl3): δ 1.12 (3H, CH3-
CH2-O-CO-C(CH3)2, Ha), 1.24 (6H, O-CO-C(CH3)2, Hc), 1.42 (s, 9H, -C-(CH3)3, Hi), 1.80 (s, 3H, 
CH2-C-CH3, He), 1.80-1.94 (2H, CH2-C(CH3)-CO, Hd), 1.96 (CH2CH-CO, Hh), 2.24 (CH2CH-CO, 
Hg), 3.57 (s, 3H, CH3-O-CO, Hf), 4.08 (3H, CH3-CH2-O-CO-C(CH3)2, Hb); 13C NMR (175 MHz, 
CDCl3): δ 16.42 (Ca), 18.60, 27.92 (Ch), 27.97 (Cn), 28.06 (Cd), 38.21 (Ce), (41.37, 41.82, 42.28 
Cg), (44.52, 44.62 (Ck), (44.84, 44.87 (Cf), 51.77 (Cj), 52.47, 53.38 (Cl), 54.17, 54.36,  60.46 (Cb), 
80.30 (Co), (174.11 (Cc),  (176.94, 177.10 (Cm), (177.76, 178.02, 178.06 (Ci). 
4.2.3.4 Synthesis of Alkyne-PEG (3a) 
Commercially available 5 kDa PEG-OH (5.0 g, 1 mmol) and 4-pentynoic acid (147 mg, 
1.5 mmol) were dissolved in DCM (25 mL) and added DMAP (122 mg, 1 mmol), DCC (310 mg, 
1.5 mmol) in DCM (25 mL) at room temperature and stirred for overnight. The salts were filtered; 
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the filtrate was concentrated and precipitated in diethyl ether (3 x 500 mL) to obtain compound 
(3a) in 3.6 g with 71% yield and 92 % functionalization efficiency.  
1H NMR (500 MHz, CDCl3): δ 1.93 (s, 1H, alkyne proton), 2.38-2.60 (m, 10H, CH2CH2-
CO-O), 3.17 (s, 2H), 3.30 (s, 3H, O-CH3), 3.40-3.80 (bs, 450H, OCH2CH2), 4.18 (s, 2H CO-O-
CH2-CH2-O); 13C NMR (125 MHz, CDCl3): δ 14.07, 33.00, 58.78, 63.58, 68.43, 68.81, 69.43, 
69.82, 70.32, 71.26, 71.68, 72.21, 82.19, 106.38, 138.94, 157.07, 171.46. MALDI [M]+ Alkyne-
poly(ethylene glycol) obsd 5008. 
4.2.3.5 Synthesis of PMMA-b-PtBA-PEG (4) 
PEG-Alkyne (3a, 476 mg, 9.52 x 10-2 mmol, 1.1 equivalent), PMMA-b-PtBA-N3 (3, 710 
mg, 8.65 x 10-2 mmol, 1 equivalent), CuBr (15.1 mg, 1.05 x 10-1 mmol, 1.2 equivalent), PMDETA 
(21.9 μL, 1.05 x 10-1 mmol, 1.2 equivalent), and 6 mL of DMF were introduced into a Schlenk 
tube and the reaction mixture was degassed by three freeze-pump-thaw cycles and stirred at room 
temperature for 48 h. The reaction mixture was diluted with THF, passed through a neutral alumina 
column to remove the copper complex, and the polymer was transferred into dialysis cassette 
(MWCO 7 kDa) and dialyzed for 1 day against DI water and lyophilized to obtain crude polymer. 
The polymer product was dissolved in DCM and precipitated several times in a hexane to remove 
unreacted PEG material. The molecular weight of the PMMA-b-PtBA-b-PEG polymer (4) was 
calculated as 12,900 g/mol using 1H NMR data.  
1H NMR (500 MHz, CDCl3) δ 6.96 (bs, 1H, triazole ring proton), 4.25 (CH2CH-triazole 
and CO-O-CH2), 4.05 (2H, CH3-CH2-O-CO), 3.64 (bs, O-CH2-CH2), 3.59 (s, CO-O-CH3), 3.38 (s, 
3H, CH2-CH2-O-CH3), 3.05 (2H, triazole-CH2-CH2-CO-O), 2.76 (2H, triazole-CH2-CH2-CO-O), 
2.26 (CH2-CH-CO), 1.93-0.83 (6H, O-CO-C(CH3)2, CO-O-C(CH3)3, CH2-CCH3). 
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4.2.3.6 Boc deprotection from PMMA-b-PtBA-b-PEG (5) 
PMMA-b-PtBA-b-PEG (4, 20 mg, 0.0014 mmol), was dissolved in DCM (2 mL) and added 
TFA (1.5 mL) at 0 °C and stirred at room temperature for overnight. The solvents were evaporated 
on rotavapor (40 °C) and the residue was transferred into dialysis bag (MWCO 1 kDa) and dialyzed 
for 1 day against DI water and lyophilized to obtain PMMA-b-PAA-b-PEG copolymer (5), in 18 
mg, 94% yield.  
1H NMR (700 MHz, CDCl3): δ 6.92 (bs, 1H, triazole ring proton), 4.25 (CH2CH-triazole 
and CO-O-CH2), 4.05 (2H, CH3-CH2-O-CO), 3.64 (bs, O-CH2-CH2), 3.59 (s, CO-O-CH3), 3.38 (s, 
3H, CH2-CH2-O-CH3), 3.05 (2H, triazole-CH2-CH2-CO-O), 2.76 (2H, triazole-CH2-CH2-CO-O), 
2.26 (CH2-CH-CO), 1.93-0.83 (6H, O-CO-C(CH3)2, CH2-CCH3). The molecular weight of the 
PMMA-b-PAA-b-PEG copolymer (5) are Mn,NMR = 11,722 g/mol. 
4.2.3.7 Synthesis of PMMA-b-PtBA-b-PEG-NHS copolymer (6) 
Compound PMMA-b-PtBA-N3 polymer (3, 60 mg, 5.12 x 10-2 mmol per azide unit), CuBr 
(11 mg, 7.68 x 10-2 mol), PMDETA (16 µL, 1.45 x 10-7 mmol) and commercially available Alkyne-
PEG-NHS (40 mg, 8.04 x 10-3 mmol) in DMF (3 mL) was added into a schlenck tube (25 mL) 
under argon atmosphere. The mixture was degassed by three freeze–pump–thaw cycles and stirred 
at room temperature for 2 days. After the given time, the reaction mixture was diluted with THF 
and passed through a neutral alumina column to remove the copper complex and evaporated the 
solvent by rotary evaporator. The mixture was precipitated in cold diethyl ether. After decantation 
of ether, material was dried under air, then dissolved in DCM and hexane was added into it until 
it gets cloudy (precipitated), obtained PMMA-b-PtBA-b-PEG-NHS (6) in 70 mg, 70% yield. 
1H NMR (500 MHz, CDCl3, δ): 0.80 (s, 50H, Hc), 0.88 (s, 3H), 0.98 (s, 26H, He), 1.08 (s, 
3H), 1.14-1.24 (t, 6H, including Ha), 1.29 (s, 8H), 1.39 (bs, 199H, Hi), 1.77 (bs, 35H, Hd), 1.82-
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2.04 (m, 27H), 2.18 (bs, 20H, Hg), 2.28 (bs, 15H, Hg), 2.36 (t, 6H, J = 7.0 Hz), 2.48 (t, 2H, J = 2.0 
Hz), 2.54 (t, 2H, J = 2.0 Hz), 2.90 (s, 3H), 2.99 (s, 4H), 3.34-3.50 (m, 14H), 3.55 (s, 96H, Hf), 3.60 
(s, 450H, PEG protons, Hl), 3.74 (t, 8H, J = 5.0 Hz, Hk), 4.04 (t, 2H, J = 6.0 Hz, Hb), 4.19 (t, 1H, 
J = 5.0 Hz, Hh), 7.46 (bs, 1H, Hj); 13C NMR (125 MHz, CDCl3): δ 14.73 (Ca), 16,35, 18.64, 24.99 
(Cc), 27.85, 27.94, 28.01 (all 3 belongs to Boc carbons, Ci), 29.59 (Ce), 35.05, 35.27 (Cg), 35.59, 
37.11, 39.10, 3917, 41.29, 41.76, 42.22, 44.44, 44.79, 51.69 (Cf), 52.56, 54.11, 54.31 (Cd), 60.38 
(Cb), 68.44 (Ck), 69.71, 69.78, 69.87, 70.00, 70.10 (Cl), 70.33, 70.45, 72.46 (Ch), 80.23 (Boc 
quaternary carbon), 173.85 (C3), 174.07, 176.85 (C1), 177.68 (C2), 177.97 (C4). 
4.2.3.8 Synthesis of PMMA-b-PtBA-b-PEG-pVTK polymer (7) 
PMMA-b-PtBA-b-PEG-NHS (6, 27 mg, 2.16 x 10-3 mmol) was dissolved in DMF (1.5 
mL) and added EDC (1.24 mg, 6.48 x 10-3 mmol), HOBt (0.87 mg, 6.48 x 10-3 mmol), and DIPEA 
(2.25 µL 1.29 x 10-2 mmol) and stirred for 15 min.  pVTK (5.45 mg, 2.59 x 10-3 mmol) was 
dissolved in DMSO (1 mL) and added slowly, drop wisely and stirred at room temperature for 2 h 
then heated to 35 °C for 2 days. After the given time, the mixture was cooled down to room 
temperature diluted with DI water (2 mL) and transferred into dialysis cassette (MWCO 7 kDa) 
and dialyzed against deionized water for 24 h followed by lyophilization to obtain PMMA-b-
PtBA-b-PEG-pVTK copolymer (7) in 28 mg, 90% yield.  
1H NMR (700 MHz, CD3SOCD3): δ  0.73 (s, 50H, Hc), 0.84 (s, 12H, valine CH3), 0.93 (s, 
26H, He), 1.06 (s, 3H), 1.22 (s, 16H, including Ha), 1.29 (s, 8H), 1.38 (bs, 200H, Hi), 1.60-2.04 
(m, 75H, including Hd), 2.04-2.20 (m, 20H), 2.22-2.30 (m, 20H, Hg), 2.30-2.34 (m, 12H), 2.34-
2.44 (m, 6H), 2.58 (bs, 2H), 2.72 (m, 2H), 2.79 (s, 3H), 2.93 (s, 4H), 3.14-3.24 (m, 14H), 3.35-
3.45 (m, 100H, Hf), 3.45-3.75 (s, 450H, PEG protons, Hl), 3.78-3.84 (m, 8H, Hk), 4.02 (t, 2H, J = 
5.0 Hz, Hb), 4.19 (t, 1H, Hh), 4.74 (s, 1H), 5.03 (s, 1H), 5.31 (s, 1H), 5.54 (s, 2H), 5.63 (s, 4H), 
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6.46-8.50 (m, 14H, including Hj); 13C NMR (175 MHz, CD3SOCD3): δ 13.92, 14.17 (Ca), 16.06, 
16.24, 18.43, 22.07, 24.43, 24.86 (Cc), 25.08, 26.58, 27.46, 28.44, 28.55, 28.68, 28.83 (all 6 
belongs to Boc carbons, Ci), 29.01, 29.46 (Ce), 31.27, 33.46, 33.57, 34.06, 35.08 (Cg), 36.60, 38.56, 
40.81, 41.47, 43.87, 44.25, 51.70 (Cf), 53.76 (Cd), 60.08 (Cb), 62.62, 63.06, 64.12, 65.46, 66.94, 
69.10 (Ck), 69.27, 69.42, 69.59, 69.65, 69.77, 70.46, 71.20 (PEG carbons, Cl), 72.47 (Ch), 79.92 
(Boc quaternary carbon), 83.72, 109.90, 118.90, 124.06, 126.32, 127.66, 129.61, 142.84, 169.99, 
170.28, 171.01, 171.58(C3), 172.93, 173.21, 173.77, 176.13 (C1), 177.09 (C2), 177.33 (C4); 31P 
NMR (283 MHz, CD3SOCD3): δ 2.04.  
4.2.3.9 Synthesis of PMMA-b-PAA-b-PEG-pVTK polymer (8) 
PMMA-b-PtBA-b-PEG-pVTK copolymer (7, 22 mg, 1.51 x 10-3 mmol) was dissolved in 
DCM:TFA (1.5:1, 3 mL) and stirred at 0 °C for 2 h, later stirred at room temperature for another 
2 h. The solvents were evaporated by rotary evaporation (temperature 30 °C) and added DCM (2 
mL) several times and evaporated until there is no TFA left. Finally, the compound was dissolved 
in double distilled water/THF mixture and transferred into dialysis cassette (MWCO 7 kDa) and 
dialyzed against deionized water for 24 h followed by lyophilization to obtain PMMA-b-PAA-b-
PEG-pVTK copolymer (8) in 18 mg, 90% yield. 
1H NMR (700 MHz, CDCl3): δ  0.75-0.90 (bs, 69H, Hc, Valine CH3), 1.00 (bs, 26H, He), 
1.11 (s, 4H), 1.24 (s, 110H, including Ha), 1.36-145 (m, 16H), 1.61 (bs, 15H), 1.74-2.06 (m, 50H, 
including Hd), 2.22-2.60 (m, 16H, Hg), 2.96 (s, 3H), 3.04 (s, 4H), 3.42-3.54 (m, 100H, Hf), 3.54-
3.75 (s, 450H, PEG protons, Hl), 3.86-3.94 (m, 8H, Hk), 3.98-4.24 (m, 16H, including  Hb), 4.32-
4.64 (m, 7H, including Hh), 4.88 (bs, 1H), 5.02 (s, 1H), 5.28 (s, 1H), 5.33 (s, 2H), 6.03 (s, 2H), 
6.54-7.12 (m, 6H), 7.30-8.50 (m, 20H, including Hj, COOH peaks); 13C NMR (175 MHz, CDCl3): 
δ 13.99, 14.88 (Ca), 16.45, 18.73, 22.63, 24.85 (Cc), 25.15, 27.16, 27.86, 29.07, 29.19, 29.30, 
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29.40, 29.69 (Ce), 31.86, 32.68, 33.53, 33.96, 34.09, 34.99, 35.71, 35.84 (Cg), 37.32, 37.60. 39.50, 
41.37, 44.51, 44.85, 45.48, 51.77 (Cf), 52.50, 53.38 (Cd), 54.13, 54.37, 60.48 (Cb), 63.29, 64.50, 
64.73, 65.08, 65.56, 66.00, 67.41, 67.99, 68.33, 68.53, 69.57 (Ck), 69.93, 70.15, 70.42 (PEG 
carbons, Cl), 71.36, 72.30, 73.24, 75.99, 82.64, 114.38, 114.71, 116.03, 127.73, 129.61, 129.81, 
129.87, 130.00, 159.21, 172.05, 173.88, 174.19, 174.26, 176.14, 176.96, 177.12, 177.77, 178.07, 
178.36; 31P NMR (283 MHz, CDCl3): δ -20.22.  The approximate molecular weight of PMMA-b-
PAA-b-PEG-pVTK is 13190. 
4.2.3.10 Synthesis of 1-(3-(tert-butoxy)-3-oxopropyl)-1H-imidazole-4-carboxylic acid (9)  
N-alkylation of Imidazole 4-carboxilic acid was carried out according to known method 
with some modifications [274]. Commercially available imidazole 4-carboxilic acid (0.25 g, 2.23 
mmol) was dissolved in DI water (3 mL) and added KOH (0.375 g, 6.69 mmol) at room 
temperature and stirred for 3 h. After the given time, water was evaporated by rotary evaporation 
and dried over high vacuum. The residue was dissolved in DMSO:1,4 Dioxane (4:1, 5 mL) and 
added DIPEA (1.16 mL, 6.69 mmol) followed by tert-butylbromo-propionate (0.74 mL, 4.46 
mmol) at room temperature and stirred at 50 °C for 24 h. After the given time, the reaction mixture 
was cooled down to 0 °C, and neutralized with 1 N HCl and extracted twice with chloroform:iso-
propanol mixture (8:2, 100 mL). The combined organic layer was washed with brine (25 mL) and 
dried over Na2SO4. The solvents were evaporated; residue was purified by precipitation method 
(THF: Hexane, 1:10) afforded undesired compound (9a), in 0.3 g, 73% yield.  
1H NMR (400 MHz, DMSO-d6): δ 2.07 (t, 2H, J = 10.5 Hz, 1CH2, Hd), 2.53 (t, 2H, J = 
10.5 Hz, 1CH2, Hc), 7.30 (bs, 1H, Ha), 7.55 (bs, 1H, Hb). ESI-MS [M-H]- C7H7N2O4 calcd 183.04, 
obsd 183.03. 
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We also tried other neutralization methods like using citric acid, Amberilite 120 H+ resin, 
could not serve the purpose. Later, we adopted a simple method; evaporating organic solvents on 
rotary evaporator and air dry to obtain solid 1-(3-(tert-butoxy)-3-oxopropyl)-1H-imidazole-4-
carboxylic acid (9). This dry material was used for further reaction without purification. A portion 
of the crude material (20 mg) was purified for analytical confirmation purpose. The material was 
dissolved in chloroform:iso-propanol (7:3) and purified by preparative column chromatography 
using chloroform:iso-propanol (7:3) afforded compound (9), in 12 mg, 70% yield. The yield is 
based on recovered pure material after column chromatography.  
1H NMR (700 MHz, DMSO-d6): δ 1.36 (s, 9H, C-(CH3)3, He), 2.71 (bs, 2H, CH2, Hd), 4.12 
(bs, 2H, CH2, Hc), 7.30 (bs, 1H, Ar-CH, Ha), 7.45 (bs, 1H, Ar-CH, Hb); 13C NMR (175 MHz, 
DMSO-d6):  δ 27.67 (Ce), 36.26 (Cd), 42.16 (Cc), 80.43 (Cf), 121.08 (Ca), 136.24 (Cb), 141.49 (Ci), 
166.07 (Ch), 169.93 (Cg). HR-MS [M+H]+ C11H17N2O4 calcd 241.1188, obsd 241.1186. 
4.2.3.11 Synthesis of tert-butyl 3-(4-(chlorocarbonyl)-1H-imidazol-1-yl)propanoate (10) 
Compound (9) (20 mg, 0.083 mmol) was dissolved in DMSO (1.5 mL) and added PCl5 (86 
mg, 0.416 mmol) at room temperature and stirred for 4 h. After the given time, the material was 
used for further coupling reaction. A portion of the material (8 mg) was purified for analytical 
confirmation purpose. The material was dissolved in chloroform:iso-propanol (7:3) and purified 
by preparative column chromatography using chloroform:iso-propanol (7:3) afforded compound 
(10), in 5 mg, 70% yield. The yield is based on recovered pure material after column 
chromatography.  
1H NMR (700 MHz, DMSO-d6): δ 1.28 (s, 9H, C-(CH3)3, He), 2.92 (bs, 2H, CH2, Hd), 4.22 
(bs, 2H, CH2, Hc), 8.45 (bs, 1H, Ar-CH, Ha), 9.45 (m, 1H, Ar-CH, Hb). ESI-MS [M+K]+ 
C11H15ClKN2O3 calcd 297.0408, obsd 295.2877. 
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4.2.3.12 Synthesis of Alk-PEG-NHBoc (11) 
Commercially available 5 kDa BocHN-PEG-NH2 (500 mg, 0.1 mmol) and 4-pentynoic 
acid (49mg, 0.5 mmol) were dissolved in DMF (7 mL) and added DIPEA (87 µL, 0.5 mmol) 
followed by EDC (38 mg, 0.2 mmol) at room temperature and stirred for overnight. The reaction 
mixture was precipitated in DCM/diethyl ether, then in THF/Hexane to obtain compound (11) in 
430 mg, 86% yield; functionalization efficiency: 92 %.   
1H NMR (700 MHz, CDCl3): δ 1.32 (a, 9H, C-(CH3)3, Hf), 1.92 (t, 1H, alkyne proton, j = 
2.1 Hz, Ha), 2.29 (t, 2H, CH2,  j = 7.0 Hz, Hb), 2.39 (t, 2H, CH2, j = 7.0 Hz, Hc), 2.62 (bs, 2H), 3.19 
(d, 2H, HN-CH2,  j = 4.2 Hz, Hd), 3.32-3.36 (m, 2H, CH2CH2-CO-O), 3.40-3.65 (m, 450H, 
OCH2CH2, He), 5.02 (bs, 1H), 6.41 (bs, 1H, NH); 13C NMR (175 MHz, CDCl3): δ 14.45 (Cc), 
28.08 (Ci), 34.74 (Cd), 38.90 (Cf), 39.97 (Ck), 68.97 (Cj), 69.43 (Ca), 69.811, 69.86, 70.19 (Cg), 
70.91, 82.76 (Cb), 155.8 (Ch), 170.62 (Ce). MALDI [M]+ Alk-PEG-NHBoc, obsd 5009.19. Note: 
Boc group might not survive during the analysis.  
4.2.3.13 Synthesis of Alk-PEG-NH2 (12) 
Compound (11) (300 mg, 0.0059 mmol) was dissolved in DCM (12 mL) and added TFA 
(6 mL) at 0 °C and stirred at room temperature for overnight. The solvents were evaporated by 
rotary evaporation (40 °C) and the residue was transferred into dialysis bag (MWCO 1 kDa) and 
dialyzed for 1 day against DI water and lyophilized to obtain compound (12), in 260 mg, 94% 
yield.  
1H NMR (700 MHz, CDCl3): δ 1.96 (t, 1H, alkyne proton, j = 2.1 Hz, Ha), 2.34 (t, 2H, CH2, 
j = 7.0 Hz, Hb), 2.44 (dt, 2H, CH2, j = 7.0, 2.1 Hz, Hc), 3.11 (bs, 2H, HN-CH2, Hd), 3.36-3.40 (m, 
2H, CH2CH2-CO-O), 3.42-3.72 (m, 450H, OCH2CH2, He), 5.26 (bs, 1H), 6.43 (bs, 1H, NH), 7.55 
(bs, 2H, NH2); 13C NMR (175 MHz, CDCl3): δ 14.59 (Cc), 29.42, 34.90 (Cd), 39.05 (Cf), 39.82, 
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66.78, 69.08 (Ca), 69.56, 69.63, 69.66, 69.74, 69.80, 69.86, 70.19 (Cg), 70.91, 82.86 (Cb), 170.83 
(Ce). MALDI [M]+ Alk-PEG-NH2 obsd 5006.33. 
4.2.3.14 Synthesis of Alk-PEG-Imidazole-ester (13) 
The solubilized tert-butyl 3-(4-(chlorocarbonyl)-1H-imidazol-1-yl)propanoate (10, 26 mg, 
0.101 mmol) in DMSO (1.5 mL), added DIPEA (17.5 µL 0.101 mmol) and stirred for 15 min.  
Alk-PEG-NH2 (12, 0.1g, 0.0202 mmol) was dissolved in DMF (2 mL) and added slowly (drop 
wisely), stirred at room temperature for 4 h, later the temperature raised to 40 °C and stirred for 2 
days. After the given time, the mixture was cooled down to room temperature, diluted with 2 mL 
of water and transferred into dialysis cassette (MWCO 3.5 kDa) and dialyzed against deionized 
water for 24 h followed by lyophilization. The dried polymer was dissolved in DCM and 
precipitated in hexane to obtain (Alk-PEG-NH-Imidazole ester) (13) in 86 mg, 83% yield.  
1H NMR (700 MHz, CDCl3): δ 1.36 (s, 9H, C(CH3)3, Hj), 1.96 (bs, 1H, alkyne proton, Ha), 
2.18 (bs, 2H, CH2, Hb), 2.38 (t, 2H, CH2, j = 7.0 Hz, Hc), 2.78 (bs, 2H, CH2, Hi), 3.09 (bs, 2H, HN-
CH2, Hd), 3.36-3.40 (m, 2H, CH2CH2-CO-O), 3.40-3.80 (m, 450H, OCH2CH2, He), 4.18 (bs, 2H, 
CH2, Hh), 4.45-4.55 (m, 2H), 5.76 (bs, 2H), 6.43 (bs, 1H, NH), 6.64 (bs, 1H, Hf), 6.84 (bs, 1H, 
Hg), 7.36 (bs, 1H, NH); 13C NMR (175 MHz, CDCl3): δ 14.75 (Cc), 20.77, 29.01, 29.59, 29.84 
(Cn), 31.88 (Cd), 34.29, 35.07 (Cl), 39.18 (Cf), 39.74, 42.09, 43.19 (Ck), 50.44, 55.95, 61.98, 69.14 
(Ca), 69.78, 70.13, 70.46 (Cg), 71.40, 73.28, 76.10, 77.95, 83.04 (Cb), 119.04, 126.13 (Ci), 126.90, 
127.63, 128.65 (Cj), 129.52, 136.45, 149.93 (Cm), 155.15 (Ch), 170.90 (Ce). MALDI [M]+ Alk-
PEG-Imidazole-ester obsd 5194.68. 
4.2.3.15 Synthesis of Alk-PEG-Imidazole-acid (14) 
Alk-PEG-NH-Imidazole ester (13, 80 mg, 0.154 mmol) in DI H2O (3 mL) and added 1 N 
HCl solution at 0 °C to adjust the pH to 3.0 and stirred for 1 h.  After the given time, the temperature 
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raised to room temperature and transferred into dialysis bag (MWCO 1 kDa) and dialyzed against 
DI water for 24 h followed by lyophilization. The dried polymer was dissolved in DCM and 
precipitated in hexane to obtain (Alk-PEG-Imidazole acid) (14) in 70 mg, 90% yield.  
1H NMR (700 MHz, CDCl3): δ 1.96 (bs, 1H, alkyne proton, Ha), 2.20 (bs, 2H, CH2, Hb), 
2.38 (bs, 2H, CH2, Hc), 2.68 (bs, 2H, CH2, Hi), 3.40-3.80 (m, 450H, OCH2CH2, He), 4.45-4.55 (m, 
2H), 5.21 (bs, 2H), 5.56 (bs, 1H), 6.82 (bs, 1H, Hf), 7.14 (bs, 1H, Hg), 7.36 (bs, 1H, NH). MALDI 
[M]+ Alk-PEG-Imidazole-acid obsd 5076.77. 
4.2.3.16 Synthesis of Alk-PEG-NH-Imidazole diphosphate (15) 
Diphosphorilation of imidazole derivative was carried out according to known procedure 
with little modifications [275]. Accordingly, Alk-PEG-NH-Imidazole acid (14, 65 mg, 0.0127 
mmol) was dissolved in chlorobenzene (3 mL) and added H3PO3 (2.8 mg, 0.0344 mmol) at room 
temperature. The temperature of the reaction mixture was increased to 80 °C, and added POCl3 
(4.7 mg, 0.0306 mmol) and stirred for 2.5 h.  The reaction mixture was cooled down to 60 °C and 
added water (4 mL). Two layers were separated and water layer was refluxed for 18 h. It was then 
cooled to room temperature and diluted with methanol (3 mL) and stirred for 3 h. After the given 
time, the mixture was transferred into dialysis bag (MWCO 1 kDa) and dialyzed against deionized 
water for 24 h followed by lyophilization. The dried polymer was dissolved in DCM and 
precipitated in hexane to obtain (Alk-PEG-Imidazole diphosphate, 15) in 38 mg, 58% yield. 
1H NMR (700 MHz, CDCl3): δ 2.00 (t, 1H, alkyne proton, j = 7.0 Hz, Ha), 2.39 (t, 2H, CH2, 
j = 7.5 Hz Hb), 2.50 (dt, 2H, CH2, j = 6.5, 2.0 Hz, Hc), 2.76 (t, 2H, CH2, j = 5.5 Hz, Hi), 3.20 (bs, 
2H, HN-CH2, Hd), 3.40-3.50 (m, 4H, CH2CH2-CO-O), 3.52-3.84 (m, 430H, OCH2CH2, He), 4.16-
4.26 (m, 2H, CH2, Hh), 6.52 (bs, 1H, NH), 7.58 (bs, 1H, Hf), 7.68 (bs, 1H, NH), 7.80 (bs, 1H, Hg); 
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31P NMR (283 MHz, CDCl3): δ -19.98. MALDI [M]+ Alk-PEG-Imidazole-diphosphate obsd 
5238.31. 
4.2.3.17 “Click” coupling to obtain PMMA-b-PtBA-b-PEG-Imidazole-diphosphate (16) 
Alk-PEG-NH-Imidazole diphosphate (15, 7.3 mg, 0.00139 mmol, 1.1 equivalent), PMMA-
b-PtBA-N3 (3, 10 mg, 0.00127 mmol, 1 equivalent), CuBr (0.3 mg, 0.00278 mmol, 2 equivalent), 
PMDETA (0.5 μL, 0.00278 mmol, 2 equivalent), and 2 mL of DMF were introduced into a Schlenk 
tube and the reaction mixture was degassed by three freeze-pump-thaw cycles before stirring for 
48 h at room temperature. After the given time, the reaction mixture was transferred into dialysis 
cassette (MWCO 7 kDa) and dialyzed against DI water for 48 h followed by lyophilization. The 
dried polymer was dissolved in DCM and precipitated in hexane to obtain PMMA-b-PtBA-b-PEG-
Imidazole-diphosphate (16) in 15 mg, 94% yield.  
1H NMR (700 MHz, CDCl3): δ 7.72 (bs, 1H, Hj), 7.52 (bs, 1H, Hi), 7.42 (bs, 2H, NH), 6.98 
(bs, 1H, triazole ring proton, Hg), 5.34 (bs, 2H), 5.00 (s, 2H, O=P-OH), 4.15 (CH2CH-triazole, Hk 
and CO-O-CH2, Hb), 4.05 (2H, CH3-CH2-O-CO), 3.64 (bs, O-CH2-CH2, Hh), 3.59 (s, CO-O-CH3, 
Hd), 2.42 (2H, CH2, He), 2.12 (2H, CH2, Hc), 1.36 (9H, CO-O-C(CH3)3 , Hf), 1.22 (s, 3H, -CH2-
CH3, Ha); 31P NMR (283 MHz, CDCl3): δ -13.50 
4.2.3.18 Boc deprotection to obtain PMMA-b-PAA-b-PEG-BP (17) 
PMMA-b-PtBA-b-PEG-NH-Imidazole diphosphate (16, 20 mg, 0.00139 mmol), was 
dissolved in DCM (2 mL) and added TFA (1.5 mL) at 0 °C and stirred at room temperature for 
overnight. The solvents were evaporated by rotary evaporation (40 °C) and the residue was 
transferred into dialysis bag (MWCO 1 kDa) and dialyzed for 1 day against DI water and 
lyophilized to obtain copolymer (17), in 18 mg, 94% yield.  
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1H NMR (700 MHz, CDCl3): δ 7.43 (bs, 1H, Hj), 7.40 (bs, 1H, Hi), 6.97 (bs, 1H, NH), 6.97 
(bs, 1H, triazole ring proton, Hg), 5.36 (bs, 2H), 5.00 (s, 2H, O=P-OH), 4.15 (CH2CH-triazole, Hk 
and CO-O-CH2, Hb), 4.05 (2H, CH3-CH2-O-CO), 3.63 (bs, O-CH2-CH2, Hh), 3.57 (s, CO-O-CH3, 
Hd), 2.42 (2H, CH2, He), 2.12 (2H, CH2, Hc), 1.22 (s, 3H, -CH2-CH3, Ha). 
4.2.3.19 Synthesis of Alkyne-PEG-NH-FITC (18) 
Commercially available 5 kDa Alkyne-PEG-NH2 (20 mg, 4 x 10-3 mmol) was dissolved in 
DI water (2 mL), and added FITC (1.9 mg, 4.8 x 10-3 mmol) in acetone (0.5 mL) and stirred at 
room temperature for 24 h. After the given time, water (3 mL) was added to the reaction mixture 
and transferred into dialysis bag (MWCO 1 kDa) and dialyzed against DI water for 24 h, followed 
by lyophilization to obtain compound (18) in 20 mg, 90% yield.  
1H NMR (700 MHz, CDCl3): δ 1.55 (p, 2H, J = 4.5 & 11.00 Hz, CH2),  1.74 (p, 2H, J = 
4.5 & 11.00 Hz, CH2), 1.95 (t, 1H, J = 1.5 Hz, alkyne proton), 2.19 (t, 4H, J = 5.0Hz, CH2), 3.44 
(q, 4H, J = 7.0 Hz, CH2), 3.48-3.55 (m, 8H, CH2CH2-CO-O), 3.55-3.72 (bs, 430H, OCH2CH2), 
4.74 (t, 4H CO-O-CH2-CH2-O), 6.12-8.40 (m, 10H, FITC aromatic protons); 13C NMR (175 MHz, 
CDCl3): δ 18.15, 24.72, 27.93, 29.29, 29.62, 64.97, 68.63, 69.61, 69.85, 70.17, 70.51, 71.45, 72.39, 
84.09, 95.22, 97.07, 103.02, 108.87, 172.64, 231.37. MALDI [M]+ Alkyne-PEG-FITC obsd 5376. 
4.2.3.20 Synthesis of PMMA-b-PtBA-b-PEG-FITC (19) 
Alk-PEG-NH-FITC (18, 216 mg, 4.02 x 10-2 mmol, 1.1 equivalent), PMMA-b-PtBA-N3 
(3, 300 mg, 3.65 x 10-2 mmol, 1 equivalent), CuBr (6.2 mg, 4.39 x 10-2 mmol, 1.2 equivalent), 
PMDETA (9.1 μL, 4.39 x 10-2 mmol, 1.2 equivalent), and 5 mL of DMF were introduced into a 
Schlenk tube and the reaction mixture was degassed by three freeze-pump-thaw cycles and stirred 
at room for 48 h. The reaction mixture was diluted with THF, and dialyzed against DI water for 2 
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days and lyophilized. The polymer was dissolved in DCM and precipitated several times in hexane 
mixture to remove unreacted PEG material.  
1H NMR (500 MHz, CDCl3): δ 7.46 (bs, 1H, triazole ring proton), 4.25 (CH2CH-triazole 
and CO-O-CH2), 4.05 (2H, CH3-CH2-O-CO), 3.64 (bs, O-CH2-CH2), 3.59 (s, CO-O-CH3), 3.38 (s, 
3H, CH2-CH2-O-CH3), 3.05 (2H, triazole-CH2-CH2-CO-O), 2.76 (2H, triazole-CH2-CH2-CO-O), 
2.26 (CH2-CH-CO), 1.93-0.83 (6H, O-CO-C(CH3)2, CO-O-C(CH3)3, CH2-CCH3). 
4.2.3.21 Boc deprotection to obtain PMMA-b-PAA-b-PEG-FITC polymer (20) 
PMMA-b-PtBA-b-PEG-FITC (19, 20 mg, 0.00139 mmol), was dissolved in DCM (2 mL) 
and added TFA (1.5 mL) at 0 °C and stirred at room temperature for overnight. The solvents were 
evaporated by air circulation and the residue was transferred into dialysis bag (MWCO 1 kDa) and 
dialyzed for 2 days against DI water and lyophilized to obtain compound (20), in 18 mg, 94% 
yield.  
1H NMR showed complete loss of the tert-butyl protons at 1.36 ppm.; 1H NMR (700 MHz, 
CDCl3): δ 7.72 (bs, 1H, Hj), 7.52 (bs, 1H, Hi), 7.42 (bs, 2H, NH), 6.98 (bs, 1H, triazole ring proton, 
Hg), 5.34 (bs, 2H), 5.00 (s, 2H, O=P-OH), 4.15 (CH2CH-triazole, Hk and CO-O-CH2, Hb), 4.05 
(2H, CH3-CH2-O-CO), 3.64 (bs, O-CH2-CH2, Hh), 3.59 (s, CO-O-CH3, Hd), 2.42 (2H, CH2, He), 
2.12 (2H, CH2, Hc), 1.22 (s, 3H, -CH2-CH3, Ha). 
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Figure 4.2 A schematic drawing showing i) scheme for synthesis of PMMA-b-PtBA-N3 copolymers, 
ii) PMMA-b-PAA-b-PEG, iii) PMMA-b-PAA-b-PEG-pVTK, iv) PMMA-b-PAA-b-PEG-BP, and v) 
PMMA-b-PAA-b-PEG-FITC. 
 
4.2.4 Formulation of PMMA-b-PAA-b-PEG copolymers into micelles  
We formulated the non-targeted and a variety bone binding contents of micelles with two 
different targeting ligands (pVTK or BP). To prepare non-targeted or targeted particles we used 
our previous published protocol [273]. For example, to formulate non-targeted particles, 
amphiphilic PEG-b-PAA-b-PMMA copolymer (10 mg, 9.38x10-4 mmol) was dissolved in 1.5 mL 
of THF and stirred for 5 minutes before being added dropwise into 7.5 mL of water in a sonicating 
water bath. To formulate 5% pVTK micelles (M-pVTK5%), 9.5 mg of PEG-b-PAA-b-PMMA 
copolymer (8.91x10-4 mmol) and PMMA-b-PAA-b-PEG-pVTK copolymer (0.6 mg, 4.46x10-5 
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mmol) were dissolved in 1.5 mL of THF and stirred for 5 minutes before being added dropwise 
into 7.5 mL of water in a sonicating water bath. To prepare 10% pVTK micelles (M-pVTK10%) 
and 20% pVTK micelles (M-pVTK20%), the same procedure was followed by keeping the total 
mole of the polymers constant but changing the mole:mole ratio of the targeting polymer 
block:non-targeted polymer block. With the same strategy, we prepared BP-micelles with different 
mole to mole ratio such as 5% BP (M-BP5%), 10% BP (M-BP10%), and 20% BP (M-BP20%) 
micelles. For instance, to prepare M-BP5%, 9.5 mg of PEG-b-PAA-b-PMMA copolymer (8.91x10-
4 mmol) and PMMA-b-PAA-b-PEG-BP copolymer (0.5 mg, 4.46x10-5 mmol) were dissolved 
together in 1.5 mL of THF and stirred for 5 minutes before being added dropwise into 7.5 mL of 
water in a sonicating water bath. By changing the amount of non-targeted copolymer block and 
BP-copolymer block we prepared 10 and 20% BP targeting micelles with the same procedure. 
After sonication, all particle formulations were stirred at room temperature for 1 h. To 
cross-link the particles, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 
8.28 mg, 4.32x10-2 mmol) in 150 µL of 100 mM 2-(N-morpholino)ethanesulfonic acid (MES) 
solution and N-hydroxy succinimide (NHS, 2.49 mg, 2.16x10-2 mmol)  in 150 µL of 100 mM MES 
solution were added and stirred for 3 h to obtain the NHS esters of the carboxylic acid groups in 
the central PAA block of the copolymers. Before adding to the pH sensitive cross-linker, the pH 
of the micelle solution was adjusted to 9.2 using 1N NaOH solution. Once the 2,2’-(Propane-2,2-
diylbis(oxy))-diethanamine cross-linker added, the particle solutions were stirred for 6 h at room 
temperature. The particle solution mixture was transferred into a dialysis bag (MWCO 1kDa), 
which was placed in a large water bath for 24 hours before lyophilization. 
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4.2.5 Micelle Characterization  
The size and zeta potential of empty non-targeted M, M-pVTK, (5, 10, and 20% pVTK 
mole/mole targeting density), and M-BP (5, 10, and 20% BP mole/mole targeting density) micelles 
were measured using a 90Plus particle size analyzer with ZetaPALS capability (Brookhaven 
Instruments Corporation, Holtsville, NY) at 25 °C following established protocols [217]. Results 
are presented as the mean of three replicates  standard error of the mean (SEM). 
4.2.6 Binding of M-pVTK and M-BP Particles to Bone Powder 
The binding capability of the different particle formulations were tested on the granulated 
rat bone powder Rat bone powder was synthesized as previously described [276]. Briefly, rat 
forelimbs and hindlimbs were dissected free from soft tissue, bone marrow was flushed, bones 
were defatted (CHCl3-MeOH for 4h, and 100% EtOH for 1h), dried overnight at 37 °C, 
homogenized using a cryomill at -150 °C, and sieved from 42 to 295 m in diameter. The binding 
calculation relied on the fluorescence of either FITC-labeled pVTK peptide or FITC-labeled 
PMMA-b-PAA-b-PEG particles. The 4% (mole:mole) FITC-labeled M-pVTK5%, M-pVTK10%, 
M-pVTK20%, M-BP5%, M-BP10%, and M-BP20% were prepared as described above. FITC-labeled 
particles (1 mg/mL) were dissolved in Trizma buffer (50 mM). Various particle solutions at 
different weights of volumes were incubated (100 µL) with 50 µL of bone powder (10 mg/mL) for 
3 h. The background FITC-fluorescence (λex: 490 nm λem: 520 nm) of each particle formulation 
was measured before particle incubation with bone powder. After 3 h incubation, the particles 
incubated with bone powder were centrifuged with 0.65 µm hydrophilic, low protein binding 96-
well filter plate (MultiScreen®, Millipore) at 3000 rpm for 10 min. The filtered solutions were 
measured with Fluoroskan again to get post-fluorescence value for the calculation of particle 
binding. The volume-adjusted fluorescence difference between pre and post-fluorescence values 
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were normalized to the percent fluorescence of the particles in the absence of HA to obtain binding 
rates.  The binding kinetics of pVTK peptide, M-pVTK, and M-BP were calculated from the bone 
powder or HA powder binding experiments. Results are presented as the mean of three replicates 
 standard error of the mean (SEM). 
4.2.7 Cell Culture 
PC-3 and C4-2B cells were cultured following published protocols [218]. Briefly, PC-3 
and C4-2B cells were cultured in RPMI-1640. Culture media for both cell lines was supplemented 
with 10% fetal bovine serum (FBS; Gibco, Carllsbad, CA) and 1% antibiotic-antimycotic solution 
(Gibco, Carllsbad, CA). MC3T3 and RAW 264.7 cell lines were cultured with the guidance of a 
published protocol [139]. To differentiate RAW 264.7 cells to osteoclast, mouse recombinant 
RANKL (Sigma R0525, St. Louis) at the final concentration of 50 ng/mL was used in the medium 
during the cell culture for 4-5 days [277]. All cell lines were incubated at 37 °C and 5% CO2 while 
changing the culture medium every other day and passaging the cells using 0.05% Trypsin-EDTA 
solution after reaching 80% confluence except RAW 264.7 cells, which required a cell stripper to 
detach the cells from the plate surface.  
4.2.7.1 Cellular uptake studies 
PC-3, C4-2B, MC3T3, and RAW 264.7 cells were seeded in 24-well plates (regular cell 
culture plate) at a seeding density of 2 x 105 cells/well and allowed to adhere for 24 h before 
incubating with FITC-labeled non-targeted micelles, M-pVTK10%, and M-BP (0%, 5%, 10%, and 
20% BP mole/mole) micelles at 40 µg/mL for 3 h. The treated cells were washed with PBS before 
being trypsinized with 0.05% trypsin-EDTA solution except for RAW 264.7 cells, which we used 
cotton swab to remove the cells from the surface, then centrifuged all cells at 1000 rpm for 5 min 
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to form pellets, suspended in 1 mL PBS, and analyzed using flow cytometry CyAn™ ADP 
Analyzer (Beckman Coulter, Brea, CA) with a characteristic FITC excitation laser at λex = 488 nm. 
The second particle uptake experiment designed as four cells lines were seeded first on the 
BLS at a seeding density of 2 x 105 cells/well and allowed to adhere for 24 h. RAW 264.7 cells 
were treated with RANKL for 4 days by changing the medium/RANKL every 2 days before the 
experiment set. During the experiment they were also treated with RANKL (50 ng/mL of final 
concentration). After 24 h cell attachment, 40 µg/mL of FITC label non-targeted micelles, M-
pVTK10%, and M-BP20% in OPTI-MEM medium were added to each well and incubated for 3 h. 
Results are presented as the mean of three replicates  standard error of the mean (SEM). 
4.2.8 Calculation of CTX loading content of the particles 
CTX-loaded micelles were formulated following the same micelle preparation protocol 
[273]. In designed experiments we used CTX-loaded non-targeted micelles, M-pVTK10%, and M-
BP20%. Briefly, the interested polymer mixture (dissolved in 0.75 mL of THF) was mixed with 1 
mg of CTX in 0.75 mL of THF and stirred for 30 minutes. This solution was added dropwise into 
7.5 mL of double distilled water while sonicating to trigger micelle formation followed by stirring 
for 3 h at room temperature. To cross-link the CTX-loaded particles, we followed the same 
procedure described earlier to prepare bone targeting particles. The particles were transferred to 
dialysis bags with MWCO of 1 KDa and dialyzed against double distilled water for 36 hours to 
remove free CTX and any impurity from the micelles solution. At the end, each particle solution 
was lyophilized to obtain CTX-loaded non-targeted M, M-pVTK, and M-BP as dry powder 
(Figure 4.3). 
We measured the amount of CTX in dry powder after obtained from lyophilization. 1 mg 
of dry powder was dissolved in THF (10 mL) and following our previous published protocol 
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briefly mentioned below [273]. We calculated the loading content and efficiency based on a 
concentration versus absorbance calibration curve (CTX 0-300 µM) by the following equations 
(1). 
Loading efficiency (%) =   (Amount of the drug in the particles)/
(Total amount of drug used in the preperation of particles)  x 100 %  Eq. 4.1 
Briefly, CTX solutions were analyzed using a C18 Ascentis Express column (Water Corp, 
Milford, MA; 2.7 μm, 15 cm x 3.0 mm) connected to a Waters HPLC system equipped with a UV 
dual absorbance detector. A mixture of solvent A (650 mL of H2O and 350 mL of ACN) and 
solvent B (250 mL of H2O and 750 mL of ACN) was used as a mobile phase to separate free CTX 
on the C18 column using an A:B gradient of 100:0 for 7 min, 62:38 for 29 min, 22:78 for 0.1 min, 
and 100:0 for 9 min at a flow rate of 0.6 mL/min while keeping the column at 40 °C throughout 
the run. Absorbance of eluting CTX molecules was measured at 230 nm. We determined the total 
amount of released CTX present in solution by integrating CTX absorbance versus elution volume 
using Waters Breeze software and comparing the observed values against a CTX calibration curve. 
Results are presented as the mean of three replicates  standard error of the mean (SEM). 
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Figure 4.3 A schematic drawing of the formulation of PMMA-b-PAA-b-PEG tri-block copolymer 
into “smart” micelles i) M-pVTK or FITC tagged FITC-pVTK-Micelle and ii) M-BP or FITC-BP-
Micelle. 
 
4.2.9 Therapeutic activity of CTX-loaded micelles through bone like surface  
The cells (PC-3, C4-2B, MC3T3, RAW 264.7, and activated RAW 264.7) were seeded at 
a seeding density of 60 x 103 cells/well in 24-well plates with a BLS and incubated for 24 h. CTX-
loaded particles (non-targeted micelles, M-pVTK10%, and M-BP20%) at the concentration of 0.1, 1, 
and 10 nM CTX-loaded particle concentrations in 400 µL of the medium, and free CTX at 
equivalent concentration were added to the cells on the BLS and incubated for 48 h. At the end of 
the incubation period, the culture medium was aspirated and cells were washed with PBS to 
remove particles, then incubated with 1000 μL of Resazurin Dye at a dilution of 1/10 in the OPTI-
MEM medium for 3-4 h before measuring solution fluorescence (λex= 570 nm, λem= 590 nm) using 
the Fluoroskan Ascent FL plate reader. Fluorescence values were normalized to that observed with 
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four cell lines incubated in the regular culture medium (control group) to calculate the percentage 
of viable cells in response to different particle groups. Results are presented as the mean of three 
replicates  standard error of the mean (SEM). 
4.2.10 Statistical analysis 
Results are representative of at least three independent trials of each experiment, and data 
is represented as the mean of those replicates + SEM. Analysis of the data were done using a two-
tailed Student’s t-test where the population means were statistically significant at P ≤ 0.05. 
 
4.3 Results and Discussion 
4.3.1 Synthesis of Amphiphilic PMMA-b-PAA-b-PEG Copolymer 
We synthesized PMMA-b-PAA-b-PEG polymer as described in our previous paper [273]. 
We merged an ATRP technique and alkyne-azide “click” coupling to synthesize amphiphilic 
polymer with a well-defined composition and molecular weight. This is essential to accomplish 
the control over the size/molecular weight of the hydrophilic and hydrophobic blocks to trigger 
the assembly of narrowly dispersed micelles. In the literature, we find that the 5kDa PEG “brush” 
is necessary to inhibit the non-specific adsorption of serum proteins to the particle surface and to 
prevent subsequent clearance by phagocytic macrophages. We used MMA and tBA monomers to 
synthesize the hydrophobic PMMA block and central PAA block, respectively. PMMA, PtBA, 
and PAA polymers, which are approved by the FDA to be used as excipients in controlled-release 
pharmaceutical formulations. To achieve a hydrophilic/hydrophobic balance in polymer 
composition, the target molecular weight of the hydrophobic block was approximately 5kDa. By 
adjusting the molar feed ratio of the MMA monomer, the ethyl-2-bromoisobutyrate initiator, and 
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PMDETA ligand to 200/1/1 and allowing the polymerization reaction for 21 min at 40 °C, we were 
able to synthesize the PMMA block with the desired molecular weight. Calculating the ratio 
between the methyl protons of the MMA monomers appearing at 3.57 ppm to the initiator protons 
at 4.21 ppm shows the polymerization of 50 MMA units forming the PMMA block (1) with a 
MnNMR of 5,201 g/mol (Appendix E, Figure E.1). 
1H NMR confirms successful synthesis of the 
PMMA block with the desired molecular weight. 
PMMA-Br was preferred as a macro-initiator to start the polymerization of tBA monomers 
with the goal of extending the PMMA block with 25 units of tBA monomers. By adjusting the 
ratio of tBA monomer, PMMA-Br as a macroinitiator, and PMDETA ligand to 100/1/1, 21 tBA 
monomers were polymerized into the PtBA block to form PMMA-b-PtBA-Br (2) with MnNMR of 
7,892 g/mole as shown in the 1H NMR spectrum (Appendix E, Figure E.3). The terminal Br 
groups were transformed into azide groups with NaN3 in DMF at 50 °C to obtain PMMA-b-PtBA-
N3 (3). The 1H NMR and FT-IR confirms the transformation was successful (Appendix E, Figure 
E.5). To synthesize the PEG-alkyne, commercially available PEG was reacted with 4-pentynoic 
acid, EDC, HOBt, and DIPEA in DCM to obtain PEG-alkyne (3a), with functionalization 
efficiency of 92% (Appendix E, Figure E.7). We then “click” coupled PMMA-b-PtBA-N3 (3) 
with PEG-alkyne (3a) to obtain PMMA-b-PtBA-b-PEG copolymer (4), which was confirmed by 
1H NMR. The characteristic proton of the triazole ring was observed at 7.16 ppm (Appendix E, 
Figure E.10) and loss of the azide and alkyne peaks on the FTIR spectrum. The 1H NMR spectrum 
of PMMA-b-PtBA-b-PEG polymer shows that the molecular weight of the polymer is 
Mn,NMR=12,900 g/mol. Afterwards the tert-butyl groups were deprotected by acid-mediated 
hydrolysis using TFA, which was confirmed by the disappearance of the methyl protons of the 
129 
 
tert-butyl groups at 1.42 ppm (Appendix E, Figure E.11). The molecular weight of the PMMA-
b-PAA-b-PEG copolymer (5) is Mn,NMR = 11,722 g/mol. 
4.3.2 Synthesis of PMMA-b-PAA-b-PEG-pVTK conjugate polymer 
We synthesized triblock amphiphilic copolymers having pVTK peptide, which acts as a 
targeting ligand to the surface of bone. Compound PMMA-b-PtBA-N3 polymer (3) and 
commercially available alkyne-PEG-NHS (5kDa) was “click” coupled in the presence of CuBr, 
PMDETA to obtain PMMA-b-PtBA-b-PEG-NHS polymer (6), which was confirmed by 1H-NMR. 
The characteristic proton of the triazole ring was observed at 6.62 ppm and PMMA methyl ester 
peak/PEG ethylene dioxide peaks at 3.50-3.60 ppm (Appendix E, Figure E.12). PMMA-b-PtBA-
b-PEG-NHS (6) peptide was coupled with pVTK targeting ligand to obtain PMMA-b-PtBA-b-
PEG-pVTK copolymers (7), which was confirmed by 1H-NMR. The characteristic aromatic 
protons of histidine and tyrosine was observed at 7.00-8.00 ppm along with PMMA’s methyl ester 
peak and PEG’s ethylene dioxide peaks at 3.50-3.60 ppm (Appendix E, Figure E.14). Finally, the 
tert-butyl groups of PtBA was deprotected by acid-hydrolysis using TFA, which was confirmed 
by the disappearance of the methyl protons of the tert-butyl groups at 1.42 ppm (Appendix E, 
Figure E.17). The 31P NMR also confirms the PEG-pVTK attachment to PMMA-b-PtBA and the 
phosphate peaks were observed at -20.22 ppm (in CDCl3, Appendix E, Figure E.19). The 
molecular weight of the PMMA-b-PAA-b-PEG-pVTK copolymer (8) is Mn,NMR = 13,190 g/mol. 
4.3.3 Synthesis of PMMA-b-PAA-b-PEG-BP conjugate polymer 
We synthesized triblock amphiphilic copolymers having BP as a targeting ligand, which is 
a zoledronic acid derivative. We synthesized the zoledronic acid derivative BP following a known 
method with some modifications [274]. N-alkylation of imidazole 4-carboxilic acid was reacted 
with KOH in DI water to obtain its potassium salt. After evaporating the water and subsequently 
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drying the sample, the residue was dissolved in DMSO:1,4 Dioxane (4:1, 5 mL) and added DIPEA 
followed by tert. butylbromo-propionate to obtain 1-(3-(tert-butoxy)-3-oxopropyl)-1H-imidazole-
4-carboxylic acid (9), which was confirmed by 1H NMR and mass spectrum. The aromatic peaks 
were observed at 7.30 and 7.45 ppm, whereas tertiary butyl group observed at 1.36 ppm. 
(Appendix E, Figure E.23). The compound 9’s carboxylic acid group was converted into acid 
chloride with PCl5 to obtain acid chloride compound 10. 1H NMR shows that the aromatic peaks 
were shifted to 8.45 and 9.45 ppm (Appendix E, Figure E.26). The aromatic proton shifted to 
down field attributed to acid chloride formation. 
To synthesize alkyne-PEG-NH2 (11), commercially available 5 kDa BocHN-PEG-NH2 
was coupled to 4-pentynoic in the presence of DIPEA, EDC with the functionalization efficiency 
of 92%.  The 1H-NMR confirmed the coupling and its characteristic peak for alkyne proton was 
observed at 1.92 ppm (Appendix E, Figure E.28). The Boc group was deprotected with TFA to 
obtain alkyne-PEG-NH2 (12). 1H NMR confirmed the Boc deprotection as its characteristic peak 
at 1.36 ppm was disappeared (Appendix E, Figure E.31). Compound (12) was coupled to acid 
chloride (10) in the presence of DIPEA in DMF:DMSO to obtain Alk-PEG-NH-Imidazole ester 
(13). 1H NMR confirmed the coupling and its characteristic peak for alkyne proton was observed 
at 1.96 ppm and Boc group at 1.36 ppm (Appendix E, Figure E.34). Alk-PEG-NH-imidazole 
ester, undergo ester hydrolysis in the presence of 1 N HCl solution (adjusted pH 3.0) at 0 °C to 
obtain Alk-PEG-Imidazole acid (14). 1H NMR confirmed the Boc deprotection as its characteristic 
peak at 1.36 ppm disappeared and all other peaks remained intact (Appendix E, Figure E.37). 
Diphosphorylation of the imidazole derivative was carried out according to a known procedure 
with little modifications [275]. Alk-PEG-NH-Imidazole acid (14) on reaction with H3PO3, POCl3 
in chlorobenzene gave Alk-PEG-Imidazole diphosphate (15) in 58% yield. From the 1H NMR the 
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aromatic peaks were observed at 7.80 and 7.58 ppm, and the alkyne peak was observed at 2.00 
ppm (Appendix E, Figure E.39). The 31P NMR confirmed the phosphorylation and its phosphate 
peak was observed at -19.98 ppm (Appendix E, Figure E.40). The click coupling between Alk-
PEG-NH-Imidazole diphosphate (15) and PMMA-b-PtBA-N3 (3) was carried out in the presence 
of CuBr, PMDETA to obtain in PMMA-b-PtBA-b-PEG-Imidazole-diphosphate (16). 1H NMR 
confirms the coupling, the characteristic peak from both addendums observed in the NMR. The 
aromatic peaks were observed at 7.72 and 7.52 ppm, whereas triazole ring proton observed at 6.98 
ppm and PMMA and PEG protons observed at 3.50-3.60 ppm (Appendix E, Figure E.41). The 
31P NMR showed that the phosphate group was shifted to -13.50 ppm (Appendix E, Figure E.42). 
All these NMR confirmations indicate that the coupling carried out successfully. The molecular 
weight of the PMMA-b-PtBA-b-PEG-BP polymer (16) is Mn,NMR = 13130 g/mol. 
Finally, we removed the tert-butyl groups of PtBA middle block polymer by acid-
hydrolysis using TFA, which was confirmed by the disappearance of the methyl protons of the 
tert-butyl groups at 1.42 ppm (Appendix E, Figure E.43). The molecular weight of the PMMA-
b-PAA-b-PEG-ZA copolymer (17) is Mn,NMR = 11953 g/mol. 
4.3.4 Synthesis of PMMA-b-PAA-b-PEG-FITC conjugate polymer 
We synthesized triblock amphiphilic copolymer having FITC labeling for the particle HA 
affinity and cellular uptake studies. Commercially available 5 kDa Alkyne-PEG-NH2 was treated 
with FITC in water:acetone (3:1) to obtain  Alkyne-PEG-NH-FITC (18). 1H NMR shows that the 
FITC aromatic peaks were observed at 6.12-8.40 ppm, and the alkyne peak observed at 1.95 ppm 
(Appendix E, Figure E.44). We then “click” coupled PMMA-b-PtBA-N3 (3) with FITC-PEG-
alkyne (18) to obtain PMMA-b-PtBA-b-PEG-FITC polymer (19), which is confirmed by 1H-
NMR, the characteristic proton of the triazole ring was observed at 7.46 ppm, along with PMMA 
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and PEG protons between 3.35-3.55 ppm (Appendix E, Figure E.46 and Figure E.47). From the 
1H NMR spectrum, the molecular weight of the PMMA-b-PtBA-b-PEG-FITC is MnNMR of 13,282 
g/mol. Finally, we deprotected the tert-butyl groups by acid-mediated hydrolysis using TFA, 
which is confirmed by the disappearance of the methyl protons of the tert-butyl groups at 1.42 
ppm (Appendix E, Figure E.48). From the 1H NMR spectrum, the molecular weight of the 
PMMA-b-PAA-b-PEG-FITC copolymer (20) is Mn,NMR = 12,105 g/mol. 
4.3.5 Bone Targeted Micelles formulation and characterization   
In our previous study we showed that non-targeted triblock amphiphilic copolymers are 
able to self-assemble in aqueous solution [273]. Following the same protocol two different bone-
targeted cross-linked particles, pVTK or BP decorated particles, with different targeting densities 
(0, 5, 10, 20% mole/mole) were formulated as seen in Figure 4.3. These particles were measured 
by dynamic light scattering (DLS) and measurements show that the particle size of each particle 
formulation spanned between 60-90 nm with no statistical difference in Figure 4.4. The size of 
bone targeted particles allows particle penetration not only from the permeable vasculature with 
average endothelial gaps typically between 200-600 nm (called the enhanced permeation and 
retention (EPR) effect [242]), but also from the sinusoidal gap in bone that has a cut-off pore size 
less than 80 nm [143]. Therefore, the size of these bone-targeted particles is ideal to efficiently 
penetrate tumor tissue in the metastasized bone. In addition, we incorporated a PEG brush (to form 
a corona) and a negative zeta potential to impart hemocompatibility on the “smart” particle during 
blood circulation with resistance against adsorption of serum proteins, lack of interaction with 
blood cells (i.e. platelets and RBCs) and minimize the non-specific particle uptake by these and 
healthy cells [247, 278, 279]. 
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Figure 4.4 Bone-targeted particles characterizations. 
(A) Size and (B) zeta-potential characterization of 0, 5, 10, 20% targeting ligand M-pVTK and M-BP 
particles. Results show the average + standard error of the mean (SEM) of three independent solutions 
for each micelle formulation. 
 
4.3.6 Bone Powder Binding Kinetics of the M-pVTK and M-BP Particles 
The main constituent of bone is HA, which is altered in the presence of diseased conditions. 
It is well-documented that phosphorylated or acidic peptides and BPs show a strong affinity to HA 
due to phosphonate, carboxyl groups, and negative charge of the moieties [139, 280]. To test the 
binding capability of pVTK conjugated polymers, pVTK-particles, and BP-particles we used HA 
powder, bone powder, and bone chips in seperate experiments. It is well understood that the pVTK 
peptide is capable of binding to HA surfaces [139-141]. We confirmed this by assessing whether 
pVTK-polymers have binding capability to HA powder, and we compared binding rates of pVTK-
polymers to pVTK peptide alone. To do this we used FITC-labeled pVTK peptide and FITC-
pVTK decorated PEG-b-PAA-b-PMMA to quantitatively determine the binding affinity to HA 
powder. After incubation for 3 h at 37 °C, 64% of pVTK peptide and 63% of pVTK-conjugated 
triblock copolymer bound to HA (Figure 4.5A). Furthermore, the binding isotherm of pVTK and 
pVTK-conjugated copolymer was calculated to be 27.16 and 26.40 µM, respectively. These results 
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indicate that pVTK decorated triblock amphiphilic copolymers are able to bind HA as efficiently 
as free pVTK with similar kinetics without statistical difference. 
Along with this result, we formulated FITC-labeled pVTK and BP micelles containing 
different targeting block densities such as 0, 5, 10, 20% (mole:mole) to estimate the binding 
affinity of bone-targeted particles to bone powder derived from rat bones. The bone powder was 
suspended in 100 mM Trizma buffer (pH 7.4) at the concentration of 10 mg/mL. Particles targeted 
either by pVTK or BP ligands prepared at varying concentration were dissolved in the same Trizma 
buffer then added to the bone powder suspensions and the mixtures were shaken for 3 h at 37 °C. 
Each particle solution was also treated without bone powder following the same protocol as 
control. After centrifugation the FITC fluorescence intensities of the filtered solutions were 
measured. The reduction in the FITC fluorescence intensity corresponding to the initial 
fluorescence intensity and untreated bone powder revealed the amount bound to bone powder. 
With this strategy we demonstrated the binding isotherms of bone targeted particles. 5, 10, and 
20% bone targeting ligand containing pVTK micelles did not show statistically different binding 
kinetics compared to each other (Figure 4.5B). On the other hand, 10 and 20% BP targeting ligand-
containing micelles had higher binding kinetics compared to 5% BP micelles as seen in Figure 
4.5C. Both pVTK and BP bone-targeted particles with each formulation followed the Langmuir 
isotherm model [281]. Furthermore, we tested pVTK particles (5, 10, 20%) on HA disks to see 
whether or not any affinity changing due to decreasing the surface area of binding site of the HA 
disk compared to HA powder. The HA disk binding results of M-pVTK5%, M-pVTK10%, and M-
pVTK20% exhibited 58%, 60% and 61% as measured by the fluorescent intensity of the particles, 
respectively (Figure 4.5D). However, 20% pVTK bone targeting particles were affected by 
quenching of the FITC signal so the fluorescence image of post-treated HA chip has less 
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fluorescence intensity compared to M-pVTK5% and M-pVTK10%. Among M-pVTK5% and M-
pVTK10% particles, we quantified the highest fluorescence of the pVTK particle-bound HA chip 
from M-pVTK10% particle (Figure 4.5D). Therefore, M-pVTK10% particles were preferred in 
future cellular experiments. 
 
Figure 4.5 Binding of the particles to bone powder. 
(A) The percentage bound of pVTK-FITC peptide and pVTK-FITC coupled PMMA-b-PAA-b-PEG 
triblock copolymer on HA powder (B) M-pVTK binding kinetics, (C) M-BP binding kinetics, and (D) 
5, 10, 20% mole of pVTK targeting particle binding to HA disk and the fluorescence images of these 
disks after pVTK targeting particle binding. Results show the average + SEM of three independent 
solutions for each bone targeted particle formulation. 
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4.3.7 Cancer cell uptake of FITC-labeled particles  
The cellular uptake of pVTK-conjugated bone-targeted particles (M-pVTK10%) was 
investigated in regular cell culture plates and BLS with comparison to non-targeted particles.  
Briefly, FITC labeled micelles at the concentration of 40 µg/mL were added to the seeded cancer 
cells - PC-3 and C4-2B - or bone cells - preosteoblast MC3T3 and preosteoclast RAW 264.7, or 
RANKL activated RAW 264.7 - in the presence of OPTI-MEM cell culture medium. All cells 
were treated with the particles for 3h at 37 °C. The internalized FITC-labeled micelles were 
quantified by measuring the percentage of labeled cells and fluorescence signal per cell using flow 
cytometry. First, we quantified M-pVTK10% bone-targeted particles and micelles alone. 68%, and 
78% of PC-3 cells; 38%, and 50% of C4-2B cells; 86%, and 95% of MC3T3; and 88% and 98% 
of RAW 264.7 cells on the regular surface were labeled by the FITC-tagged non-targeted micelles 
and M-pVTK10% particles, respectively as seen in Figure 4.6A. The overall trend of cell labeling 
for non-targeted and pVTK-decorated particles was that the bone cells were significantly stained 
more than cancer cells. Further, the percentage of FITC-labeled MC3T3 and RAW 264.7 cells that 
were treated with pVTK-decorated particles were statistically higher (p<0.05) than non-targeted 
particles. Furthermore, we normalized the fluorescence intensity of FITC-labeled cells against 
non-treated cells to explore the difference in intracellular concentration of particle formulations 
(Figure 4.6B). The results demonstrate that the relative FITC fluorescence intensities augmented 
15- and 15- in PC-3; 10- and 9- in C4-2B; 18- and 28- in MC3T3, and 14- and 20-fold in RAW 
264.7 cells for FITC-tagged non-targeted, and M-pVTK10% particles, respectively. The comparison 
of non-targeted and pVTK bone-targeted relative fluorescence intensity shows that there is no 
statistically difference between the particles in all cell lines. However, it is clear that the highest 
relative fluorescence fold is obtained by MC3T3 cells treated with pVTK particles. On the other 
hand, we conducted the same experiment settings in the presence of BLS to explore the changes 
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of bone-targeted particle internalization within BLS. The percentages of FITC-labeled PC-3 cells 
were 94, and 95 after incubating with non-targeted and M-pVTK10% particles, respectively. A 
similar trend was also observed for C4-2B cells. Specifically, 97%, and 100% of these cells were 
labeled with non-targeted, and M-pVTK10% particles, respectively. Moreover, 86%, and 96% 
(p<0.01) of MC3T3, and 43%, and 85% (p<0.001) of aRAW 264.7 cells were labeled by the FITC-
tagged non-targeted, and M-pVTK10% particles, respectively (Figure 4.6A). 
 
Figure 4.6 Prostate and bone cells uptake of the particles from regular cell culture plates and BLS. 
The cells first seeded on the plate. After 24 h the particles are added to the top of the cells and incubated 
for 3 h. (A) M-pVTK10% percent cell label, (B) Normalized mean fluorescence of FITC labelled cells. 
Results are the average of at least nine samples of triplicate experiments + SEM. Percentage of labeled 
the cells and normalized mean fluorescence increase by M-pVTK10% were compared to FITC label non-
targeted micelles using a two-tailed Student’s t-test where * denotes P < 0.05, and *** denotes P < 0.001. 
 
Furthermore, the relative fluorescence intensity of FITC labeled cells results show that 7, 
and 7-fold increased fluorescence intensity in PC-3 cells; 14, and 36-fold (p<0.001) increased 
fluorescence intensity in C4-2B cells; 5, and 6-fold (p<0.01) increased fluorescence intensity in 
MC3T3; and 5, and 12-fold (p<0.001) increased fluorescence intensity in aRAW 264.7 cells were 
treated by the FITC tagged micelles, and M-pVTK10% particles, respectively (Figure 4.6B). As 
indicated in the FITC-labeled cell percentage, C4-2B and MC3T3 cells incubated with pVTK 
particles exhibited a statistically higher uptake rate compared to non-targeted particles. Thus, 
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pVTK targeting peptide might be an effective strategy to deliver therapeutics to C4-2B prostate 
cancer and osteoblasts in bone microenvironment. 
In the second part of bone-targeted particle uptake of prostate cancer cells and bone cells, 
we evaluated the effect of BP targeting ligand on the internalization of FITC-labeled BP particles 
as a function of BP density (5, 10, and 20% BP particles) both in regular cell culture plate and 
BLS. We then compared there to non-targeted particles following the same procedure of pVTK 
particles. The results show that 91%, 88%, 89%, and 88% of PC-3 cells; 75%, 71%, 75%, and 73% 
of C4-2B cells; 96%, 89%, 94%, and 90% of MC3T3; and 97%, 98%, 99%, and 99% of RAW 
264.7 cells were labeled by the FITC tagged non-targeted, M-BP5%, M-BP10%, and M-BP20% 
particles, respectively (Figure 4.7A). Moreover, the normalized relative FITC fluorescence values 
of all particle values for PC-3, C4-2B, and MC3T3 were around 6, 5, and 9-fold, respectively. 
There was no statistical difference between non-targeted particles and the BP targeting particles in 
these cell lines. However, increasing the BP density 5%, 10%, and 20% of bone targeted particles 
in RAW 264.7 macrophage cells increased the normalized relative FITC fluorescence values 17- 
(p<0.05), 23- (p<0.001), and 57-fold (p<0.001) compared to 14-fold increase of non-targeted 
particles, respectively as seen in Figure 4.7B. This higher relative internalization by macrophage 
trend is supported by earlier reports showed that negatively charged particles and BPs or BP-
decorated particles could target scavenger receptors on the cell membrane of macrophages cells 
[282, 283]. This result indicates BP-decorated bone-targeted particles are able to target 
macrophages. Since the highest relative fluorescence was measured with the 20% BP particle 
formulation, after this point we preferred to use this particle in further cellular experiments. 
Finally, we designed a second BLS experiment set-up to explore the M-BP20% particles 
uptake by seeding prostate cancer cells (PC-3 or C4-2B cells), or bone cells (MC3T3 or RANKL 
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activated RAW 264.7 cells), on BLS and maintained for 24 h in the incubator. Afterwards, the 
cells were treated with FITC-tagged particle that were either non-targeted, or M-BP20% at a 
concentration of 40 µg/mL in OPTIMEM medium for 3 h at 37 °C. We followed the cellular uptake 
protocol that we described in previous cell uptake studies. The percentage FITC-labeled cells and 
the normalized intensity of intracellular fluorescence of the particles were quantified using flow 
cytometry. The percentages of FITC-labeled PC-3 cells were 94%, and 91% after incubating with 
non-targeted, and M-BP20% particles, respectively. A similar trend was also observed for C4-2B 
cells. Specifically, 97%, and 94% of these cells were labeled with non-targeted, and M-BP20% 
particles, respectively. Moreover, 86%, and 86% of MC3T3, and 43%, and 30% (p<0.01) of 
aRAW 264.7 cells were labeled by the non-targeted, and M-BP20% particles, respectively (Figure 
4.7C). Furthermore, the relative fluorescence intensity of FITC-labeled cells results show that 7, 
and 6-fold increased fluorescence intensity in PC-3 cells; 14, and 12-fold increased fluorescence 
intensity in C4-2B cells; 5, and 5-fold increased fluorescence intensity in MC3T3; and 5, and 4-
fold increased fluorescence intensity in aRAW 264.7 cells were treated by the FITC-tagged non-
targeted, and M-BP20% particles, respectively (Figure 4.7D). 
All in all, when Figure 4.6, and 4.7 are compared in general cellular labeling or 
fluorescence intensity fold increase, it is clear that bone-targeted particle internalization through 
cancer and bone cells act differently because of the presence of BLS. For instance, PC-3 cells can 
be labeled about 90% when the cells are attached to the surface without the presence of a BLS. 
Another prostate cancer cell line, C4-2B, which is a mixed form (osteoblastic and osteolytic 
character) of bone metastasis cells can internalize comparatively less particles with PC-3 on 
regular tissue culture plate. These particle internalization rates are similar to our previous 
published study [273]. However, under the same experimental setup but with BLS (Figure 4.6) 
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the particle internalization rates increase to more than 90% range and pVTK bone-targeted 
particles are able to label 100% with a maximum of 36-folds relative fluorescence intensity 
increase. This pVTK-targeted particle uptake fold-enhancement in C4-2B is the highest rate 
comparing to MC3T3 and activated RAW 264.7 cells with p<0.001 and p<0.01, respectively. The 
reason of higher pVTK bone-targeted particle uptake profile of C4-2B cell line could be its 
osteoblast-like phenotype nature that are capable of mineralization with the production of bone 
surface alkaline phosphatase, osteocalcin, osteonectin, bone sialoprotein, and osteoprotegerin 
[284, 285]. Most importantly, the C4-2B cells produced hydroxyapatite mineral in vitro. This in 
vitro hydroxyapatite mineral production could raise up the pVTK-bone targeted particle affinity 
[286].  
The MC3T3 cell line is a mouse preosteoblast cell. We also tested the pVTK and BP bone-
targeted particles in MC3T3 cells using methodology similar to the tumor cells. The initial tests 
with particles in medium incubated in tissue culture plates show that both bone targeted particles 
have high cellular internalization rate (~90%). However, pVTK-particles achieve the highest 
statistically different cellular labeling with 95% and 28-folds relative intracellular fluorescence 
increase, as seen in Figure 4.6. However, in the case of cells on BLS and particles added 
afterwards in medium, we observe higher rates of internalization for all particle formulations. 
pVTK bone-targeted particles, in particular, have the highest MC3T3 cellular labeling with 96% 
and an increase in intracellular normalized fluorescence intensity by 6-folds (Figure 4.6). These 
results clearly show that pVTK particles can be internalized by osteoblasts. Even pVTK-targeted 
particles show statistically higher cellular uptake in MC3T3, once compared in different cell lines 
(C4-2B and activated RAW 264.7), this particle shows the lowest normalized fluorescence fold 
with p<0.001 and p<0.05, respectively. Further, pVTK is a well-characterized peptide formulation 
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that is able to adsorb to the apatite surface and inhibits the mineralization in pre-osteoblastic cells 
with a dose dependent response [142]. Because of the direct interaction of pVTK with mineralized 
surface or cells, pVTK particles are preferentially internalized by MC3T3 and C4-2B cells. 
Lastly, we investigated the bone-targeted particles uptake interactions with RAW 264.7 
macrophage cells on regular tissue culture plate and RANKL-activated RAW 264.7 cells to 
osteoclasts on the BLS. Macrophage cells are capable of phagocytosis which means they  
 
Figure 4.7 Prostate and bone cells uptake of the particles from regular cell culture plates and BLS. 
The cells first seeded on the plate. After 24 h the particles are added to the top of the cells and incubated 
for 3 h. (A) FITC-label non-targeted Micelles, M-BP5%, M-BP10%, and M-BP20%, percent cell label on 
regular cell culture plates, (B) Normalized mean fluorescence of cells treated with FITC-label non-
targeted Micelles, MI-pBP5%, MI-pBP10%, and MI-pBP20% on regular cell culture plates. (C) FITC-label 
non-targeted micelles, and MI-BP20% percent cell label on BLS, (D) Normalized mean fluorescence of 
cells treated with FITC-label non-targeted Micelles, and M-BP20% on BLS. Results are the average of at 
least nine samples of triplicate experiments + SEM. Percentage of labeled the cells and normalized mean 
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fluorescence increase by M-BP particles were compared to non-targeted FITC-M micelles using a two-
tailed Student’s t-test where * denotes P < 0.05. 
 
inherently internalize more particles compared to other cell lines. In the literature, negatively-
charged particles and BP-targeted particles are known to be recognized by macrophages and also 
tumor activated macrophages (TAMs), which form approximately half of the tumor mass [287]. 
Many studies denote that TAMs contribute to drug resistance [288] and elevated number of TAMs 
are correlated with therapy failure and poor diagnosis [289, 290]. Therefore, direct effects on these 
cells in the tumor microenvironment could contribute to the treatment of bone metastasis [291]. 
Our results confirm the high affinity between macrophages and these types of particles, as both 
bone-targeted particles are able to label RAW 264.7 cells almost 100% (Figure 4.7A). Increasing 
the number of BP targeting ligands displayed on the particles, the relative fluorescence intensity 
increases up to 57-folds (Figure 4.7B). Therefore, by increasing the number of BP on the particle, 
these particle formulations can be used to deliver specific agents to macrophages or TAMs. 
Interestingly, when RAW 264.7 cells are differentiated with RANKL on the BLS we do not see 
higher internalization of BP-targeted particles compared to other particle formulations. Also, it is 
important that ruffled bordered macrophages indicative of osteoclasts activation and subsequent 
bone resorption with acidic enzymes. The lack of forming ruffled borders might affect the BP-
particle uptake profile. This might be a mandatory effect in Figure 4.7 that the cells are first seeded 
and followed by particle incubation with the cells. Because of inability to form ruffled border in 
osteoclasts treated with BP targeting particles, the labeled cells are the lowest with 30% between 
all particles. Furthermore, inhibition of ruffled border formations by BP-targeting particles as well 
as loading with an anti-cancer agent might have a synergistic effect in the treatment of bone 
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metastasis. Whereas, as seen in Figure 4.6, pVTK-targeted particles have the highest osteoclast 
uptake with the percentage of 85% and 12-fold normalized relative fluorescence increase.  
Taken these cellular uptake results together, we can conclude that if bone metastasized 
cells are in osteolytic form (like PC-3 cells), BP-based targeting ligands are the ideal strategy to 
target cancer cells and TAMs. On the other hand, if the metastasized bone tumor is in a mixed 
format of both osteoblastic and osteolytic characteristics (like C4-2B cells), pVTK-targeting 
ligands are the preferred strategy for drug delivery.  
4.3.8 Cytotoxicity of CTX-loaded micelles  
To test the therapeutic effect of the bone targeted particles, we loaded CTX as a model 
anticancer agent in the core of the particles using our established drug encapsulation protocol 
[273]. The CTX loading content was measured in non-targeted, M-pVTK10%, and M-BP20% 
particles by HPLC. The loading efficiency was calculated based on a concentration versus CTX 
absorbance calibration curve. Results show that encapsulation efficiencies of CTX in non-targeted 
particles, M-pVTK10%, and M-BP20% particles were 30.03 ± 1.31%, 32.33 ± 4.87%, and 32.23 ± 
4.75%, respectively. In our reference study, we determined the CTX IC50 values of free and CTX-
loaded particles in PC-3 and C4-2B cells between 0.6-5.0 nM. Based on the established previous 
study and bone targeted-particles cellular uptake experiments we examined the therapeutic activity 
of these CTX-loaded particles at 0.1, 1.0, and 10 nM CTX concentrations in comparison to equal 
concentrations of free CTX for 48 h using the established resazurin cytotoxicity assay. We 
expected that CTX-loaded bone-targeted particles would exhibit higher therapeutic effect since 
they are able to bind to the bone surface and higher particle internalization by cancer cells based 
on the type of targeting ligands. Results show the % of surviving all cell types decrease with the 
increase of the concentration of CTX incubated with all cell lines (Figure 4.8). CTX-loaded non-
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targeted particles exhibited the highest survival percentage between all concentrations and all cell 
lines on BLS comparing to free CTX and as well as pVTK- and BP- targeted particles. The reason 
of this higher survival rate is that free CTX can be internalized by all cell lines via diffusion 
mechanism, bone-targeted particles are able to be adsorbed on BLS leading to likely increase 
particles contact to the cells, and more particle internalization with bone targeting ligands. Once 
each cell line is evaluated with the highest treated CTX concentration with details, PC-3 cells are 
survival 60%, 83% (p<0.001), 78% (p<0.001), and 66% (p<0.05) with the treatment of free CTX, 
CTX-M, CTX-M-pVTK10%, and CTX-M-BP20%, respectively (Figure 4.8A). BP bone-targeted 
particles display the lowest survival rate comparing to CTX-loaded particle formulations. The 
reasons of higher therapeutic effect could be BP-targeted particles having higher PC-3 cell uptake 
and as well as BP has anticancer effect. C4-2B cell viability percentages treated with free CTX, 
CTX-M, CTX-M-pVTK10%, and CTX-M-BP20%, are 41, 70 (p<0.001), 42, and 54 (p<0.001), 
respectively (Figure 4.8B). CTX-loaded M-pVTK10% shows overall similar cytotoxicity 
percentage like free CTX. This enhanced therapeutic effect could be contributed by the pVTK 
targeting motive, which gains specific internalization of M-pVTK particles by C4-2B. The survival 
rates of MC3T3 cells after treating with free CTX, CTX-M, CTX-M-pVTK10%, and CTX-M-
BP20%, are 80%, 90 % (p<0.001), 79, and 85 (p<0.05), respectively (Figure 4.8C). MC3T3 has 
higher survival rates with all CTX concentrations comparing to all other cell lines due to the fact 
that the model drug, CTX, is capable of targeting to epithelial cell lines such as prostate cancer 
cells not direct effect in osteoblasts. Because of the affinity of pVTK-targeted particles towards 
MC3T3 cells, the lowest viability rate is obtained by CTX-M-pVTK10%. The treatment of RAW 
264.7 macrophage cells with free CTX, CTX-M, CTX-M-pVTK10%, and CTX-M-BP20%, exhibit 
52%, 93 % (p<0.001), 66 (p<0.001), and 56, respectively (Figure 4.8D). We found that M-BP20% 
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particles have the highest total fluorescence in RAW 264.7 cells indicating higher BP bone-
targeted particle uptake profile comparing to other particle formulations. Because of higher particle 
internalization, CTX-loaded M-BP20% show higher therapeutic effect in comparison to other 
formulations. Lastly, RANKL activated RAW 264.7 cells were treated with the same therapeutics 
-free CTX, CTX-M, CTX-M-pVTK10%, and CTX-M-BP20%- showing 72%, 82%, 73%, and 67% 
cell viability without statistically difference comparing to free CTX (Figure 4.8E). However, the 
lowest viability is acquired with the treatment of CTX-loaded M-BP20% particles, which is 
statistically different in comparison to CTX-loaded non-targeted particles (p< 0.01). 
Once these in vitro results are interpolated to in vivo, it is noteworthy that free CTX, which 
is the highest viability knock-down for almost all cell lines, is lack of targeting of metastasized 
bone. Therefore, we do not expect to see efficient therapeutic effect because of not significant 
amount of free CTX accumulated in bone. Whereas, CTX-loaded non-targeted particles does not 
exhibit a higher cell viability inhibition effect in tumor cells as in vitro. However, some portion of 
non-targeted particles might accumulate in the bone metastasized tumor lesion due to EPR effect. 
Nevertheless, CTX-loaded pVTK-targeted particles exhibit similar therapeutic effect like free 
CTX in C4-2B cells whereas CTX-loaded BP-targeted particles show that a better therapeutic 
efficiency than other particles formulations in vitro conditions. Similarly, it is expected to observe 
higher in vivo therapeutic efficacy with both bone-targeted particles against prostate cancer 
metastasized in bone as comparing as comparing to free CTX and CTX-loaded non-targeted 
particles. Even the targeted-particles act efficiently, non-specific cytotoxicity or bone-targeted 
particle-associated osteonecrosis of the jaw could be possible limitations of this targeted therapy 
[292]. However, the number of bone-targeted particles accumulation in jaw could be minimized 
by changing the number of targeting number density on the particle formulation. 
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In here we showed that we could efficiently delivery of CTX-loaded bone-targeted 
particles to bone. CTX is only a model anti-cancer drug we have used. However, therapeutics 
could be chosen from a variety of options such as, anti-body, cytokines, proteins, or other 
anticancer agents with the proper bone-targeted strategy to inhibit a specific cell line and at the 
same time the cross-talk between bone and cancer cells. By doing this strategy, it is possible get 
more efficient and higher therapeutic effect. 
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Figure 4.8 Therapeutic activity of CTX, and CTX-loaded particles in prostate and bone cells on 
BLS. 
(A) PC-3, (B) C4-2B, (C) MC3T3, (D) RAW 264.7, and (E) RANKL activated RAW 264.7. The 
resazurin viability assay results of treated cells that normalized with untreated cells. Results are the 
average of triplicate experiments + SEM. Percentage of cell viability was compared to untreated cells 
using a two-tailed Student’s t-test where * denotes P < 0.05, ** denotes P < 0.01, and *** denotes P < 
0.001. 
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4.4 Conclusions 
In summary, we have successfully synthesized two different bone-targeted pVTK-peptide 
and BP-decorated triblock amphiphilic copolymers via ATRP and “click” reactions. These 
copolymers self-assemble in an aqueous environment and form 60-90 nm size micelles with pH-
sensitive cross-linking shells as a function of bone-targeted block densities. The results show that 
pVTK and BP decorated “smart” particles were able to bind to bone HA surface. pVTK bone- 
targeted particles exhibited preferential uptake into C4-2B prostate cancer cells and osteoblasts on 
the BLS. Whereas, BP bone-targeted “smart” particles were internalized preferentially by RAW 
264.7 macrophage cells in regular tissue culture plates, and PC-3 cells internalized these particles 
higher than other cell lines on BLS. This cellular uptake difference on BLS reveals insights into 
personal medicine for the treatment of bone metastasis based on the metastasis type, either 
osteoblastic, osteolytic, or mix form.  Further, these bone targeted particles were able to 
encapsulate Cabazitaxel, an anti-cancer agent, in the core with more than 30% drug-loading, 
enhancing the solubility and efficiency of a water insoluble drug. Moreover, CTX-loaded bone 
targeted particles showed higher therapeutic effect in prostate cancer cells on the BLS compared 
to free CTX and CTX-loaded non-targeted particle formulations. These results collectively show 
that pVTK and BP bone-targeting “smart” particles are an ideal drug carrier for selective delivery 
of anticancer agents into metastasized prostate cancer lesion in bone. We will investigate these 
particles in vivo to assess the efficacy of targeting ligands to metastatic prostate cancer in bone.  
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Conclusion and Future Direction 
5.1 Conclusion 
Throughout this dissertation, we reported the design and synthesis of tri-block copolymer 
based nanoparticle systems that served as a platform technology for the treatment of primary as 
well as bone metastasized prostate cancer. Specifically, this research study successfully validated 
the use of the tri-block polymer platform in several applications ranging from (i) targeted 
nanodroplet-mediated histotripsy experiments that resulted in primary prostate cancer cell ablation 
at the 2-D cellular as well as 3-D spheroidal levels, ii) the efficacious delivery of anti-cancer drugs 
into primary prostate cancer cells via pH-sensitive “smart” micellar nanoparticles compared to the 
free drug. Furthermore, we demonstrated specific prostate cancer cell selectivity and functional 
delivery of anti-cancer drugs into bone metastasized prostate lesion using “smart” micellar 
nanoparticle formulations decorated with two different bone targeting agents (peptide vs 
bisphosphonate). 
In the first part of this dissertation, we explored the effects of pre-defined ultrasound 
parameters on a library of well-characterized nanodroplet formulations (investigated in Appendix 
1, 2, and 3). We previously showed that perfluoropentane, a widely used PFC, was successfully 
encapsulated in the core of tri-block amphiphilic copolymers that “self-assembled” into 
nanodroplet micelles (less than 200 nm in size) in aqueous systems. These acoustically active 
nanodroplets significantly reduced histotripsy cavitation threshold pressure in the phantom model 
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from 25-30 MPa to 8-13 MPa, thereby exhibiting the potential clinical application of NMH for 
targeted tissue ablation [46, 79]. Moreover, our studies also showed that lower frequencies (335 
kHz and 500 kHz) improved the effectiveness of NMH by increasing the size of the focal region 
which, in turn, increased bubble expansion, and decreased cavitation threshold [80]. In another 
study, we evaluated the physico-chemical properties of nanodroplet formulations comprising two 
different perfluorocarbons namely, perfluoropentane (PFP) and perfluorohexane (PFH). While 
both nanodroplet formulations significantly reduced NMH cavitation thresholds compared to 
regular histotripsy interventions, we observed starkly different sustainable nuclei cavitation 
profiles in PFH-nanodroplet formulation over multiple pulses. The PFH-loaded nanodroplets 
showed a 20-fold higher cavitation activity over that of PFP-loaded nanodroplets because of the 
higher boiling point and surface tension of PFH [81, 82]. Finally, to explore the underlying 
physical mechanism of the nanodroplet cavitation process, we elucidated the role of positive and 
negative pressure on cavitation nucleation in NMH. The results showed that the cavitation 
nucleation phenomenon of NMH is closely related to the peak negative pressure of the incident 
wave [83]. 
In Chapter 2, we investigated the feasibility of achieving selective ablation of PC-3 and 
C4-2B prostate cancer cells in 3-D spheroid tissue mimic models using PFP-loaded and PFH-
loaded nanodroplets at low acoustic pressure. Results showed that PFH- nanodroplets could be 
efficiently used for the ablation of tumor spheroids in the relevant 3-D microenvironment 
comparing to PFP-nanodroplets because of sustainable nuclei cavitation profiles in PFH-
nanodroplet formulation over multiple pulses. Further, this result is a significant advancement 
upon previous NMH work and suggest that NMH can be used for targeted tumor ablation. 
Moreover, the significantly reduced pressure threshold values achieved through the use of PFH-
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loaded nanodroplets compared to that of the current histotripsy methods using the tissues intrinsic 
gas pockets allows for the selective ablation of 3-D tumor models and as well as in vivo. Thereby, 
preserving the surrounding normal tissue, devoid of ND’s, that require higher threshold pressure 
values to facilitate histotripsy-induced fractionation. Furthermore, the resulting PFP or PFH gas 
bubbles can function as ultrasound contrast agents, that can help identify tumor sites upon 
ultrasound imaging to facilitate guided and real-time tumor imaging during histotripsy treatment. 
In Chapter 3, we reported the synthesis of new amphiphilic tri-block copolymers composed 
of a hydrophilic poly(ethylene glycol) (PEG) block, a central poly(acrylic acid) (PAA) block, and 
a hydrophobic poly(methyl methacrylate) (PMMA) block. Using standard characterization 
techniques, we showed the successful synthesis of amphiphilic tri-block copolymers, (PMMA-b-
PAA-b-PEG), which proved to self-assemble in aqueous solutions forming nano-sized micelles 
that efficiently encapsulate hydrophobic small molecules such as Nile Red (NR, a hydrophobic 
fluorescent dye) and Cabazitaxel (CTX, model anticancer drug) into the hydrophobic core. Upon 
loading the desired concentration of hydrophobic small molecules into the core, we established 
acid-labile cross linkages between adjacent polymer chains forming shell cross-linked micelles 
(SCLM), specifically, through the reaction of 2, 2-(propane-2, 2-diylbis(oxy) diethanamine) with 
the carboxylic acid groups of the PAA block. We then evaluated the release profile of the loaded 
cargo (i.e., NR and CTX) from non-cross-linked micelles (NSCLM) and SCLM upon incubation 
in aqueous buffer solutions at both physiologic (pH = 7.4) and endosomal (pH = 5.0) pH values. 
The acid-labile cross linkages allow for a controlled and tunable release of the desired encapsulated 
cargo. Results illustrated that the SCLM-50 (half of the PAA units in the formulation are reacted 
with the pH-labile cross-linker) family exhibited the highest cytotoxic activity towards PC-3 and 
C4-2B cancer cells in vitro with IC50 values that were significantly lower than free CTX. 
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Moreover, SCLM-50 micelles did not cause hemolysis of red blood cells (RBCs), trigger platelet 
activation, acquire an albumin corona, or get phagocytosed by activated macrophages, which 
makes this micelle platform an ideal carrier for in vivo delivery of CTX into prostate tumors. 
In chapter 4, we report the synthesis of two novel bone targeting nanoparticle strategies 
that comprised of coupling either a peptide, namely pVTK or bisphosphonate (BP) ligand to the 
PEG block of the tri-block copolymer to form two targeted, pH sensitive “smart” nanoparticle 
formulations. The objective of decorating the free end of the PEG block with either pVTK or BP 
ligands was to help facilitate selective binding and accumulation of the “smart” nanoparticles 
reported in Chapter 3 to metastasized bone. We evaluated the physicochemical properties of 
different molar ratios of targeting ligands (0, 5, 10, 20%) in both pVTK or BP nanoparticle 
formulations. We compared the binding capability of FITC-labeled pVTK and BP-coupled 
nanoparticles upon incubation in aqueous buffer solution with bone powder at pH 7.4 as a function 
of the targeting ligand density. The results showed that both pVTK and BP decorated “smart” 
particles were able to bind to bone HA surface. Further, we investigated the uptake profiles of 
FITC-labeled non-targeted, pVTK-labeled, and BP-labeled nanoparticles into PC-3 and C4-2B 
prostate cancer cells, MC3T3 pre-osteoblasts, and activated RAW 264.7 osteoclasts cultured on 
regular tissue culture plates and bone like surface plates. Finally, the anti-cancer agent, CTX, was 
loaded into the core of non-targeted, pVTK and BP-decorated nanoparticles with more than 30% 
loading efficiency. pVTK-targeted nanoparticles exhibited a preferential uptake into C4-2B 
prostate cancer cells and osteoblasts grown on the bone mimic surface. While, BP-targeted 
nanoparticles showed significantly higher internalization into RAW 264.7 macrophage cells 
cultured on regular tissue culture plates. Further, PC-3 cells cultured on bone like surfaces 
demonstrated higher uptake of BP-labeled nanoparticles compared to C4-2B prostate cancer cells. 
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Finally, we explored the therapeutic effect of non-targeted, pVTK, or BP-targeted particles that 
were either empty or CTX-loaded on the following four cell lines on pretreated BLS: PC-3, C4-
2B, MC3T3, and RANKL activated RAW 264.7 cells. The results demonstrated that CTX-loaded 
bone targeted nanoparticles showed higher therapeutic effect in prostate cancer cells on the bone 
like surface compared to free CTX and CTX-loaded non-targeted particle formulations. All these 
results collectively show that pVTK and BP bone targeting “smart” nanoparticles are an ideal drug 
carrier for selective delivery of anticancer agents into prostate cancer lesion in bone. 
 
5.2 Future Directions 
Our immediate strategy is to perform pre-clinical validation studies with the ultimate goal 
of establishing two potentially promising and robust clinically-viable, nanotherapy platforms for 
the treatment of primary prostate cancer using targeted nanodroplet-mediated histotripsy systems 
as well as the treatment of bone metastasizing prostate cancer using either pVTK-peptide or BP-
decorated nanoparticles encapsulating the desired anti-cancer drug. The pre-clinical phase will 
encompass the in vivo biodistribution of these nanoparticles in primary cancer and metastatic bone 
prostate cancer animal-tumor models, respectively. This initial study will assist us in the 
identification of the most efficient targeting strategy from a pharmacokinetics perspective that will 
result in the greatest preferential accumulation of the targeted particles in prostate cancer tissue or 
prostate cancer lesion in bone metastasis, respectively. 
5.2.1 Development of Tumor Targeted Nanodroplets 
To design prostate cancer targeted nanodroplets, we propose the use of J591, a monoclonal 
antibody [293], A-10 RNA [294] or peptide (sequence of WQPDTAHHWATL) [295, 296] that 
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will specifically bind to the extracellular domain of PSMA overexpressed on the surface of prostate 
cancer cells [297], as previously reported in the literature. We will conjugate these targeting 
ligands to the carboxylic group of COOH-PEG-Alkyne via the standard EDC/NHS coupling 
reaction following published protocols [298] to prepare the respective targeted-PEG-alkyne 
conjugates, which we will then react with PAA and P(MMA-co-HDFMA) blocks following 
methods described earlier in Chapter 2, Appendix 1, 2, and 3. We will design a library of targeted 
copolymers by varying the molar ratio of targeted-polymer conjugates (10%, 25%, and 50%) 
mixed with non-targeted tri-block copolymer to vary the number of the targeting ligands displayed 
on nanodroplets surface to determine the optimum targeted tri-block copolymer density on the 
nanodroplet formulations with conducting of cellular uptake experiments using flow cytometry. 
We will further investigate the physicochemical properties, echogenicity, and stability of targeted 
nanodroplets using the methods described in Appendix 1, 2, 3, and Chapter 2.  
5.2.2 In vivo Nanodroplet Mediated Ultrasound Imaging 
After defining well-characterized NMH US parameters and development of prostate cancer 
targeted nanodroplets, we will investigate the feasibility of using targeted nanodroplets for US 
imaging of prostate cancer micro-foci in vivo. 
5.2.3 In vivo imaging of prostate cancer cells using targeted nano-bubbles 
We will establish orthotopic tumors using approved IACUC animal protocols by injecting 
~1x106 C4-2B-Lux and PC-3-Lux prostate cancer cells (expressing the luciferase enzyme) into the 
dorsolateral lobe of the prostate gland of male mice and monitor their growth by bioluminescence 
imaging (BLI) using IVIS imaging system (Caliper Life Sciences) [299, 300]. We will use this 
orthotopic mouse model (C42B-Lux) to investigate if targeted nanodroplets can selectively 
“home” into the implanted cancer cells and enhance their contrast with US imaging. We will 
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separate the tumor-bearing mice into two groups (n = 5 mice/group) where we will administer 
targeted nanodroplets (test group) and an equal volume of saline (control group) via tail vein 
injections. We will monitor the change in tumor volume using luminescence imaging every 3 days 
for a total of 6 weeks following established BLI protocols [300, 301]. Using the Verasonics system 
and 10 MHz imaging probe, we will image the prostate in both mice groups on the same day of 
the BLI following established US imaging protocols [302, 303]. Briefly, we will start image 
acquisition 10s before administering the assigned nanodroplets or saline solutions at pre-defined 
time points for 2 hours after injection. The fold enhancement in echogenic signal as a function of 
time will be calculated by subtracting the baseline value from each time point for each mouse. We 
will compare the calculated fold enhancement in echogenic signal in mice treated with targeted 
nanodropleted to the calculated echogenic signal in mice treated with saline at the same time points 
to determine: i) if targeted nanodroplets “home” into tumor lesions, and ii) the smallest tumor 
volume that can be imaged using these targeted nanodroplets. We will compare the hyper 
echogenic zone on US images to the zone of highest luminescence on BLI in all studies to confirm 
that enhanced scattering is localized to prostate cancer cells. 
5.2.4 In vivo toxicity of targeted nanodroplets 
We will investigate the toxicity profiles of our targeted nanodroplets by evaluating their 
hematologic (RBC & WBC and hematocrit value), liver (serum levels of ALT and AST enzymes), 
kidney (serum creatinine level), and heart (serum ROS level) toxicity compared to saline-treated 
mice 24-hours after each injection. The UM histology core will carry a blinded examination of the 
heart, lungs, liver, kidneys, and spleen isolated from both mice groups at the end of the imaging 
experiments to identify pathological signs of nano-droplet toxicity. 
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5.2.5 In vivo Nanodroplet Mediated Tumor Ablation 
We will investigate the feasibility of ablating prostate cancer cells in vivo using targeted 
nano-bubbles combined with histotripsy.  
5.2.5.1 Selective in vivo ablation of prostate cancer cells using targeted nano-bubbles 
C42B-Lux cancer cells will be injected into the prostate of twenty mice and will be 
monitored for 5 weeks to determine changes in tumor volume using BLI before dividing the mice 
into four groups (n = 5 mice/group) where each group will receive a different treatment with the 
guidance of our approved protocol [300, 301]. We will administer 100 μL of targeted nanodroplets 
solution to the mice in group 1 (test) via tail vein injections. We will apply the histotripsy 
parameters that were most effective in ablating prostate spheroids in vitro to group 1 and evaluate 
the resulting therapeutic activity by measuring the reduction in the intensity of the luminescence 
signal after the treatment compared to its baseline value before the treatment using BLI. We will 
also use US imaging to monitor the drop in echogenic signal (hypoechogenic) of the cancer lesion 
after the histotripsy treatment. We will investigate the independent effect of targeted nanodroplets 
alone (group 2) and histotripsy alone (group 3) on ablation of prostate cancer cells using the same 
nanodroplets dose and histotripsy parameters applied to group 1, respectively. Saline will be 
injected to group 4 as a control. We will harvest the prostates from all mice and through a 
microscopic analysis by the histology core determine the size of the ablated tumor region and the 
extent of damage of the neighboring healthy tissue in response to each treatment. This pilot study 
will establish the therapeutic potential of targeted nanodroplet contrast agents in combination with 
histotripsy in ablating prostate cancer cells. 
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5.2.6 In vivo Validation of Bone Targeted Particles 
After in vitro characterization of both bone targeted particles, we will focus on 
investigating the evaluation of bone targeting micelle particles activity in vivo. 
5.2.6.1 Synthesis of Radio-Labeled and NIR Dye Labeled Copolymers 
To do that, first we will synthesize radio-labeled particles using N-akylation reaction of 
NH2 under reaction of iodoacetamide under basic conditions (pH 10) [304, 305]. Alkyne-PEG-
NH2 will be functionalized with I-[14C] and then followed by alkyne-azide click chemistry strategy 
coupled to the copolymer block that we have used in targeting ligand and NIR 680RD dye 
functionalization of triblock copolymer. These radio and NIR 680RD labeled bone targeted 
particles will be used to quantify particles biodistribution and tracing in bone microenvironment.  
5.2.6.2 Evaluation of Bone Targeted Particles Biodistribution 
Two different bone metastatic prostate cancer mice models, which exhibit osteolytic (PC-
3) [306], and osteoblastic/osteolytic mixed (C4-2B) [307] characters will be established by 
injecting a cell suspension comprising of either PC-3 or C4-2B cells (2x105 cells) into the proximal 
tibia.  After tumors are established, the following experiments might be conducted. Each group of 
tumor-bearing mice model (n = 4) will be given a single bolus dose of [14C]-pVTK and [14C]-BP 
targeted particles (0.67 mg) via intravenous (I.V.) administration through tail-vein injections. The 
distribution of the particles as a function of time after injection (0.5, 2, 4, 8, 24, 36, 48, and 72 
hours) will be quantified. The amount of radioactive nuclide present in the systemic circulation, 
tumor, bone, brain, heart, lungs, liver, kidney, spleen, and excretions will be quantified per 
microgram of each tissue through liquid scintillation counting. The amount of [14C]-labeled 
particles distributed to each tissue will be normalized to the corresponding extraction efficiency 
for that tissue and results for each treatment group will be presented as the average % of the 
injected dose per tissue ± SEM [308]. The biodistribution results will also be used to evaluate the 
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blood to bone particle distribution ratio, blood to tumor distribution ratio, plasma retention time, 
and tumor retention ability of the particles per gram of organ. From the tumor retention time 
calculation, the dosing regimen, which is related to repeating injection interval based on the time 
point that the concentration of micelles in tumor starts to decrease, will be determined. 
5.2.6.3 Tracing of bone targeted, NIR 680RD dye labeled particles  
In previous in vitro bone mimic surface uptake studies, we showed that different targeting 
ligands exhibited varying binding propensities for different prostate cancer cell lines. For instance, 
pVTK is good at for targeting C4-2B and osteoblast cells, whereas BPs is a good candidate for 
targeting to PC-3 and macrophages. To evaluate if a similar trend extends to in vivo model, we 
will validate the targeting capabilities of our nanoparticles by tracing the NIR 680RD labeled bone 
targeted nanoparticles [309-311]. Briefly, we will inject NIR 680RD labeled both pVTK-targeted 
and BP-targeted nanoparticles into either the above mentioned bone metastatic mice models and 
healthy mice as a control via tail vein injections. Post particle injection, the proximal tibia’s will 
be shaved and depilated, and the proximal tibial fluorescence will be monitored by in vivo non-
invasive serial imaging at 2, 6, and 24 h (Maestro, CRi). After 24 h, the mice will be euthanized, 
following the dissection of the tibia and femur, and ex vivo imaging for to determine the spatial 
localization of the nanoparticles. Following fluorescent imaging, tibia and femurs will be imaged 
by micro–computed tomography (mCT) and the images reconstructed at 18-mm voxel size to 
correlate bone fluorescence with bone surface area in the distal femur/tibia following established 
protocols [309-311].  
5.2.6.4 In vivo Anticancer Activity and Toxicity of CTX-Loaded Bone-Targeted Particles 
The anticancer activity of the CTX-loaded bone targeted nanoparticles (~1.42 mg, 
calculated based on the maximum non-lethal dose for mice (25 mg/kg)) will be explored [312] by 
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injecting them into tumor-bearing mice models as a function of dosing regimen period as well as 
measuring tumor toxicity, in terms, of tumor volume compared to control treatments of free CTX 
(0.75 mg) and saline, and CTX-loaded non-targeted particles. The anticancer activity will be 
monitored by measured tumor volume up to 12 weeks for PC-3 and C4-2B tumor models, as well 
as by monitoring mouse survival rate. Further, at the end of in vivo anticancer activity study, the 
biocompability tests involving hematology evaluation of red blood cell count, neutrophil count, 
reticulocyte count, hemoglobin, hematocrit, white blood cell count, white blood cell percentage, 
platelet count will be conducted and organ/tissue pathology samples of the bone, brain, liver, 
kidney, spleen, heart, etc. will be collected and evaluated for organ toxicity by pathological 
evaluation performed with help of the UM histology and pathology facility. Free CTX will be used 
as a control in all cases.
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Appendices 
 
The Effects of Ultrasound Frequency on Nanodroplet-Mediated 
Histotripsy 
 
The material in this chapter is published from the following article: E. Vlaisavljevich, O. Aydin, 
Y. Y. Durmaz, K-W Lin, B. Fowlkes, M. ElSayed, and Z. Xu “The Effects of Ultrasound 
Frequency on Nanodroplet-Mediated Histotripsy” Ultrasound in Medicine and Biology, 41(8), 
2135, 2015. 
Introduction 
Histotripsy is a noninvasive, image-guided tissue ablation method that controllably 
fractionates soft tissue through cavitation generated by high pressure, short duration ultrasound 
pulses [43, 49, 313]. Histotripsy depends on the initiation and maintenance of a dense cavitation 
bubble cloud to produce mechanical tissue fractionation [314, 315]. Previous work has shown that, 
using a 1-2 cycle pulse with a single dominant negative pressure phase, histotripsy bubbles can be 
reproducibly generated in tissue when the peak negative pressure is raised above the histotripsy 
intrinsic threshold of ~25-30 MPa [44, 316]. In order to effectively fractionate tissue into acellular 
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debris, histotripsy requires bubbles to rapidly expand into large cavitation bubbles, often greater 
than ~50μm in diameter [79, 313, 317, 318]. Using a pressure high enough to initiate a bubble 
cloud, histotripsy has been shown capable of completely fractionating soft tissue into a liquid-
appearing homogenate with no cellular structures remaining [43, 49, 161]. Histotripsy is currently 
being studied for many clinical applications in which non-invasive tissue removal is desired 
including benign prostatic hyperplasia [319], deep vein thrombosis [164], congenital heart disease 
[165, 166], and cancer ablation [45, 167]. 
Although histotripsy has shown promise for many clinical applications including tumor 
ablation, this approach is limited to applications in which the target tissue can be identified and 
imaged prior to treatment, which is often not feasible in cancer patients with many small tumor 
nodules and micro-metastases. As a result, our team has developed a new targeted ablation 
approach combining perfluoropentane (PFP) encapsulated nanodroplets with histotripsy [46, 79]. 
This nanodroplet-mediated histotripsy (NMH) approach takes advantage of the significantly 
reduced cavitation threshold of the nanodroplets, allowing for cavitation to be selectively 
generated only in regions containing the nanodroplets [79]. Preparing nanodroplets in the size 
range of ~100-400 nm allows them to diffuse across the leaky tumor vasculature and preferentially 
accumulate in the tumor, which allows NMH to potentially achieve selective ablation of tumors 
[46, 79]. In a previous study [79], the initial feasibility of this approach was demonstrated, with 
results supporting our hypothesis that nanodroplets significantly decrease the histotripsy threshold 
to form a cavitation bubble cloud while maintaining the effectiveness of histotripsy tissue ablation. 
NMH was shown capable of creating microbubble expansion and collapse as well as well-defined 
ablation similar to histotripsy but at significantly lower pressure [79]. Furthermore, the potential 
to use this approach for simultaneous multi-focal ablation was demonstrated [79].  
162 
 
To build upon our initial study, this work aims to investigate the effects of ultrasound 
frequency on NMH. We hypothesize that lower frequency will offer multiple advantages for NMH 
therapy. First, as the transducer focal zone scales with the wavelength, a low frequency transducer 
will yield a large focal zone, allowing histotripsy to be applied simultaneously to cover large and/or 
multi-nodule tumors seeded with our nanodroplets, thus increasing the treatment efficiency for 
such tumors. Lower frequency is also more resistant to acoustic aberration and attenuation from 
bone obstruction and long overlying tissue, resulting in deeper penetration depth. The use of 
nanodroplets targeted for tumor uptake will allow selective ablation of such tumors without need 
to otherwise identify the treatment location, keeping the selectivity of targeting the tumor despite 
the larger focal zones. Additionally, we hypothesize that lower frequency will decrease the 
cavitation threshold using nanodroplets while facilitating greater bubble expansion compared to 
higher frequency. In this study, we tested this hypothesis by exposing tissue phantoms with and 
without nanodroplets to histotripsy pulses produced by 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz 
histotripsy transducers. First, the probability of generating inertial cavitation from a single 1-2 
cycle histotripsy pulse was measured for each frequency, with the cavitation threshold defined as 
the peak negative pressure at which the probability of generating cavitation, pcav, from a single 
histotripsy pulse was 0.5 (i.e. pcav = 0.5). Next, the effect of frequency on the size of NMH bubbles 
was compared using high speed optical imaging. Finally, the ability of PFP-encapsulated 
nanodroplets to act as sustainable cavitation nuclei over multiple pulses was investigated, as 
multiple pulses (often>100) are needed to completely destroy all the tumor cells within the 
treatment volume. Overall, these results will improve our understanding of the NMH process and 
help guide parameter optimization for multi-focal tumor ablation using NMH. 
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Methods 
Formulation and Characterization of Nanodroplets   
The ideal polymer composition and PFP content of the nanodroplets used in this study were 
identified in our previous study [46]. A poly(ethylene glycol)-b- poly(acrylic acid)-b-
poly(heptadecafluorodecyl methacrylate-co-methyl methacrylate) triblock copolymer was 
synthesized using a combination of atom transfer radical polymerization (ATRP) and “click” 
coupling techniques to prepare PFP-loaded nanodroplets [46]. Briefly, the copolymers were 
dissolved in tetrahydrofuran anhydrous (THF, >99.9 %, Sigma-Aldrich, St. Louis, MO, USA) 
(0.2% w/v) and cooled down to 0 oC before the addition of perfluoropentane (PFP, 97% ca. 85% 
n-isomer, Alfa Aesar, Ward Hill, Massachusetts, USA) (2% v/v) while vigorously stirring the 
reaction mixture. An equal amount of water was slowly added to this solution mixture to trigger 
micelle formation and the mixture was stirred for 1h in an ice bath. The micelles solution was 
transferred into a dialysis bag (MWCO of 1 KDa, Spectrum, Rancho Dominguez, CA, US) and 
dialyzed against ice-cold 2-(N-morpholino) ethanesulfonic acid monohydrate solution (MES, 99 
%, Acros Organics, Geel, Belgium) of pH 5.5 for 12 hours to remove the THF and get a milky 
solution of non- cross-linked PFP-loaded nanodroplets. This milky solution was transferred to a 
round bottom flask and mixed with the 2,2`-(ethylenedioxy)-bis(ethylamine) cross-linker (98% 
2,2`-(ethylenedioxy)-bis(ethylamine), Sigma-Aldrich, St. Louis, MO, USA) which reacts with the 
central PAA block in the polymer backbone via NHS/EDC coupling chemistry (97% N-hydroxy 
succinimide; 98% N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, Sigma-
Aldrich, St. Louis, MO, USA) forming cross-linked nanodroplets with a flexible polymer shell. 
Shell cross-linked nanodroplets were dialyzed against ice-cold water for 12 hours to remove the 
byproducts of the cross-linkage reaction. 
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Concentration and size distribution of the nanodroplets were measured using Nanoparticle 
Tracking Analysis (NTA). Briefly, the NanoSight™ LM10 (Malvern Instruments, Amesbury, 
UK), equipped with a temperature-controlled 405 nm laser module, high sensitivity Scientific 
Complementary Metal–Oxide–Semiconductor (sCMOS) camera (Hamamatsu, Orca, Hamamatsu 
City, Japan), and a syringe pump was used for the collection of NTA data. Upon diluting the 
nanodroplet solution to the appropriate particle concentration with deionized (DI) water (Thermo 
Scientific, GenPure, Waltham, MA, US), image capture and analysis was carried out using the 
NTA software (Version 3.0, Build 0066, Malvern Instruments, Amesbury, UK) at 37°C. The 
samples were measured by capturing 60s videos (5 videos per each sample). Figure A.1 is a 
representative plot showing the size distribution for a single sample of nanodroplets. The error 
bars represent the standard deviation of the repeat measurements of each sample. The mean size 
and standard deviation values obtained by the NTA software correspond to arithmetic values 
calculated with the sizes of all particles analyzed for each sample (n=5). Results from all samples 
demonstrated that the average size of the nanodroplets (NDs) was 177.9±1.9 nm with 10% of NDs 
have a diameter ≤ 111±1.4 nm, 50% of the NDs have a diameter ≤ 155.7±2.1 nm, 90% of the NDs 
have a diameter ≤ 268.5±6.7 nm, and >99% of the NDs smaller than 400 nm and <0.01% larger 
than 600 nm. These results clearly show that the average size of the NDs is much smaller than the 
size cutoff (∼500 nm) of the tumor vasculature [320, 321]. 
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Figure A.1 Nanodroplet size distribution results show an average nanodroplet size of 177.9±1.9 
nm. 
 
Preparation of Tissue Phantoms  
Agarose phantoms were used to provide a well-controlled viscoelastic medium for this 
study, as histotripsy bubble behavior is highly dependent on the tissue mechanical properties [322-
324]. The Young’s modulus of the agarose tissue phantom was 38kPa, which is within the range 
of the Young’s modulus of hepatocellular carcinoma tumors (20.4–75 kPa), metastatic liver tumors 
(23.6–75 kPa), and prostate tumors (24 kPa) [325-327]. Tissue phantoms containing 1% agarose 
w/v were prepared by slowly mixing agarose powder (Agarose Type VII; Sigma-Aldrich, St. 
Louis, MO, USA) into saline solution (0.9% sodium chloride; Hospira, Lake Forest, Illinois, USA) 
heated to boiling temperature. The solution was stirred on a hot plate until the gel turned 
completely transparent and then allowed to boil for ten minutes. After boiling, solutions were 
allowed to cool and were degassed under a partial vacuum (~20 kPa, absolute) for 30 minutes. 
After degassing, phantoms containing nanodroplets were prepared by slowly adding the 
nanodroplets (2.0x108 particles/mL) into the agarose solution while stirring. The agarose mixtures 
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were poured into rectangular polycarbonate holders with acoustic windows and placed in a 
refrigerator at 4°C to allow the solution to solidify, forming tissue phantoms with embedded 
nanodroplets (test) or without nanodroplets (control). A nanodroplet concentration of 2.0x108 
particles/mL was used for all samples, as preliminary experiments demonstrated that lower 
concentrations (i.e. ~106-107 particles/mL) did not significantly reduce the cavitation threshold in 
comparison to control conditions.  
Histotripsy Pulse Generation 
Histotripsy pulses were generated at four ultrasound frequencies (345 kHz, 500 kHz, 1.5 
MHz, and 3 MHz) using three custom-built histotripsy transducers. The 345 kHz pulses were 
generated by a twenty-element array transducer with a geometric focus of 150 mm, an aperture 
size of 272 mm, and an effective f-number of 0.55. The 1.5 MHz pulses were generated by a six-
element array transducer with a geometric focus of 55 mm, an aperture of 79 mm in the elevational 
direction and 69 mm in the lateral direction, and effective f-numbers of 0.7 and 0.8 in the 
elevational and lateral directions, respectively. The 500 kHz and 3 MHz pulses were generated by 
a dual frequency array transducer that consisted of twelve 500-kHz elements and seven 3-MHz 
elements. For the 500 kHz elements, the geometric focus was 40 mm, the aperture size was 71 
mm, and the effective f-number was 0.56. For the 3 MHz elements, the geometric focus was 40 
mm, the aperture size was 80 mm, and the effective f-number was 0.5. The design of this dual 
frequency transducer has been described in detail in a previous study [328].  
To compare the NMH cavitation threshold with the histotripsy intrinsic threshold, short 
pulses with a single dominant negative pressure half-cycle were applied to the tissue phantoms 
with and without nanodroplets. To generate a short therapy pulse, a custom high-voltage pulser 
developed in-house was used to drive the transducers. The pulser was connected to a field-
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programmable gate array (FPGA) board (Altera DE1 Terasic Technology, Dover, DE, USA) 
specifically programmed for histotripsy therapy pulsing. This setup allowed the transducers to 
output short pulses of less than two cycles. A fiber-optic probe hydrophone built in-house [172] 
was used to measure the acoustic output pressure of the transducers. At higher pressure levels (p- 
> 23 MPa), the acoustic output could not be directly measured due to cavitation at the fiber tip. 
These pressures were estimated by a summation of the output focal peak negative pressure (p-) 
values from individual transducer elements. This approximation assumes minimal nonlinear 
distortion of the waveform occurs within the focal region. In a previous study [44], this estimated 
p- was found to be accurate within 15% compared to direct focal pressure measurements in water 
and in a medium (1,3 butanediol) with a higher cavitation threshold. Sample acoustic waveforms 
produced by the four frequency transducers are shown in Figure A.2. 
 
Figure A.2 Acoustic waveforms. Example of a 2-cycle histotripsy pulses generated by the 345 kHz, 
500 kHz, 1.5 MHz, and 3 MHz histotripsy transducers. 
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Optical Imaging and Image Processing 
High speed optical imaging was used to capture images of the focal zone after the 
propagation of each pulse through the focus for water and agarose tissue phantoms using two high 
speed cameras (Figure A.3). The optics were varied for the different transducers to provide the 
highest resolution based on the geometric constraints of the transducers and the available optical 
windows. For experiments with the 345 kHz and 1.5 MHz transducers, a high-speed, 1 megapixel 
CCD camera (Phantom V210, Vision Research, Wayne, NJ, USA) was aligned with the transducer 
and backlit by a continuous white-light source. The camera was focused using a macro-bellows 
lens (Tominon 1:4.5, F=105 mm; Kyocera, Kyoto, Japan), giving the captured images a resolution 
of approximately 5.9 µm per pixel and 3.4 µm per pixel for 345 kHz and 1.5 MHz, respectively.  
 
Figure A.3 Experimental set-up. The focus of the histotripsy transducer was aligned inside tissue 
phantoms with and without nanodroplets. 
Cavitation was monitored using high speed optical imaging and passive cavitation detection using one 
of the therapy elements. 
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For experiments with the 500 kHz and 3 MHz dual frequency transducer, a digital, 1.3-
megapixel CCD camera (PN: FL3-U3-13Y3M-C, Flea® 3, PointGrey, Richmond, BC, Canada) 
was positioned perpendicularly to the dual-frequency array transducer facing one of the 
transducer’s optical windows. A Nikon 4X objective was attached to the camera with extension 
tubes to magnify the image plane, giving the captured images a resolution of approximately 2.5 
µm per pixel. A pulsed white-light LED was placed on the diametrically-opposed optical window 
of the dual-frequency array transducer, which provided back-lit illumination. The cameras were 
triggered to record one image for each applied pulse. After acquisition, shadowgraph images were 
converted from grayscale to binary by an intensity threshold determined by the background 
intensity using image processing software (MATLAB, The Mathworks, Natick, MA, USA), as 
described in a previous study [44]. Bubbles were indicated as any black regions greater than 5 
pixels in diameter. By this criterion, the minimum resolvable bubble radius was 14.75 μm, 6.25 
μm, 8.5 μm, and 6.25 μm for the 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz transducers, respectively.  
Passive Cavitation Detection (PCD)  
In addition to high speed imaging, an acoustic method was used to identify cavitation in 
the focal zone for cavitation threshold experiments. For each experiment, one of the transducer’s 
therapy elements was also used for passive cavitation detection (PCD) to detect the presence of 
cavitation in the focal region (Figure A.3). The PCD signal was connected to an oscilloscope 
(LT372; Lecroy, Chestnut Ridge, NY, USA) with the time window selected to record the 
backscattering of the therapy pulse from cavitation bubbles [44, 316, 323]. To determine whether 
cavitation occurred during a pulse, the signal generated by backscattering of the incident pulse 
from the focus was analyzed following the method used in previous studies [44, 316]. A significant 
fraction of the incident wave energy is scattered when a cavitation bubble expands, greatly 
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increasing the backscattered pressure amplitude received by the PCD. This signal appeared on the 
PCD at the time point corresponding to two times the time of flight for the focal length of the 
respective transducers. The integrated frequency power spectrum (SPCD) of the backscatter signal 
was used as a measure of whether cavitation occurred according to the method previously 
described by Maxwell et al [44].  
NMH Cavitation Threshold  
For cavitation threshold experiments, 100 pulses were applied inside each sample at each 
pressure level at a pulse repetition frequency (PRF) of 0.5 Hz. The PRF was kept low to minimize 
the possibility that cavitation from one pulse would change the probability of cavitation on a 
subsequent pulse. In a previous study, it was demonstrated that cavitation during a pulse increased 
the likelihood of cavitation on a following pulse for PRFs > 1 Hz, but this effect was not observed 
for PRFs below 1 Hz [44]. In addition to this low PRF, the focus was translated for each pulse by 
1 mm transverse to the acoustic propagation direction in a 10 × 10 grid in order to minimize the 
effects of cavitation damage to the nanodroplets or tissue phantom sample from altering the 
probability of cavitation. For each pulse, cavitation was monitored using both high speed imaging 
and PCD, and the fraction of total pulses (out of 100) for which cavitation was detected was 
determined as the cavitation probability. 
The probability of observing cavitation followed a sigmoid function, given by 
𝑃(𝑝−) =
1
2
+ 𝑒𝑟𝑓 (
𝑝−  −  𝑝𝑡
√2𝜎2
)  Eq. 6.1   
where erf is the error function, pt is the negative pressure at which the probability pcav=0.5, σ is a 
variable related to the width of the transition between pcav=0 and pcav=1, with ± σ giving the 
difference in pressure from about pcav=0.15 to pcav=0.85 for the fit [44]. The cavitation threshold 
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for each sample, pt, is defined as the p- corresponding to pcav=0.5 as calculated by the curve fit. 
Curve fitting for all data sets was performed using an OriginLab curve fitting program (OriginPro 
9.1; OriginLab Corporation, Northampton, MA, USA). The fit curves for all samples were 
analyzed statistically to determine whether the differences in the values of pt were significantly 
different from each other. The standard errors for pt were estimated by a covariance matrix using 
the delta method [329]. The curves were compared using a two-sample t-test with statistic 
𝑡 (𝑝𝑖𝑛𝑡1 − 𝑝𝑖𝑛𝑡2, √𝑆𝐸1
2+𝑆𝐸2
2) at a 95% confidence interval. Results were considered statistically 
significant for p<0.05. Note that the standard error does not include the uncertainty in absolute 
pressure from the hydrophone measurement, only the uncertainty in the fit, because the values pt 
are relative. A sample size of 3 tissue phantoms was used for each experimental condition. 
 NMH Bubble Size 
To determine if nanodroplet-mediated cavitation bubbles were expanded similarly to 
histotripsy bubbles at higher pressure, optical images of the growth and collapse of bubbles were 
recorded by the high-speed camera. Nanodroplet-mediated cavitation bubbles were generated by 
the 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz transducers at peak negative pressures slightly above 
the nanodroplet cavitation threshold at each frequency. More specifically, the peak negative 
pressure was 10.8 MPa (345 kHz), 10.3 MPa (500 kHz), 12.9 MPa (1.5 MHz), and 14.7 MPa (3 
MHz). For comparison, bubbles were produced in tissue phantoms without nanodroplets at 
estimated peak negative pressures of 26.4 MPa (345 kHz), 26.3 MPa (500 kHz), 26.8 MPa (1.5 
MHz), and 28.8 MPa (3 MHz), which is slightly above the intrinsic threshold without 
nanodroplets. The maximum radius of bubbles was compared by reconstructing the average 
expansion and collapse behavior using a series of time-delayed images of the bubbles produced by 
identical histotripsy pulses. The specific delay times were varied based on the frequency and 
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sample in order to reconstruct a sequence of bubble images and determine the time point 
corresponding to the maximum bubble radius, Rmax. The Rmax was compared between samples by 
analyzing results from 20 identical histotripsy pulses recorded at the time of maximum expansion, 
with each pulse applied to a different point in the sample (2 mm spacing) to prevent the effects of 
cavitation damage from altering the tissue phantom and nanodroplet properties. The size of single 
bubbles was measured for all twenty pulses to determine the bubble radius, and the mean and 
standard deviation in bubble radius were calculated. A sample size of 6 tissue phantoms was used 
for each experimental condition. 
 NMH Multi-pulse Sustainability 
To determine if nanodroplets are sustainable cavitation nuclei over multiple pulses, 1000 
ultrasound pulses were applied to a single focal region in tissue phantoms containing nanodroplets 
at a PRF of 1 Hz and peak negative pressures of 10.8 MPa (345 kHz), 10.3 MPa (500 kHz), 12.9 
MPa (1.5 MHz), and 14.7 MPa (3 MHz). In a previous study, nanodroplet-mediated histotripsy 
created consistent, well-defined fractionation in tissue phantoms at 10 Hz PRF by maintaining 
cavitation at over multiple pulses [79]. However, it is unclear whether the nanodroplets themselves 
or the residual nuclei from previous pulses are responsible for seeding cavitation after the first few 
pulses. As a result, the PRF in this study was kept low (1 Hz) to minimize the contributions of 
residual nuclei from a previous pulse from effecting cavitation generation on a subsequent pulse 
in order to determine if nanodroplets continue to function as viable cavitation nuclei after the first 
few pulses or if the nanodroplets are destroyed in the cavitation process. Cavitation was monitored 
using high speed optical imaging, and the number of bubbles produced by each pulse was 
compared for 1000 histotripsy pulses in each sample. In order to quantify the ability of 
nanodroplets to sustain a cavitation bubble cloud over multiple pulses, the number of pulses before 
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cloud extinction, PExt, was plotted as a function of frequency. A sample size of 6 tissue phantoms 
was used for each experimental condition. 
 
Results 
NMH Cavitation Threshold 
To investigate the effects of ultrasound frequency on the NMH threshold, histotripsy pulses 
were applied to tissue-mimicking agarose phantoms with and without nanodroplets using the 345 
kHz, 500 kHz, 1.5 MHz, and 3 MHz histotripsy transducers. For all frequencies, cavitation bubbles  
 
Figure A.4 Cavitation detection. Sample passive cavitation detection (PCD) signals (top) and high 
speed optical images (bottom) used for cavitation detection. 
Results showed good agreement between the two methods. Representative images shown above are from 
345 kHz histotripsy pulses applied to tissue phantoms containing nanodroplets. 
were observed on the high-speed camera when a certain negative pressure was exceeded, with 
close agreement between optical imaging and PCD detection methods (Figure A.4), as seen in 
174 
 
previous studies [44, 316]. Results from phantoms without nanodroplets show that the histotripsy 
intrinsic threshold, pt_int, was pt_int =24.8±1.1 MPa, with σmean = 2.0 MPa for 345 kHz; pt_int = 
25.5±1.7 MPa, with σmean = 1.8 MPa for 500 kHz; pt_int = 26.7±0.4 MPa, with σmean = 1.0 MPa for 
1.5 MHz; and pt_int = 26.8±0.5 MPa, with σmean = 0.9 MPa for 3 MHz (Figure A.5). Note that at 
lower amplitudes, cavitation was occasionally observed that deviated from the curve function, 
especially at lower frequency. These cavitation events were probably caused by contamination of 
the sample by heterogeneities in the liquid that could not be entirely avoided throughout the 
experiment. The effects of nanodroplets on the cavitation threshold demonstrated a significant 
decrease in the cavitation threshold compared to the histotripsy intrinsic threshold (Figure A.5). 
The NMH threshold for phantoms containing PFP nanodroplets, pt_PFP, was pt_PFP =7.4±0.1 MPa, 
with σmean = 1.4 MPa for 345 kHz; pt_PFP = 9.2±0.9 MPa, with σmean = 0.8 MPa for 500 kHz; pt_PFP 
= 10.5±0.2 MPa, with σmean = 0.4 MPa for 1.5 MHz; and pt_PFP = 13.2±0.4 MPa, with σmean = 0.6 
MPa for 3 MHz (Figure 6.5). The results of the cavitation threshold for all frequencies are plotted 
in Figure 6.6. Comparing the results for the NMH threshold and histotripsy intrinsic threshold 
demonstrated a significant decrease in the cavitation threshold and a significant increase in the 
steepness of the S-curve (σ) for samples containing nanodroplets at all frequencies. Additionally, 
it was observed that the NMH threshold was significantly decreased at lower frequency (Figure 
A.6). 
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Figure A.5 Cavitation threshold curves. Probability curves for tissue phantoms with and without 
nanodroplets. 
Results showed a significant decrease in the cavitation threshold with nanodroplets compared to controls. 
Results also showed a significant increase in the nanodroplet cavitation threshold with increasing 
frequency. 
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Figure A.6 Cavitation threshold results. Bar plots show the cavitation threshold results for tissue 
phantoms with and without perfluoropentane (PFP) nanodroplets at all frequencies studied in this 
work. 
 
NMH Bubble Size 
To study the effects of ultrasound frequency on the expansion of NMH bubbles, the 
maximum bubble radius, Rmax, produced by 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz histotripsy 
pulses was measured in phantoms with and without nanodroplets. The peak negative pressure used 
for each frequency was chosen to be slightly above the cavitation threshold at each frequency so 
that cavitation was always generated (Pcav=1). Optical imaging results demonstrated that NMH 
bubbles were significantly smaller than histotripsy bubbles generated above the intrinsic threshold 
(Figure A.7). Note that different image magnifications were used for each frequency for the 
images shown in Figure A.7, to provide a better image of the bubbles produced at each frequency. 
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Figure A.7 Bubble Rmax Images: Optical images of bubbles formed in tissue phantoms, with and 
without nanodroplets, by 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz histotripsy pulses. 
Results show a significant decrease in bubble size for nanodroplet-mediated histotripsy bubbles 
compared with control bubbles produced at the same frequency at higher pressure. Results further show 
a significant decrease in bubble size with increasing frequency. Note: Different image magnifications 
were used for the above images to better image the bubbles at each frequency. 
 
At all frequencies, results showed that the Rmax for NMH bubbles was between 30%-40% of the 
Rmax measured for histotripsy bubbles produced above the intrinsic threshold (Figure A.8). Results 
further showed that larger bubbles were observed at lower frequency for both the histotripsy only 
and NMH conditions (Figure A.8). For example, Rmax for NMH bubbles was shown to decrease 
from 126.7±47.5 µm at 345 kHz to 106.5±17.6 µm, 34.7±13.4 µm, and 12.9±5.3 µm at 500 kHz, 
1.5 MHz, and 3 MHz, respectively (Table A.1). Comparing Rmax for NMH and histotripsy bubbles 
showed that, although NMH bubbles were significantly smaller than histotripsy bubbles for all 
frequencies, NMH bubbles produced at the lower two frequencies (345 kHz, 500 kHz) grew larger 
than histotripsy bubbles produced at the two higher frequencies (1.5 MHz, 3 MHz). For example, 
the Rmax of NMH bubbles produced at 345 kHz and 500 kHz (126.7±47.5 µm and 106.5±17.6 µm) 
were significantly larger than the Rmax of histotripsy bubbles generated above the intrinsic 
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threshold at 1.5 MHz and 3 MHz (79.5±11.5µm and 34.3±8.5) (Figure A.8). The complete list of 
Rmax results are listed in Table 6.1 along with the peak negative pressure applied for each 
condition. 
 
Figure A.8 Bubble Rmax results. Plot shows a comparison of the maximum bubble radius produced 
in tissue phantoms with and without nanodroplets by 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz 
histotripsy pulses. 
The peak negative pressures (p-) applied for each condition are listed in Table 1. 
 
NMH Multi-pulse Sustainability 
To determine if nanodroplets are sustainable cavitation nuclei over multiple pulses, 1000 
histotripsy pulses were applied to a single focal region in phantoms containing nanodroplets at a 
PRF of 1 Hz. Results demonstrated that a bubble cloud consisting of many bubbles was observed 
after the first pulse (Figure A.9). However, the number of bubbles observed inside the cloud 
significantly decreased with increasing number of pulses (Figure A.9). 
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Table A.1 Bubble Rmax results. Table shows the maximum bubble radius produced in tissue 
phantoms with and without nanodroplets, along with the peak negative pressure (p-) applied for 
each condition. The p- for each condition was chosen to be slightly above the nanodroplet-mediated 
histotripsy (NMH) and intrinsic cavitation thresholds of the sample at each frequency. 
 
 
For example, for the 3 MHz sample shown in Figure A.9, only one bubble was observed after 5 
pulses with no bubbles remaining after 10 pulses. At lower frequency, bubbles were generated for 
more pulses than at higher frequency, but still showed the same trend of decreasing number of 
bubbles with increasing pulse number (Figure A.9). It is likely that bubbles lasted for more pulses 
at lower frequency due to enhanced bubble expansion resulting in a larger population of residual 
nuclei and a corresponding increase in dissolution time. Figure A.10 shows the number of pulses 
before cloud extinction, PExt, as a function of frequency (n=6). Results demonstrated a significant 
decrease (p<0.05) in PExt at higher frequencies, with PExt observed to decrease from 80.5±10.3 
pulses at 345 kHz to 51.7±7.3 pulses, 15.7±4.8 pulses, and 5.5±1.9 pulses at 500 kHz, 1.5 MHz, 
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and 3 MHz, respectively (Figure A.10). For all frequencies, no bubbles were observed after 100 
pulses were applied to the samples. 
 
Figure A.9 Bubble cloud multi-pulse images. Optical images show NMH bubbles produced by 345 
kHz (p-=10.8 MPa) and 3 MHz (p-=14.7 MPa) at a single focal point in tissue phantoms containing 
nanodroplets at a pulse repetition frequency (PRF) of 1 Hz. 
Results showed a decrease in the number of bubbles observed at the focus with increasing pulse number. 
 
Discussion 
In this work, we investigated the effects of frequency on nanodroplet-mediated histotripsy 
(NMH) using our polymer encapsulated PFP nanodroplets [46]. This work builds upon two 
previous studies which demonstrated that NMH has the potential to be used for targeted tissue 
ablation by decreasing the pressure threshold required to generate histotripsy bubbles [46, 79]. In 
this study, we investigated the effects of frequency in order to optimize the acoustic parameters 
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used for NMH therapy. Since one of the goals of NMH therapy is to efficiently treat large and/or 
multi-focal tumor nodules, NMH parameters should be optimized to increase the size of the focal 
zone, decrease the NMH cavitation threshold, and increase NMH bubble expansion, all of which 
were improved at lower frequencies as shown in this study. 
 
Figure A.10 Bubble cloud multi-pulse sustainability. Plot shows the number of pulses before cloud 
extinction, PExt, as a function of frequency. 
Results demonstrated a significant decrease (p<0.05) in PExt with increasing frequency. A sample size of 
6 tissue phantoms was used for each experimental condition. 
 
In the first part of this study, the effects of frequency on the NMH cavitation threshold 
were investigated, with results demonstrating that PFP nanodroplets significantly reduced the 
cavitation threshold compared to the histotripsy intrinsic threshold. At all frequencies tested, the 
NMH threshold was significantly lower than the histotripsy intrinsic threshold, while maintaining 
a steep threshold behavior. This distinct threshold behavior is promising for the development of 
NMH therapy, in which the applied pressure must be chosen in the region above the NMH 
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threshold but below the histotripsy intrinsic threshold to ensure cavitation is only generated in 
regions containing nanodroplets. The results of this study suggest that all the frequencies 
investigated (345kHz-3MHz) could be used for NMH, with lower frequencies offering the largest 
drop in threshold compared to the histotripsy intrinsic threshold while maintaining the distinct 
threshold behavior. 
The frequency dependence of the NMH cavitation threshold observed in this study is 
opposite to that reported in previous work on acoustic droplet vaporization (ADV) which showed 
that the ADV threshold decreases with increasing frequency [330-332]. However, those studies 
used larger droplets, higher frequency ranges, and/or longer duration exposures. Recent work has 
revealed that the decrease in the ADV threshold at higher frequencies is due to superharmonic 
focusing inside the droplet, which is significantly enhanced at higher frequencies and in larger 
droplets [333, 334]. These previous studies help to explain why the cavitation thresholds in this 
study do not follow the trends observed for ADV, since the extent of superharmonic focusing is 
negligible for the droplet size (<400 nm) and frequencies (≤3MHz) used in this study [334]. In 
contrast to those previous studies, the results of this work suggest that NMH bubbles are generated 
inside the droplets directly from the incident p- (tensile portion of the incident wave), similar to 
histotripsy bubbles generated above the intrinsic threshold [316]. This hypothesis is supported by 
the trends in the cavitation threshold with lower frequencies resulting in a lower cavitation 
threshold, likely due to the longer duration of the applied p- and the larger focal zone at lower 
frequencies, which increases the volume of PFP exposed to the p- and therefore increases the 
probability of nucleating cavitation inside the PFP nanodroplets. This would also imply that the 
NMH threshold will be affected by nanodroplet concentration, since a higher concentration of 
nanodroplets would result in a larger volume of PFP being exposed to the applied p-. This would 
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explain why a concentration of 2.0x108 particles/mL was required in order to reduce the cavitation 
threshold in this study while concentrations <~106-107 particles/mL did not significantly reduce 
the cavitation threshold compared to the histotripsy intrinsic threshold. This threshold behavior 
suggests that the nanodroplets decrease the cavitation threshold by carrying a lower threshold 
media (PFP) rather than by acting as discrete nuclei as would be the case for gas-filled contrast 
agents. Future work will further investigate the role of droplet concentration on NMH therapy. 
In the second part of this study, the effects of frequency on NMH bubble expansion were 
investigated, with results showing that lower frequencies facilitated larger bubble expansion. 
While it is likely that NMH will be able to fractionate tissue even at higher frequencies, the results 
of this study suggest that NMH will be more efficient at lower frequencies due to enhanced bubble 
expansion. A previous study investigating the effects of frequency on histotripsy bubble expansion 
demonstrated that the increase in bubble expansion at lower frequencies is due the increased 
duration of the applied rarefactional pressure [317]. This same effect likely explains the results of 
this study in which NMH bubbles at lower frequencies grew larger than bubbles produced by 
histotripsy without nanodroplets at higher frequencies, despite a >18 MPa decrease in the peak 
negative pressure of the applied pulses. For example, NMH bubbles produced at 345 kHz and 500 
kHz grew larger than bubbles produced by histotripsy without nanodroplets at 1.5 MHz and 3 
MHz, which have previously been shown capable of achieving tissue fractionation [324, 328]. This 
finding supports our hypothesis that NMH can be used to efficiently create histotripsy lesions when 
using lower frequencies.  
In the final part of this work, the ability of PFP nanodroplets to act as sustainable cavitation 
nuclei over multiple pulses was investigated. In a previous study, nanodroplet-mediated histotripsy 
created consistent, well-defined fractionation at pressure levels (11-20 MPa) significantly below 
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the histotripsy intrinsic threshold (~26-30 MPa) in tissue phantoms at a PRF of 10 Hz by 
maintaining cavitation at over multiple pulses [79]. However, it is unclear whether the 
nanodroplets themselves or residual nuclei from previous pulses were responsible for seeding 
cavitation after the first few pulses. In this study, the PRF was kept low (1 Hz) to minimize the 
contributions of residual nuclei from a previous pulse, with results showing a significant reduction 
in the number of bubbles generated by NMH with increasing number of pulses. For all frequencies, 
no bubbles were observed in tissue phantoms after 100 pulses. These results suggest that the 
nanodroplets are destroyed by the cavitation process and only function as cavitation nuclei for the 
first few pulses, potentially due to the PFP being dissolved after undergoing the NMH cavitation 
process. This finding indicates that NMH will need to be applied at a higher PRF in order sustain 
cavitation for the duration of the treatment. It is also possible that nanodroplets containing a higher 
boiling point perfluorocarbon, such as perfluorohexane, would re-condense into a liquid and 
remain sustainable nuclei over multiple pulses, which would be a major benefit for NMH therapy, 
as previous work has shown a decrease in ablation efficiency for higher PRF treatments that rely 
on residual nuclei from previous pulses to maintain the cavitation bubble cloud [335]. However, 
higher boiling point droplets may also require a higher pressure in order to generate cavitation, 
which would not be desired for NMH therapy. Future work will investigate the possibility of using 
nanodroplets containing a higher boiling point perfluorocarbon for NMH therapy.  
Conclusions 
In this work, the effects of ultrasound frequency on nanodroplet-mediated histotripsy were 
investigated, with results supporting our hypothesis that using a lower frequency will improve 
NMH therapy. The results demonstrated that the NMH threshold was significantly reduced at 
lower frequencies, ranging from 7.4 MPa at 345 kHz to 13.2 MPa at 3 MHz. Furthermore, the 
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results demonstrated that NMH bubble expansion was enhanced at lower frequency, generating 
bubbles with a maximum radius >100 µm despite the reduced pressure applied. Finally, multi-
pulse experiments demonstrated that nanodroplets are destroyed during the first few pulses at 1Hz 
PRF. Overall, the results of this study provide significant insight in the role of ultrasound 
parameters in NMH therapy and will provide a rational basis to specifically tailor acoustic 
parameters in order to improve NMH tissue fractionation.  
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The Effects of Droplet Composition on Nanodroplet-Mediated 
Histotripsy 
 
The material in this chapter is published from the following article: E. Vlaisavljevich, O. Aydin, 
Y. Y. Durmaz, K-W Lin, B. Fowlkes, Z. Xu, and M. ElSayed “The Effects of Droplet Composition 
on Nanodroplet-Mediated Histotripsy” Ultrasound in Medicine and Biology 42(4), 931, 2016. 
Introduction 
Histotripsy is a noninvasive tissue ablation method that controllably fractionates soft tissue 
through cavitation generated by high pressure, short duration ultrasound pulses [49, 160, 336]. 
Histotripsy depends on the initiation and maintenance of a dense cavitation bubble cloud to 
produce mechanical tissue fractionation [314, 315]. Previous work has shown that, using a 1-2 
cycle pulse with a single dominant negative pressure phase, cavitation bubbles can be reproducibly 
generated in tissue when the peak negative pressure (p-) is raised above the histotripsy intrinsic 
threshold of ~25-30 MPa [44, 337]. In order to effectively fractionate tissue into acellular debris, 
histotripsy requires a dense cavitation bubble cloud to be initiated and maintained over multiple 
pulses (often >100)  until the tissue is completely fractionated into a liquid-appearing homogenate 
with no cellular structures remaining [49, 161, 336]. Histotripsy is currently being studied for many 
clinical applications where non-invasive tissue removal is desired including benign prostatic 
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hyperplasia [319], deep vein thrombosis [164], congenital heart disease [165, 166], and cancer [45, 
167]. 
Although histotripsy has shown promise for many clinical applications including tumor 
ablation, this approach is limited to applications in which the target tissue can be identified and 
imaged prior to treatment, which is often not feasible in cancer patients with many small tumor 
nodules and micro-metastases. As a result, our group has developed a targeted ablation approach 
combining polymer encapsulated nanodroplets with histotripsy [46, 79, 338]. This nanodroplet-
mediated histotripsy (NMH) approach takes advantage of the significantly reduced cavitation 
threshold of the nanodroplets, allowing for cavitation to be selectively generated only in regions 
where  nanodroplets localize [79]. NMH has the potential for selective ablation of tumors given 
the small size (~100-400 nm) of the synthesized nanodroplets, which enables their diffusion across 
the leaky tumor vasculature and preferential accumulation in the tumor tissue [46, 79]. Previous 
work has demonstrated that NMH can be used to create well-defined ablation similar to histotripsy 
but at significantly lower pressure and has demonstrated the potential to use NMH for 
simultaneous multi-focal ablation [79]. Furthermore, a previous study by Yuksel Durmaz et al 
investigated the optimal characteristics of polymer encapsulated perfluoropentane (PFP) 
nanodroplets, with results showing optimal NMH ablation for nanodroplets with a shell-cross-
linked triblock amphiphilic copolymer composed of a poly(ethylene glycol) (PEG) block that 
forms a biocompatible corona, a poly(acrylic acid) (PAA) middle block reacting with the cross-
linker to form a flexible shell, and a poly(heptadecafluorodecyl methacrylate-co-methyl 
methacrylate) (P(HDFMA-co-MMA)) fluorinated hydrophobic block encapsulating 2% v/v PFP 
[46]. However, although this previous study determined the optimal conditions for PFP 
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nanodroplets, the effects of perfluorocarbon boiling temperature on NMH therapy have not been 
previously investigated. 
In this study, we compare perfluoropentane (PFP, boiling point ~29°C) and 
perfluorohexane (PFH, boiling point ~56°C) nanodroplets for NMH therapy. Based on previous 
work comparing PFP and PFH droplets for acoustic droplet vaporization [339, 340], we 
hypothesize that PFH nanodroplets will have a slightly higher cavitation threshold than PFP 
droplets but the cavitation threshold of both droplets will be significantly lower than the histotripsy 
intrinsic threshold. To test this hypothesis, tissue phantoms containing PFP nanodroplets, PFH 
nanodroplets, and no nanodroplets were exposed to histotripsy pulses produced by 345 kHz, 500 
kHz, 1.5 MHz, and 3 MHz custom-built histotripsy transducers. The probability of generating 
inertial cavitation from a single 1-2 cycle histotripsy pulse was measured, with the cavitation 
threshold defined as the peak negative pressure at which the probability of generating cavitation, 
pcav, from a single histotripsy pulse was pcav=0.5. In addition to the effects of droplet composition 
on the cavitation threshold, we also investigate the effects of droplet composition on cavitation 
sustainability over multiple histotripsy pulses. In previous studies, PFP nanodroplets were used to 
create consistent, well-defined fractionation at pressure levels (11-20 MPa) significantly below the 
histotripsy intrinsic threshold (~26-30 MPa) in tissue phantoms at a pulse repetition frequency 
(PRF) of 10 Hz by maintaining cavitation over multiple pulses [46, 79]. However, it was also 
observed that cavitation was not maintained over multiple pulses when ultrasound was applied at 
a lower PRF (1 Hz) [46, 79, 338]. A low PRF (1 Hz) has been shown to produce more efficient 
tissue fractionation and is not affected by the cavitation memory effect, in which residual gas 
bubbles from previous cavitation events function as nuclei for generating cavitation on a 
subsequent pulse [335]. This result suggests that PFP nanodroplets are destroyed during the first 
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few pulses, requiring cavitation on subsequent pulses to be generated from residual nuclei 
remaining from previous pulses. We hypothesize that, due to their higher boiling point, PFH 
nanodroplets will re-condense into a liquid after cavitation and remain as sustainable nuclei over 
multiple (>100) pulses, allowing cavitation to be maintained over multiple pulses even at low PRF. 
To test this hypothesis, 1000 histotripsy pulses were applied to a single focal zone tissue in 
phantoms containing PFP and PFH nanodroplets, and the number of NMH bubbles generated was 
compared after each pulse. In addition, tissue phantoms containing a layer of embedded red blood 
cells were used to compare the damage generated for NMH treatments using PFP and PFH 
droplets. Overall, these results will improve our understanding of the NMH process and help to 
determine the optimal nanodroplet characteristics for NMH therapy. 
 
Materials 
 Methyl methacrylate (MMA, Sigma-Aldrich, 99 %), 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10 
heptadecafluorodecyl methacrylate (HDFMA, Sigma-Aldrich, 97 %), tert-butyl acrylate (tBA, 
Sigma-Aldrich, 98 %) and N, N, N’, N’’, N’’-pentamethyldiethylenetriamine (PMDETA, Sigma-
Aldrich, 99 %) were passed through a basic alumina column to remove the inhibitor. Copper (I) 
bromide (CuBr, Sigma-Aldrich, 99.9 %), 2-bromoisobutyryl bromide (Fluka, >97 %), 
tetrahydrofuran anhydrous (THF, Sigma-Aldrich, >99.9 %), N,N’-Dicyclohexylcarbodiimide 
(DCC, Sigma-Aldrich, 99 %), dimethylaminopyridine (DMAP, Acros, 99 %), 4-pentynoic acid 
(Sigma-Aldrich, 99 %), furan (Sigma-Aldrich, ≥99 %), maleic anhydride (Fluka, ≥99 %), 9 
anthracene methanol (Aldrich, ≥ 99%), perfluoropentane (PFP, Alfa Aesar, 97% ca. 85% n 
isomer), perfluorohexane (PFH, SynQuest Lab, > 98%) N-hydroxy succinimide (NHS, Fluka, 97 
%), N-(3-Dimethylaminopropyl)-N ethylcarbodiimide hydrochloride (EDC, Fluka >98 %), 
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poly(ethylene glycol) monomethylether (Me-PEG, Mn : 2000 g/mol, Sigma-Aldrich), sodium 
azide (NaN3, Acros, 99 %), 2-(N-morpholino)ethanesulfonic acid monohydrate (MES, Acros, 99 
%), triethylamine (TEA, Sigma-Aldrich, ≥ 99%), trifluoroacetic acid (TFA, Acros, 99 %), ethylene 
carbonate (Sigma-Aldrich, 98 %), 2,2`- (ethylenedioxy)-bis(ethylamine) (Sigma-Aldrich, 98%) 
agarose powder (Type VII, Sigma-Aldrich), citratephosphate-dextrose (CPD, Sigma-Aldrich), 
heptane fraction (Sigma-Aldrich, > 99%),  dicholoromethane (DCM or CH2Cl2, Sigma-Aldrich, 
>99.5%) were used as received. 
 
Methods 
Nanodroplet Formulation and Characterization 
A well-defined, triblock amphiphilic copolymer containing a hydrophilic poly(ethylene 
glycol) (PEG) block, a middle block poly(acrylic acid) (PAA) block, and a hydrophobic random 
copolymer of heptadecafluorodecyl methacrylate (HDFMA) and methyl methacrylate (MMA) was 
synthesized using a combination of atom transfer radical polymerization (ATRP) and “click” 
coupling techniques as previously described (Figure 7.1) [46]. The synthesized P(HDFMA8-co-
MMA20)-b-PAA12-b-PEG45 triblock amphiphilic copolymer was used to prepare PFP- and PFH-
loaded nanodroplets. Briefly, the copolymers were dissolved in tetrahydrofuran (THF) (0.2% w/v) 
and cooled down to 0 °C before the addition of PFP (2% v/v) or PFH (2% v/v) while vigorously 
stirring the copolymer-perfluorocarbon mixture. An equal amount of deionized water was added 
drop-wise to this solution mixture to initiate micelle formation and the mixture was stirred for 1h 
in an ice bath. The micelles solution was transferred into a dialysis bag (MWCO of 1 KDa, 
Spectrum, Rancho Dominguez, CA) and dialyzed overnight against ice-cold MES solution (pH 
5.5) to remove the THF and get a milky solution of non-cross-linked PFP-loaded nanodroplets and 
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non-cross-linked PFH-loaded nanodroplets. The milky nanodroplets solutions were transferred to 
round bottom flasks and mixed with the 2,2`-(ethylenedioxy)-bis(ethylamine) cross-linker, which 
reacts with the carboxyl groups of the central PAA block in the copolymer via NHS/EDC coupling 
chemistry forming cross-linked nanodroplets with a flexible polymer shell. Shell cross-linked 
nanodroplets were dialyzed against ice-cold water for 12 hours to remove unreacted cross-linker 
and reaction byproducts. 
 
Figure B.1 Synthesis of the P(HDFMA-co-MMA)-b-PtBA-b-PEG triblock copolymer and 
formulation of PFP- and PFH-loaded nanodroplets 
(A) The chemical structure of each block and (B) the one-pot “click” reaction to obtain P(HDFMA-co-
MMA)-b-PtBA-b-PEG copolymer. (C) Hydrolysis of the tBA group to obtain the P(HDFMA-co-MMA)-
b-PAA-b-PEG polymer. (D) Formulation of the P(HDFMA-co-MMA)-b-PtBA-b-PEG polymer into 
PFP- and PFH-loaded nanodroplets. 
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Concentration and size distribution of the nanodroplets were measured using Nanoparticle 
Tracking Analysis (NTA). Briefly, the NanoSight™ LM10 (Malvern Instruments, Amesbury, 
UK), equipped with a temperature-controlled 405 nm laser module, high sensitivity scientific 
Complementary Metal–Oxide–Semiconductor (sCMOS) camera (Hamamatsu, Orca, Hamamatsu 
City, Japan), and a syringe pump was used for the collection of NTA data. Upon diluting the 
nanodroplets solution to the appropriate particle concentration with deionized water, image capture 
and analysis was carried out using the NTA software (Version 3.0, Build 0066) at 37 °C. 
Concentration and size distribution of the nanodroplets in each sample were analyzed using 5 
videos per sample each lasting 60s. Based on these videos, nanodroplet concentration was plotted 
as a function of droplet size, with the error bars representing the standard deviation of the repeat 
measurements of each sample. The mean size and standard deviation values obtained by the NTA 
software correspond to arithmetic values calculated with the sizes of all particles analyzed for each 
sample (n=5). 
Preparation of Tissue Phantoms 
Agarose phantoms were used to provide a well-controlled viscoelastic medium for this 
study. Tissue phantoms containing 1% agarose w/v were prepared by slowly mixing agarose 
powder (Agarose Type VII; Sigma-Aldrich, St. Louis, MO, USA) into saline solution (0.9% 
sodium chloride; Hospira, Lake Forest, Illinois, USA) heated to boiling temperature. The solution 
was stirred on a hot plate until the gel turned completely transparent and then allowed to boil for 
ten minutes. After boiling, solutions were allowed to cool and were degassed under a partial 
vacuum (~20 kPa, absolute) for 30 minutes. After degassing, phantoms containing nanodroplets 
were prepared by slowly adding the nanodroplets (2.0×108 particles/ml) into the agarose solution 
while stirring. The agarose mixtures were poured into rectangular polycarbonate holders with 
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acoustic windows and placed in a refrigerator at 4°C to allow the solution to solidify, forming 
tissue phantoms with embedded PFP nanodroplets, PFH nanodroplets, or without nanodroplets 
(control). The temperature of the agarose was ~40 °C when the nanodroplets were added. As this 
temperature is close to the temperature at which the NTA analysis was performed (37°C), it is 
expected that the size and concentration of nanodroplets was not be significantly affected by the 
casting process. This hypothesis is further supported by previous studies showing that PFP and 
PFH nanodroplets have vaporization temperatures much higher than their reported boiling points. 
For example, the vaporization temperatures of PFP and PFH nanodroplets between 250-350 nm 
have been reported to be higher than 80°C and 140 °C, respectively, suggesting that the droplets 
will remain stable during the casting process (40 °C) and experimental temperatures (37 °C) [341, 
342].  
For cell fractionation experiments, tissue phantoms with a red blood cell (RBC) layer were 
prepared using porcine RBCs in 0.9% isotonic saline and 1% agarose solutions with PFP or PFH 
nanodroplets. Fresh porcine blood was obtained from research subjects in an unrelated study and 
added to an anticoagulant solution of citratephosphate-dextrose (CPD) (Sigma-Aldrich Co., St. 
Louis, MO) with a CPD-to-blood ratio of 1:9 mL. Whole blood was separated in a centrifuge at 
3000 rpm for 10 min. The plasma and white buffy coat were removed, and the RBCs were saved 
for addition to the phantom. To prepare the RBC phantom, an initial layer of 1% agarose mixture 
(with PFP or PFH nanodroplets) was poured into a rectangular polycarbonate housing to fill half 
of it at 40°C. The housing was placed in a refrigerator at 4 °C to allow the agarose to cool and 
solidify. The remaining solution was kept at 40 °C. A small amount of agarose solution was mixed 
with the RBCs (5% RBCs v/v). The frame with solidified agarose was removed from refrigeration, 
and a thin layer of the RBC-agarose solution was poured onto the gel surface to allow the entire 
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surface to coat in a thin layer. After 5 min, the RBC-agarose layer was solidified, and the remaining 
agarose solution without RBCs was poured to completely fill the frame. This procedure created a 
thin layer of RBCs suspended in the center of the agarose phantom. 
Histotripsy Pulse Generation 
Histotripsy pulses were generated at four ultrasound frequencies (345 kHz, 500 kHz, 1.5 
MHz, and 3 MHz) using three custom-built histotripsy transducers. The 345 kHz pulses were 
generated by a twenty-element array transducer with a geometric focus of 150 mm, an aperture 
size of 272 mm, and an effective f-number of 0.55. The 1.5 MHz pulses were generated by a six-
element array transducer with a geometric focus of 55 mm, an aperture of 79 mm in the elevational 
direction and 69 mm in the lateral direction, and effective f-numbers of 0.7 and 0.8 in the 
elevational and lateral directions, respectively. The 500 kHz and 3 MHz pulses were generated by 
a dual frequency array transducer that consisted of twelve 500-kHz elements and seven 3-MHz 
elements. For the 500 kHz elements, the geometric focus was 40 mm, the aperture size was 71 
mm, and the effective f-number was 0.56. For the 3 MHz elements, the geometric focus was 40 
mm, the aperture size was 80 mm, and the effective f-number was 0.5. The design of the dual 
frequency transducer has been described in detail in a previous study [328]. 
To compare the NMH cavitation threshold with the histotripsy intrinsic threshold, short 
pulses with a single dominant negative pressure half-cycle were applied to the tissue phantoms 
with and without nanodroplets inside a water bath heated to at 37 °C. To generate a short therapy 
pulse, a custom high-voltage pulser developed in-house was used to drive the transducers. The 
pulser was connected to a field-programmable gate array (FPGA) board (Altera DE0-Nano Terasic 
Technology, Dover, DE, USA) specifically programmed for histotripsy therapy pulsing. This setup 
allowed the transducers to output short pulses of less than two cycles. A fiber-optic probe 
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hydrophone built in-house [172] was used to measure the acoustic output pressure of the 
transducers. At higher pressure levels (p- > 23 MPa), the acoustic output could not be directly 
measured due to cavitation at the fiber tip. These pressures were estimated by a summation of the 
output focal p- values from individual transducer elements. This approximation assumes minimal 
nonlinear distortion of the waveform occurs within the focal region. In a previous study [44], this 
estimated p- was found to be accurate within 15% compared to direct focal pressure measurements 
in water and in a medium (1,3 butanediol) with a higher cavitation threshold. Sample acoustic 
waveforms produced by the four frequency transducers are shown in Figure B.2A. 
Optical Imaging and Image Processing 
High speed optical imaging was used to capture images of the focal zone after the 
propagation of each pulse through the focus using two high speed cameras (Figure B.2B). For 
experiments with the 345 kHz and 1.5 MHz transducers, a high-speed, 1 megapixel CCD camera 
(Phantom V210, Vision Research, Wayne, NJ, USA) was aligned with the transducer and backlit 
by a continuous white-light source. The camera was focused using a macro-bellows lens 
(Tominon, Kyocera), giving the captured images a resolution of approximately 5.9 µm per pixel 
and 3.4 µm per pixel for 345 kHz and 1.5 MHz, respectively. For experiments with the 500 kHz 
and 3 MHz dual frequency transducer, a digital, 1.3-megapixel CCD camera (PN: FL3-U3-
13Y3M-C, Flea® 3, PointGrey, Richmond, BC, Canada) was positioned perpendicularly to the 
dual-frequency array transducer facing one of the transducer’s optical windows. A Nikon 4X 
objective was attached to the camera with extension tubes to magnify the image plane, giving the 
captured images a resolution of approximately 2.5 µm per pixel. A pulsed white-light LED was 
placed on the diametrically-opposed optical window of the dual-frequency array transducer, which 
provided back-lit illumination. The cameras were triggered to record one image for each applied 
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pulse. After acquisition, shadowgraph images were converted from grayscale to binary by an 
intensity threshold determined by the background intensity using image processing software 
(MATLAB, The Mathworks, Natick, MA, USA), as described in a previous study [44]. 
 
Figure B.2 (A) Example waveforms for 2-cycle histotripsy pulses generated by custom-built 345 
kHz, 500 kHz, 1.5 MHz, and 3 MHz transducers. (B) Experimental set-up showing the focus of the 
histotripsy transducers aligned inside tissue phantoms containing PFP, PFH, or no nanodroplets.  
Cavitation was monitored using high speed optical imaging and passive cavitation detection using one 
of the therapy elements. 
Bubbles were indicated as any black regions >5 pixels. By this criterion, the minimum resolvable 
bubble radius was 14.75 μm, 6.25 μm, 8.5 μm, and 6.25 μm for the 345 kHz, 500 kHz, 1.5 MHz, 
and 3 MHz transducers, respectively. 
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Passive Cavitation Detection (PCD)  
In addition to high speed imaging, an acoustic method was used to identify cavitation in 
the focal zone for cavitation threshold experiments. For each experiment, one of the transducer’s 
therapy elements was also used for PCD to detect the presence of cavitation in the focal region 
(Figure 7.2B). The PCD signal was connected to an oscilloscope (LT372; Lecroy, Chestnut Ridge, 
NY, USA) with the time window selected to record the backscattering of the therapy pulse from 
cavitation bubbles [44, 323, 337]. To determine whether cavitation occurred during a pulse, the 
signal generated by backscattering of the incident pulse from the focus was analyzed following the 
method used in previous studies [44, 337]. A significant fraction of the incident wave energy is 
scattered when a cavitation bubble expands, greatly increasing the backscattered pressure 
amplitude received by the PCD. This signal appeared on the PCD at the time point corresponding 
to two times the time of flight for the focal length of the respective transducers. The integrated 
frequency power spectrum (SPCD) of the backscatter signal was used as a measure of whether 
cavitation occurred according to the method previously described by Maxwell et al [44]. 
NMH Cavitation Threshold  
For cavitation threshold experiments, 100 pulses were applied to each sample inside a 
water bath heated to 37 °C at each pressure level at a pulse repetition frequency (PRF) of 0.5 Hz. 
The PRF was kept low to minimize the possibility that cavitation from one pulse would change 
the probability of cavitation on a subsequent pulse. In a previous study, it was demonstrated that 
cavitation during a pulse increased the likelihood of cavitation on a following pulse for PRFs > 1 
Hz, , but this effect was not observed for PRFs < 1 Hz [44]. In addition to this low PRF, the focus 
was translated for each pulse by 1 mm transverse to the acoustic propagation direction in a 10 × 
10 grid in order to minimize the effects of cavitation damage to the nanodroplets or tissue phantoms 
from altering the probability of cavitation. For each pulse, cavitation was monitored using both 
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high speed imaging and PCD, and the fraction of total pulses (out of 100) for which cavitation was 
detected was determined as the cavitation probability. 
The probability of observing cavitation followed a sigmoid function, given by 
𝑃(𝑝−) =
1
2
+ 𝑒𝑟𝑓 (
𝑝−  −  𝑝𝑡
√2𝜎2
)  Eq. 7.1   
where erf is the error function, pt is the negative pressure at which the probability pcav=0.5, σ is a 
variable related to the width of the transition between pcav=0 and pcav=1, with ± σ giving the 
difference in pressure from about pcav=0.15 to pcav=0.85 for the fit [44]. The cavitation threshold 
for each sample, pt, is defined as the p- corresponding to pcav=0.5 as calculated by the curve fit. 
Curve fitting for all data sets was performed using an OriginLab curve fitting program (OriginPro 
9.1; OriginLab Corporation, Northampton, MA, USA). The fit curves for all samples were 
analyzed statistically to determine whether the differences in the values of pt were significantly 
different from each other. The standard errors for pt were estimated by a covariance matrix using 
the delta method [329]. The curves were compared using a two-sample t-test with statistic 
𝑡 (𝑝𝑖𝑛𝑡1 − 𝑝𝑖𝑛𝑡2, √𝑆𝐸1
2+𝑆𝐸2
2) at a 95% confidence interval. Results were considered statistically 
significant for p<0.05. Note that the standard error does not include the uncertainty in absolute 
pressure from the hydrophone measurement, only the uncertainty in the fit. A sample size of 3 
tissue phantoms was used for each experimental condition (i.e. PFP nanodroplets, PFH 
nanodroplets, or no nanodroplets). 
 NMH Multi-pulse Sustainability 
To test the hypothesis that PFH nanodroplets will remain sustainable cavitation nuclei over 
multiple pulses while PFP nanodroplets will be destroyed during the first few pulses, 1000 
ultrasound pulses were applied to a single focal region in tissue phantoms containing PFP and PFH 
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nanodroplets inside a water bath heated to 37 °C. Pulses were applied at a PRF of 1 Hz and peak 
negative pressures of 11.8 MPa (345 kHz), 12.6 MPa (500 kHz), 14.3 MPa (1.5 MHz), and 15.6 
MPa (3 MHz). The PRF in this study was kept low (1 Hz) to minimize the contributions of residual 
nuclei from a previous pulse from effecting cavitation generation on a subsequent pulse in order 
to determine if PFP and PFH nanodroplets continue to function as viable cavitation nuclei after 
the first few pulses or if the nanodroplets are destroyed in the cavitation process. Furthermore, a 
PRF of 1 Hz was also chosen as previous work has shown an increase in ablation efficiency for 1 
Hz treatments in comparison to higher PRF treatments that rely on residual nuclei from previous 
pulses to maintain the cavitation bubble cloud [335, 343]. Cavitation was monitored using high 
speed optical imaging, and the number of bubbles produced by each pulse was compared for 1000 
histotripsy pulses in each sample.  
NMH RBC Phantom Ablation 
Agarose gel phantoms with an embedded RBC layer were used to characterize cell 
fractionation induced by NMH. Fractionation of the RBCs turns the color of the embedded cell 
layer from opaque red to translucent as the RBCs are lysed, which allows direct visualization of 
the histotripsy-induced fractionation process [344]. Previous studies have also shown that the 
lesion visualized in RBC phantoms is similar to the lesion generated in tissue identified by 
histology [344]. For RBC experiments, 2000 histotripsy pulses were applied to the center of the 
red blood cell phantom layer at PRFs of 1 Hz and 10 Hz (n=4). The bubble cloud and resulting 
cell fractionation were recorded by high-speed optical imaging after each pulse. Cell fraction was 
compared between RBC phantoms with PFP and PFH nanodroplets. 
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Results 
Nanodroplets Characterization 
In this study, we aimed to encapsulate PFH into the triblock amphiphilic P(HDFMA8-co-
MMA20)-b-PAA12-b-PEG45 copolymer in order to compare the cavitation ability of PFH-loaded 
nanodroplets with PFP-loaded nanodroplets. In our previous study, we demonstrated that PFP can 
be encapsulated in the fluorinated copolymer, forming nanodroplets containing an elastic shell 
with an average size of ~100-400 nm [46]. In contrast to PFP, the solubility of PFH is limited in 
most common polar solvents as well as water. Moreover, PFH is not miscible with any of these 
solvents and exhibits a clear phase separation from organic solvents. In this study, we hypothesized 
that PFH could be encapsulated by the P(HDFMA8-co-MMA20)-b-PAA12-b-PEG45 copolymer 
forming nanodroplets with similar size and characteristics to the PFP droplets described in our 
previous study [46]. Results demonstrate that both PFP and PFH encapsulated into stable 
nanodroplets in the desired size range (100-600 nm). NTA size analysis showed similar 
characteristics for the PFP and PFH droplets (Figure B.3). PFP-loaded nanodroplets size ranged 
from 100-450 nm with the major peak <300 nm. The size distribution of PFH-loaded nanodroplets 
was slightly larger than the PFP-loaded ones, ranging from 100-600 nm. Three additional high-
intense peaks in the range of 200-300 nm, 300-450 nm, and 450-600 nm were observed in the large 
size portion of the PFH nanodroplet size plot (Figure B.3B). The larger size of the PFH-loaded  
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Figure B.3 Nanoparticle Tracking Analysis (left) demonstrated similar characteristics for 
(A) PFP- and (B) PFH-loaded nanodroplets. Size distribution plots (right) show the average size of the 
droplets was 177.9±1.9 nm and 233.9±3.9 nm for PFP and PFH nanodroplets, respectively. 
nanodroplets is possibly due to the difference in PFH miscibility with the THF/copolymer mixture 
compared to PFP. For example, PFP was observed to homogenously disperse in the 
THF/copolymer mixture in the beginning of droplets formulation, whereas PFH remained separate 
from the mixture on the bottom of the round-bottom flask. This energetically-favored phase 
separation was broken up by drop-wise addition of water to trigger the micellization process of the 
amphiphilic copolymer under vigorous stirring. This strategy allowed for uniform mixing of the 
PFH and efficient encapsulation in the droplets core. Both types of droplets were dispersed 
throughout the aqueous solution without aggregation or settling down in solution due to the 
hydrophilic PEG corona. PFP- and PFH-loaded nanodroplets exhibited similar concentrations and 
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size distribution (Figure B.3). The error bars on the size distribution plots represent the standard 
deviation of the repeat measurements of each sample. The mean size and standard deviation values 
obtained by the NTA software correspond to arithmetic values calculated with the sizes of all 
particles analyzed for each sample (n=5). Results from all samples demonstrated an average size 
of 177.9±1.9 nm and 233.9±3.9 nm for PFP and PFH nanodroplets, respectively. 
NMH Cavitation Threshold 
To investigate the effects of nanodroplet composition on the NMH threshold, histotripsy 
pulses were applied to tissue-mimicking agarose phantoms with PFP nanodroplets, PFH 
nanodroplets, and no nanodroplets using the 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz histotripsy 
transducers. For all experimental conditions, cavitation bubbles were observed on the high-speed 
camera in an increasingly larger area with increasing pressure once a certain negative pressure was 
exceeded, with complete agreement between optical imaging and PCD detection methods (Figure 
B.4), as seen in previous studies [44, 337]. Plotting the probability of cavitation as a function of 
peak negative pressure demonstrated a significant decrease in the cavitation threshold with both 
PFP and PFH nanodroplets compared to controls at all frequencies (Figure B.5). Additionally, 
results showed a slight increase in the nanodroplet cavitation threshold for PFH nanodroplets 
compared to PFP nanodroplets (Figure B.5). Cavitation threshold results for all experimental 
conditions are listed in Table B.1. Comparing the threshold results for phantoms containing PFH 
nanodroplets with control phantoms demonstrated that the cavitation threshold was decreased by 
14.4 MPa, 15 MPa, 13.7 MPa, and 11.9 MPa at 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz, 
respectively (Figure B.6). 
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Figure B.4 Sample PCD signals (top) and high speed optical imaging (bottom) were used for 
cavitation detection for cavitation threshold experiments. 
Results showed good agreement between the two methods. Representative images shown above are from 
1.5 MHz histotripsy pulses applied to tissue phantoms containing PFH nanodroplets. 
 
Table B.1 Threshold results. Table shows the values for the peak negative pressure, pt, at which 
the fit curve set Pcav = 0.5 for each sample as well as the mean values for pt and σ. A two-way 
ANOVA showed all differences in pt_mean between samples were statistically significant (p<0.05). 
Frequency Material Pt (1) Pt (2) Pt (3) Pt (mean) σ(mean) 
345 kHz No Droplets 25.9 23.7 24.7 24.8 2.0 
 PFP Droplets 7.3 7.4 7.4 7.4 1.4 
 PFH Droplets 10.5 10.1 10.6 10.4 0.9 
500 kHz No Droplets 23.5 26.3 26.7 25.5 1.8 
 PFP Droplets 9.4 10.0 8.2 9.2 0.8 
 PFH Droplets 10.4 10.8 10.3 10.5 0.8 
1.5 kHz No Droplets 26.8 27.0 26.3 26.7 1.0 
 PFP Droplets 10.3 10.7 10.5 10.5 0.4 
 PFH Droplets 12.8 13.0 13.1 13.0 0.3 
3 MHz No Droplets 26.9 27.2 26.3 26.8 0.9 
 PFP Droplets 13.1 12.9 13.7 13.2 0.6 
 PFH Droplets 14.6 14.6 15.4 14.9 0.4 
 
 
When comparing phantoms containing PFP and PFH nanodroplets (Figure B.6), a decrease of 3 
MPa, 1.3 MPa, 2.5 MPa, and 1.7 MPa was observed for PFP phantoms at 345 kHz, 500 kHz, 1.5 
MHz, and 3 MHz, respectively (Figure B.6). For all experimental conditions, the cavitation 
threshold was observed to decrease at lower frequency, as has been observed in previous studies 
(Figure B.6) [79, 337]. A two-way ANOVA was performed on the data shown in Figure B.6, 
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demonstrating all differences between the cavitation threshold in PFP, PFH, and control phantoms 
were significant (p<0.05). 
 
Figure B.5 Plots show sample cavitation probability curves for tissue phantoms containing PFP 
nanodroplets, PFH nanodroplets, and no nanodroplets at 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz. 
At all frequencies, results showed a significant decrease in the cavitation threshold with both PFP and 
PFH nanodroplets compared to controls. Results also showed a slight increase in the nanodroplet 
cavitation threshold for PFH nanodroplets compared to PFP nanodroplets. 
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Figure B.6 Bar plots show the complete cavitation threshold results for tissue phantoms containing 
PFP nanodroplets, PFH nanodroplets, and no nanodroplets. 
All differences in the cavitation threshold between samples were statistically significant (p<0.05). 
 
NMH Multi-pulse Sustainability 
To compare the ability of nanodroplets to act as sustainable cavitation nuclei over multiple 
pulses, 1000 histotripsy pulses were applied to a single focal region in phantoms containing PFP 
and PFH nanodroplets at a PRF of 1 Hz. Results demonstrated that a bubble cloud consisting of 
many bubbles was observed after the first pulse for both types of droplets (Figure B.7). However, 
the bubble cloud generated in PFH phantoms was a more well-defined bubble cloud, similar to 
those previously observed for histotripsy above the intrinsic threshold [337, 345]. At all 
frequencies, over all 1,000 pulses, a dense bubble cloud was produced in PFH phantoms, with the 
bubbles more tightly confined inside the focal region and no significant change in the number of 
bubbles inside the cloud (Figure B.7 and B.8). In comparison, after the first pulse, the bubble 
cloud generated in the PFP phantom is sparsely populated (Figure B.7 and B.8). At all 
frequencies, the number of bubbles observed inside PFP phantoms significantly decreased with 
206 
 
increasing number of pulses, and bubbles distinguished after ~5-50 pulses. At a higher frequency, 
the bubble cloud distinguished with fewer pulses. For example, no bubbles were observed after 
~50 pulses in PFP phantoms exposed to 500 kHz (p-=12.6 MPa) pulses and after ~5 pulses exposed 
to 3 MHz (p-=15.6 MPa) pulses. 
 
Figure B.7 Optical images show NMH bubbles produced by 500 kHz (p-=12.6 MPa) pulses at a 
single focal point in tissue phantoms containing PFP and PFH nanodroplets at a PRF of 1 Hz. 
Results for PFP phantoms showed a decrease in the number of bubbles observed at the focus, with 
increasing pulse number, with no bubble observed after ~50 pulses. PFH phantom results demonstrated 
no significant decrease in the number of bubbles observed at the focus with increasing pulse number, 
with well-defined dense bubble clouds still observed after 1,000 pulses. 
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Figure B.8 Optical images show NMH bubbles produced by 3 MHz (p-=15.6 MPa) pulses at a single 
focal point in tissue phantoms containing PFP and PFH nanodroplets at a PRF of 1 Hz. Results for 
PFP phantoms showed a decrease in the number of bubbles observed at the focus, with increasing pulse 
number, with no bubble observed after ~5 pulses. PFH phantom results demonstrated well-defined NMH 
bubble clouds were still observed after 1,000 pulses. 
 
NMH RBC Phantom Ablation 
Agarose tissue phantoms embedded with RBC layers were used to compare NMH ablation 
for phantoms containing PFP and PFH nanodroplets. Results demonstrated that NMH generated 
consistent, well-defined lesions for RBC phantoms containing PFH nanodroplets, with the results 
being consistent for NMH treatments applied at 1 Hz and 10 Hz PRF. For example, Figures B.9 
and B.10 show images of NMH lesions generated inside RBC phantoms containing PFH droplets 
using the 345 kHz (Figure B.9) and 1.5 MHz (Figure B.10) transducers. 
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Figure B.9 Optical images show NMH fractionation produced by 345 kHz (p-=12.6 MPa) pulses in 
RBC phantoms containing PFP and PFH nanodroplets at PRFs of 1 Hz and 10 Hz. 
Results showed significantly larger and more well-defined lesions generated inside the PFH tissue 
phantoms, compared to the sparse lesions inside the PFP tissue phantoms. 
 
For all cases, dense cavitation bubble clouds were generated inside the PFH phantom on 
every pulse, resulting in sharp lesions with well-defined boundaries between the fractionated lesion 
and intact RBCs (Figure B.9 and B.10). In contrast, only sparse lesions were formed inside the 
PFP phantoms. For example, for the 10 Hz PRF treatments using the 345 kHz transducer, sparse 
cavitation bubble clouds were observed over the course of the treatment, with the location of the 
bubbles remaining consistent from pulse to pulse inside the PFP phantoms, resulting in sparse 
lesions (Figure B.9). For the 1 Hz treatments inside the PFP phantoms using the 345 kHz 
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transducer, cavitation was only observed on the initial pulses (<10 pulses) and was not maintained 
for the duration of the treatment, resulting in very small lesions after treatment (Figure B.9). 
 
Figure B.10 Optical images show NMH fractionation produced by 1.5 MHz (p-=15.7 MPa) pulses 
in RBC phantoms containing PFP and PFH nanodroplets at PRFs of 1 Hz and 10 Hz. 
Results showed well-defined lesions generated inside the PFH tissue phantoms. No visible lesions were 
observed for treatments applied to tissue phantoms containing PFP droplets. 
 
At higher frequency (i.e. 1.5 MHz), no visible lesions were observed in the PFP phantoms 
for either 1 Hz or 10 Hz treatments, with bubbles only visible on the first pulse (Figure B.10). 
Quantifying the lesions areas for RBC phantoms (n=4) demonstrated a significant decrease in 
lesion size for phantoms containing PFP droplets in comparison to PFH phantoms. For example, 
at 345 kHz the lesion areas inside the PFH phantoms were 14.35±1.13 mm2 (1 Hz) and 15.01±1.61 
mm2 (10 Hz), which were significantly larger than the lesion areas inside the PFP phantoms of 
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0.05±0.04 mm2 (1 Hz) and 3.24±0.29 mm2 (10 Hz). At 1.5 MHz, the lesion areas inside the PFH 
phantoms were 1.31±0.09 mm2 (1 Hz) and 1.17±0.13 mm2 (10 Hz), which were significantly larger 
than the lesion areas inside the PFP phantoms of 0.00±0.00 mm2 (1 Hz, 10 Hz). 
 
Discussion 
In this study, the effects of droplet composition on NMH therapy were investigated using 
perfluoropentane (boiling point~29°C, surface tension~9.5 mN/m) and perfluorohexane (boiling 
point~56°, surface tension~11.9 mN/m) nanodroplets. In the first part of this study, PFP and PFH 
droplets were  synthesized using a previous developed method [46]. The results from the 
nanodroplet characterization suggest that the droplet preparation method described by Durmaz et 
al can be used to create nanodroplets with similar surface characteristics within the media while 
the composition of the encapsulated perfluorocarbon can be modulated as desired [46]. The design 
of the triblock amphiphilic copolymer acts to increase the particle’s solubility in aqueous 
environments due the hydrophilic character of the outer PEG block while also improving 
hemocompatibility (i.e. no protein adsorption on the particles, no macrophage recognition, and 
minimum interaction with blood cells during blood circulation) [46, 247, 249]. The results of this 
study suggest that the PFC inside the nanodroplets can be easily modified to take advantage of 
perfluorocarbons with different boiling points without losing the benefits of the functionalized 
polymer shell. 
In the second part of this study, the effects droplet composition on the histotripsy cavitation 
threshold were investigated, with resulting showing a significant decrease in the cavitation 
threshold for both types of nanodroplets compared to controls, with a slightly lower threshold 
observed for PFP phantoms, likely due to the decrease in surface tension for PFP. These results 
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support our hypothesis that both PFP and PFH nanodroplets can be used to significantly reduce 
the pressure required to generate histotripsy bubbles for NMH therapy. At all frequencies tested, 
the NMH threshold for both types of droplets was significantly lower (>10 MPa decrease) than the 
histotripsy intrinsic threshold, while maintaining a steep threshold behavior. In fact, the σmean 
values calculated by the curve fit decreased (i.e. sharper threshold curve) for phantoms containing 
nanodroplets, with the lowest σmean values observed for phantoms containing PFH droplets (Table 
B.1). This distinct threshold behavior is promising for the development of NMH therapy in which 
the applied pressure must be chosen in the region above the NMH threshold but below the 
histotripsy intrinsic threshold to ensure cavitation is only generated in regions containing 
nanodroplets. The results of these threshold experiments suggest that both PFP and PFH 
nanodroplets could be used for NMH, with PFP droplets offering a slightly lower threshold (~1-3 
MPa decrease). With everything else equal, one might expect a lower cavitation threshold for the 
larger PFH droplets (233.9±3.9 nm) compared to PFP droplets (177.9±1.9 nm). It is possible that 
the slight decrease in threshold for PFP droplets is due to the lower surface tension of PFP (9.5 
mN/m) compared to PFH (11.9 mN/m), as previous work has demonstrated that the cavitation 
threshold is highly dependent upon the surface tension of the media (i.e. bulk fluid inside the 
droplet) when using the 1-2 cycle pulses used in this study [44, 337]. These results suggest that 
the nanodroplets may actually decrease the cavitation threshold by carrying a lower threshold 
medium, rather than each droplet acting as single cavitation nuclei as would be the case for an air 
contrast agent. Based on this finding, the results of this work suggest that the NMH threshold can 
be selectively modulated by changing the droplet composition, with lower surface tension/boiling 
point droplets resulting in a decreased cavitation threshold. The finding that the NMH threshold 
can be finely tuned by changing droplet composition while maintaining the distinct threshold 
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behavior is a significant benefit for the development of NMH therapy as well as for other 
nanodroplet applications such as selective drug delivery [346]. 
In the final part of this study, the effects of droplet composition on cavitation sustainability 
and tissue fractionation were investigated, with results showing that PFH nanodroplets were 
sustainable cavitation nuclei over multiple pulses, while PFP nanodroplets were destroyed during 
the initial pulses. This effect resulted in well-defined lesions being generated inside the red blood 
cell phantom containing PFH droplets under all treatment conditions. In contrast, only sparse 
lesions were formed inside the PFP phantoms for the 345 kHz treatments applied at 10 Hz PRF, 
with no visible lesions observed at higher frequency (i.e. 1.5 MHz) or lower PRF (i.e. 1 Hz). The 
increased cavitation sustainability of the PFH droplets is most likely due to the re-condensing of 
PFH droplets into a liquid after the cavitation event occurs, due to the higher boiling point of the 
PFH droplets. The finding that PFH nanodroplets act as sustainable cavitation nuclei over multiple 
pulses, while PFP droplets are destroyed during the initial pulses, supports our hypothesis that 
using droplets with a higher boiling point is advantageous for NMH therapy. Results suggest that 
PFH droplets may re-condense into a liquid after the collapse of the cavitation bubble while the 
PFP bubbles are destroyed by the cavitation process (i.e. do not return to liquid form). These results 
suggest that higher boiling point droplets can be used to significantly reduce the nucleation 
threshold for generating cavitation bubbles over multiple pulses, allowing NMH therapy to be 
applied for multiple pulses until the targeted tissue is completely fractionated, even at low PRF. In 
contrast, due to the lower boiling point, PFP nanodroplets are only capable of reducing the 
cavitation threshold on the initial pulses, requiring cavitation on subsequent pulses to be generated 
from residual nuclei remaining in the focal region from previous pulses. The finding that higher 
boiling point droplets can serve as functional cavitation nuclei over multiple pulses is therefore a 
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major benefit for NMH therapy, as previous work has shown a decrease in ablation efficiency for 
higher PRF treatments that rely on residual nuclei from previous pulses to maintain the cavitation 
bubble cloud [335].  
In addition to the finding that PFH droplets acted as sustainable cavitation nuclei over 
multiple pulses, it was also observed that the NMH bubble clouds produced from PFH droplets 
were more well-defined and densely populated compared to the sparse bubble clouds produced by 
the PFP droplets, even when comparing bubble clouds produced on the first pulse. The well 
confined, dense bubble clouds produced inside the PFH phantoms closely match the behavior of 
bubble clouds previously observed for histotripsy treatments above the intrinsic threshold, which 
have been shown to be efficient and precise at fractionating the target tissue [44, 337, 343, 345]. 
In contrast, the more sparse bubble clouds produced inside the PFP phantoms resemble bubble 
clouds generated at higher PRF or bubble clouds that rely upon residual nuclei in order to maintain 
cavitation, which have been shown to be less efficient at fractionating tissue while increasing 
collateral damage to surrounding tissue [335]. This observation suggested that NMH bubble clouds 
produced using PFH droplets will be more efficient at fractionating tissue and provide less 
collateral damage to surrounding tissue compared to NMH therapy using PFP droplets, which was 
validated by the final set of experiments in this study comparing NMH ablation in red blood cell 
phantoms. 
 
Conclusion 
In this work, the effects of droplet composition on NMH therapy were investigated using 
perfluoropentane (boiling point~29°C, surface tension~9.5 mN/m) and perfluorohexane (boiling 
point~56°, surface tension~11.9 mN/m) droplets. The results demonstrated a significant decrease 
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in the cavitation threshold for both types of nanodroplets compared to controls, with a slightly 
lower threshold observed for PFP phantoms, likely due to the decrease in surface tension for PFP. 
Results further demonstrated that PFH nanodroplets were sustainable cavitation nuclei over 
multiple pulses, while PFP nanodroplets were destroyed during the initial pulses. This effect is 
most likely due to the re-condensing of PFH droplets into a liquid after the cavitation event occurs, 
due to the higher boiling point of the PFH droplets.  In the final part of this study, tissue phantoms 
containing a layer of embedded red blood cells were used to compare the damage generated for 
NMH treatments using PFP and PFH droplets, with results showing PFH nanodroplets 
significantly improved NMH ablation, allowing for well-defined lesions to be generated at all 
frequencies and PRFs tested. The results of this study suggest that NMH therapy can be 
significantly enhanced by modulating droplet composition in order to optimize the cavitation 
threshold (decrease droplet surface tension) and increase the multi-pulse sustainability (increase 
droplet boiling point). Overall, the results of this study provide significant insight in the role of 
droplet composition in NMH therapy and will provide a rational basis to specifically tailor droplet 
parameters in order to improve NMH tissue fractionation. 
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Pressure on Cavitation Nucleation in Nanodroplet-Mediated Histotripsy” Phys. Med. Biol, 30, 
61(2), 663-682, 2015. 
Introduction 
Histotripsy is a noninvasive tissue ablation method that controllably fractionates soft tissue 
through cavitation generated by high pressure, short duration ultrasound pulses [49, 313, 336]. 
Histotripsy is currently being studied for many clinical applications where non-invasive tissue 
removal is desired including benign prostatic hyperplasia [319], deep vein thrombosis [164], 
congenital heart disease [165, 166], fetal interventions [347, 348], and cancer [45, 167]. Although 
histotripsy has shown promise for many clinical applications including tumor ablation, this 
approach is limited to applications in which the target tissue can be identified and imaged prior to 
treatment, which is often not feasible in cancer patients with many small tumor nodules and micro-
metastases. Histotripsy also requires very high pressure (P–>20MPa), which may not be 
achievable in some target tissues with limited acoustic access. Due to these limitations, our group 
has recently developed a targeted ablation approach combing polymer encapsulated nanodroplets 
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with histotripsy [46, 79]. Nanodroplet-mediated histotripsy (NMH) takes advantage of the 
significantly reduced cavitation threshold of the nanodroplets, allowing for cavitation to be 
selectively generated only in regions containing nanodroplets [79]. By synthesizing nanodroplets 
in a size range (~100-400 nm) in which they can diffuse through the leaky tumor vasculature and 
preferentially accumulate in the tumor, NMH has the potential for selective ablation of tumors [46, 
79]. Previous work has demonstrated that NMH can be used to create well-defined ablation similar 
to histotripsy but at significantly lower pressure and has the potential to be used for simultaneous 
multi-focal ablation [79]. 
Understanding the physical mechanisms underlying the NMH cavitation process is 
essential for the development of NMH therapy. Previous studies on acoustic droplet vaporization 
(ADV) have shown that the ADV vaporization thresholds do not appear to follow the trends 
predicted by classical nucleation theory (CNT), which predicts that cavitation will be nucleated 
inside the droplets directly from the applied negative pressure (p-) [330-332, 349-354]. These 
studies have led to the hypothesis that nanodroplet nucleation in ADV is caused by a different 
mechanism than what is predicted by CNT, such as droplet deformation, hydrodynamic cavitation, 
or acoustic heating [330, 353, 354]. However, these ADV studies used larger droplets, higher 
frequency ranges, and pulses with more acoustic cycles than those used in NMH therapy [46, 79, 
80, 330-332, 353-355]. Furthermore, recent work reveals that the decrease in the ADV threshold 
at higher frequencies is due to superharmonic focusing, which significantly increases the amplitude 
of the p- inside the droplet and is enhanced at higher frequencies and in larger droplets [333, 334]. 
Therefore, it is possible that ADV nucleation does in fact follow the predictions of CNT, once the 
effects of pressure focusing are accounted for. 
218 
 
In NMH, cavitation bubbles are generated from nanodroplets <600 nm in diameter using 
single-cycle ultrasound pulses at frequencies in the hundreds of kHz to low MHz range, resulting 
in  cavitation thresholds significantly higher than the vaporization thresholds previously measured 
for ADV [46, 79, 80, 353, 355], with the trends appearing the follow the predictions of CNT [337, 
349-352]. For example, previous work has demonstrated a significant reduction in the histotripsy 
cavitation threshold for both perfluoropentane (PFP) and perfluorohexane (PFH) nanodroplets 
exposed to single cycle histotripsy pulses [44, 80, 337, 355, 356]. The NMH cavitation threshold 
decreases at lower frequencies [80, 355], in contrast to the increasing ADV threshold with higher 
frequency observed using micron sized droplets [330-332, 353]. The NMH frequency dependence 
appears to agree with CNT, which predicts that lower frequency will decrease the cavitation 
threshold due to the longer duration of the applied p- and the larger focal zone at lower frequencies 
[80, 337, 349-352, 355]. Furthermore, a slight increase in the NMH cavitation threshold has been 
observed for PFH nanodroplets compared to PFP droplets due to the increase in the surface tension 
and boiling point of PFH, which also agrees with the predictions of CNT [80, 337, 349-352, 355].  
Based on these previous studies, we hypothesize that NMH bubbles are generated after 
cavitation is nucleated inside the droplets directly from the incident p- (tensile portion of the 
incident wave), similar to histotripsy bubbles generated without nanodroplets when the negative 
pressure directly exceeds the intrinsic threshold [44, 337, 357].  In order to test this hypothesis, in 
this study we separate the effects of negative and positive pressure on NMH cavitation nucleation 
using near half-cycle ultrasound pulses with dominant negative (negative-polarity pulses) or 
positive (positive-polarity pulses) pressure phases. This paper reports the first study that separately 
investigates the effects of negative and positive pressure on the NMH cavitation process. The 
generation of near monopolar pulses was made possible by using a frequency compounding 
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transducer recently developed in our lab, which aligns the positive or negative phases of multiple-
frequency components while destructive interference occurs elsewhere in space and time, leading 
to pulses with a single dominant negative or positive pressure phase [357]. Tissue phantoms 
containing PFH nanodroplets and control phantoms without droplets were exposed to negative-
polarity and positive-polarity pulses, and optical imaging was used to measure the NMH cavitation 
threshold as a function of peak negative (P–) and peak positive (P+) pressure. The NMH cavitation 
threshold definition is similar to the ADV threshold, with the difference being in the type of bubble 
that is generated from the nanodroplets (i.e. transient cavitation bubble vs. stable ADV bubble). 
Finally, to help explain the experimental results, CNT was used to theoretically investigate the 
expected cavitation thresholds for samples with and without PFH nanodroplets, with the CNT 
results compared to the experimentally observed thresholds. Overall, the results of this study will 
improve our understanding of the physical mechanisms underlying the NMH cavitation process, 
which is essential for the development of NMH therapy. 
 
Methods 
Nanodroplet Formulation and Characterization 
Polymer encapsulated perfluorohexane (PFH, SynQuest Lab, > 98%)  nanodroplets were 
used for this study based on recent work demonstrating that PFH droplets have many benefits for 
NMH therapy [355]. A PEG45-b-PAA12-b-P(HDFMA8-co-MMA20) triblock copolymer was 
synthesized using a combination of atom transfer radical polymerization (ATRP) and “click” 
coupling chemistry to prepare PFH-loaded nanodroplets following our published method [46]. 
Formulation of PFH-loaded nanodroplets started by dissolving the polymer in tetrahydrofuran 
(THF) (0.2% w/v) and cooling the solution down to 0oC before adding PFH (2% v/v) while 
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vigorously stirring the reaction mixture. An equal volume of deionized water was added drop-wise 
to this solution to initiate micelle formation and the mixture was stirred for 1 hour in an ice bath. 
The micelles solution was transferred to a dialysis bag (MWCO of 1 KDa, Spectrum, Rancho 
Dominguez, CA) and dialyzed overnight against ice-cold MES buffer solution (pH 5.5) to remove 
the THF solvent and get a milky solution of non-cross-linked PFH-loaded nanodroplets. The milky 
nanodroplets solution was transferred to a round bottom flask and mixed with the 2,2`-
(ethylenedioxy)-bis(ethylamine) cross-linker to react with the carboxyl groups of the central PAA 
block in the polymer backbone via NHS/EDC coupling chemistry forming cross-linked 
nanodroplets with a flexible polymer shell. Shell cross-linked nanodroplets were dialyzed against 
ice-cold water for 12 hours to remove unreacted cross-linker and reaction byproducts. 
Concentration and size distribution of the nanodroplets were measured using Nanoparticle 
Tracking Analysis (NTA). Briefly, the NanoSight™ LM10 (Malvern Instruments, Amesbury, 
UK), equipped with a temperature-controlled 405 nm laser module, high sensitivity Scientific 
Complementary Metal–Oxide–Semiconductor (sCMOS) camera (Hamamatsu, Orca, Hamamatsu 
City, Japan), and a syringe pump was used for the collection of NTA data. Upon diluting the 
nanodroplet solution to the appropriate particle concentration with deionized (DI) water (Thermo 
Scientific, GenPure, Waltham, MA, USA), image capture and analysis was carried out using the 
NTA software (Version 3.0, Build 0066, Malvern Instruments, Amesbury, UK) at 37°C. The 
samples were measured by capturing 60s videos (5 videos per each sample). These values were 
determined in order to collect sufficient data such that the shape of the histogram no longer 
changed significantly with additional data (i.e. NTA analyzed hundreds or thousands of particles 
in order to calculate a representative particle size distribution). Figure C.1 is a representative plot 
showing the size distribution of the PFH nanodroplets. The error bars represent the standard 
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deviation of the repeat measurements of each sample. The mean size and standard deviation values 
obtained by the NTA software correspond to arithmetic values calculated with the sizes of all 
particles analyzed for each sample (n=5). Results from all samples demonstrated that the average 
size of the nanodroplets (NDs) was 233±3.9 nm with 10% of NDs have a diameter ≤ 135.3±2.6 
nm, 50% of the NDs have a diameter ≤ 192.7±5.3 nm, 90% of the NDs have a diameter ≤ 373.7±7.2 
nm, and >99% of the NDs are  ≤ 600 nm. 
 
Figure C.11 Nanodroplet characterization. Nanoparticle Tracking Analysis demonstrated PFH 
nanodroplets had an average size of 233.9±3.9 nm. 
 
Preparation of Tissue Phantoms 
Agarose phantoms were used to provide a well-controlled viscoelastic medium for this 
study. Tissue phantoms containing 1% agarose w/v were prepared by slowly mixing agarose 
powder (Agarose Type VII; Sigma-Aldrich, St. Louis, MO, USA) into saline solution (0.9% 
sodium chloride; Hospira, Lake Forest, Illinois, USA) heated to boiling temperature. The solution 
was stirred on a hot plate until the gel turned completely transparent and then allowed to boil for 
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ten minutes. After boiling, solutions were allowed to cool and were degassed under a partial 
vacuum (~20 kPa, absolute) for 30 minutes. After degassing, phantoms containing nanodroplets 
were prepared by slowly adding the nanodroplets (2.0×108 particles/ml) into the agarose solution 
while stirring. The agarose mixtures were poured into polycarbonate holders and placed in a 
refrigerator at 4°C to allow the solution to solidify, forming tissue phantoms with embedded PFH 
nanodroplets and without nanodroplets (control). Tissue phantoms containing PFH nanodroplets 
were assumed to have a nearly uniform distribution of droplets throughout the phantom, which is 
supported by the observations in previous NMH studies which showed similar cavitation 
thresholds and bubble activity for treatments applied throughout all regions of these tissue 
phantoms [46, 79, 80]. The attenuation coefficients of the agarose tissue phantoms with and 
without PFH droplets were measured to be <0.1 dB/cm for the pulses used in this study. These 
values, along with the short propagation distance through the phantom (<2 cm), suggest that 
attenuation from the tissue phantoms will have a negligible impact on the reported pressure values 
which were measured in free field. 
Histotripsy Pulse Generation 
Histotripsy pulses with dominant negative (negative-polarity pulse) and positive (positive-
polarity pulse) pressure phases were generated used a frequency compounding transducer, adapted 
from a previous study [357]. The frequency-compounding transducer was composed of 12 
elements (20 mm in diameter) with various resonant frequencies: 500 kHz (three elements), 1 MHz 
(two elements), 1.5 MHz (two elements), 2 MHz (two elements), and 3 MHz (three elements) 
[357]. The elements had a common geometric focus at 40 mm and were populated in a scaffold in 
a specific order to ensure that adjacent elements did not have the same frequency. This was done 
to reduce nonlinear propagation effects that occur when acoustic waves of the same frequency 
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propagate closely in space and interfere constructively. Additionally, the frequency-compounding 
transducer has two diametrically opposed optical windows to allow for optical imaging at the 
geometric focus. The design of the frequency compounding transducer has been described in detail 
in a previous study [357]. 
A custom high voltage pulser with 12 parallel channels was used to drive the frequency-
compounding transducer. The pulser was connected to a field-programmable gated array (FPGA) 
development board (Altera DE1, Terasic Technology, Dover, DE, USA) specifically programmed 
for frequency compounding pulse generation. This setup allowed each element to individually 
output short pulses with only one large negative or positive pressure phase. The generation of 
negative-polarity pulses was achieved by adjusting the arrival times of individual frequency 
components to allow their principal negative phase peaks to arrive at the focus of the transducer 
concurrently (Figure C.2A). In this situation, destructive interference occurs elsewhere in space 
and time, leading to a diminution of the peak positive pressure of the combined ultrasound pulse 
(Figure C.2A). For the generation of positive-polarity pulses, the driver pulses for the individual 
elements were inverted, resulting in ultrasound pulses with a single principal positive phase from 
each element. The arrival times of individual frequency components were then adjusted to allow 
their principal positive phase peaks to arrive at the focus concurrently (Figure C.2B). 
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Figure C.12 Acoustic waveforms. 
Example of (A) negative-polarity and (B) positive-polarity pulses produced by the frequency 
compounding transducer compared with a (C) dual-polarity pulse (500 kHz) previously used in NMH 
therapy. 
  
A fiber-optic probe hydrophone (FOPH) built in-house [172] was used to calibrate and 
measure the acoustic output of the frequency-compounding transducer, with example waveforms 
shown in Figure C.2. For threshold experiments, the probability of cavitation (measured by optical 
imaging) was plotted as a function of both the peak negative (P–) and peak positive (P+) pressure. 
In order to determine the peak pressure values for the negative and positive polarity pulses, 2D 
spatial pressure fields were directly measured using the FOPH in order to identify the locations 
corresponding to the P– and P+ in the focal region. The ratio of P– to P+ measured for the negative-
polarity pulses in this location was between 2.9-3.7 for the pressure ranges used in this study. For 
the positive-polarity pulses, the 2D spatial pressure fields measured by the FOPH demonstrated 
the location of the P– in the focal region occurred ~0.5 mm away from the geometric focus, while 
the location of the P+ remained near the geometric focus (Figure C.3). This effect is due to the 
temporal alignment of the principle peak positive peaks of the individual frequency components 
at the geometric focus, which resulted in a near monopolar positive pulse at the geometric focus 
with two low-negative-pressure lobes outside of the focal region. The ratio of P+ to P– for the 
positive-polarity pulses was measured to be between 3.2-3.9 for the pressure ranges used in this 
study using the P+ and P– measured at the maximum locations in the field. For the positive polarity 
225 
 
pulses, the pressure was directly measured up to the maximum output of the transducer, P–
/P+=16.3/55.1 MPa. For the negative polarity pulses, the pressure at the focus could only be 
directly measured up to P–/P+=21.5/7.6 MPa due to cavitation at the fiber tip at higher pressures. 
The pressures above this value were estimated using a linear summation of the pressures measured 
for individual elements, as outlined in previous studies [44, 337, 345, 357]. 
 
Figure C.13 Positive-polarity Pulse: Pressure Fields. 2D spatial pressure fields were measured by 
the FOPH for a positive-polarity pulse. 
(A) Results demonstrated the location corresponding to the highest positive pressure was near the 
geometric focus. (B) The location corresponding to the highest negative pressure was ~0.5 mm away 
from the geometric focus in the axial direction. 
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Optical Imaging and Image Processing 
High speed optical imaging was used to capture images of the focal zone after the 
propagation of each pulse through the focus. The frequency compounding transducer was placed 
on the bottom of a tank of degassed water, and a tissue phantom attached to a 3-axis motorized 
positioning system was lowered into the focus of the transducer (Figure C.4). A digital, 1.3-
megapixel CCD camera (PN: FL3-U3-13Y3M-C, Flea® 3, PointGrey, Richmond, BC, Canada) 
was positioned perpendicularly to the frequency compounding transducer facing one of the 
transducer’s optical windows (Figure C.4). 
 
Figure C.14 Experimental set-up. 
Tissue phantoms with and without PFH nanodroplets were placed at the focus of the frequency-
compounding transducer [357] for cavitation threshold experiments. Cavitation was monitored using 
high-speed optical imaging through the transducer’s optical windows. 
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A Nikon 4X objective was attached to the camera with extension tubes to magnify the 
image plane, giving the captured images a resolution of approximately 3.6 µm per pixel. A pulsed 
white-light LED was placed on the diametrically-opposed optical window of the dual-frequency 
array transducer, which provided back-lit illumination. The cameras were triggered to record one 
image after the passage of each pulse at a time point approximately corresponding to the maximum 
bubble expansion. This time point was determined for the negative-polarity and positive-polarity 
pulses prior to experiments by changing the delay time on the camera to identify the time 
corresponding to maximum bubble expansion, as described in previous studies [80, 337, 345]. 
After acquisition, shadowgraph images were converted from grayscale to binary by an intensity 
threshold determined by the background intensity using image processing software (MATLAB, 
The Mathworks, Natick, MA, USA), as described in a previous study [44]. Bubbles were indicated 
as any black regions greater than 5 pixels in diameter. By this criterion, the minimum resolvable 
bubble radius was 9 μm. 
NMH Cavitation Threshold 
For cavitation threshold experiments, 100 pulses were applied inside each sample at each 
pressure level at a pulse repetition frequency (PRF) of 0.5 Hz. The PRF was kept low to minimize 
the possibility that cavitation from one pulse would change the probability of cavitation on a 
subsequent pulse. In a previous study, it was demonstrated that cavitation during a pulse increased 
the likelihood of cavitation on a following pulse for PRFs > 1 Hz, but this effect was not observed 
for PRFs < 1 Hz [44]. In addition to this low PRF, the phantom sample was translated for each 
pulse by 1 mm transverse to the acoustic propagation direction in a 10 × 10 grid in order to 
minimize the effects of cavitation damage to the nanodroplets from altering the probability of 
cavitation. Using this method, each point in the tissue phantom was exposed to a single pulse at a 
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single pressure amplitude. For each pulse, cavitation was monitored using high speed imaging, 
and the fraction of total pulses at a given pressure level (out of 100) for which cavitation was 
detected was determined as the cavitation probability. 
The probability of observing cavitation followed a sigmoid function, given by 
𝑃(𝑝) =
1
2
+ 𝑒𝑟𝑓 (
𝑝 −  𝑝𝑡
√2𝜎2
)  Eq. 8.1   
where erf is the error function, pt is the pressure at which the probability pcav=0.5, σ is a variable 
related to the width of the transition between pcav=0 and pcav=1, with ± σ giving the difference in 
pressure from about pcav=0.15 to pcav=0.85 for the fit [44]. The cavitation threshold for each 
sample, pt, is defined as the pressure, p, corresponding to pcav=0.5 as calculated by the curve fit. 
Curve fitting for all data sets was performed using an OriginLab curve fitting program (OriginPro 
9.1; OriginLab Corporation, Northampton, MA, USA). The fit curves for all samples were 
analyzed statistically to determine whether the differences in the values of pt were significantly 
different from each other. The standard errors for pt were estimated by a covariance matrix using 
the delta method [329]. The curves were compared using a two-sample t-test with statistic 
𝑡 (𝑝𝑖𝑛𝑡1 − 𝑝𝑖𝑛𝑡2, √𝑆𝐸1
2+𝑆𝐸2
2) at a 95% confidence interval. Results were considered statistically 
significant for p<0.05. Note that the standard error does not include the uncertainty in absolute 
pressure from the hydrophone measurement, only the uncertainty in the fit, because the values pt 
are relative. For each sample, the curves were analyzed as a function of both positive and negative 
pressure, with the corresponding cavitation threshold values calculated as pt(+) and pt(–), 
respectively. A sample size of 3 tissue phantoms was used for each experimental condition (i.e. 
phantoms containing PFH nanodroplets or no nanodroplets exposed to negative-polarity or 
positive-polarity pulses).  
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Classical Nucleation Theory Simulation 
A theoretical analysis was performed based on classical nucleation theory (CNT) in order 
to theoretically investigate the expected cavitation thresholds [349, 350, 352, 358]. Previous 
studies using CNT suggest that the cavitation threshold is dependent upon the properties of the 
media (i.e. temperature, surface energy) as well as the spatial and temporal distribution of the 
applied p- [349, 358].  In this study, CNT was used to calculate the theoretical cavitation thresholds 
for samples with and without PFH nanodroplets. The CNT results were then compared to the 
experimental thresholds measured for the near monopolar pulses used in this study as well as for 
dual polarity pulses at frequencies ranging from 345 kHz to 3 MHz used in previous studies [80, 
337]. The threshold predicted by CNT, pCNT, was calculated as 
𝑝𝐶𝑁𝑇 = (
16𝜋𝛼3
3𝑘𝑏𝑇 ∗ ln
𝛤0𝑉𝑓𝜏𝑓
ln 2
) 0.5     Eq. 8.2 
where α is the surface energy, kb is the Boltzmann’s constant, T is temperature in Kelvin, Γ0 is a 
prefactor, Vf is the focal volume for a given frequency, and τf is the time the focal volume is above 
a given pressure [349-352, 358]. Γ0 was set to Γ0=1033 similar to previous work [337, 358]. Vf and 
τf were modified for each frequency with τf set to one fourth of the acoustic period and Vf 
representing the volume of fluid exposed to the applied pressure. An effective frequency of 1.8 
MHz was used for the frequency compounding transducer, as calculated based on the duration of 
the applied p- pressure cycle shown in Figure C.2A. The values of Vf_water were calculated from 
the -6 dB FWHM beam profiles of the transducers assuming an ellipsoidal focus, and were 47.07 
mm3, 7.89 mm3, 2.30 mm3, 0.072 mm3, and 1.04 mm3 for 345 kHz, 500 kHz, 1.5 MHz, 3 MHz, 
and the frequency compounding transducer (1.8 MHz), respectively. For simulations of the 
cavitation threshold without droplets, the surface energy of water, αw, was set to 19 mN/m, ~25% 
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of the macroscopic surface tension of water, based on previous work showing this value provides 
a more  reasonable agreement with experimentally observed cavitation thresholds [337, 349, 352]. 
 To theoretically investigate the cavitation threshold in phantoms containing PFH droplets, 
the CNT simulation was modified to account for the lower surface energy of PFH, αPFH, which 
was set to 11.9 mN/m. In addition, the PFH threshold simulation was corrected to account for only 
the volume of PFH within the focal region. The volume of PFH in the focal region, Vf_PFH, was 
calculated by multiplying Vf_water by the amount of PFH in a unit volume of water, as calculated 
from the particle concentration and size distribution data shown in Figure C.1. The resulting 
values of Vf_PFH were 0.31 mm3, 0.051 mm3, 0.015 mm3, 0.00046 mm3, and 0.0068 mm3 for 345 
kHz, 500 kHz, 1.5 MHz, 3 MHz, and the frequency compounding transducer (1.8 MHz), 
respectively.  
 
Results 
NMH Cavitation Threshold: Negative-Polarity Pulse 
In the first set of experiments, the histotripsy cavitation threshold was measured for agarose 
tissue phantoms with and without PFH nanodroplets exposed to negative-polarity pulses (Figure 
C.2A). For both types of phantoms, cavitation bubbles were only observed on the high-speed 
camera once a certain pressure threshold was exceeded (Figure C.5), as seen in previous studies 
[44, 80, 337, 355]. As the pressure was further raised above this threshold value, cavitation was 
observed in an increasingly larger region of the focal area, forming well-defined histotripsy bubble 
clouds similar to those observed in previous work using dual-polarity pulses at various frequencies 
[44, 80, 337, 345, 355]. Plotting the probability of cavitation as a function of P– demonstrated a 
significant decrease in pt(–) for tissue phantoms containing nanodroplets compared to control 
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phantoms (Figure C.6A and C.6B), with the P– threshold measured to be pt_(–) = 29.8±0.3 MPa, 
with σmean = 0.7 MPa for control phantoms without nanodroplets and pt(–) = 11.7±0.2 MPa, with 
σmean = 0.4 MPa for PFH phantoms. These results closely matched the P– thresholds measured in 
previous studies using single-cycle dual-polarity pulses with center frequencies ranging from 
345kHz to 3MHz (Table C.1). 
 
Figure C.15 Bubble Images: Negative-polarity Pulses. Optical Images of cavitation bubbles 
generated from negative-polarity pulses inside (A) control phantoms and (B) PFH phantoms. 
The single-cycle dual-polarity pulses commonly used in histotripsy studies contain both 
high amplitude positive and negative pressure phases (Figure C.2C). The P– thresholds for 
generating cavitation previously measured with the dual-polarity pulse were 24 MPa–27 MPa 
without nanodroplets and 10 MPa–15 MPa with PFH nanodroplets (Table C.1) [80, 337, 355]. 
Plotting the probability of cavitation for the negative-polarity pulses as a function of P+ 
demonstrated a significant decrease in pt(+) for tissue phantoms containing nanodroplets compared 
to control phantoms (Figure C.7A and C.7B), with the P+ threshold measured to be pt_(+) = 
9.9±0.1 MPa, with σmean = 0.2 MPa for control phantoms and pt(+) = 4.0±0.1 MPa, with σmean = 
0.2 MPa for PFH phantoms. The P+ threshold results measured for the negative-polarity pulses 
were significantly different than the P+ thresholds measured in previous studies using dual-polarity 
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pulses, which ranged from pt(+) = 28.1 MPa–51.2 MPa and pt(+) = 10.2 MPa–15.8 MPa for control 
and PFH phantoms, respectively (Table C.1). 
 
Figure C.16 Cavitation Probability vs. Negative Pressure. Plots show the cavitation probability as 
a function of negative pressure for (A, C) control and (B, D) PFH phantoms exposed to (A, B) 
negative-polarity pulses and (C, D) positive-polarity pulses. 
The P– threshold measured for the negative-polarity and positive-polarity pulses showed close agreement 
for PFH phantoms. Cavitation couldn’t be generated in control phantoms exposed to positive-polarity 
pulses (Max P–=18.4 MPa). 
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Figure C.17 Cavitation Probability vs. Positive Pressure. 
Plots show the cavitation probability as a function of positive pressure for (A, C) control and (B, D) PFH 
phantoms exposed to (A, B) negative-polarity pulses and (C, D) positive-polarity pulses. A significant 
increase in the P+ threshold was observed for both control and PFH phantoms exposed to the positive-
positive polarity pulses. 
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Table C.2 Threshold Results Comparison. Table shows the values for the P– and P+ thresholds 
measured for control and PFH phantoms exposed to the negative-polarity and positive-polarity pulses 
generated by the frequency compounding transducer along with the thresholds previously measured 
using dual-polarity pulses at 345 kHz, 500 kHz, 1.5 MHz, and 3 MHz [80, 337, 355]. Note: Italics 
represents data taken from previous studies. 
 
NMH Cavitation Threshold: Positive-Polarity Pulse 
In the second set of experiments, the histotripsy cavitation threshold was measured for 
tissue phantoms with and without PFH nanodroplets exposed to positive-polarity pulses (Figure 
C.2B). For control phantoms without nanodroplets, cavitation bubbles were not consistently 
observed in the focal region at any of the pressure levels tested (Figure C.8). Plotting the 
probability of cavitation as a function of P– (Figure C.6C) and P+ (Figure C.7C) for control 
phantoms without nanodroplets demonstrated that the cavitation threshold was not reached even 
when the frequency compounding transducer was driven at its maximum output pressure for the 
positive-polarity pulses (P–/P+=18.4/61.1 MPa). This finding matched previous work studying the 
histotripsy intrinsic threshold which has shown that cavitation is only generated when the P– is 
raised above the intrinsic threshold (~25-30 MPa) [44, 337, 343, 357].  
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Figure C.18 Bubble Images: Positive-polarity Pulses. 
Optical Images of cavitation bubbles generated from positive-polarity pulses inside (A) control phantoms 
and (B) PFH phantoms. Arrows on the plot indicate the locations in the focal region corresponding to 
the highest positive (P+) and negative (P–) pressures as measured by the FOPH (Figure 8.3). Dashed 
lines correspond to the approximate regions with a P– above ~12 MPa (Figure 8.3). 
 
For PFH phantoms exposed to the positive-polarity pulses, cavitation was observed once a 
certain pressure threshold was exceeded (Figure C.8). However, cavitation did not occur at the 
geometric focus of the transducer. Instead, the location of the cavitation was ~0.5 mm from the 
geometric focus, closely matching the location in the field with the highest P– (Figure C.3). As 
the pressure was further increased above the NMH cavitation threshold, two separate regions 
containing cavitation were observed in the PFH phantoms (Figure C.7), with these locations 
closely corresponding to the two regions of highest P– as measured by the FOPH (Figure C.3). 
The probability of cavitation for PFH phantoms exposed to positive-polarity pulses was plotted as 
a function of P– (measured at the location corresponding to the highest P–), with the results 
demonstrating pt(–) = 11.4±0.1 MPa, with σmean = 0.1 MPa (Figure C.5D). This P– threshold 
closely matched the P– threshold for the negative-polarity pulses as well as the P– thresholds 
previously measured using dual-polarity pulses (Table C.1). Plotting the probability of cavitation 
for PFH phantoms exposed to positive-polarity pulses as a function of P+ resulted in a P+ threshold 
of pt(+) = 42.6±0.2 MPa, with σmean = 0.4 MPa (Figure C.6D). This P+ threshold was significantly 
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different than the P+ thresholds measured for the negative-polarity pulses as well as the P+ 
thresholds previously measured for dual-polarity pulses (Table C.1). Figure C.9 shows a 
comparison of the P– and P+ thresholds measured for PFH phantoms exposed to the positive-
polarity and negative polarity pulses generated in this study as well as dual-polarity pulses at 
various frequencies (345 kHz–3MHz) measured in a previous study [355], with results strongly 
suggesting that the NMH threshold is a function of the applied P–. 
 
Figure C.19 NMH Threshold Results Comparison. 
Plot compares the P– and P+ thresholds measured for PFH phantoms in this study (negative-polarity and 
positive-polarity pulses) with the thresholds previously measured using dual-polarity pulses (f=345kHz, 
500kHz, 1.5MHz, 3 MHz) [355]. Results suggest NMH cavitation is generated directly from the P– of 
the incident wave. 
 
Classical Nucleation Theory Simulation 
A theoretical analysis was performed based on classical nucleation theory (CNT) in order 
to theoretically investigate the expected cavitation thresholds for phantoms with and without PFH 
nanodroplets. Figure C.10 shows pCNT compared with the average pt(–) measured for the near 
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monopolar pulses used in this study as well as for dual polarity pulses at frequencies ranging from 
345 kHz to 3 MHz used in previous studies [80, 337]. The CNT results predicted a significant 
decrease in the cavitation threshold for phantoms containing PFH nanodroplets, with the results 
closely matching the thresholds measured experimentally (Figure C.10). 
 
Figure C.20 CNT Simulation. 
Classical nucleation theory was used to predict the cavitation thresholds for histotripsy pulses applied to 
phantoms with and without PFH nanodroplets. Results showed close agreement between the CNT 
simulation and the experimentally measured thresholds. Note that the waveforms produced by the 
frequency compounding transducer are plotted as an effective frequency of 1.8 MPa. 
 
For example, the predicted P- cavitation threshold for PFH phantoms exposed to the 
negative-polarity pulses used in this study was calculated to be pCNT_PFH = 12.4 MPa, which was 
close to the experimental measured threshold of pt(–) = 11.7±0.2 MPa. The CNT results also 
predicted a slight increase (~1-3 MPa) in pCNT with increasing frequency, once again matching the 
trends observed experimentally (Figure C.10). This slight increase in threshold at higher 
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frequency is due to the smaller focal zone and shorter duration of the applied p-. In fact, since 
bubbles are generated directly from the single p- phase of the incident wave, the results of this 
study suggest that it is more appropriate to use the duration of the applied p- as a metric to predict 
the probability of generating cavitation from these single cycle pulses. The only significant 
deviation between the experimental and CNT results was observed for phantoms without 
nanodroplets exposed to the negative-polarity pulses, with the experimental results measuring a 
threshold ~3.5 MPa greater than predicted by CNT. This difference is likely explained by 
inaccuracies in the reported pressure values for high pressures (P–>21.5), which were estimated 
using a linear summation of individual elements as described in the Methods.  
 
Discussion 
In this work, we were able to generate pulses with dominant negative and positive pressure 
phases, which allowed us to investigate the effects of positive and negative pressure on the NMH 
cavitation threshold separately. The results supported our hypothesis that NMH bubbles are 
generated after cavitation is nucleated inside the droplets directly from the incident p- (tensile 
portion of the incident wave), similar to histotripsy bubbles generated without nanodroplets when 
the p- directly exceeds the intrinsic threshold of the target media. Results showed close agreement 
in the P– threshold for PFH phantoms exposed to negative-polarity (11.4±0.1 MPa), positive-
polarity (11.7±0.2 MPa), and dual-polarity (10-15 MPa) pulses. The P+ thresholds, in contrast, 
were measured to be significantly different for PFH phantoms exposed to negative-polarity 
(4.0±0.1 MPa), positive-polarity (42.6±0.2 MPa), and dual-polarity (10–16 MPa) pulses. These 
results support our hypothesis that NMH cavitation is purely dependent upon the applied p-. This 
hypothesis was further supported by the observation that exposing PFH phantoms to positive-
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polarity pulses resulted in cavitation only being generated in the regions with the highest P– 
(Figure C.8), as measured by the FOPH (Figure C.3).  
The results of this study provide significant insight into the nanodroplet nucleation process 
and support the hypothesis that the nucleation in NMH can be explained by classical nucleation 
theory (CNT). The ADV literature has hypothesized that droplet nucleation in ADV is caused by 
a different mechanism than what is predicted by classical nucleation theory (CNT), based on 
previous studies showing that the ADV threshold decreases with increasing frequency [330-332, 
353, 354]. Many alternative mechanisms have been proposed to explain the discrepancy between 
the trends predicted by CNT and the experimental trends observed for ADV including droplet 
deformation, hydrodynamic cavitation, or acoustic heating [330, 353, 354]. The results of this 
study, however, suggest that the nucleation process involved in NMH does in fact follow the 
mechanism described by CNT, which predicts that cavitation is nucleated inside the droplets 
directly from the applied p-. These results suggest that nanodroplets reduce the cavitation threshold 
by carrying a lower threshold medium, with the probability of nucleation being a function of the 
p- exposed to the PFC. We think this theory can also be extended to explain the nucleation 
mechanism for ADV using multi-cycle pulses and various droplet sizes, as recent work has 
revealed that the decrease in the ADV threshold at higher frequencies is due to superharmonic 
focusing, which significantly increases the amplitude of the p- inside the droplet and is enhanced 
at higher frequencies and in larger droplets [333, 334]. It is likely that the probability of nucleation 
in ADV will still follow the trends predicted by CNT once the pressure focusing effects are 
accounted for. 
Although the results of this work and previous ADV studies suggest that the same 
nucleation process may be responsible in ADV and NMH, it is important to note that the resulting 
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bubble dynamics are significantly different in these two cases. For example, stable bubbles are 
formed in ADV [330, 353, 359-363] while NMH produces cavitation bubbles that rapidly expand 
and then violently collapse [46, 79, 80, 348]. There are many factors determining the resulting 
bubble behavior after nucleation, including the ultrasound pulse parameters, initial droplet 
characteristics, and the properties of the surrounding microenvironment. For example, the higher 
frequencies and multi-cycle pulses commonly used in ADV result in oscillatory bubble growth, 
which allows ADV bubbles to stabilize [359, 361]. In contrast, NMH bubbles are exposed to a 
single large p- at lower frequencies, producing bubbles that rapidly expand to sizes much larger 
(Rmax~10-150 μm) than those observed for nanodroplet ADV (Rmax~1-10 μm), followed by the 
violent collapse of the NMH bubbles [46, 79, 80, 359]. In addition to the effects of ultrasound 
parameters, the resulting bubble behavior is dependent upon the droplet properties (i.e. size, 
concentration, and PFC boiling point) [359-361]. Finally, the bubble behavior will also be highly 
dependent upon the properties of the surrounding media including the temperature, Young’s 
modulus, viscosity, surface tension, and gas concentration [79, 80, 345, 359-361]. It is therefore 
important to understand the impact of these properties on the resulting bubble dynamics of ADV 
or NMH therapies, even though the underlying nucleation process is likely the same for these two 
approaches. 
The finding that the nanodroplet nucleation thresholds are determined by the applied P- 
and exhibit a distinct threshold behavior is promising for the development of NMH. This distinct 
P- threshold is dependent upon the droplet properties and can be changed by modulating droplet 
composition (i.e. changing droplet surface tension to modulate the nucleation threshold) [355]. 
With knowledge of the applied pressure fields and droplet characteristics (i.e. size, composition, 
concentration), predictable and reliable NMH therapy strategies can be developed. For example, 
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the applied P– in NMH therapy must be chosen in the region above the NMH threshold but below 
the histotripsy intrinsic threshold to ensure cavitation is only generated in regions containing 
nanodroplets. This approach also suggests that NMH therapy will share the same advantages of 
histotripsy treatments performed above the intrinsic threshold, such as the generation of precise 
lesions matching the portion of the beam profile above the P– threshold as well as the ability to 
manipulate bubble dynamics by changing the pulse parameters [44, 337, 343, 345]. Furthermore, 
the sharp P– threshold behavior observed in this study suggests that generating cavitation from 
nanodroplets is more predictable and reproducible than generating cavitation from micron-sized 
air contrast agents, which do not require nucleation (i.e. phase transition) in order to initiate the 
cavitation process and therefore do not show the same distinct threshold behavior [337, 364, 365]. 
Overall, the results of this study improve our understanding of the physical mechanisms underlying 
the nanodroplet nucleation process, which will help to guide the development of NMH therapy. 
 
Conclusion 
In this work, the effects of positive and negative pressure on the NMH cavitation threshold   
were investigated separately, with results supporting our hypothesis that the NMH cavitation 
threshold is determined by the incident p-. Close agreement was observed for the P– thresholds 
measured for PFH tissue phantoms exposed to negative-polarity (11.4±0.1 MPa) and positive-
polarity (11.7±0.2 MPa) pulses. The P+ thresholds, in contrast, were significantly different for the 
negative-polarity (4.0±0.1 MPa) and positive-polarity (42.6±0.2 MPa) pulses. Furthermore, the 
positive-polarity pulse experiments demonstrated that cavitation was preferentially generated in 
the regions with the largest P–. In the final part of this study, the experimental results were 
compared to the cavitation thresholds predicted by classical nucleation theory (CNT), with results 
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showing close agreement between simulations and experiments. Overall, the results of this study 
support our hypothesis that nanodroplet nucleation is determined by the applied p- and provide 
significant insight into the physical mechanisms underlying the NMH process. 
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Supplementary of Chapter 3 
 
The material in this chapter is published from the following article: O. Aydin, I. Youssef, Y. Y. 
Durmaz, G. Tiruchinapally, and M. E. H. ElSayed, “Formulation of Acid-Sensitive Micelles for 
Delivery of Cabazitaxel into Prostate Cancer Cells” Molecular Pharmaceutics, 2016, 13 (4), 
1413–1429 (2016). 
 
Figure D.1 1H NMR spectrum of PMMA in CDCl3 
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Figure D.2 1H NMR spectrum of PMMA-b-PtBA-Br in CDCl3. 
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Figure D.3 1H NMR spectrum of PMMA-b-PtBA-N3 in CDCl3. 
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Figure D.4 1H NMR spectrum of alkyne-PEG in CDCl3. 
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Figure D.5 1H NMR spectrum of PMMA-b-PtBA-b-PEG in CDCl3. 
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Figure D.6 1H NMR spectrum of PMMA-b-PAA-b-PEG in CDCl3. 
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Figure D.7  1H NMR of Compound X 2,2’-(Propane-2,2-diylbis(oxy))bis(diethane-
2,1diyl)bis(isoindoline-1,3-dione) in CDCl3. 
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Figure D.8  13C NMR of Compound X 2,2’-(Propane-2,2-diylbis(oxy))bis(diethane-
2,1diyl)bis(isoindoline-1,3-dione) in CDCl3. 
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Figure D.9 GPC results of PEG-b-PAA-b-PMMA block copolymer and its precursors. 
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Supplementary of Chapter 4 
 
The material in this chapter is submitted to the following journal: O. Aydin, I. Youssef, G. 
Tiruchinapally, H. Ramaraju, Y. Y. Durmaz, K. Kozloff, D. H. Kohn, and M. ElSayed 
“Differential Targeting of Prostate Cancer Cells, Osteoblasts, and Osteoclasts using pVTK 
Peptide- and Bisphosphonate-Functionalized Micelles”, Biomaterials. 
 
 
Figure E.1 1H NMR of compound 1 in CDCl3. 
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Figure E.2 13C NMR of compound 1 in CDCl3. 
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Figure E.3 1H NMR of compound 2 in CDCl3. 
 
 
 
 
 
 
 
 
 
 
255 
 
 
Figure E.4 13C NMR of compound 2 in CDCl3. 
 
 
 
 
 
 
 
 
 
256 
 
 
Figure E.5 1H NMR of compound 3 in CDCl3. 
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Figure E.6 13C NMR of compound 3 in CDCl3. 
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Figure E.7 1H NMR of compound 3a in CDCl3. 
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Figure E.8 13C NMR of compound 3a in CDCl3. 
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Figure E.9 MALDI-TOF of Compound 3a (Alkyne-PEG). 
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Figure E.10 1H NMR of Compound 4 (PMMA-b-PtBA-PEG) in CDCl3. 
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Figure E.11 1H NMR of Compound 5 (PMMA-b-PAA-b-PEG) in CDCl3. 
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Figure E.12 1H NMR spectrum of compound 6 in CDCl3. 
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Figure E.13 13C NMR spectrum of compound 6 in CDCl3. 
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Figure E.14 1H NMR spectrum of compound 7 in DMSO-d6. 
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Figure E.15 13C NMR spectrum of compound 7 in DMSO-d6. 
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Figure E.16 31P NMR spectrum of compound 7 in DMSO-d6. 
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Figure E.17 1H NMR spectrum of compound 8 in CDCl3. 
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Figure E.18 13C NMR spectrum of compound 8 in CDCl3. 
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Figure E.19 31P NMR spectrum of compound 8 in CDCl3. 
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Figure E.20 1H NMR of compound 9a in DMSO-d6. 
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Figure E.21 ESI-MS of compound 9a. 
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Figure E.22 1H NMR of compound 9 in DMSO-d6 (before purification). 
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Figure E.23 1H NMR of compound 9 in DMSO-d6 (after purification). 
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Figure E.24 13C NMR of compound 9 in DMSO-d6. 
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Figure E.25 HR-MS (ESI-MS) of compound 9. 
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Figure E.26 1H NMR of compound 10 in DMSO-d6 (DIPEA in DMSO-d6, non-purified 
material). 
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Figure E.27 ESI-MS of compound 10. 
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Figure E.28 1H NMR of compound 11 in CDCl3. 
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Figure E.29 13C NMR of compound 11 in CDCl3. 
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Figure E.30 MALDI-spectrum of compound 11. 
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Figure E.31 1H NMR of compound 12 in CDCl3. 
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Figure E.32 13C NMR of compound 12 in CDCl3. 
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Figure E.33 MALDI-spectrum of compound 12. 
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Figure E.34 1H NMR of compound 13 in CDCl3. 
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Figure E.35 13C NMR of compound 13 in CDCl3. 
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Figure E.36 MALDI-spectrum of compound 13. 
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Figure E.37 1H NMR of compound 14 in CDCl3. 
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Figure E.38 MALDI-spectrum of compound 14. 
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Figure E.39 1H NMR of compound 15 in D2O. 
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Figure E.40 31P NMR of compound 15 in D2O. 
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Figure E.41 1H NMR of compound 16 in CDCl3. 
 
  
293 
 
 
Figure E.42 31P NMR of compound 16 in D2O. 
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Figure E.43 1H NMR of compound 17 in CDCl3. 
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Figure E.44 1H NMR of compound 18 in CDCl3. 
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Figure E.45 13C NMR of compound 18 in CDCl3. 
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Figure E.46 1H NMR of Compound 19 (PMMA-b-PtBA-b-PEG-NHFITC) in CDCl3. 
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Figure E.47 expanded 1H NMR of Compound 19 (PMMA-b-PtBA-b-PEG-NHFITC, (5.5-9.0 
ppm) in CDCl3. 
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Figure E.481H NMR of Compound 20 (PMMA-b-PAA-b-PEG-NHFITC) in CDCl3. 
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